 
 
Offici al Titl e:  E N VI SI O N: A P h as e [ADDRESS_1025613] u d y wit h a n  O p e n -l a b el E xt e nsi o n t o E v al u at e t h e Effic ac y 
a n d  S af et y of Gi v osir a n i n P ati e nts wit h Ac ut e H e p atic  P or p h yri as  
 
N C T N u m b er:    N C T 0 3 3 3 8 8 1 6  
 
D oc u m e nt D at e:   Cli nic al St u d y Pr ot oc ol , [ADDRESS_1025614] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 I N V E S TI G A T O R’ S A G R E E M E N T  
 
I h a ve rea d  t he A L N -A S [ADDRESS_1025615] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 P R O T O C O L S Y N O P SI S  
P r ot oc ol Title  
E N VI SI O N: A P hase [ADDRESS_1025616] N a me  
Gi v osira n ( A L N -A S 1)  
I n dic ati o n  
Treat me nt of ac ute he patic p or p h yrias ( A H P) i n a d ult a n d a d olesce nt patie nts  
P h ase  
P hase [ADDRESS_1025617] u d y ce nter(s)   
T he st u d y will be c o n d ucte d at a p pr o xi matel y [ADDRESS_1025618] u d y ce nters w orl d wi de.  
O bjecti ves  
P ri m ar y  
• E val uate t he effect of s u bc uta ne o us ( S C) gi v osira n ( A L N -A S 1), c o m pare d t o place b o, o n t he rate 
of p or p h yria attac ks re q uiri n g h os pi[INVESTIGATOR_1314] o n, ur ge nt healt hcare visit, or i ntra ve n o us (I V) he mi n 
a d mi nistrati o n at h o me  i n patie nts wit h ac ute i nter mitte nt p or p h yria ( AI P)    
Sec o n d ar y  
• E val uate t he effect of gi v osira n, c o m pare d t o place b o, o n uri nar y a mi n ole v uli nic aci d ( A L A) 
le vels i n patie nts wit h AI P  
• E val uate t he effect of gi v osira n, c o m pare d t o place b o, o n uri nar y p or p h o bili n o ge n ( P B G) le vels i n 
patie nts wit h  AI P  
• E val uate t he effect of gi v osira n, c o m pare d t o place b o, o n he mi n usa ge i n patie nts wit h AI P  
• E val uate t he effect of gi v osira n, c o m pare d t o place b o, o n t he rate of p or p h yria attac ks re q uiri n g 
h os pi[INVESTIGATOR_1314] o n, ur ge nt healt hcare visit, or I V he mi n a d mi nistrati o n at h o me  i n patie nts wit h a n y 
A H P  
• E val uate t he effect of gi v osira n, c o m pare d t o place b o, i n patie nts wit h AI P o n t he s y m pt o ms of 
pai n, na usea, a n d fati g ue  
• E val uate t he effect of gi v osira n, c o m pare d t o place b o, i n patie nts wit h AI P o n t he P h ys ical 
C o m p o ne nt S u m mar y ( P C S) of t he 1 2 -ite m S h ort -F or m Healt h S ur ve y ( S F -1 2)  
• E val uate t he safet y a n d t olera bilit y of gi v osira n i n patie nts wit h a n y A H P  
E x pl or at or y  
• E val uate t he effects of gi v osira n, c o m pare d t o place b o, i n patie nts wit h AI P a n d i n patie nts wit h 
a n y A H P o ver t he 6 -m o nt h treat me nt peri o d o n:  
− Rate of all p or p h yria attac ks (re q uiri n g h os pi[INVESTIGATOR_1314] o n, ur ge nt healt hcare visit, I V he mi n 
a d mi nistrati o n at h o me, or treat me nt at h o me wit h o ut I V he mi n)  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 − Uri nar y a mi n ole v uli nic aci d s y nt hase ( A L A S 1) messe n ger R N A ( m R N A) le vels  
− A nal gesic usa ge  
− A d diti o nal q ualit y of life ( Q O L) meas ures, i ncl u di n g misse d da ys of w or k/sc h o ol  
− Patie nt e x perie nce q uesti o n naire a n d p atie nt's i m pressi o n of healt h stat us c ha n ge  
• Assess t he treat me nt effect of gi v osira n at e v al uate d d oses d uri n g t he o pe n -la bel e xte nsi o n ( O L E) 
peri o d i n patie nts wit h AI P a n d i n patie nts wit h a n y  A H P w h o ha d pre vi o usl y bee n ra n d o mize d t o 
place b o treat me nt  
• Assess t he l o n g -ter m treat me nt effect of gi v osira n i n patie nts wit h AI P a n d i n patie nts wit h a n y 
A H P  
• C haracterize t he p har mac o ki netics ( P K) a n d assess t he a nti dr u g a nti b o dies ( A D A) of gi v osira n i n 
patie nts wit h a n y A H P  
E n d p oi nts  
P ri m ar y  
• A n n ualize d rate of p or p h yria attac ks re q uiri n g h os pi[INVESTIGATOR_1314] o n, ur ge nt healt hcare visit, or I V 
he mi n a d mi nistrati o n at h o me i n patie nts wit h AI P o ver t he 6 -m o nt h treat me nt peri o d  
Sec o n d ar y  
• Uri nar y A L A i n patie nts wit h AI P at 3 m o nt hs  
• Uri nar y A L A i n patie nts wit h AI P at 6  m o nt hs  
• Uri nar y P B G i n patie nts wit h AI P at 6 m o nt hs  
• A n n ualize d rate of a d mi nistere d he mi n d oses i n patie nts wit h AI P o ver t he 6 -m o nt h treat me nt 
peri o d  
• A n n ualize d rate of p or p h yria attac ks re q uiri n g h os pi[INVESTIGATOR_1314] o n, ur ge nt healt hcare visit, or I V 
he mi n a d m i nistrati o n at h o me i n patie nts wit h a n y A H P o ver t he 6 -m o nt h treat me nt peri o d  
• Dail y w orst pai n sc ore as meas ure d b y Brief Pai n I n ve nt or y -S h ort F or m ( B PI -S F) n u meric 
rati n g scale ( N R S)  i n patie nts wit h AI P o ver t he 6 -m o nt h treat me nt peri o d  
• Dail y w orst na us ea sc ore as meas ure d b y N R S i n patie nts wit h AI P o ver t he 6 -m o nt h 
treat me nt peri o d  
• Dail y w orst fati g ue sc ore as meas ure d b y Brief Fati g ue I n ve nt or y -S h ort F or m ( B FI -S F) N R S 
i n patie nts wit h AI P o ver t he 6 -m o nt h treat me nt peri o d  
• C ha n ge fr o m baseli ne i n t he P C S of t he S F -[ADDRESS_1025619] orat or y e n d p oi nts will be meas ure d i n patie nts wit h AI P a n d i n patie nts wit h a n y A H P o ver t he 6 -
m o nt h treat me nt peri o d a n d o ver t he O L E peri o d at d oses e val uate d:  
• Rate of p or p h yria attac ks re q uiri n g h os pi[INVESTIGATOR_1314] o n, ur ge nt healt hcare visit, or I V he mi n 
a d mi nistrati o n at h o me  
• Rate of all p or p h yria attac ks  
• Rate of a d mi nistere d he mi n d oses  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 • Uri nar y A L A a n d P B G le vels  
• Uri nar y A L A S 1 m R N A le vels  
• Dail y w orst pai n, dail y w orst na usea, a n d dail y w orst fati g ue sc ore o ver 1 2 m o nt hs  
• P C S of t he S F -1 2  
• E Q -5 D -5 L i n de x sc ore  
• Patie nt Gl o bal I m pressi o n of C ha n ge ( P GI C)  
• P or p h yria Patie nt E x perie nce Q uesti o n naire ( P P E Q)  
• A nal gesic usa ge ( o pi [INVESTIGATOR_2495] d a n d n o n -o pi [INVESTIGATOR_2495] d)  
• P K pr ofile of gi v osira n  
• I nci de nce a n d titer of A D As  
S af et y  
• I nci de nce, se verit y, seri o us ness, a n d relate d ness of a d verse e ve nts d uri n g t he [ADDRESS_1025620] u d y desi g ne d t o e val uate t he efficac y a n d safet y 
of gi v osira n i n a d ults a n d a d olesce nts ( ≥ 1 2 years of a ge) wit h a d oc u me nte d dia g n osis of AI P.  T he 
efficac y a n d safet y of gi v osira n will als o be i n vesti gate d i n t he ot her A H Ps t y pes, i ncl u di n g 
Here ditar y C o pr o p or p h yria ( H C P), Varie g ate P or p h yria ( V P), a n d A L A de h y dratase deficie nt 
p or p h yria ( A D P).  
Patie nts w h o are o n he mi n pr o p h yla xis pri or t o e nr oll me nt will be eli gi ble t o partici pate if t he y meet 
t he attac k e ntr y criteria. I n t his st u d y, patie nts ma y be gi ve n he mi n f or t he treat me n t of ac ute attac ks if 
cli nicall y i n dicate d b ut ma y n ot use he mi n pr o p h ylacticall y. He mi n pr o p h yla xis is n ot per mitte d i n 
t his st u d y beca use gi v osira n is i nte n de d as m o n ot hera p y t o pre ve nt attac ks a n d t he re g ular c o -
a d mi nistrati o n of he mi n c o ul d c o nf o u n d ef ficac y a n d safet y si g nals relate d t o gi v osira n.  
I n t he first part of t he st u d y, c o nse nti n g (a n d asse nti n g, w here a p plica ble) patie nts w h o meet all 
eli gi bilit y criteria will be ra n d o mize d i n a 1: 1 rati o t o recei ve 2. 5 m g/ k g gi v osira n or place b o o nce 
m o nt hl y  f or a 6 -m o nt h d o u ble -bli n d treat me nt peri o d; b ot h gi v osira n a n d place b o will be a d mi nistere d 
s u bc uta ne o usl y.  Ra n d o mizati o n i nt o treat me nt gr o u ps will be stratifie d at st u d y e ntr y b y A H P t y pe 
(AI P [ wit h m utati o n i n t he  H M B S  ge ne] vs H C P, V P, A D P, or a n y A H P wit h o ut i de ntifie d m utati o n 
i n a p or p h yria -relate d ge ne ); all patie nts i n t he AI P gr o u p will be f urt her stratifie d b y eac h patie nt's 
use of he mi n pr o p h yla xis re gi me n at t he ti me of scree ni n g a n d b y eac h patie nt's hist orical a n n ualize d 
attac k rate.  Pati e nts o n a he mi n pr o p h yla xis re gi me n pri or t o st u d y e ntr y will be stratifie d b y t heir 
hist orical a n n ualize d attac k rate: < 7 attac ks vs ≥ [ADDRESS_1025621] orical 
a n n ualize d attac k rate: < 1 2 attac ks vs ≥ [ADDRESS_1025622] u d y, t he O L E peri o d d uri n g w hic h t he y will be treate d wit h gi v osira n f or u p t o 2 9 m o nt hs . Patie nts 
w h o cr osse d o ver t o t he O L E peri o d pri or t o t he i m ple me ntati o n of a me n d me nt 3 (ie, u n der 
a me n d me nt versi o n 1 or 2) a n d are recei vi n g a 2. 5  m g/ k g o nce m o nt hl y gi v osira n d ose will re mai n o n 
t hat d ose.  U p o n e ntr y t o t he O L E peri o d u n der a me n d me nt versi o n 3, patie nts will cr oss o ver t o 
recei ve a 1. 2 5  m g/ k g o nce m o nt hl y d ose of gi v osira n.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 After i m ple me ntati o n of a m e n d me nt  3 a n d u ntil i m ple me ntati o n of a me n d me nt  5, patie nts assi g ne d t o 
t he o nce m o nt hl y 1. 2 5 -m g/ k g treat me nt gr o u p w h o e x perie nce i na de q uate disease c o ntr ol ma y be 
all o we d t o ha ve t heir m o nt hl y d ose i ncrease d t o 2. 5  m g/ k g starti n g at t he M o nt h  [ADDRESS_1025623] u d y Vi sit ( w he n 
6 m o nt hs of o pe n -la bel gi v osira n d osi n g ha ve bee n c o m plete d at 1. 2 5  m g/ k g) base d o n disc ussi o n a n d 
a gree me nt b y t he I n vesti gat or a n d me dical m o nit or, de m o nstrati o n of t olera bilit y t o gi v osira n, a n d 
f ulfill me nt of A L A a n d cli nical acti vit y criteri a.  
U p o n i m ple me ntati o n of a me n d me nt  5, all patie nts recei vi n g 1. 2 5  m g/ k g gi v osira n o nce m o nt hl y w h o 
d o n ot ha ve o n g oi n g cli nicall y rele va nt tra nsa mi nase ele vati o ns will ha ve t heir d ose i ncrease d t o 
2. 5  m g/ k g gi v osira n o nce m o nt hl y base d o n t olera bilit y al o ne, wit h o ut a n y criteria f or A L A re d ucti o n 
or cli nical acti vit y.  See Secti o n  6. 2. 3. [ADDRESS_1025624] u d y site, a n d a visit b y a h o me healt hcare 
pr ofessi o nal is n ot p ossi ble d ue t o circ u msta nces relate d t o t he C O VI D -1 9 pa n de mic, gi v osira n ma y 
be a d mi nistere d b y t he patie nt or t he care gi ver u n der t he o versi g ht of t he I n vesti gat or, a n d f oll o wi n g 
c o ns ultati o n wit h t he me dical m o nit or, as all o we d b y a p plica ble  c o u ntr y a n d l ocal re g ulati o ns.  
Patie nts or care gi vers will be pr o vi de d wit h a n electr o nic diar y (e Diar y) t o rec or d se verit y of dail y 
pai n, na usea, a n d fati g ue, as well as a nal gesic usa ge.  P ote ntial p or p h yria attac ks will be re p orte d b y 
patie nts a n d care g i vers t hr o u g h t he e Diar y w he n t he y occ ur; st u d y ce nters will be n otifie d w he n 
p ote ntial p or p h yria attac ks are re p orte d i n t he e Diar y.  I n i nsta nces w he n t he e Diar y is n ot use d t o 
re p ort p ote ntial p or p h yria attac ks, st u d y ce nters ma y be n otifie d b y tele p h o n e b y patie nts, care gi vers, 
or ot her healt hcare pr o vi ders.  All p ote ntial p or p h yria attac ks will be c o nfir me d b y t he I n vesti gat or.  
Patie nts ma y recei ve gi v osira n as l o n g as t he y d o n ot f ulfill a n y of t he st u d y disc o nti n uati o n criteria or 
u ntil gi v osira n is c o m merciall y a vaila ble i n t he patie nt’s territ or y or t he gi v osira n de vel o p me nt 
pr o gra m is disc o nti n ue d ( w hic he ver c o mes first).  
A n e xter nal i n de pe n de nt Data M o nit ori n g C o m mittee ( D M C) will m o nit or safet y o ver t he c o urse of 
t he d o u ble -bli n d treat me nt peri o d  a n d u ntil all patie nts ha ve bee n i n t he O L E peri o d f or at least 
[ADDRESS_1025625] u d y will i ncl u de a d ults a n d a d olesce nts ( ≥ 1 2 years of a ge) wit h a d oc u me nte d dia g n osis of 
A H P (i ncl u di n g AI P, H C P, V P, or A D P) base d o n cli nical feat ures, d oc u me nte d e vi de nce of uri nar y 
or plas ma A L A or P B G ele vati o ns ≥ 4 × u p per li mit of n or mal ( U L N) wit hi n t he past year pri or t o or 
d uri n g t he Scree ni n g peri o d a n d d oc u me nte d ge netic e vi de nce of a m utati o n i n a p or p h yria -relate d 
ge ne.  If t he res ults of t he patie nt’s ge netic testi n g d o n ot i de ntif y a p or p h yria -relate d ge ne m utati o n, 
t he patie nt ma y be e li gi ble f or t he st u d y base d o n cli nical feat ures acc o m pa nie d b y s u p p orti ve 
bi oc he mical criteria.  
I n a d diti o n t o cli nical, bi oc he mical, a n d ge netic feat ures of A H P, patie nts are als o re q uire d t o ha ve 
ha d at least [ADDRESS_1025626] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025627], D ose a n d M o de of A d mi nistr ati o n  
Gi v osira n is a s y nt hetic c he micall y m o difie d s mall i nterferi n g R N A (si R N A) tar geti n g A L A S [ADDRESS_1025628] osa mi ne li ga n d c o nj u gate d t o t he se nse stra n d.   
Patie nts ra n d o mize d t o recei ve gi v osira n will be a d mi nistere d 2. 5 m g/ k g S C m o nt hl y  d uri n g t he 
6-m o nt h treat me nt peri o d; patie nts will recei ve 1. 2 5  m g/ k g or 2. 5 m g/ k g S C m o nt hl y d uri n g t he O L E 
peri o d  
Ref ere nce T her a p y, D ose a n d M o de of A d mi nistr ati o n  
Place b o (s o di u m c hl ori de 0. 9 % w/ v f or S C a d mi nistrati o n).   
D ur ati o n of Tre at me nt  
T he esti mate d t otal ti me o n st u d y f or eac h patie nt is u p t o 3 8 m o nt hs, i ncl u di n g u p t o 2 m o nt hs of 
scree ni n g, u p t o 3 5 m o nt hs of treat me nt ( 6 -m o nt h treat me nt peri o d ( d o u ble -bli n d) + u p t o a 2 9 -m o nt h 
o pe n -la bel e xte nsi o n peri o d), a n d a [ADDRESS_1025629] u d y was desi g ne d wit h t he ass u m pti o n of a mea n a n n ualize d attac k rate of 8, a sta n dar d 
de viati o n ( S D) of [ADDRESS_1025630] 9 0 % p o wer t o detect a 4 5 % re d ucti o n i n t he 
a n n ualize d attac k rate wit h gi v osira n at a 2 -si de d 5 % si g nifica nce le vel, usi n g a ne gati ve bi n o mial 
m o del wit h [ADDRESS_1025631] 8 0 % p o wer e ve n if t he dr o p o ut rate is 
as hi g h as 1 5 % u n der t he sa me ass u m pti o ns.   
T he o verall T y pe I err or rate will be str o n gl y c o ntr olle d at a [ADDRESS_1025632] ors (stat us of he mi n pr o p h yla xis use pri or t o st u d y 
e ntr y a n d hist orical attac k rate). T he n u m ber of da ys t hat patie nts s pe n d i n t he 6 -m o nt h treat me nt 
peri o d will be i ncl u de d i n t he m o del as a n offset varia ble. T his a nal ysis will i ncl u de all ra n d o mize d 
patie nts wit h AI P ( wit h m utati o n i n t he H M B S  ge ne) w h o recei ve d  at least 1 d ose of 
gi v osira n/ place b o, gr o u pe d acc or di n g t o t heir ra n d o ml y assi g ne d treat me nt ar m (t he AI P f ull a nal ysis 
set [ F A S AI P ]).  
A n esti mate d rati o of mea n a n n ualize d attac k rates bet wee n treat me nt ar ms, wit h its c orres p o n di n g 
9 5 % c o nfi de nce i nter va l, will be esti mate d fr o m t he ne gati ve bi n o mial re gressi o n m o del. Descri pti ve 
statistics f or t he me dia n a n d i nter q uartile ra n ge of t he a n n ualize d attac k rate will als o be prese nte d f or 
eac h treat me nt ar m.   
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  9 Se nsiti vit y a nal yses will be detaile d i n t he stat istical a nal ysis pla n ( S A P).  
T he a nal ysis of t he a n n ualize d rate of p or p h yria attac ks  re q uiri n g h os pi[INVESTIGATOR_1314] o n, ur ge nt healt hcare 
visit, or I V he mi n a d mi nistrati o n at h o me i n patie nts wit h a n y A H P w h o recei ve d at least 1 d ose of 
gi v osira n/ place b o  (t he A H P  f ull a nal ysis set [ F A S]) d uri n g t he 6 -m o nt h treat me nt peri o d a n d t he 
a n n ualize d rate of he mi n d oses will be c o n d ucte d usi n g t he sa me a p pr oac h as t he pri mar y a nal ysis.    
F or t he a nal ysis of uri nar y A L A -relate d e n d p oi nts, A L A le vels will be c o m pare d bet wee n treat me nt 
ar ms usi n g a mi xe d -effects m o del re peate d meas ures ( M M R M) wit h baseli ne A L A as a c o nti n u o us 
c o variate, t he fi xe d effect ter ms i ncl u di n g treat me nt ar ms, stratificati o n fact ors f or AI P patie nts ( pri or 
he mi n pr o p h yla xis stat us a n d hist orical attac k rates), visit, a n d treat me nt b y visit i nteracti o n .  P B G -
relate d e n d p oi nts will als o be a nal yze d usi n g t his met h o d ol o g y.    
Dail y pai n, na usea, a n d fati g ue sc ores will be a nal yze d se paratel y usi n g t he area u n der t he c ur ve 
( A U C) a p pr oac h: t he A U C o ver [ADDRESS_1025633] 3 m o nt hs of t he treat me nt peri o d. T he e n d p oi nt f or t his i nteri m a nal ysis is t he A L A le vel at 3 
m o nt hs. T he A L A le vel at 3 m o nt hs will be c o m pare d bet wee n treat me nt ar ms usi n g a n a nal ysis of 
c o varia nce ( A N C O V A) m o del wit h t he fi xe d effect of treat me nt ar ms, stratificati o n fact ors f or AI P 
patie nts ( pri or he mi n pr o p h yla xis stat us a n d hist orical attac k rates), a n d wit h baseli ne A L A as a 
c o variate.  A n al p ha -s pe n di n g f u ncti o n will be use d t o a dj ust t he si g nifica nce le vel t o e ns ure t he 
o verall t y pe I err or rat e is n ot i nflate d; t he err or s pe n di n g f u ncti o n will be s pecifie d i n t he statistical 
a nal ysis pla n. T he si g nifica nce le vel f or t he c o m paris o n at t he i nteri m is 0. 0 0 1 ( 2 si de d).  
St o p pi n g f or efficac y or f utilit y is n ot pla n ne d i n t his st u d y.  T o e ns ure t hat  t he st u d y is a de q uatel y 
p o were d f or t he pri mar y e n d p oi nt c o m paris o n at t he fi nal a nal ysis, t he a n n ualize d attac k rates ma y 
als o be e val uate d i n a bli n de d ma n ner f or sa m ple size reassess me nt at t he ti me of t he i nteri m a nal ysis.   
Details will be descri be d i n t he S A P.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me n t 7, [ADDRESS_1025634] or y c ollecte d will i nc or p orate t he patie nt’s p or p h yria hist or y, i ncl u di n g t heir t y pi[INVESTIGATOR_750006] k c haracteristics, t ri g gers, a n d treat me nt, as well as 
ce ntral ve n o us access hist or y,  ir o n o verl oa d hist or y, a n d pri or li ver disease hi st or y.  
e A c o m plete p h ysical e xa mi nati o n will be perf or me d at Scree ni n g, Da y 1, a n d M o nt h 6.  At all ot her visits, a tar gete d p h ysical  e xa mi nati o n will be perf or me d as 
descri be d i n Secti o n  7. 5. 3 .  T he p h ysical e xa mi nati o n will be perf or me d pri or t o d osi n g.   
f D osi n g wei g ht (i n kil o gra ms) will b e c ollecte d d uri n g t he cli nical st u d y ce nter visits. W ei g ht c ollecte d at eit her t he pre vi o us st u d y ce nter visit or c urre nt st u d y 
ce nter visit ma y be use d f or d ose calc ulati o ns. T he Scree ni n g Visit wei g ht will be use d f or d ose -calc ulati o n o n St u d y Da y 1. Hei g ht (i n ce nti meters) will be 
meas ure d a n d B MI calc ulate d at cli nic visits e ver y 6 m o nt hs ( o n Da y 1 a n d M o nt h 6).  B MI will be a ut o maticall y calc ulate d wit hi n t he data b ase.  
g Ser ol o g y i ncl u des he p atitis B s urface a nti b o d y ( H bs A b), he patitis B s urface a nti ge n ( H bs A g), a n d a nti -H C V a nti b o d y. F S H testi n g ma y be perf or me d t o 
c o nfir m s us pecte d p ost -me n o pa usal stat us.  
h Vital si g ns i ncl u de bl o o d press ure, heart rate, b o d y te m perat ure, a n d res pi[INVESTIGATOR_1305] y rate a n d will be meas ure d w he n patie nts are i n a seate d or s u pi [INVESTIGATOR_050] p ositi o n 
(s h o ul d be c o nsiste nt acr oss st u d y visits wit h eac h patie nt) after t he patie nt has reste d f or [ADDRESS_1025635] d ose ( + 1 5  mi n utes).   O n all ot her d osi n g da ys, vital si g ns will b e c ollecte d pre d ose.  
i Si n gle 1 2 -lea d E C G will be perf or me d i n t he s u pi [INVESTIGATOR_050] p ositi o n after t he patie nt has reste d c o mf orta bl y f or 5 mi n utes. E C Gs will be c ollecte d pri or t o a n y bl o o d 
dra ws.  
j Tri plicate 1 2 -lea d E C Gs will be perf or me d at pre d ose a n d 2 -h o urs ( + 1 5  mi n utes) p ost -d ose o n t he Da y  1, M o nt h 5, a n d M o nt h 6 visits, usi n g vali date d E C G 
ser vices e q ui p me nt fr o m a ce ntral facilit y; tri plicate meas ure me nts s h o ul d be se p arate d b y a p pr o xi matel y 1 mi n ute wit h t he patie nt i n t he s u pi [INVESTIGATOR_050] p ositi o n after 
he or s he has reste d c o mf orta bl y f or 5 mi n utes.  W he n E C G a n d bl o o d sa m ple c ollecti o n (e g, f or P K assess me nt) occ ur at t he sa me ti me,  E C G assess me nts 
s h o ul d be perf or me d bef ore bl o o d sa m ples are dra w n .  I n a pres pecifie d s u bset of a p pr o xi matel y [ADDRESS_1025636] u d y ce nters (i ncl u di n g all p atie nts 
at East Asia n st u d y ce nters [i n J a p a n, S o ut h K orea, a n d T ai wa n]), a n a d diti o nal E C G ( wit h paire d P K assess me nt) at 2 4 h o urs ( ± 2 h o urs) p ost -d ose will b e 
c ollecte d a t Da y 1 a n d M o nt h 6.  
k Cli nical la b orat or y para meters will i ncl u de: ser u m c he mistr y i ncl u di n g L F Ts, li pase, a m ylase, he mat ol o g y, c o a g ulati o n, a n d ur i nal ysis. Bl o o d a n d uri ne 
sa m ples f or cli nical la b orat or y e val uati o ns will be c ollecte d pre d ose. Ser u m ferri ti n assess me nts will b e c ollecte d at St u d y Da y 1 a n d M o nt h 6.  D -di mer 
assess me nts will be perf or me d at Scree ni n g, Da y 1, M o nt h 3, a n d M o nt h 6; as a cli nical res earc h para meter o nl y, d -di mer res ults will n ot b e c o m m u nic ate d t o 
t he st u d y ce nters.  Res ults f r o m A L T, T B L, a n d I N R tests c ollecte d wit hi n t he [ADDRESS_1025637] will be perf or me d at Scree ni n g; t hereafter, ser u m or uri ne pre g na nc y tests will b e perf or me d 
m o nt hl y.  Res u lts m ust b e a vaila ble bef ore d osi n g.  
m At t he M o nt h [ADDRESS_1025638] u d y will be a d mi nistere d after all sc he d ule d 6 -m o nt h assess me nts (f or t he 
c o m pleti o n of t he d o u ble -bli n d peri o d) ha ve bee n perf or me d.  T he uri ne A L A a n d P B G sa m ple m ust b e c ollecte d pri or t o t he first o pe n -la bel d ose of gi v osira n.  
If t he A L A a n d P B G sa m ple c ollecti o n is dela ye d d ue t o he mi n usa ge wit hi n [ADDRESS_1025639]  occ ur w he n t he 
patie nt is n ot ha vi n g a n attac k, a n d ≥ [ADDRESS_1025640] he mi n d o se T w o scree ni n g uri ne sa m ples (c ollecte d o n 
2 differe nt d a ys) s h o ul d be c ollecte d f or A L A/ P B G; o ne scre e ni n g uri ne sa m ple s h o ul d be c ollecte d f or A L A S [ADDRESS_1025641] u g d osi n g; h o we ver, if he mi n is us e d f or a n attac k, sc he d ule d uri nar y 
A L A, P B G a n d A L A S 1 m R N A will be c ollecte d 4 da ys ( + 4 da ys) after t he patie nt’s last h e mi n d ose.  At t he M o nt h [ADDRESS_1025642] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me n t 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 3  o W here all o we d per l ocal re g ul ati o ns a n d I R B/ E C a p pr o val, ser u m, plas ma, a n d uri ne sa m pl es f or e x pl orat or y bi o mar ker t esti n g, a n d meas uri n g h o m oc ystei ne 
le vels, will be c ollecte d pri or t o d osi n g.  
p Ge netic testi n g of p or p h yria -r elate d ge nes is o nl y re q uire d i n patie nts wit h o ut pri or d oc u me nte d ge netic testi n g f or p or p h yria. See Secti o n  7. 6. 2  f or details.  
q W here all o we d per l ocal re g ul ati o ns, I R B/I E C a p pr o val, a n d patie nt c o nse nt (a n d asse nt, w here a p plica ble), a v ol u ntar y bl o o d sa m ple ma y be c ollecte d f or later 
D N A a nal ysis . See Secti o n  7. 6. 2  f or details .   
r Sa m ple t o be c ollecte d pre d ose.  
s Bl o o d sa m ples f or P K a nal ysis will be c ollecte d i n all patie nts at t he ti me p oi nts liste d i n  T a ble  8. A n a d diti o nal 2 4 -h o ur ( ± 2 h o ur) P K assess me nt ( wit h paire d 
E C G meas ure me nt) will be perf or me d o n Da y [ADDRESS_1025643] u d y 
ce nters (i n J a p a n, S o ut h K orea, or T ai wa n), bl o o d sa m ples f or P K a nal ysis will be c ollecte d at t he ti me p oi nts liste d i n T a ble  9 ( w hic h i ncl u des all t h ose ti me 
p oi nts liste d i n T a ble  8).  
t I n patie nts at East Asia n st u d y ce nters, s p ot ( pre d ose) a n d p o ole d ( p ost d ose) uri ne sa m ples will b e c ollecte d f or P K a nal ysis o n Da y 1 a n d M o nt h 6 at t he ti me 
p oi n ts  liste d i n T a ble  1 0 . 
u Q O L q uesti o n naires t o be c o m plete d i ncl u de S F -1 2, E Q -5 D -5 L, a n d da ys of misse d w or k/s c h o ol.  
v T he P GI C assesses a patie nt’s percei ve d o verall healt h stat us c ha n ge si nce t he be gi n ni n g of t he st u d y usi n g a si n gle -ite m scale.  
w T he P P E Q is a set of q uesti o ns t o assess treat me nt e x perie nc e a n d i m pacts t o t he patie nt's life t hat are n ot c ollecte d b y t he  ot her Q O L assess me nts.  
x D ur i n g t he scree ni n g peri o d, patie nts a n d care gi vers will rec or d a mi ni m u m of [ADDRESS_1025644] u d y ( fr o m scree ni n g  t hr o u g h t he E O S visit).  e Diar y trai ni n g will b e c o m plete d at t he st u d y ce nter at Scree ni n g. F urt her 
details o n e Diar y trai ni n g ca n be f o u n d i n t he St u d y Ma n ual.   
y Seri o us a d verse e ve nts ( S A Es) will be c ollecte d starti n g at t he ti me t hat i nf or me d c o nse nt is si g ne d a n d t hr o u g h t he d urati o n  of t he st u d y; A Es will be c ollecte d 
starti n g at t he ti me t he first d ose of st u d y dr u g is a d mi niste re d ( St u d y Da y 1) t hr o u g h t he d urati o n of t he st u d y 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me n t 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 5  n or malize d rati o; L F T =li ver f u ncti o n test(s); M = m o nt h; m R N A = messe n ger ri b o n ucleic aci d; P B G = p or p h o bili n o ge n; P GI C = P atie nt Gl o bal I m pressi o n of 
C ha n ge; P K = p har mac o ki netics; P P E Q = P or p h yria P atie nt E x perie nce Q uesti o n naire; Q =e v er y; Q O L = q uali t y of life; S C =s u bc uta ne o us; T B L =t otal bilir u bi n  
N ote:  
• W hite b o xes re prese nt visits t o t he cli nical st u d y ce nter; gre y b o xes re prese nt st u d y visits t hat ma y be c o n d ucte d b y a h o me healt hcare pr ofessi o nal, 
w here a p plica ble c o u ntr y a n d l ocal re g ulati o ns a n d i nfrastr u ct ure all o w. I n t he e ve nt t hat a patie nt is u na ble t o c o me t o t he st u d y ce nter f or a sc he d ule d 
cli nical st u d y visit or t he pr oce d ure (s) ca n n ot b e c o m plete d d uri n g t he visit, vital si g n ass ess me nts, la b orat or y sa m ple c ol lecti o n, a n d/ or st u d y dr u g 
a d mi nistrati o n ma y be c o n d ucte d b y a h o me healt hcare pr ofessi o nal, w here a p plica ble c o u ntr y a n d l ocal re g ulati o ns a n d i nfrast r uct ure all o w, after 
c o ns ultati o n wit h t he me dical m o nit or  
• St u d y pr oce d ures, i ncl u di n g gi v osira n a d mi nistrati o n, ma y occ ur at t he p atie nt’s h o me at t he discreti o n of t he I n vesti gat or, base d o n safet y a n d 
t olera bilit y.  
a P atie nts w h o disc o nti n ue treat me nt will be as ke d t o c o m plet e t heir ne xt cli nic visit, as well as a safet y f oll o w -u p assess me nt at 3 m o nt hs ( 8 4 [ + 7] da ys) after 
t heir last d ose of gi v osira n.  
b Starti n g at M o nt h 1 3, patie nts o n t he o nce m o nt hl y 1. 2 5 m g/ k g d ose ma y ha ve t heir m o nt hl y d ose i ncrease d t o 2. 5 m g/ k g  base d o n I n vesti gat or j u d ge me nt wit h 
c o nsi derati o n of t he criteria descri be d i n Secti o n  6. 2. 3. 4 .  
c A c o m plete p h ysical e xa mi nati o n will be perf or me d at t he M o nt h 1 2 a n d M o nt h 1 8 visit.  At all ot her visits, a tar gete d p h ysic al e xa mi nati o n will be perf or me d.  
T he p h ysical e xa mi nati o n will be perf or me d pri or t o d osi n g.   
d D osi n g wei g ht (i n kil o gra ms) wil l b e c ollecte d d uri n g t he cli nical st u d y ce nter visits. W ei g ht c ollecte d at eit her t he pre vi o us st u d y ce nter visit or c urre nt  st u d y 
ce nter visit ma y be use d f or d ose calc ulati o ns. Hei g ht (i n ce nti meters) will be meas ure d a n d B MI will be calc ulate d at cli ni c visits e ver y 6 m o nt hs.  B MI will be 
a ut o maticall y calc ulate d wit hi n t he data b ase.  
e Vital si g ns i ncl u de bl o o d press ure, heart rate, b o d y te m perat ure, a n d res pi[INVESTIGATOR_1305] y rate a n d will be c ollecte d pre d ose. Vital s i g ns will be meas ure d w he n patie nts 
are i n a seate d or s u pi [INVESTIGATOR_050] p ositi o n (s h o ul d be c o nsiste nt acr oss st u d y visits wit h eac h patie nt) after t he patie nt has reste d f or 1 0 mi n.   
f Tri plicate 1 2 -lea d E C Gs will be perf or me d at pre d ose a n d 2 -h o urs ( + 1 5  mi n utes) p ost -d ose at t he M o nt h 1 2 visit, usi n g vali d ate d E C G ser vices e q ui p me nt 
fr o m a ce ntral facilit y; tri plicate meas ure me nts s h o ul d be se parate d b y a p pr o xi matel y 1 mi n ute, wit h t he patie nt i n t he s u pi n e p ositi o n after he or s he has reste d 
c o mf orta bl y f or 5 mi n utes. W he n E C G a n d bl o o d sa m ple c ollecti o n ( e g, f or P K assess me nt) occ ur at t he sa me ti me, E C G assess me nts s h o ul d be perf or me d 
bef ore bl o o d sa m ples are dra w n.  
g Cli nical la b orat or y para meters will i ncl u de: ser u m c he mistr y i ncl u di n g L F Ts, li pase, a m ylase, he mat ol o g y, c o a g ulati o n, a n d ur i nal ysis. Bl o o d a n d uri ne 
sa m ples f or cli nical la b orat or y e val uati o ns will be c ollecte d pre d ose.  Ser u m ferriti n assess me nts will b e c ollecte d at t he M o nt h 1 2 a n d M o nt h 1 8 visits. 
D-di mer assess me nts will be perf or me d at t he M o nt h 9 a n d M o nt h 1 2 visits; as a cli nical r esearc h para meter o nl y, d -di mer res ults will n ot b e c o m m u ni cate d t o 
t he st u d y ce nters.  Res ults fr o m A L T, T B L, a n d I N R tests c ollecte d wit hi n t he [ADDRESS_1025645] b e a vaila ble bef or e d osi n g.  
i P atie nts w h o cr osse d o ver t o t he O L E peri o d pri or t o i m ple me ntati o n of a me n d me nt 3 (ie, u n der a me n d me nt versi o n 1 or 2) a n d a re recei vi n g 2. 5  m g/ k g o nce 
m o nt hl y will re mai n o n t hat d ose.  U p o n e ntr y t o t he O L E p eri o d u n der a me n d me nt versi o n 3, patie nts will cr oss o ver t o recei ve a 1. 2 5 m g/ k g o nce m o nt hl y 
d ose of gi v osira n.  
j S p ot uri ne sa m ples f or A L A, P B G, a n d A L A S [ADDRESS_1025646] u d y s h o ul d be c ollecte d pre d ose; h o we ver, if he mi n is use d f or a n attac k, 
sc he d ule d uri nar y A L A, P B G a n d A L A S 1 m R N A will b e c ollecte d 4 da ys ( + 4 da ys) after t he patie nt’s last he mi n d ose. W here a p pli ca ble c o u ntr y a n d l ocal 
re g ulati o ns a n d i nfrastr uct ure all o w, uri ne sa m ples f or A L A, P B G, a n d A L A S [ADDRESS_1025647] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me n t 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 6  k F or patie nts o n t he o nce m o nt hl y 1. 2 5 m g/ k g d ose w h o ha ve de m o nstrate d t olera bilit y t o gi v osira n, b ut ha v e i na d e q uate cli nical res p o nse, A L A meas ure me nts 
fr o m a pre vi o us visit or a l ocal la b orat or y ma y be use d b y I n vesti gat ors c o nsi deri n g d ose escalati o n t o 2. 5  m g/ k g o nce m o nt hl y.  D ose escalati o n f or patie nts o n 
t he 1. 2 5  m g/ k g m o nt hl y d ose ma y be c o nsi dere d starti n g at M o nt h 1 3.  See Secti o n  6. 2. 3. 4  f or f urt her i nf or mati o n o n d ose escalati o n criteria.    
l W here all o we d per l ocal re g ul ati o ns a n d I R B/ E C a p pr o val, ser u m, plas ma, a n d uri ne sa m pl es f or e x pl orat or y bi o mar ker t esti n g, a n d meas uri n g h o m oc ystei ne 
le vels, will be c ollecte d pri or t o d osi n g.  
m Bl o o d sa m ples f or P K a nal ysis will be c ollecte d pre d ose a n d at t he ti me p oi nts liste d i n T a ble  8 or T a ble  9. 
n Sa m ples will be c ollecte d pre d ose.  
o Q O L q uesti o n naires t o be c o m plete d i ncl u de S F -1 2, E Q -5 D -5 L, a n d misse d da ys of w or k/s c h o ol  
p T he P GI C assesses a patie nt’s percei ve d o verall healt h stat us c ha n ge si nce t he be gi n ni n g of t he st u d y usi n g a si n gle -ite m scale.  
q T he P P E Q is  a set of q uesti o ns t o assess treat me nt e x perie nc e a n d i m pacts t o t he patie nt's life t hat are n ot c ollecte d b y t he ot her Q O L a ssess me nts.  
r Electr o nic diar y e ntries (i ncl u di n g pai n, na usea, a n d fati g ue meas ure me nt b y N R S a n d a nal gesics q uesti o n) will be c o m plete d dail y b y patie nts a n d care gi vers 
t hr o u g h t he M o nt h 1 2 visit; p ote ntial p or p h yria attac ks will be re p orte d i n t he e Diar y w he n t he y occ ur b y patie nts a n d care gi vers t hr o u g h o ut t he d urati o n of t he 
st u d y (fr o m scree ni n g t hr o u g h t he E O S visit). P atie nt s/care gi vers will be trai ne d o n t he ne w a p pr oac h f or usi n g t he e diar y after M o nt h [ADDRESS_1025648] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me n t 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 9  e Si n gle 1 2 -lea d E C G will be perf or me d i n t he s u pi [INVESTIGATOR_050] p ositi o n after t he patie nt has reste d c o mf orta bl y f or 5 mi n utes. E C Gs will be c ollec te d pre d ose a n d pri or t o 
a n y bl o o d dra ws.  W he n E C G a n d bl o o d sa m p le c ollecti o n (e g, f or P K assess me nt) occ ur at t he sa me ti me, E C G assess me nts s h o ul d be perf or me d bef ore bl o o d 
sa m ples are dra w n.  U p o n i m ple me ntati o n of A me n d me nt 6, E C Gs are n o l o n ger re q uire d at t he M o nt h 2 4 a n d 3 6 visits.  
f Cli nical la b orat or y para meters will i ncl u de: ser u m c he mistr y i ncl u di n g L F Ts, li pase, a m ylase, he mat ol o g y, c o a g ulati o n, a n d uri nal ysis. Bl o o d a n d uri ne 
sa m ples f or cli nical la b orat or y e val uati o ns will be c ollecte d pre d ose.  Bl o o d a n d uri ne sa m ples f or cli nical la b orat or y asses s me nts ma y be c ollecte d offsite b y a 
h o me healt hcare pr ofessi o nal at all ti me p oi nts, w here a p pli ca ble c o u ntr y a n d l ocal re g ulati o ns a n d i nfrastr uct ure all o w.  Re s ults fr o m A L T a n d T B L tests 
c ollecte d wit hi n [ADDRESS_1025649] b e a vaila ble bef or e d osi n g.  
h P atie nts w h o cr osse d o ver t o t he O L E peri o d pri or t o i m ple me ntati o n of a me n d me nt 3 (ie, u n der a me n d me nt versi o n 1 or 2) a n d a re recei vi n g 2. 5  m g/ k g o nce 
m o nt hl y w ill re mai n o n t hat d ose.  U p o n e ntr y t o t he O L E p eri o d u n der a me n d me nt versi o n 3, patie nts will cr oss o ver t o recei ve a 1. 2 5  m g/ k g o nce m o nt hl y 
d ose of gi v osira n. Starti n g at M o nt h 1 3, a d ose i ncrease t o 2. 5  m g/ k g o nce m o nt hl y ma y b e per mitte d base d o n I n v esti gat or j u d g me nt i n c o nsi derati o n of d osi n g 
criteria descri be d i n Secti o n  6. 2. 3. 4 .  U p o n i m ple me ntati o n of a me n d me nt  5, all patie nts recei vi n g 1. 2 5  m g/ k g gi v osira n o nce m o nt hl y w h o d o n ot ha ve 
o n g oi n g cli nicall y rele va nt tra nsa mi nase ele vati o ns will ha ve t heir d ose i ncrease d t o 2. 5  m g/ k g gi v osira n o nce m o nt hl y.  See Secti o n  6. 2. 3. [ADDRESS_1025650] u d y s h o ul d be c ollecte d pre d ose; h o we ver, if he mi n is use d f or a n attac k, 
sc he d ule d uri nar y A L A, P B G a n d A L A S 1 m R N A will b e c ollecte d 4 da ys ( + 4 da ys) after t he patie nt’s last he mi n d ose. W here a p pli ca ble c o u ntr y a n d l ocal 
re g ulati o ns a n d i nfrastr uct ure all o w, uri ne sa m ples f or A L A, P B G, a n d A L A S [ADDRESS_1025651] u d y ce nter at t he ne xt visit.  
j W here all o we d per l ocal re g ul ati o ns a n d I R B/ E C a p pr o val, ser u m, plas ma, a n d uri ne sa m pl es f or e x pl orat or y bi o mar ker t esti n g, a n d meas uri n g h o m oc ystei ne 
le vels, will be c ollecte d pri or t o d osi n g.  
k Bl o o d sa m ples f or P K a nal ysis will be c ollecte d pri or t o d osi n g at t he ti me p oi nts liste d i n T a ble  [ADDRESS_1025652] u d y ce nter visit.  
m Q O L q uesti o n naires t o b e c o m plete d i ncl u de S F -1 2, E Q -5 D -5 L, a n d misse d da ys of w or k/s c h o ol.  I n sit uati o ns w here a pla n ne d st u d y visit ca n n ot b e 
c o m plete d at t he st u d y ce nter, t he patie nt will c o m plete t he Q o L q uesti o n naires at h o me.  
n T he P P E Q is a set of q uesti o ns t o assess tr eat me nt e x perie nc e a n d i m pacts t o t he patie nt's life n ot c ollecte d b y t he ot her Q O L assess me nts.  I n sit uati o ns w here 
a pla n ne d st u d y visit ca n n ot b e c o m plete d at t he st u d y ce nter, t he patie nt will c o m plete t he P P E Q q uesti o n naire at h o me.  
o P ote ntial p or p h yria attac ks will b e re p orte d i n t he e Diar y w h e n t he y occ ur t hr o u g h o ut t he d urati o n of t he st u d y (fr o m scre e ni n g t hr o u g h t he E O S visit).  
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 0  T A B L E O F C O N T E N T S   
S P O N S O R P R O T O C O L A P P R O V A L  ................................ ................................ ...........................  2 
I N V E S TI G A T O R’ S A G R E E M E N T  ................................ ................................ ..............................  [ADDRESS_1025653] u d y A L N -A S 1 -0 0 1  ................................ ................................ ....................  3 2  
1. 2. 2. 2.  P hase 1/ [ADDRESS_1025654] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 1  4. 4.  Met h o d of Assi g ni n g Patie nts t o Treat me nt Gr o u ps  ................................ ..................  4 4  
4. 5.  Bli n di n g  ................................ ................................ ................................ ......................  4 5  
4. 6.  Patie nt Electr o nic Diar y (e Diar y)  ................................ ................................ ...............  [ADDRESS_1025655] u g a n d/ or St u d y  ................................ .............................  [ADDRESS_1025656] a n d Pr ocess t he Patie nt’s Pers o nal Data  ..............  [ADDRESS_1025657] u g  ................................ ................................ ........................  5 0  
6. 2. 1.  Descri pti o n  ................................ ................................ ................................ .................  5 0  
6. 2. 2.  D ose a n d A d mi nistrati o n  ................................ ................................ ............................  5 1  
6. 2. 2. 1.  D uri n g t h e 6 -M o nt h Treat me nt Peri o d ( Da y 1 t o M o nt h 6)  ................................ .......  5 2  
6. 2. 2. 2.  D uri n g t h e O pe n -La bel E xte nsi o n Peri o d ( After M o nt h 6 t hr o u g h E n d of 
Treat me nt)  ................................ ................................ ................................ ..................  [ADDRESS_1025658] Res ults  .......................  5 3  
6. 2. 3. 2.  M o nit ori n g a n d D osi n g R ules Base d o n Li pas e a n d A m ylas e Res ults  ......................  5 7  
6. 2. 3. 3.  M o nit ori n g a n d D osi n g R ules i n Patie nts wit h P ote ntial Cases of 
A na p h yl actic Reacti o n  ................................ ................................ ...............................  5 8  
6. 2. 3. 4.  D ose Escalati o n G ui da n ce f or Gi v osira n fr o m 1. 2 5 m g/ k g O nce M o nt hl y t o 
2. 5  m g/ k g O nce M o nt hl y i n t he O pe n -La b el Peri o d  ................................ ..................  [ADDRESS_1025659] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 2  6. 3. 3.  A nal gesic Usa ge  ................................ ................................ ................................ .........  6 1  
6. 3. 4.  Vita mi n B 6 S u p ple me ntati o n  ................................ ................................ .....................  6 2  
6. 4.  C o ntrace pti ve Re q uir e me nts  ................................ ................................ ......................  6 2  
6. 5.  Treat me nt C o m plia nce  ................................ ................................ ...............................  6 3  
7.  S T U D Y  A S S E S S M E N T S  ................................ ................................ ..........................  6 3  
7. 1.  Scree ni n g Assess me nts  ................................ ................................ ..............................  6 3  
7. 1. 1.  Retesti n g  ................................ ................................ ................................ .....................  6 4  
7. 1. 2.  Rescree ni n g  ................................ ................................ ................................ ................  6 4  
7. 2.  Efficac y Assess me nts  ................................ ................................ ................................ . 6 4  
7. 2. 1.  P or p h yria Attac k Re p orti n g  ................................ ................................ .......................  6 4  
7. 2. 2.  Pai n a n d Pai n -Relate d Assess me nts  ................................ ................................ ...........  6 5  
7. 2. 3.  Assess me nts of Na usea a n d Fati g ue  ................................ ................................ ..........  6 5  
7. 2. 4.  Q ualit y of Lif e ( Q O L)  ................................ ................................ ................................  [ADDRESS_1025660] u d y Ce nters  ....................  6 7  
7. 5.  Safet y Assess me nts  ................................ ................................ ................................ ....  6 7  
7. 5. 1.  Vital Si g ns  ................................ ................................ ................................ ..................  6 7  
7. 5. 2.  Wei g ht a n d Hei g ht  ................................ ................................ ................................ .....  6 7  
7. 5. 3.  P h ysical E x a mi nati o n  ................................ ................................ ................................ . 6 8  
7. 5. 4.  Electr ocar di o gra m  ................................ ................................ ................................ ......  6 8  
7. 5. 5.  Cli nical La b orat or y Assess me nts  ................................ ................................ ...............  6 8  
7. 5. 5. 1.  I m m u n o ge nicit y  ................................ ................................ ................................ .........  7 1  
7. 5. 5. 2.  Pre g n a nc y T esti n g  ................................ ................................ ................................ ......  7 1  
7. 5. 6.  A d verse E v e nts  ................................ ................................ ................................ ...........  7 1  
7. 5. 6. 1.  Def i niti o ns  ................................ ................................ ................................ ..................  7 1  
7. 5. 6. 2.  Eliciti n g a n d Rec or di n g A d verse E v e nts  ................................ ................................ ...  7 3  
7. 5. 6. 3.  Seri o us A d verse E v e nts Re q uire I m me diate Re p orti n g t o S p o ns or/ Desi g nee  ...........  7 4  
7. 5. 6. 4.  S p o ns or Safet y Re p orti n g t o Re g ulat or y A ut h oriti es  ................................ .................  7 5  
7. 5. 6. 5.  Seri o us A d verse  E v e nt N otificati o n t o t he I nstit uti o nal Re vie w 
B oar d/I n de pe n d e nt Et hics C o m mittee  ................................ ................................ .......  [ADDRESS_1025661] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025662] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 4  1 0.  LI S T O F R E F E R E N C E S  ................................ ................................ ...........................  8 5  
1 1.  P H A R M A C O KI N E TI C/ P H A R M A C O D Y N A MI C A S S E S S M E N T TI M E 
P OI N T S  ................................ ................................ ................................ ......................  8 7  
1 1. 1.  Bi oc he mical Dia g n osis of A H P i n t he A bse nce of I d e ntifie d M utati o n i n a 
P or p h yria -rel ate d Ge n e  ................................ ................................ ..............................  9 3  
1 1. 2.  A na p h yl actic Reacti o ns  ................................ ................................ ..............................  9 4  
 
LI S T O F T A B L E S  
Ta ble  1:  Sc he d ule of Assess me nts – Scree ni n g a n d 6 -M o nt h Tr eat me nt Peri o d 
( Scree ni n g t hr o u g h M o nt h 6)  ................................ ................................ .....................  1 0  
Ta ble  2:  Sc he d ule of Assess me nts – O pe n -La b el E xte nsi o n Peri o d: After M o nt h 6 
t hr o u g h M o nt h 1 8  ................................ ................................ ................................ .......  1 4  
Ta ble  3:  Sc he d ule of Assess me nts f or O pe n -La bel E xte nsi o n Peri o d: M o nt h [ADDRESS_1025663] u d y  ................................ ................................ ................................ . 1 7  
Ta ble  4:  M o nit ori n g a n d D osi n g R ules i n Patie nts wit h Ala ni ne Tra ns a mi nase ( A L T) 
Ele vati o ns  ................................ ................................ ................................ ...................  5 4  
Ta ble  5:  He patic Assess me nts i n Patie nts W h o E x perie nce Ele vate d Tra nsa mi nases  .............  5 6  
Ta ble  6:  M o nit ori n g a n d D osi n g R ules i n Patie nts wit h Li pase or A m ylas e Ele vati o ns  .........  5 7  
Ta ble  7:  Cli nica l La b orat or y Assess me nts  ................................ ................................ ...............  7 0  
Ta ble  8:  P har mac o ki netic, E C G, a n d A D A Ti me P oi nts f or All Patie nts ( E x ce pt 
Patie nts at East Asia n Sites ) ................................ ................................ .......................  8 7  
Ta ble  9:  P har mac o ki netic, E C G, a n d A nti -Dr u g A nti b o d y Assess me nt Ti me P oi nts f or 
Patie nts at East Asia n St u d y Ce nters ( Bl o o d Sa m ples)  ................................ .............  8 9  
Ta ble  1 0:  Uri ne P har ma c o ki netic/ P har mac o d y n a mic Ti me p oi nts f or Patie nts at East 
Asia n St u d y Ce nters  ................................ ................................ ................................ ...  9 1  
Ta ble  1 1:  Bi oc he mical Criteria i n A d diti o n t o A L A a n d P B G f or Dia g n osis of A H P i n 
t he A bse nce of a n I de ntifie d M utati o n i n a P or p h yria -rel ate d Ge n e  .........................  9 3  
Ta ble  1 2:  Sa m ps o n Criteria f or A n a p h yl actic Reacti o ns  ................................ ...........................  9 4  
 
LI S T O F FI G U R E S  
Fi g ure  1:  He me Bi os y nt hetic Pat h wa y a n d E nz y m e Deficie nc y Res ulti n g i n Ac ute 
He patic P or p h yria  ................................ ................................ ................................ .......  2 8  
Fi g ure  2:  St u d y Desi g n  ................................ ................................ ................................ ..............  [ADDRESS_1025664] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025665] u g a nti b o d y  
A D P  A L A D deficie nt p or p h yria  
A H P  Ac ute he patic p or p h yria  
A L A  A mi n ole v uli nic aci d  
A L A D  A L A de h y dratase  
A L A S 1  A mi n ole v uli nic aci d s y nt hase  
A L P  Al kali ne p h os p hatase  
A L T  Ala ni ne a mi n otra nsferase  
A S G P R  Asial o gl yc o pr otei n rece pt or  
A S H E  As y m pt o matic hi g h e xcreter  
A S T  As partate a mi n otra nsferase  
A U C  Area u n der t he c ur ve  
B MI  B o d y mass i n de x  
B U N  Bl o o d urea nitr o ge n  
C H E  C hr o nic hi g h e xcreters  
C H M P  C o m mittee f or Me dici nal Pr o d ucts f or H u ma n Use  
C L/ F  A p pare nt cleara nce  
Cma x  Ma xi m u m plas ma c o nce ntrati o n  
C O VI D -[ADDRESS_1025666] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025667] o x y met h yl bila ne S y nt hase  
H bs A b  He patitis B s urface a nti b o d y  
H bs A g  He patitis B s urface a nti ge n  
H B V  He patitis B vir us  
H C P  Here ditar y C o pr o p or p h yria  
H C V  He patitis C vir us  
HI V  H u ma n i m m u n o deficie nc y vir us  
I B  I n vesti gat or’s br oc h ure  
I C 5 0  Half -ma xi mal i n hi bit or y c o nce ntrati o n  
I C F  I nf or me d c o nse nt f or m  
I C H  I nter nati o nal C o nfere nce o n Har m o nizati o n  
I E C  I n de pe n de nt Et hics C o m mittee  
I N R (e q ui vale nt t o P T/I N R)  I nter nati o nal n or malize d rati o (e q ui vale nt t o pr ot hr o m bi n 
ti me/i nter nati o nal n or malize d rati o)  
I R B  I nstit uti o nal Re vie w B oar d  
I R S  I nteracti ve res p o nse s yste m  
I S R  I nj ecti o n site reacti o n  
I V  I ntra ve n o us  
L F T  Li ver f u ncti o n tests  
M A D  M ulti ple asce n di n g d ose  
M D R D  M o dificati o n of  diet i n re nal disease  
M M R M  mi xe d -effects m o del re peate d meas ures  
m R N A  Messe n ger R N A  
N O A E L  N o o bser ve d a d verse effect le vel  
N O E L  N o o bser ve d -effect le vel  
N R S  N u merical rati n g scale  
N S AI Ds  N o n -ster oi dal a nti -i nfla m mat or y dr u gs  
O L E  O pe n -la bel e xte nsi o n  
O T C  O ver t he c o u nter  
P B G  P or p h o bili n o ge n  
P B G D  P or p h o bili n o ge n Dea mi nase  
P C S  P h ysical C o m p o ne nt S u m mar y  
P D  P har mac o d y na mic  
P GI C  Patie nt Gl o bal I m pressi o n of C ha n ge  
P K  P har mac o ki netic  
P P E Q  P or p h yria Patie nt E x perie nce Q uesti o n naire  
P T  Pr ot hr o m bi n ti me  
Q O L  Q ualit y of life  
R B C  Re d bl o o d cells  
R N A  Ri b o n ucleic aci d  
R N Ai  R N A i nterfere nce  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 7  S A D  Si n gle asce n di n g d ose  
S A E  Seri o us a d verse e ve nt  
S A P  Statistical a nal ysis pla n  
S C  S u bc uta ne o us  
S D  Sta n dar d de viati o n  
S F -1 2  1 2 -ite m S h ort -F or m Healt h S ur ve y  
Si R N A  S mall i nterferi n g R N As  
S U S A R  S us pecte d u ne x pecte d seri o us a d verse reacti o ns  
T B L  T otal bilir u bi n  
Tma x  Ti me t o ma xi m u m plas ma c o nce ntrati o n  
t ½ β  Eli mi nati o n half -life  
U L N  U p per li mit of n or mal  
U S  U nite d States  
V A S  Vis ual a nal o g scale  
V/ F  A p pare nt v ol u me of distri b uti o n  
V P  Varie gate p or p h yria  
W H O  W orl d Healt h Or ga nizati o n  
 
Cli nic al St u d y Pr ot oc ol A L N- A S 1- 0 0 3 gi v osir a n ( A L N- A S 1) 
A me n d me nt 7, 2 9 M arc h 2 0 2 1 
Al n yl a m P h ar m ace utic als C o nfi de nti al 2 8 1. I N T R O D U C TI O N 
1. 1.  Dise ase O ver vie w 
T he ac ute h e patic p or p h yrias ( A H Ps) are a fa mil y of rare, seri o us a n d life-t hreate ni n g meta b olic 
dis or ders pre d o mi na ntl y ca use d b y a ge netic m utati o n i n 1 of t he 8 e nz y m es res p o nsi ble f or he m e 
s y nt hesis ( Fi g ure 1 ).  T h e A H Ps i ncl u de Ac ut e I nter mitte nt P or p h yria ( AI P), Her e ditar y 
C o pr o p or p h yri a ( H C P), Varie gat e P or p h yria ( V P), or A L A d e h y dratas e deficie nt p or p h yria 
( A D P) ( 1) ; AI P is t he m ost c o m m o n A H P t y pe.  All A H P are d ue t o a ut os o mal d o mi na nt l oss- of- 
f u ncti o n m utati o ns i n e nz y m es i n t he he m e bi os y nt hetic pat h wa y, wit h t he e x ce pti o n of A D P, 
w hic h is t he res ult of a ut os o mal recessi ve m utati o ns ( 2, 3).   
Fi g ure 1:  He me Bi os y nt hetic P at h w a y a n d E nz y me Deficie nc y Res ulti n g i n Ac ute 
He p atic P o r p h yri a 
Refere nce:  J a mes, et al 2 0 0 0 ( 4)
Ac ute attac ks are tri g gere d b y str ess fact ors t hat i n d uce t he e x pressi o n of a mi n ole v uli nic aci d 
s y nt hase 1 ( A L A S 1), w hi c h is t he rate li miti n g ste p i n he me s y nt hesis.  I n w o me n, attac ks oft e n 
occ ur ar o u n d t he me nstr u al c ycle d u e t o c ha n ges i n A L A S [ADDRESS_1025668] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 9  p or p h yri n prec urs ors, a mi n ole v uli nic  aci d ( A L A) a n d/ or p or p h o bili n o ge n ( P B G), t he ca usal 
fact ors dri vi n g cli nic al ma nifestati o ns of diseas e .  
Disease s y m pt o m o nset i n A H P patie nts t y pi[INVESTIGATOR_1306] y occ urs after p u bert y, wit h w o me n ( ~ 8 0 %) m ore 
c o m m o nl y affecte d t ha n me n (5).  Patie nts e x perie nci n g ac ut e attac ks pr es e nt wit h hi g hl y m or bi d 
a n d p ote ntiall y life -t hreate ni n g s y m pt o ms t hat relate t o wi des prea d d ysf u ncti o n acr oss t he ce ntral, 
peri p heral, a n d a ut o n o mi c ner v o us s yste m.  T he m ost de bilitati n g a n d fre q u e nt s y m pt o m d uri n g 
ac ute attac ks is diff use, s e vere n e ur o visceral p ai n , m ost ofte n i n t he a b d o me n, bac k, or li m bs.  
Ot her c o m m o n attac k si g ns a n d s y m pt o ms i ncl u de na usea a n d v o miti n g, fati g ue, h y p erte nsi o n, 
tac h ycar dia, m ot or wea k ness, h y p o n atre mia, a n d me ntal stat us c ha n ges (3, 6).  T he attac k 
ma nifestati o ns a n d pai n are ofte n s o se v ere t h at t he y re q uir e h os pi[INVESTIGATOR_27967] o n, s u p p orti ve care a n d 
t he use of hi g h -d ose i ntra ve n o us o pi [INVESTIGATOR_27968] (7).  Li m b n u m b ness, wea k ness or paresis d ue t o a 
se ns or y or m ot or ne ur o pat h y, res pecti vel y, ca n als o occ ur, wit h pr o gressi o n t o paral y sis, 
res pi[INVESTIGATOR_1305] y fail ure a n d deat h (1, 8, 9).   
Dia g n osis of A H P is ma de wit h t he c o m bi nati o n of t y pic al cli nical pres e ntati o n a n d s y m pt o ms as 
descri be d a b o ve, al o n g wit h bi oc he mical testi n g f or ele vate d uri ne A L A a n d/ or P B G, a n d ge n etic 
testi n g t o i de ntif y a m utati o n i n t he res pecti ve ca usati ve ge ne ( Fi g ure  1). I n rare i nsta n ces, A H P 
ca n be dia g n os e d i n t he a bse nce of a n i de ntifie d m utati o n i n a p or p h yri a -rel ate d ge ne, i n w hi c h 
case a d diti o nal bi oc h e mical testi n g of plas ma a n d st o ol p or p h yri ns ca n disti n g uis h AI P fr o m t he 
ot her A H Ps ( H C P, V P, a n d A D P) (1, 5). 
T here h as bee n i ncreasi n g rec o g niti o n t hat A H P patie nts ha ve si g nifica nt c hr o nic disease 
ma nifestati o ns be y o n d attac ks.  Data fr o m St u d y A L N -A S 1 -N T -0 0 1 ( E X P L O R E, a n 
o bser vati o nal nat ural hist or y st u d y), c o n d ucte d i n a se verel y affect e d A H P patie nt p o p ulati o n wit h 
rec urre nt atta c ks, deter mi ne d t hat 6 4 % of patie nts ha ve c hr o ni c s y m pt o ms, wit h al m ost 5 0 % 
e x peri e nci n g s y m pt o ms o n a dail y b asis, m ost c o m m o nl y p ai n, f oll o we d b y na us ea a n d fati g ue 
(1 0 ).    
F urt her m ore, nat ur al hist or y st u dies d o n e b ot h i n t h e U S a n d i n S we de n i n AI P p atie nts 
deter mi ne d t hat 1 8 t o 2 2 % of AI P patie nts e x peri e nce c hr o nic s y m pt o ms, m ost c o m m o nl y p ai n 
(i n t he a b d o me n, bac k or li m bs) a n d fati g u e (3, 1 1 ).   
O ver 7 5 % of ac ut e p or p h yria attac ks r e q uire ur ge nt me dical care a n d/ or h os pi[INVESTIGATOR_1314] o n or 
i ntra ve n o us he mi n (1 0 ).  Patie nts are i nitiall y treat e d wit h s u p p orti ve care a n d i ntra ve n o us (I V) 
gl uc ose ( 1 0 % d e xtr ose), a nal gesics a n d a ntie metics, al o n g wit h t he  re m o val of k n o w n 
preci pi[INVESTIGATOR_32455] n g tri g gers, s uc h as cert ai n me dicati o ns or dieti n g (1 2 ).  Pai n reli ef t y pi [INVESTIGATOR_1306] y re q uir es 
o pi [INVESTIGATOR_27968] u ntil p or p h yri a -s pecific t hera p y ta kes effect.  I n p atie nts wit h m o derate t o se vere attac ks, 
or w h o fail t o res p o n d t o s u p p orti ve meas ures, tr eat me nt wit h I V he mi n is use d.  After [ADDRESS_1025669] se veral wee ks, 
re q uiri n g pr ol o n ge d he mi n use a n d h os pi[INVESTIGATOR_27967] o n (1 3 ).  He mi n a d mi nistrati o n ca n res ult i n 
si g nifica n t ac ute si de effects s uc h as se v ere hea d ac he, na usea, fl u -li ke s y m pt o ms, fati g ue a n d 
t hr o m b o p hle bitis.  
T here are n o a p pr o ve d tr eat me nts f or t he pre ve nti o n of ac ute attac ks of h e patic p or p h yria, a n d 
t here is little e vi de nce p u blis he d o n h o w best t o ma na ge A H P patie nts wit h rec urre nt atta c ks. 
I nitial pre ve nti o n ste ps i ncl u de a v oi da n ce of p ote ntial tri g gers i ncl u di n g har mf ul me dicati o ns, 
s m o ki n g a n d alc o h ol us e, a n d c o ns u m pti o n of a l o w -cal ori e diet (1 3 ).  T h e [ADDRESS_1025670] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025671] o ye d t o pre ve nt attac ks are h or m o nal s u p pressi o n t hera p y, t h e off -l a bel use 
of pr o p h yl actic I V he mi n i nf usi o ns, a n d i n e xtre mel y rare cas es, li ver tra ns pla ntati o n (1 3 , 1 4 ).  
H or m o nal s u p pressi o n t h era p y usi n g a g o n a d otr o pi n -releasi n g h or m o n e ( G n R H) a nal o g ue ma y 
ha ve a b e nefici al effect i n s o me w o me n. H o we v er, t he si de effect of i n d ucti o n of me n o pa use i n a 
relati vel y y o u n g patie nt p o p ulati o n ma kes t he treat me nt diffic ult t o t olerat e (1, 1 5 ).  S o me 
p or p h yri a s pecialists ha ve res orte d t o t he off -l a bel pr o p h yla ctic use of he mi n t o pre ve nt attac ks 
des pi[INVESTIGATOR_040] u nfa v ora ble c h aracteristics f or c hr o nic t h era p y.  Gi ve n t he s h ort half -life of he mi n ( 1 0. 8 
h o urs), its be neficial effect o n t he t o xic prec urs ors A L A a n d P B G is s h ort -li ve d, wit h t heir le vels 
starti n g t o rise wit hi n 4 8 h o urs of t he i nf usi o n (1 6 , 1 7 ).  I n m ost cases, p atie nts recei ve h e mi n 
i nf usi o ns t hr o u g h a n i n d welli n g I V cat het er at a cli nic or i nf usi o n ce nter, o n a sc he d ule d b asis.  
C hr o nic he mi n a d mi nistrati o n ca n res ult i n ve n o us da ma ge, ir o n o verl oa d a n d pr o ble ms relate d t o 
ha vi n g a n i n d welli n g I V cat heter (i nfecti o n or t hr o m b osis).  D ue t o t hese d escri be d li mitati o ns 
a n d lac k of str o n g effic ac y dat a, off -l a bel pr o p h yla ctic he mi n is n ot u nif or ml y c o nsi dere d 
sta n dar d of care a m o n g p or p h yri a s peci alists f or c hr o nic treat me nt or pre v e nti o n of p or p h y ri a 
attac ks.  
I n p atie nts w h o are refract or y t o he mi n or w h o n o l o n ger ha ve a de q u ate ve n o us access, li ver 
tra ns pla ntati o n has occasi o nall y bee n perf or me d.  After li ver tra ns pla ntati o n, t he A L A a n d P B G 
le vels n or maliz e i n 2 4 h o urs a n d ac ut e attac ks cease.  I n a d diti o n, patie nt q ualit y of life h as bee n 
s h o w n t o si g nifica ntl y i m pr o ve (1 8 ).  H o we v er, gi ve n t he i n vasi ve a n d hi g h -ris k nat ure of 
tra ns pla ntati o n a n d li mite d a vaila bilit y of or ga ns, it is rarel y perf or me d (5, 1 9 ).   
A H P is ass ociate d wit h si g nifica nt m or bi dit y a n d m ortalit y, a n d ne gati vel y affects acti vities of 
dail y li vi n g as well as t he q ualit y of life of patie nts. T here is a clear u n met n ee d f or n o v el 
t hera pe utics wit h fa v ora ble  safet y pr ofiles t hat effecti vel y a n d  d ura bl y decrease t he fre q ue n c y of 
de bilitati n g attac ks, di mi nis h t he c hr o nic s y m pt o ms i n bet wee n attac ks, a n d i m pr o ve patie nts’ 
q ualit y of life.  I n a d diti o n, t hera pe utics t hat d o n ot re q uire c hr o nic i n d welli n g cat heters f or 
i ntra ve n o us a d mi nistrati o n w o u l d re d uce c o m plicati o ns ass ociate d wit h a d mi nistrati o n, i ncl u di n g 
i nfecti o n, dee p v ei n t hr o m b osis a n d i n e xtre me cases t he nee d f or li ver tra ns pla ntati o n d ue t o l oss 
of ve n o us access.  
1. 2.  Gi v osir a n  
Gi v osira n is a s y nt h etic c he micall y m o difie d s mall i nterferi n g  R N A (si R N A) tar geti n g A L A S [ADDRESS_1025672] osa mi ne ( Gal N Ac) li ga n d ( A L N -
6 0 5 1 9) t o facilitate deli v er y t o of t he si R N A t o t he li ver ( w hic h is t he pri mar y site of A L A S 1 
s y nt hesis).  Gi v osira n acts via R N A i nt erfere nce ( R N Ai) t o i n hi bit s y nt hesis of li ver A L A S 1 a n d 
is  f or m ulate d f or a d mi nistrati o n via s u bc uta ne o us ( S C) i njecti o n.  
Gi v osira n is c urre ntl y i n de vel o p me nt f or tr eat me nt of ac ute he p atic p or p h yrias ( A H Ps) i n a d ult 
a n d a d olesce nt patie nts.  
1. 2. 1.  S u m m ar y of N o ncli nic al D at a wit h Gi v osir a n  
T he p har mac ol o g y, safet y p har mac ol o g y, dr u g m eta b olis m a n d p har mac o ki netics a n d t o xic ol o g y 
of gi v osira n were e v al uat e d i n a series of i n vitr o a n d i n vi v o n o ncli nical st u dies.  
Gi v osira n is p har mac ol o gic all y acti ve i n r o de nts,  m o n ke ys, a n d h u ma ns d u e t o c o nser vati o n 
wit hi n t he si R N A tar get s e q ue nce.  Tra nsfecti o n assa ys i n h u ma n li ver carci n o ma cell li ne -G [ADDRESS_1025673] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 1  ( He p G 2) cells s h o we d d ose -de pe n d e nt i n hi biti o n of e n d o ge n o us A L A S 1 messe n ger R N A 
( m R N A) le vels wit h a half -ma xi mal i n hi bit or y c o nce ntrati o n (I C 5 0 ) of a p pr o xi matel y [ADDRESS_1025674] u dies wit h mice, rats a n d m o n ke ys, gi v osira n h as d e m o nstrate d p ote nt 
a n d d ose -de p e n de nt p har mac ol o gi c acti vit y w he n a d mi nistere d s u bc uta ne o usl y, res ulti n g i n 
c o nsiste nt re d ucti o n of A L A S 1 m R N A i n t he li ver.  After si n gle d ose a d mi nistrati o n, A L A S 1 
m R N A s u p pressi o n i n li ver is d ura ble ( 1 -4 w ee ks) de pe n di n g o n t he d ose a d mi nistere d a n d 
c orrel ates wit h t he e xte nt of A L A S [ADDRESS_1025675] u dies i n r o de nt AI P m o d els ha ve c o nfir me d t hat A L A S 1 m R N A s u p pressi o n wit h 
gi v osira n tr eat me nt c orrelates wit h decreases i n A L A a n d P B G h e me i nter me diates.  
A G o o d La b orat or y Practice ( G L P) -c o m plia nt safet y p har m ac ol o g y st u d y c o n d ucte d i n m o n ke ys 
s h o we d n o f u ncti o nal c ar di o vasc ular or res pi[INVESTIGATOR_1305] y effects, wit h a n o o bser ve d -effect le v el 
( N O E L) of 1 5 0 m g/ k g. N e ur ol o gi cal assess me nts were c o n d ucte d as part of a [ADDRESS_1025676] u d y i n m o n ke ys ( o nce wee kl y d osi n g); n o gi v osira n -relat e d 
ne ur o be ha vi oral o bser v ati o ns occ urre d i n eit her st u d y. T he N O E L f or ne ur ol o gical effects was 
1 5 0 m g/ k g a n d 1 0 0 m g/ k g i n t he [ADDRESS_1025677] u dies ( bact erial re vers e m utati o n, 
h u ma n peri p heral bl o o d l y m p h oc yte c hr o m os o mal a berrati o ns, a n d rat b o n e marr o w 
micr o n ucle us) ass a ys were all ne gati ve at I nter n ati o nal C o nfere nc e o n Har m o nizati o n (I C H) S 2 
( R 1) li mit d oses.  
T w o t o [ADDRESS_1025678] orat or y ( n o n -G L P) d ose -ra n ge fi n di n g ( D R F) t o xic ol o g y st u dies were 
c o n d ucte d wit h gi v osira n i n mice, rats, a n d m o n ke ys.  I n all 3 s pecies, n o d ose -li miti n g t o xicit y 
( D L T) w as o bser v e d u p t o t h e hi g hest d ose e val uate d ( 3 0 0 m g/ k g w ee kl y S C d ose), wit h t he rat 
a p peari n g t o be t h e m ost se nsiti ve s pecies.  T he D R F st u dies were f oll o we d b y [ADDRESS_1025679] u dies i n rats a n d m o n ke ys w here gi v osira n was a d mi nistere d o nce ( 1 0 0 m g/ k g) a n d 
o nce we e kl y at d ose le v els of 0, 3, 1 0, a n d 3 0 m g/ k g i n t he rat a n d o nce wee kl y at d ose le vels of 
0, 1 5, 5 0, or 1 5 0 m g/ k g i n t he m o n ke y.  T h e n o o bser ve d a d v erse effect le vels ( N O A E Ls) were 3 0 
m g/ k g i n t he rat a n d 1 5 0 m g/ k g i n t he m o n ke y ( hi g hest d ose t este d i n e ac h s pecies).   
I n t he c hr o nic rat G L P t o xic ol o g y st u d y, gi v osira n was a d mi nistere d o nce wee kl y at d ose le v els 
of 0, 3, 1 0, a n d 3 0 m g/ k g. T he c hr o nic rat st u d y N O A E L was 1 0 m g/ k g, base d u p o n fi n di n gs at 
3 0 m g/ k g, i ncl u di n g h e pat ocell ular si n gl e cell necr os is a n d vac u olati o n i n t he li ver wit h 
c orrel ati n g cli nical pat h ol o g y c h a n ges of i ncreas e d as partate a mi n otra nsferase a n d al k ali ne 
p h os p hatase. A d diti o nall y, a n gi ectasis i n islets of La n ger ha ns (t he e n d o cri n e a n d n ot t he e x ocri ne 
re gi o ns of t he pa n creas) was  o bser ve d i n a d ose -d e pe n de nt ma n n er a n d t h o u g ht t o be p ossi bl y 
sec o n dar y t o t he li ver fi n di n gs at 3 0 m g/ k g. I n t he c hr o nic m o n ke y G L P t o xic ol o g y st u d y, 
gi v osira n w as a d mi nistere d o nce w ee kl y at d ose l e vels of 0, 1 0, 3 0, a n d 1 0 0 m g/ k g.  At i nitiati o n 
of t h e treat me nt, t he m o n ke ys were 1 3 t o 1 7 m o nt hs ol d. M o n ke ys at 2 4 -3 6 m o nt hs of a ge are 
ge n erall y c o nsi d ere d t o c orres p o n d wit h t he de v el o p me nt a ge of h u ma n a d olesce nts > [ADDRESS_1025680] u d y N O A E L was 3 0 m g/ k g base d u p o n fi n di n gs at 1 0 0 m g/ k g, 
i ncl u di n g he p at ocell ular si n gle cell necr osis t hat c orrelate d wit h i ncreas e d ala ni ne 
a mi n otra nsferase, ga m m a gl uta m yl tra nsferase, as partate a mi n otra nsferase, a n d c h olester ol. 
A n gie ctasis i n t he pa ncreas was n ot o bser ve d i n t he m o n ke y st u d y.  
I n t he d efi niti ve rat fertilit y a n d e m br y ofet al de vel o p me nt st u d y, a d mi nistrati o n of gi v osira n di d 
n ot res ult i n a n y effects o n estr o us c ycli n g, mati n g, or fertilit y.  T h e mater nal N O A E L w as 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 2  deter mi ne d t o be 3 ( pri or c o ha bitati o n)/ 0. 5 ( Gestati o n Da y 6 – 1 7 [ G D 6 -17]) m g/ k g bas e d u p o n 
mater nal cli nical p at h ol o g y c h a n ges at ≥ 1 0 ( pri or c o ha bitati o n) / 1. 5 ( G D 6 – 1 7) m g/ k g.  T he 
de vel o p me ntal N O A E L was deter mi ne d t o b e 3 0 ( pri or c o ha bitati o n)/ 5 ( G D 6 -1 7) m g/ k g b ase d 
u p o n n o gi v osira n -relat e d effects o n e m br y o -fetal s ur v i val, fetal b o d y wei g hts or fetal 
malf or mati o ns.  
I n t he d efi niti ve ra b bit e m br y ofetal de v el o p me nt st u d y, t he mater nal N O A E L c o ul d n ot be 
deter mi ne d bas e d u p o n mater nal effects, w hic h i ncl u de d re d u ce d mater nal b o d y wei g ht gai ns a n d 
f o o d c o ns u m pti o n at all d oses, gr oss pat h ol o g y si g ns i n t he li ver at ≥ 1. 5 m g/ k g/ da y, cli nic al 
pat h ol o g y c h a n ges at ≥ 0. 5  m g/ k g/ da y, o ne a b orti o n at 5 m g/ k g/ da y a n d 2 a b orti o ns at 2 0 m g/ k g, 
a n d i ncrease d p ost -i m pla ntati o n l oss beca use of i n creas e d earl y res or pti o ns at ≥ 0. 5 m g/ k g/ da y.  
T he de vel o p me ntal N O A E L w as deter mi ne d t o be 0. 5 m g/ k g/ da y base d u p o n t he i ncreas e d p ost -
i m pla ntati o n l oss at ≥ 1. 5 m g/ k g/ da y.  
F urt her i nf or mati o n o n n o ncli nical safet y, p h ar mac ol o g y, dr u g meta b olis m, P K, a n d t o xic ol o g y of 
gi v osira n ca n be f o u n d i n t he c urre nt versi o n of t h e I n vesti gat or’s Br oc h ure.  
1. 2. 2.  S u m m ar y of Cli nic al D at a wit h Gi v osir a n  
I n t he gi v osira n cli nical pr o gra m as of 0 5 M a y 2 0 1 7, a t otal of 4 0 u ni q ue patie nts ha ve recei ve d 
gi v osira n; d oses a d mi nistere d ra n ge d fr o m 0. 3 5  m g/ k g t o 5. 0  m g/ k g.  D ata are a v aila ble fr o m [ADDRESS_1025681] u d y are ra n d o mize d si n gle -bli n de d 
si n gle as ce n di n g d ose ( S A D) a n d m ulti ple asce n di n g d ose ( M A D) e v al uati o ns i n AI P patie nts 
w h o are as y m pt o matic hi g h e x cret ers ( A S H E; als o k n o w n as c hr o nic hi g h e x creters [ C H E]); t hese 
are patie nts w h o d o n ot e x perie nce ac ut e p or p h yri a attac ks b ut ha v e bi oc he micall y acti ve disease 
(ie, e x crete a p pr o xi matel y 2 -3-f ol d hi g her le v els of uri nar y A L A a n d P B G, relati ve t o healt h y 
v ol u nteers).  Part C is a ra n d o mize d d o u ble -bli n d M A D desi g n; all Part C patie nts are re q uire d t o 
ha ve AI P wit h rec urre nt attac k s a n d ha v e e x perie nce d at least [ADDRESS_1025682] u d y A L N -A S 1 -0 0 1 ra n ge d 
fr o m 0. 0 3 5  m g/ k g t o 5. 0  m g/ k g of gi v osira n.  
T he pri mar y o bje c ti ve of A L N -A S 1 -0 0 1 is t o e val uate t he safet y a n d t olera bilit y of gi v osira n 
w he n a d mi nistere d s u bc uta ne o usl y as a si n gle d os e or m ulti ple d oses t o AI P patie nts w h o are 
C H E or w h o e x perie nce rec urre nt p or p h yria attac ks.  A d diti o nal o bjecti ves i ncl u de assess me nt of 
P K, P D ( A L A a n d P B G l o weri n g), a n d cli nical a cti vit y (a n n ualize d p or p h yria attac k rate, 
a n n ualize d he mi n usa ge, attac k -free i nter val, le vels of circ ulati n g A L A S 1 m R N A, a n d patie nt 
q ualit y of life) of gi v osira n.  All i nteri m preli mi nar y d ata pr o vi de d b el o w are as of 0 5 M a y 2 0 1 7.  
I n all parts ( A, B, a n d C) of t he P hase 1 st u d y ( A L N -A S 1 -0 0 1; n = 4 0 patie nts), gi v osira n h as bee n 
ge n erall y w ell t olerate d i n patie nts at d oses of u p t o 5. 0  m g/ k g.  T he m ost c o m m o n A Es 
( occ urri n g i n at least 2 patie nts) re p ort e d w ere n as o p har y n gitis ( Parts A, B, a n d C), a b d o mi nal 
pai n ( Parts A a n d C), diarr hea, h y p o est hesia ( Part A), pr urit us, ras h ( Part B), na usea, a b d o mi nal 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 3  diste nti o n, v o miti n g, hea dac he, p yre xia, bac k pai n, diz zi ness, mi grai ne, c o u g h, a n d or o p har y n geal 
pai n ( Part C). T here were n o d ose -de pe n d e nt A Es or cli nicall y si g nifica nt c ha n ges i n vital si g ns, 
E C G, la b orat or y val u es, or p h ysic al e x a mi nati o n fi n di n gs a n d n o dr u g -relat e d seri o us a d v erse 
e ve nts ( S A Es) or disc o nti n uati o ns d ue t o A Es were re p ort e d.  T hree pat ie nts i n Part C ha ve 
e x perie nce d a t otal of [ADDRESS_1025683] u g. O n e fat al S A E of pa ncreatitis occ urre d i n a patie nt wit h rec urre nt p or p h yria ( Part C) 
recei vi n g a d os e of 5  m g/ k g m o nt hl y t h a t was c o nsi dere d b y t he I n v esti gat or t o be u nrelat e d t o t he 
st u d y dr u g d ue t o t he prese nce of gall bla d der sl u d ge.  
Parts A a n d B of St u d y A L N -A S 1 -0 0 1 ( n = 2 3 p atie nts) de m o nstrate d d ose d e pe n de nt a n d d ura ble 
re d ucti o ns i n A L A S 1 m R N A a n d uri nar y A L A a n d P B G wi t h si n gle a n d m ulti ple gi v osira n d oses.  
A si n gle 2. 5  m g/ k g d ose of gi v osira n res ulte d i n a 6 4 % re d ucti o n i n A L A S 1 m R N A, a n 8 6 % 
re d ucti o n i n A L A le v els, a n d a 9 5 % re d ucti o n i n P B G le vels i n C H E patie nts. I n C H E p atie nts 
w h o recei ve d 2 gi v osira n d oses of 1. 0 m g/ k g a d mi nistere d 2 8 da ys a p art, re d ucti o n i n A L A S 1 
m R N A, A L A, a n d P B G of 5 4 %, 8 4 %, a n d 8 9 %, res pecti vel y, was o bs er ve d.  
I n Part C of St u d y A L N -A S 1 -0 0 1 ( n = 1 7 patie nts), a vaila ble data d e m o nstrate d mea n ma xi mal 
re d ucti o ns i n A L A S 1 m R N A relati ve t o basel i ne i n gi v osira n -tr eate d p atie nts of 3 9 % i n patie nts 
treate d wit h 2. 5 m g/ k g e ver y 3 m o nt hs, 6 6 % i n patie nts treate d wit h 2. 5 m g/ k g m o nt hl y, a n d 7 0 % 
i n patie nts treate d wit h 5 m g/ k g m o nt hl y. T hes e re d ucti o ns i n A L A S 1 were acc o m pa ni e d b y 
ra pi d, d ose -de pe n de n t a n d d ura ble l o weri n g of uri ne A L A a n d P B G t o near n or mal le vels (ie, 
si milar t o t h ose see n i n healt h y v ol u nteers) after d osi n g wit h gi v osira n at eit her 2. 5 m g/ k g or 
5 m g/ k g m o nt hl y d oses f or 3 m o nt hs ( 4 d oses). M ore o ver, t h e near -n or mali zati o n of A L A a n d  
P B G le vels was acc o m pa nie d b y i m pr o ve m e nt i n attac k s y m pt o ms.  
Patie nts de m o nstrate d a 6 3 % mea n decrease i n t h eir a n n ualize d p or p h yria attac k rat e (all attac ks) 
a n d a 7 3 % me a n decrease i n t heir a n n ualize d he mi n d oses i n t he gi v osira n treat me nt peri o d 
c o m pa re d t o t heir [ADDRESS_1025684] b o d uri n g t he treat me nt peri o d, t h ose recei vi n g gi v osira n e x perie n ce d a 7 3 % re d u cti o n i n 
t heir a n n ualize d rate of attac ks re q uiri n g h os pi[INVESTIGATOR_27967] o n, ur ge nt he alt hcare visit, or I V h e mi n 
a d mi nistrati o n at h o me.   
1. 2. 2. 2.  P h ase 1/ [ADDRESS_1025685] u d y A L N -A S 1 -0 0 2 is a P hase 1/ [ADDRESS_1025686] u d y A L N -A S 1 -0 0 1 ( Part C).   
As of [ADDRESS_1025687] u d y A L N -A S 1 -0 0 1 are recei vi n g 
o n g oi n g o pe n -la bel treat me nt wit h gi v osira n i n t h e P hase 1/ [ADDRESS_1025688] u d y ( A L N -A S 1 -0 0 2)  
a n d ha ve b ee n d ose d wit h gi v osira n at 2. 5 or 5. 0  m g/ k g m o nt hl y or e ver y 3 m o nt hs ; 4 patie nts are 
recei vi n g a 5  m g/ k g d ose of gi v osira n e ver y 3 m o nt hs, 2 patie nts are recei vi n g m o nt hl y d oses of 
5 m g/ k g, a n d 4 patie nts are recei vi n g m o nt hl y d os es of 2. 5  m g/ k g. Preli mi nar y res ults fr o m t he 
e xte nsi o n st u d y ( A L N -A S 1 -0 0 2) de m o nstrate c o nti n ue d safet y a n d t olera bilit y wit h l o n ger -ter m 
gi v osira n d osi n g; as of t h e [ADDRESS_1025689] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 4  After t he d ata c ut off of 0 5 Ma y 2 0 1 7, o n e patie nt i n t he 5 m g/ k g e ver y [ADDRESS_1025690] u g 
a d mi nistrati o n, c hr o nic v e n o us da ma ge fr o m he mi n pr o p h yl a xis, a n d t he prese nce of a n 
i n d welli n g ce ntral ve n o us cat heter.  I n a d diti o n, o ne patie n t i n t he 2. 5 m g/ k g m o nt hl y d os e gr o u p 
wit h a hist or y of ast h ma a n d m ulti ple aller gi es e x perie nce d a n S A E of a na p h yla ctic reacti o n t hat 
was deter mi ne d b y t h e I n vesti gat or t o b e defi nitel y relate d t o st u d y dr u g gi ve n t he te m p oral 
relati o ns hi p of gi v osira n tr eat me nt t o t he o nset of t he reacti o n ( wit hi n mi n utes).  T he patie nt w as 
treate d a n d rec o vere d a n d was disc o nti n ue d fr o m t he st u d y.  
F urt her i nf or mati o n o n t he safet y, effic ac y, P K a n d P D of gi v osira n are a vaila ble i n t he 
I n v esti gat or’s Br oc h ure.  
1. 2. 2. 3.  Dr u g -dr u g I nter acti o n St u d y A L N -A S [ADDRESS_1025691] u g i nteracti o n ( D DI) st u d y ( A L N -A S 1 -0 0 4) was c o n d ucte d i n AI P patie nts 
w h o are C H E t o e val uate t he effect of a si n gle d os e of 2. 5  m g/ k g gi v osira n a d mi nistere d S C o n 
t he p har mac o ki n etics of pr o be s u bstrates f or 5  maj or c yt o c hr o me P 4 5 0 ( C Y P) e nz y mes t hat 
acc o u nt f or t he meta b olis m of a p pr o xi matel y 8 0 % of prescri be d dr u gs (2 0 , 2 1 ).  Res ults fr o m t his 
st u d y de m o nstrate d t h at gi v osira n tr eat me nt r es ulte d i n wea k t o m o derate re d ucti o n i n t he 
meta b olic acti vit y of s o me of t he [ADDRESS_1025692] u die d, t here b y lea di n g t o hi g her 
c o nce ntr ati o ns of s o me s u bstrates a n d t heir met a b olites.  Trea t me nt wit h gi v osira n res ulte d i n a n 
a p pr o xi matel y 3 -f ol d i ncrease i n e x p os ure (as me as ure d b y A U C) t o caffei ne (a se nsiti ve 
s u bstrate f or C Y P 1 A 2) a n d a n a p pr o xi matel y 2 -f ol d i ncrease i n e x p os ure t o de xtr o met h or p ha n (a 
se nsiti ve s u bstrate f or C Y P 2 D 6).  E x p o s ure of mi daz ola m (a se nsiti ve s u bstrate f or C Y P 3 A 4) a n d 
o me praz ole (a se nsiti ve s u bstrate f or C Y P 2 C 1 9) i ncreas e d less t ha n [ADDRESS_1025693] of gi v osira n tr eat m e nt o n l osarta n (a s e nsiti ve s u bstrate f or 
C Y P 2 C 9).  
1. 3.  St u d y Desi g n R ati o n ale  
Data fr o m t he P has e 1 St u d y A L N -A S 1 -0 0 1 i n C H E a n d AI P patie nts has de m o nstrate d t hat 
a d mi nistrati o n of gi v osira n res ulte d i n re d u cti o n i n ser u m A L A S 1 le vels, l ea di n g t o d ose -
de pe n de nt a n d d ura ble re d ucti o ns i n uri nar y A L A a n d P B G.  F urt her m ore, i n patie nts wit h 
rec urre nt atta c ks ( Part C), t he re d ucti o n i n A L A a n d P B G was ass o ciate d wit h si g nifica nt 
re d ucti o ns i n p or p h yria disease acti vit y as i n dicat e d i n Secti o n  1. 2. 2. 1 .  P hase 1 ( A L N -A S 1 -0 0 1) 
a n d P hase 2 ( A L N -A S 1 -0 0 2) data ha v e als o de m o nstrate d e vi de n ce of cli nicall y rele v a nt 
re d ucti o n i n t he n u m ber a n d se verit y of p or p h yria attac ks a n d me a ni n gf ul i m pr o ve me nt i n ot her 
cli nical o utc o mes i n patie nts wit h p or p h yri a. F urt her details of St u dies A L N -A S 1 -0 0 1 a n d A L N -
A S 1 -0 0 2 are s u m mariz e d i n t he gi v osira n I n v esti gat or’s Br oc h ure.  
T he E N VI SI O N  St u d y ( A L N -A S 1 -0 0 3) is a m ultice nter, m ulti nati o nal P hase 3 st u d y d esi g ne d t o 
e val uate t he eff ic ac y a n d safet y of S C -a d mi nistere d gi v osira n i n patie nts wit h A H Ps ( n = 7 4); t he 
st u d y is c o m prise d of a 1: [ADDRESS_1025694] b o -c o ntr olle d d o u ble -bli n d treat me nt peri o d, all patie nts will recei ve S C 
d oses of 2. 5  m g/ k g gi v osira n or place b o o nce m o nt hl y.   
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 5  Patie nts cr ossi n g o ver t o t he O L E peri o d will recei ve a d ose bas e d o n  t he pr ot oc ol versi o n u p o n 
w hic h t he y e ntere d t he O L E.  Patie nts w h o cr osse d o ver t o t he O L E peri o d pri or t o t he 
i m ple me ntati o n of a me n d me nt 3 (ie, u n der a me n d me nt versi o n 1 or 2) a n d are recei vi n g a 2. 5 
m g/ k g o nce m o nt hl y gi v osira n d ose will re mai n o n t ha t d ose.  U p o n e ntr y t o t he O L E peri o d 
u n der a me n d me nt 3, p atie nts will cr oss o ver t o recei ve t he 1. 2 5 m g/ k g o nce m o nt hl y d ose of 
gi v osira n, e na bli n g data o n t his a d diti o nal d ose of gi v osira n t o be ge nerate d.  
After i m ple me ntati o n of a me n d me nt  3 a n d u ntil i m ple me ntati o n of a me n d me nt  5, patie nts 
assi g ne d t o t he o n ce m o nt hl y 1. 2 5 -m g/ k g treat me nt gr o u p w h o e x perie nce i na de q uate disease 
c o ntr ol ma y b e all o we d t o ha ve t heir m o nt hl y d os e i ncrease d t o 2. 5  m g/ k g starti n g at t he 
M o nt h  [ADDRESS_1025695] u d y Visit ( w he n 6  m o nt hs of  o pe n -la b el gi v osira n d osi n g ha v e bee n c o m plete d at 
1. 2 5  m g/ k g) bas e d o n disc ussi o n a n d a gree me nt b y t he I n v esti gat or a n d me dical m o nit or, 
de m o nstrati o n of t olera bilit y t o gi v osira n, a n d f ulfill me nt of A L A a n d cli nical acti vit y criteri a.  
U p o n i m ple me ntati o n of a me n d me nt  5, all patie nts recei vi n g 1. 2 5  m g/ k g gi v osira n o nce m o nt hl y 
w h o d o n ot ha ve o n g oi n g cli nicall y rele va nt tra nsa mi nase ele vati o ns will ha ve t heir d ose 
i ncreas e d t o 2. 5  m g/ k g gi v osira n o nce m o nt hl y base d o n t olera bilit y al o ne, wit h o ut a n y crite ria 
f or A L A re d ucti o n or cli nical acti vit y t o e ns ure t h at patie nts are recei vi n g t he rec o m me n d e d d ose 
w hic h was a p pr o ve d b y t he U nite d States F o o d a n d Dr u g A d mi nistrati o n ( F D A) i n N o v e m ber 
2 0 1 9 a n d recei ve d a C o m mittee f or Me dici nal Pr o d ucts f or H u ma n Us e ( C H M P) p ositi ve o pi [INVESTIGATOR_9384] o n 
i n J a n uar y 2 0 2 0.  See Secti o n  6. 2. 3. 4  f or f urt her i nf or mati o n o n d ose escal ati o n.  
T he pri mar y c o m p osite e n d p oi nt is t he a n n ualize d rate of p or p h yria attac ks re q uiri n g 
h os pi[INVESTIGATOR_27967] o n, ur ge nt he alt hcare visits, or I V h e mi n a d mi nistrati o n at h o me o ver t he 6 -m o nt h 
treat me nt peri o d.  A c ute p or p h yri a attac ks are cli nicall y me a ni n gf ul a n d p ote ntiall y 
life -t hreat e ni n g e ve nts t h at are t he m aj or c o ntri b ut ors t o disease b ur de n i n patie nts wit h A H Ps. 
T he pr o p ose d c o m p osite pri mar y e n d p oi nt of attac ks re q uiri n g h os pi[INVESTIGATOR_27967] o ns, ur ge nt healt hcare 
visits (cli nic, e mer ge nc y de part me nt or i nf usi o n ce nter), or i ntra ve n o us he mi n a d mi nistrati o n at 
h o me are cli nical e ve nts re q uiri n g maj or s pecific i nter ve nti o n a n d ca n be o bjecti vel y me as ur e d; 
base d o n res ults fr o m St u d y A L N -A S 1 -N T -0 0 1 [ E X P L O R E], a n o bser vati o nal nat ural hist or y 
st u d y (1 0 ), t h ese c h aracteristics c o m prise a p pr o xi matel y 7 6 % of all attac ks i n t he i nte n de d patie nt 
p o p ulati o n.  T he E X P L O R E st u d y p o p ulati o n c o nsiste d of a p pr o xi matel y 9 3 % patie nts wit h AI P, 
4 % wit h V P, a n d 3 % wi t h H C P; t his distri b uti o n is a p pr o xi matel y si milar t o t he p o p ulati o n 
e x pecte d f or e nr oll me nt i n t he P hase 3 st u d y ( A L N -A S 1 -0 0 3).    
Sec o n dar y e n d p oi nts i n t he P hase 3 st u d y ( A L N -A S 1 -0 0 3) i ncl u de t he uri nar y p or p h yri n 
prec urs or le vels of A L A a n d P B G at [ADDRESS_1025696] or of ne ur ot o xicit y a n d cli nical 
ma nifestati o ns of disease, s uc h as p or p h yria attac ks a n d c hr o nic s y m pt o ms bet wee n attac ks; 
e vi de nce fr o m P hase 1 ( A L N -A S 1 -0 0 1) s u g gests a gra de d relati o ns hi p bet wee n re d ucti o n i n 
A L A/ P B G a n d attac k re d ucti o n. T he i m pact of gi v osira n treat me nt o n he mi n use, na usea, fati g ue 
a n d q ualit y of lif e will als o be assesse d.  
T he e n d p oi nts will be e v al uate d a gai nst a place b o c o m parat or f or t he first [ADDRESS_1025697] u d y 
(t he d o u ble -bli n d treat me nt peri o d); after t his, all patie nts will recei ve o p e n -la bel gi v osira n f or u p 
t o a n a d diti o nal [ADDRESS_1025698] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 6  h or m o nal s u p pressi o n t hera p y, t he off -la b el use of I V he mi n as sc h e d ule d or pr o p h yl actic 
i nf usi o ns, a n d i n e xtre mel y rare cases, li ver tra ns pla ntati o n (1 3 , 1 4 , 2 2 ).  T he e vi de nce s u p p orti n g 
t he safet y a n d effi cac y of eac h of t h ese o pti o ns is li mite d t o case re p orts or s mall -u nc o ntr olle d 
st u dies. T h us, t here are n o c o nse ns us g ui deli nes f or t he use of a n y of t hese treat me nts as a 
pr o p h yla ctic re gi me n t o pre ve nt p or p h yri a attac ks. M ore o ver, eac h of t hese o pti o ns has 
si g nifica nt li mitati o ns .  
He mi n is t he o nl y lice ns e d me dici nal pr o d uct f or t he treat me nt of p or p h yria a n d it is o nl y 
a p pr o ve d f or use i n treati n g ac ute attac ks after t he y occ ur. Patie nts are per mitte d t o c o nti n ue t o 
recei v e sta n dar d of care treat me nt, i ncl u di n g he mi n, f or a n y ac ute attac ks t he y e x perie nce w hile 
partici pati n g i n t he P has e [ADDRESS_1025699] u d y p o p ulati o n will be c o m prise d of a d ult s a n d a d olesce nts ( ≥ 1 2 years of a ge) wit h a 
d oc u me nte d dia g n osis of A H P.  
O verall, bas e d o n t he t otalit y of safet y, t olera bilit y a n d effi cac y d ata a v aila ble fr o m t he P hase [ADDRESS_1025700] u d y ( A L N -A S 1 -0 0 1) a n d t he P hase 1/ [ADDRESS_1025701] u d y ( A L N -A S 1 -0 0 2), 
gi v osira n is a n a p pr o priat e ca n di dat e t o be f urt h er st u die d i n patie nts wit hi n a P hase 3 setti n g, 
gi ve n t he hi g h u n met me dical nee d i n t his p o p ulati o n.  
1. 4.  D ose R ati o n ale  
D ose selecti o n w as g ui de d b y t he pri nci ple of i de ntif yi n g a n o pti mal d ose t hat is b ot h we ll -
t olerate d a n d effic aci o us.  T he pr o p ose d P hase 3 gi v osira n d ose of 2. 5 m g/ k g a d mi nistere d 
m o nt hl y was selecte d bas e d o n o bser ve d d ata fr o m o n g oi n g cli nical st u dies, a n d p o p ulati o n 
p har mac o ki netic -p har m ac o d y n a mic m o deli n g. T h e ke y P D a n d cli nic al para met ers use d t o 
s u p p ort t he d ose selecti o n i ncl u de decreas es i n uri nar y A L A le v els, t he m ost pr o xi mate a n d direct 
P D effect of gi v osira n, as well as re d u cti o ns i n p or p h yria attac ks, h e mi n usa ge a n d p or p h yri a 
attac k -free i nter vals.  
I n t he P h ase [ADDRESS_1025702] u d y ( St u d y A L N -A S 1 -0 0 1) a n d t h e P hase 1/ [ADDRESS_1025703] u d y 
( St u d y A L N -A S 1 -0 0 2) a clear d os e res p o ns e wit h res pect t o re d ucti o n of el e vate d uri nar y A L A 
was o bser v e d, wit h m o nt hl y d osi n g yi el di n g hi g her a n d s ustai ne d re d ucti o ns c o m pare d t o d osi n g 
e ver y 3 m o n t hs. Fr o m t he d osi n g re gi me ns e val u ate d, gi v osira n d os e of 2. 5  m g/ k g a d mi nistere d 
m o nt hl y l o w ere d uri nar y A L A i n AI P p atie nts b y a b o ut 9 5 % t o le vels t hat were cl ose t o t h ose 
o bser ve d i n n or mal he alt h y v ol u nteers; t hese re d u cti o ns i n uri nar y A L A le vels were  ass ociate d 
wit h mar ke d re d u cti o ns i n p or p h yri a attac ks, he mi n usa ge a n d attac k -free i nter vals.  
I n li g ht of L F T ele v ati o ns o bser ve d i n t he st u d y, a l o wer gi v osira n d ose of 1. 2 5 m g/ k g o nce 
m o nt hl y h as bee n i ntr o d uce d as a d o w n -titrati o n d ose, as detaile d i n Secti o n  6. 2. 3. 1 .   
U n der a me n d m e nt  3, patie nts e nteri n g t he O L E p eri o d will be assi g ne d t o recei ve 1. 2 5  m g/ k g 
gi v osira n o n ce m o nt hl y i n or der t o ge n erate a d diti o nal data at t his d ose le v el. W hile t he 2. 5 m g/ k g 
o nce m o nt hl y d ose h as b ee n de m o nstrat e d t o pr o vi de near -n or malizati o n of A L A le vels i n t he 
maj orit y of AI P p atie nts wit h rec urre nt attac ks i n t he c o m plete d P hase [ADDRESS_1025704] u d y 
( Part C) a n d t he o n g oi n g P hase 1/ [ADDRESS_1025705] t hat a gi v osira n d ose of 1. 2 5 m g/ k g o n ce m o nt hl y w o ul d 
re d uce A L A le v els i n a s u bsta ntial n u m ber of pati e nts. T he pr o p ose d st u d y desi g n will e na b l e t he 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 7  e val uati o n of t he P D, effi cac y, a n d safet y of t he 1. 2 5 m g/ k g m o nt hl y d ose of gi v osira n, w hile 
c o nti n ui n g t o pr o vi de dat a o n t he 2. 5 m g/ k g m o nt hl y d ose.   Bas e d o n t he first [ADDRESS_1025706] b o i n t he d o u ble -bli n d peri o d, a 
tre n d t o war d i ncreas e d b e nefit, as i n dicate d b y greater re d ucti o ns i n c o m p osite attac ks, he mi n use, 
a n d A L A a n d P B G le vels, was o bser v e d wit h t he 2. 5 -m g/ k g o nce m o nt hl y d ose c o m pare d t o t he 
1. 2 5 -m g/ k g o nce m o nt hl y d ose.  Gi ve n  t he tre n d t o war d i ncrease d b e nefit wit h t he 2. 5 -m g/ k g 
d ose of gi v osira n c o m pare d t o t he 1. 2 5 -m g/ k g d os e a n d c o nsi deri n g t h at A H P is a disease i n 
w hic h eac h attac k is seri o us, hi g hl y m or bi d, a n d carries p ote ntial f or irre v ersi ble ne ur ol o gic 
da ma ge, i m ple me ntati o n of a me n d me nt  5 i ncreases t he d ose f or all patie nts recei vi n g 1. 2 5  m g/ k g 
gi v osira n o n ce m o nt hl y w h o d o n ot ha ve o n g oi n g cli nicall y rele va nt tra nsa mi nase ele vati o ns t o 
t he rec o m me n d e d d ose of 2. 5  m g/ k g gi v osira n S C o nce m o nt hl y, w hi c h was a p pr o ve d b y  t he 
U nite d States F D A i n N o ve m ber [ADDRESS_1025707] u d y.  
1. 5.  Be nefit -Ris k Assess me nt  
Base d o n t h e a vaila bl e n o ncli nical a n d cli nical data (see Secti o n  1. 2. 2 ), gi v osira n a d mi nistere d 
s u bc uta ne o usl y as a o n ce -m o nt hl y d ose re gi me n, ma y b e a ble t o offer d os e -de pe n de nt, p ote nt a n d 
s ustai ne d s u p pressi o n of A L A S 1, t here b y decreasi n g t he acc u m ulati o n of t h e ne ur ot o xic he me 
i nter me diates A L A a n d P B G.  T his ma y, i n t ur n, p ote ntiall y pre v e nt t he occ urre nce of ac ute 
p or p h yri a attac ks, as well as p ote ntiall y a m eli orate c hr o nic p or p h yri a s y m pt o ms t hat patie nts 
e x perie nce bet w ee n attac ks, i ncl u di n g pai n, na us ea, a n d fati g ue.  
T he gi v osira n n o ncli nical t o xic ol o g y pr o gra m, i ncl u di n g d ose -ra n gi n g st u dies i n t he m o use, rat, 
a n d m o n ke ys, f oll o we d b y cli nic al trial a p plicati o n -e na bli n g, as w ell as c hr o nic G L P t o xic ol o g y 
st u dies i n t he rat u p t o 2 6 wee ks a n d m o n k e y  (j u ve nile m o n ke ys  at i nit iati o n of t he st u d y) u p t o 3 9 
wee ks, de m o nstr ate d a n a de q uate s afet y mar gi n f or cli nical d osi n g of gi v osira n at 2. 5  m g/ k g p er 
m o nt h.  Gi v osira n was a d mi nistere d via S C i njecti o n i n all t o xic ol o g y st u dies, c o nsiste nt wit h t he 
i nte n de d cli nical r o ute of a d mi nistrati o n.  All i n vitr o a n d i n vi v o ge n etic t o xicit y st u dies were 
ne gati ve at I C H S 2 ( R 1) li mit d oses.  I n t h e rat a n d ra b bit e m br y ofet al de v el o p me ntal t o xicit y 
st u dies, gi v osira n -relate d i ncreas e d p ost -i m pla ntati o n l oss/earl y a bs or pti o n (ra b bits) a n d fe tal 
s keletal variati o n (rats a n d ra b bits) were o bser ve d.   T he o bser ve d mater nal t o xicit y ma y ha v e 
ca use d or c o ntri b ute d t o t he o bser ve d e m br y ofetal effects, w hile t here was n o detecta ble le v el of 
gi v osira n via fetal tr a nsfer at a n y d ose.  T o mi ni miz e a n y p ote ntial ris k of e m br y ofetal t o xicit y 
(terat o ge ni cit y), w o me n of c hil d -beari n g p ot e ntial m ust ha ve a ne gati ve pre g na n c y test, ca n n ot b e 
breastfee di n g, a n d m ust be willi n g t o use a n acce pta ble met h o d of c o ntr ace pti o n d uri n g st u dies 
wit h gi v osira n.  C o ntrac e pti o n re q uire me nts a n d g ui deli nes are pr o vi d e d i n t he cli nical st u d y 
pr ot oc ols.  
T he cli nical e x perie nce fr o m P hase 1 St u d y A L N -A S 1 -0 0 1 ( Part C) s u g gests t hat i n patie nts wit h 
AI P a n d rec urre nt attac ks, gi v osira n tr eat me nt is ass ociate d wit h s ustai ne d re d u cti o ns i n 
A L A/ P B G le vels, d ecrease d attac k fre q ue n c y (ra n gi n g fr o m 6 3 t o 7 5 %), a n d re d uce d h e mi n usa ge 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025708] u d y a n d P hase 1/ [ADDRESS_1025709] u d y A L N -A S 1 -0 0 1 ca n be f o u n d 
i n t he gi v osira n I B. Gi v e n t he bi ol o gical tar get of gi v osi ra n, t he a vaila ble n o ncli nical a n d cli nical 
data, a n d t he m o de of a d mi nistrati o n, ot her p ote ntial safet y c o n cer ns i ncl u d e i njecti o n site 
reacti o ns (I S Rs), ele vati o n of li ver tra nsa mi nas es, i ncreas e d ser u m creati ni n e/ decrease d esti mate d 
gl o mer ular filtrati o n rat e (e G F R), pa ncreatitis, a n d a na p h ylactic reacti o n.  A s u m mar y of 
preli mi nar y cli nical data fr o m o n g oi n g P has e 1 a n d P hase 1/ 2 st u dies of gi v osira n ca n b e f o u n d i n 
Secti o n  1. 2. 2  a n d i n t he gi v osira n I B.  
T his cli nical pr ot oc ol i ncl u des e x cl usi o n criteria i nte n de d t o mi ni mize t he ris k of tra nsa mi nitis, 
I S R a n d pa n creatitis, a n d i nc or p orates o n g oi n g m o nit ori n g f or ele vate d tra nsa mi nases, ser u m 
li pase,  a n d a na p h yl actic reacti o ns ( Secti o n  6. 2. 3 ).  S pecific r ules f or d ose wit h h ol di n g a n d 
st o p pi n g ha ve b ee n i nc or p orate d i n t he pr ot oc ol f or a b n or malities i n li ver f u ncti o n tests, a n d 
ser u m a m yl ase a n d li pas e le vels.   
Bl o o d h o m oc ystei ne le v els ma y be i ncrease d i n patie nts wit h A H P, vita mi n deficie nci es, or 
c hr o nic ki d ne y dise ase.  (2 3 -2 5 )  D uri n g treat me nt wit h gi v osira n, i ncreas es i n bl o o d 
h o m oc ystei ne l e vels ha v e bee n o bser ve d c o m pare d t o le vels bef ore treat me nt.  T he cli nical 
rele va n ce of t h e ele vati o ns i n bl o o d h o m oc ystei n e d uri n g gi v osira n treat me nt is u n k n o w n.  T he 
pr ot oc ol i ncl u des m o nit ori n g f or c ha n ges i n bl o o d h o m oc ystei ne l e vels d uri n g treat me nt wit h 
gi v osira n. It is r ec o m me n de d t hat patie nts wit h i ncrease d bl o o d h o m oc ystei ne le vels recei ve a 
s u p ple me nt c o ntai ni n g vita mi n B 6  (see Secti o n  6. 3. 4 ).  
A n I n de pe n d e nt Data M o nit ori n g C o m mittee ( D M C) will m o nit or safet y o v er t he c o urse of t he 
d o u ble -bli n d treat me nt p eri o d a n d u ntil all patie nts  ha ve bee n i n t he O L E p eri o d f or at least 
6 m o nt hs ( Secti o n  4. 7 ). 
Base d o n t h e e mer gi n g efficac y a n d safet y d ata fr o m t he o n g oi n g cli nical st u dies ( A L N -A S 1 -0 0 1 
a n d A L N -A S 1 -0 0 2) a n d t he o bser ve d precli nical mar gi ns, t he b e nefit -ris k assess me nt s u p p orts 
e val uati o n of gi v osira n i n a p hase 3 St u d y i n A H P patie nts.  
2.  O B J E C TI V E S  
2. 1.  Pri m ar y O bjecti ve  
• E val uate t he effect of S C gi v osira n, c o m pare d t o place b o, o n t he rate of p or p h yria 
attac ks re q uiri n g h os pi[INVESTIGATOR_27967] o n, ur ge nt healt hcare visit, or I V h e mi n a d mi nistrati o n at 
h o me  i n patie nts wit h AI P  
2. 2.  Sec o n d ar y O bjecti ves  
• E val uate t he effects of gi v osira n, c o m pare d t o place b o, o n uri nar y A L A le vels i n 
patie nts wit h AI P  
• E val uate t he effects of gi v osira n, c o m pare d t o place b o, o n uri nar y P B G le v els i n 
patie nts wit h AI P  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 9  • E val uate t he effects of gi v osira n, c o m pare d t o place b o, o n he mi n usa ge i n patie nts 
wit h AI P  
• E val uate t he effects of gi v osira n, c o m pare d t o place b o, o n t he rate of p or p h yria attac ks 
re q uiri n g h os pi[INVESTIGATOR_27967] o n, ur ge nt healt hcare visit, or I V he mi n a d mi nistrati o n at h o me 
i n patie nts wit h a n y A H P  
• E val uate t he effects of gi v osira n c o m pare d t o place b o i n patie nts wit h AI P o n t he 
s y m pt o ms of pai n, na usea, a n d fati g ue  
• E val uate t he effects of gi v osira n, c o m pare d t o place b o, i n patie nts wit h AI P o n t he 
P h ysical C o m p o ne nt S u m mar y ( P C S) of t he 1 2 -ite m S h ort -F or m Healt h S ur ve y 
( S F -1 2) (2 6 ) 
•  E val uate t he safet y a n d t olera bilit y of gi v osira n i n patie nts wit h a n y A H P  
2. 3.  E x pl or at or y O bjecti ves  
• E val uate t he effects of gi v osira n, c o m pare d t o place b o, i n patie nts wit h AI P a n d i n 
patie nts wit h a n y A H P o ver t he 6 -m o nt h treat me nt p eri o d o n:  
− Rate of all p or p h yria attac ks (re q uiri n g h os pi[INVESTIGATOR_27967] o n, ur ge nt he alt hcare visit, I V 
he mi n a d mi nistrati o n at h o me, or treat e d at h o me wit h o ut I V h e mi n)  
− Uri nar y A L A S 1 m R N A l e vels  
− A nal gesic usa ge ( o pi [INVESTIGATOR_2495] d a n d n o n -o pi [INVESTIGATOR_2495] d)  
− A d diti o nal q ualit y of life ( Q O L) meas ures, i ncl u di n g misse d da ys of w or k/s c h o ol  
− Patie nt e x perie nce q uesti o n naire a n d p atie nt's i m pressi o n of healt h stat us c ha n ge  
• Assess t he treat me nt effect of gi v osira n at e v al uat e d d oses o ver t h e O L E p eri o d i n  
patie nts wit h AI P a n d i n patie nts wit h  a n y A H P w h o ha d pre vi o usl y bee n ra n d o mize d 
t o place b o treat me nt  
• Assess t he l o n g -ter m treat me nt effect of gi v osira n i n patie nts wit h AI P a n d i n patie nts 
wit h a n y A H P  
• C haracterize t he P K of a n d assess t he a nti dr u g a nti b o dies ( A D A) of gi v osira n i n 
patie nts wit h a n y A H P  
3.  E N D P OI N T S  
3. 1.  Pri m ar y E n d p oi nt  
• A n n ualize d rate of p or p h yria attac ks r e q uiri n g h os pi[INVESTIGATOR_1314] o n, ur ge nt healt hcare visit, 
or I V he mi n a d mi nistrati o n at h o me i n patie nts wit h AI P o ver t he 6 -m o nt h treat me nt 
peri o d. See Secti o n  3. 5  f or t he defi niti o n of p or p h yria attac ks a n d ass ociat e d ter ms.  
3. 2.  Sec o n d ar y E n d p oi nts  
• Uri nar y A L A le vels i n patie nts wit h AI P at [ADDRESS_1025710] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 0  • Uri nar y A L A le vels i n patie nts wit h AI P at 6 m o nt hs  
• Uri nar y P B G le vels i n patie nts wit h AI P at 6 m o nt hs  
• A n n ualize d rate of a d mi nistere d he mi n d oses i n patie nts wit h AI P o ver t he 6 -m o nt h 
treat me nt peri o d  
• A n n ualize d rate of p or p h yria attac ks r e q uiri n g h os pi[INVESTIGATOR_1314] o n, ur ge nt healt hcare vis it, 
or I V he mi n a d mi nistrati o n at h o me i n patie nts wit h a n y A H P o ver t he 6 -m o nt h 
treat me nt peri o d ( Secti o n  3. 5 )  
• Dail y w orst pai n sc ore as meas ure d b y Brief Pai n I n v e nt or y -S h ort F or m ( B PI -S F) 
n u meric rati n g scale ( N R S)  i n patie nts wit h AI P o ver t he 6 -m o nt h treat me nt peri o d  
• Dail y w orst na usea sc ore as meas ure d b y N R S i n patie nts wit h AI P o ver t he 6 -m o nt h 
treat me nt peri o d  
• Dail y w orst fati g ue sc ore as meas ure d b y Brief Fati g ue I n v e nt or y -S h ort F or m ( B FI -
S F) N R S i n patie nts wit h AI P o v er t he 6 -m o nt h tr eat me nt peri o d  
• C ha n ge fr o m bas eli ne i n t he P h ysical C o m p o ne nt S u m mar y ( P C S) of t he 1 2 -ite m 
S h ort -F or m Healt h S ur ve y ( S F -1 2) (2 6 ) i n patie nts wit h AI P at [ADDRESS_1025711] orat or y e n d p oi nts will be meas ure d i n patie nts wit h AI P a n d i n p atie nts wit h a n y A H P o ver 
t he 6 -m o nt h treat me nt peri o d or o ver t he O L E peri o d at d oses e val uat e d:  
• Rate of p or p h yria attac ks re q uiri n g h os pi[INVESTIGATOR_27967] o n, ur ge nt healt hcare visit, or I V 
he mi n a d mi nistrati o n at h o me ( Secti o n  3. 5 )  
• Rate of all p or p h yria attac ks ( Secti o n  3. 5 ) 
• Rate of a d mi nistere d h e mi n d oses  
• Uri nar y A L A a n d P B G l e vels  
• Uri nar y A L A S 1 m R N A l e vels  
• Dail y w orst pai n, dail y w orst na usea, a n d dail y w orst fati g u e sc ores o ver 1 2 m o nt hs  
• P C S of t he S F -1 2 (2 6 ) 
• E Q -5 D -5 L i n de x sc ore (2 7 ) 
• Patie nt Gl o bal I m pr essi o n of C ha n ge ( P GI C)  
• P or p h yria Patie nt E x peri e nce Q u esti o n naire ( P P E Q)  
• A nal gesic usa ge ( o pi [INVESTIGATOR_2495] d a n d n o n -o pi [INVESTIGATOR_2495] d)  
• P K pr ofile of gi v osira n  
• I n ci de nce a n d titer of A D As  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 1  3. 4.  S afet y E n d p oi nts  
• I n ci de nce, se verit y, s eri o us ness, a n d relat e d ness of a d vers e e ve nts o v er t he 6 -m o nt h 
treat me nt peri o d a n d i n t he O L E peri o d i n patie nts wit h a n y A H P. Si nce p or p h yri a 
attac ks wi ll be rec or de d f or effic ac y assess me nt of gi v osira n, t he y will n ot be treate d 
as A Es or S A Es as des cri be d i n Secti o n  7. 5. 6 . 
3. 5.  Defi niti o n of P or p h yri a Att ac ks  
P or p h yria attac ks are d efi ne d as meeti n g all t he criteria bel o w:  
• a n ac ute e pis o de of ne ur o visceral pai n i n t he a b d o me n, bac k, c h est, e xtre mities a n d/ or 
li m bs  
• n o ot her me dicall y deter mi ne d ca use ot her t ha n a p or p h yri a attac k  
• re q uires tr eat me nt wit h I V de xtr ose or he mi n, car b o h y drates, or a nal gesics ( o pi [INVESTIGATOR_2495] d 
[s y nt hetic a n d n o n -s y nt h etic s u bsta nces] or n o n -o pi [INVESTIGATOR_2495] d), or ot her me dicati o ns s uc h as 
a ntie metics, at a d ose or fre q ue nc y b e y o n d t he pati e nt’s us ual dail y p or p h yria 
ma na ge me nt.  
F or t he p ur p os es of t his st u d y, t he f oll o wi n g defi niti o ns will be use d t o i de ntif y eac h n o n -
o verla p pi n g s u b -t y pe of p or p h yri a attac k e ve nts:  
• P or p h yri a att ac ks re q uiri n g h os pit aliz ati o n:  p or p h yria attac ks t hat pr o m pt a 
h os pi[INVESTIGATOR_27967] o n.  H os pi[INVESTIGATOR_27967] o n is defi ne d as a n a d missi o n t o a n i n patie nt u nit or a 
visit t o a n e mer ge nc y d e part me nt t hat res ults i n a n at least 2 4 -h o ur sta y ( or a c ha n ge i n 
cale n dar date if t he h os pi[INVESTIGATOR_307] a d missi o n or disc har ge ti mes are n ot a v aila ble).  
• P or p h yri a att ac ks re q uiri n g ur ge nt he alt hc are visit:  P or p h yri a attac ks t hat pr o m pt 
ur ge nt healt hcare visits.  A n ur ge nt healt hcare visit is defi ne d as a n ur ge nt, 
u nsc he d ule d office/ pr acti ce, i nf usi o n ce nt er, or a n e mer ge n c y de part me nt visit t hat 
d oes n ot meet t he criteria f or a h os pi[INVESTIGATOR_27967] o n.  T his e n d p oi nt i nc l u des pres e ntati o n 
wit h a p or p h yria attac k o n a pr ot oc ol -sc h e d ule d cli nic visit if t he patie nt w o ul d ha ve 
s o u g ht a n ur ge nt healt hcare visit i n t he a bse nce of t he pr ot oc ol -sc he d ul e d cli nic visit.  
• P or p h yri a att ac ks re q uiri n g I V he mi n at h o me:  P or p h yria attac ks at h o m e re q uiri n g 
I V he mi n. “ H o me” is defi ne d as a n y l ocati o n t hat d oes n ot meet t he criteria f or a 
h os pi[INVESTIGATOR_27967] o n or ur ge nt healt hcare visit.  
• P or p h yri a att ac ks at h o me n ot re q uiri n g I V he mi n:  P or p h yria attac ks at h o me t hat 
d o n ot re q ui re I V he mi n b ut are treate d wit h car b o h y drates or a n al gesics ( o pi [INVESTIGATOR_2495] d or 
n o n -o pi [INVESTIGATOR_2495] d) at a d ose or fre q ue nc y b e y o n d t he pati e nt’s us ual dail y p or p h yria 
ma na ge me nt. “ H o me” is defi ne d as a n y l ocati o n t hat d oes n ot meet t he criteria f or a 
h os pi[INVESTIGATOR_27967] o n or ur g e nt healt hcare visit.  
T he start of p or p h yri a att ac ks is c haracterize d b y ac ute a n d s ustai ne d w orse ni n g of t he p atie nt’s 
p or p h yri a ma nifest ati o ns be y o n d n or mal da y -t o -d a y varia bilit y. T h e e n d of p or p h yri a attac ks is 
c haracteriz e d b y rec o ver y fr o m p or p h yria ma nifestati o ns bac k t o wit hi n a patie nt’s n or mal da y -t o -
da y v aria bilit y.  S y m pt o ms d uri n g a n attac k ma y be si milar i n nat ure i n a gi ve n patie nt, b ut n ot 
necessaril y i n de gree or s e verit y.  Si nce p or p h yri a attac ks will be rec or de d f or effic ac y assess me nt 
of  gi v osira n, t he y will n ot be treate d as A Es or S A Es as descri be d i n Secti o n  7. 5. [ADDRESS_1025712] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025713] u d y desi g ne d t o e v al uat e t he efficac y a n d 
safet y of gi v osira n i n a d ults a n d a d olesce nts ( ≥ 1 2 years of a ge) wit h a d oc u me nte d dia g n osis of 
AI P.  T h e efficac y a n d safet y of gi v osira n will als o be i n vesti gat e d i n t he ot her A H Ps, i ncl u di n g 
H C P, V P, or A D P. A sc he matic of t he st u d y desi g n is s h o w n i n Fi g ure  2.   
Patie nts w h o were o n h e mi n pr o p h yla xis pri or t o e nr oll me nt will be eli gi bl e t o partici pate if t he y 
meet t he attac k e ntr y crit eria. I n t his st u d y, p atie nts ma y be gi v e n he mi n f or t he treat me nt of ac ute 
attac ks if cli nicall y i n dicate d b ut ma y n ot use he mi n pr o p h ylacticall y.  He mi n pr o p h yla xis is n ot 
per mitte d i n t his st u d y b eca use gi v osira n is i nte n d e d as m o n ot hera p y t o pr e ve nt attac ks a n d t he 
re g ular c o -a d mi nistrati o n of he mi n c o ul d c o nf o u n d effic ac y a n d s afet y si g n als relate d t o 
gi v osira n.  
I n t he first part of t h e st u d y, c o ns e nti n g (a n d ass e nti n g, w here a p plica ble) pati e nts w h o meet all 
eli gi bilit y criteria will be ra n d o mize d i n a 1: 1 rati o t o recei ve 2. 5  m g/ k g gi v osira n or place b o 
m o nt hl y f or a 6 -m o nt h treat me nt peri o d; b ot h gi v osira n a n d place b o will be a d mi nistere d 
s u bc uta ne o usl y. Treat me nt gr o u ps will be stratifie d a t st u d y e ntr y b y A H P t y p e ( AI P [ wit h 
ge n etic e vi de n ce of m utati o n i n t he  H M B S  ge ne] vs H C P, V P, A D P, or a n y A H P wit h o ut 
i de ntifie d m utati o n i n a p or p h yri a -relate d ge ne); all patie nts wit h AI P \will be f urt her str atifie d b y 
eac h p atie nt’s use of he mi n pr o p h yla xis re gi me n at t he ti me of scree ni n g a n d b y eac h p atie nt’s  
hist orical a n n u alize d attac k rate .  AI P p atie nts o n a he mi n pr o p h yl a xis re gi me n pri or t o st u d y 
e ntr y will be stratifie d b y t heir hist orical a n n ualize d attac k rat e: < 7 attac ks vs ≥ [ADDRESS_1025714] orical a n n ualize d attac k rate: < 1 2 attac ks vs ≥ [ADDRESS_1025715] u d y, t he O L E peri o d i n w hic h t he y  
will be treate d wit h gi v osira n f or u p t o 2 9  m o nt hs.  Patie nts w h o cr osse d o v er t o t he O L E peri o d 
pri or t o i m ple me ntati o n of a me n d me nt 3 (ie, u n d er a me n d me nt v ersi o n 1 or 2) a n d are recei vi n g a 
2. 5  m g/ k g o nce m o nt hl y gi v osira n d os e will re mai n o n t hat d ose . U p o n e ntr y t o t he O L E p eri o d 
u n der a me n d me nt v ersi o n 3, patie nts will cr oss o ver t o recei ve a 1. 2 5 m g/ k g o nce m o nt hl y d ose 
of gi v osira n.  
After i m ple me ntati o n of a me n d me nt  3 a n d u ntil i m ple me ntati o n of a me n d me nt  5, patie nts 
assi g ne d t o t he o n ce m o nt hl y 1 . 2 5 -m g/ k g treat me nt gr o u p w h o e x perie nce i na de q uate disease 
c o ntr ol ma y b e all o we d t o ha ve t heir m o nt hl y d os e i ncrease d t o 2. 5  m g/ k g starti n g at t he 
M o nt h  [ADDRESS_1025716] u d y Visit ( w he n 6  m o nt hs of o pe n -la b el gi v osira n d osi n g ha v e bee n c o m plete d at 
1. 2 5  m g/ k g) bas e d  o n disc ussi o n a n d a gree me nt b y t he I n v esti gat or a n d me dical m o nit or, 
de m o nstrati o n of t olera bilit y t o gi v osira n, a n d f ulfill me nt of A L A a n d cli nical acti vit y criteri a.  
U p o n i m ple me ntati o n of a me n d me nt  5, all patie nts recei vi n g 1. 2 5  m g/ k g gi v osira n o nce m o nt hl y 
w h o d o n ot ha ve o n g oi n g cli nicall y rele va nt tra nsa mi nase ele vati o ns will ha ve t heir d ose 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 3  i ncreas e d t o 2. 5  m g/ k g gi v osira n o nce m o nt hl y base d o n t olera bilit y al o ne, wit h o ut a n y criteria 
f or A L A re d ucti o n or cli nical acti vit y .  F or f urt her details, see  Secti o n  6. 2. 3. [ADDRESS_1025717] m o nt h of t he 
O L E p eri o d a n d t he n m o nt hl y t hr o u g h  M o nt h 1 8, a n d e ver y 3 m o nt hs t hereafter.  
If he mi n is use d f or p or p h yria attac ks, t he s c he d ul e d uri ne sa m ple f or A L A, P B G, a n d A L A S 1 
m R N A assess me nts will be c ollecte d 4 d a ys ( + 4 d a ys) after t he patie nt’s l ast he mi n d ose.  
F or partic ular visits, as s pecifie d i n t he Sc he d ul e of Assess me nts ( Ta ble  2 a n d  Ta ble  3), a n d 
w here a p plica ble c o u ntr y a n d l ocal re g ul ati o ns a n d i nfrastr uct ur e all o w, st u d y pr oce d ures ma y be 
c o n d ucte d b y a h o m e healt hcare pr ofessi o nal. St u d y dr u g a d mi nistrati o n ma y be c o n d ucte d b y a 
h o me healt hcare pr ofessi o nal f or patie nts t ha t ha v e de m o nstrate d t he a bilit y t o t olerat e t he st u d y 
dr u g at t he st u d y ce nter.  If t he patie nt is u na ble t o c o me t o t he st u d y site, a n d a visit b y a h o me 
healt hcare pr ofessi o nal is n ot p ossi ble d ue t o circ u msta nces relat e d t o t he C O VI D -[ADDRESS_1025718] rece i ve a p pr o pri ate 
trai ni n g o n gi v osira n a d mi nistrati o n a n d t he use of e pi [INVESTIGATOR_050] p hri ne (e pi [INVESTIGATOR_5836] n or e q ui vale nt) pri or t o 
d osi n g.  T his meas ur e is i nte n de d t o re mai n i n effect o nl y d uri n g peri o ds of ti me w he n t he 
C O VI D -[ADDRESS_1025719] u d y site or healt hcare 
pr ofessi o nals t o g o t o patie nts' h o mes f or d osi n g.  
Patie nts or care gi v ers will be pr o vi de d wit h a n ele ctr o nic diar y (e Diar y) t o rec or d s e verit y of dail y 
pai n, na usea, a n d fati g ue, as well as a n al gesic use. P ote ntial p or p h yria attac ks will als o be 
rec or de d i n t he e Di ar y b y patie nts a n d care gi vers w he n t he y occ ur; st u d y ce nters will be n otifie d 
w he n p ote ntial p or p h yria attac ks are re p orte d i n t h e e Diar y.  I n i nsta nces w he n t he e Diar y is n ot 
use d t o re p ort p ote ntial p or p h yri a attac ks, st u d y ce nters ma y be n otifie d b y tele p h o ne b y patie nts, 
care gi v ers, or ot her healt hcare pr o vi ders.  All p ote ntial p or p h yri a attac ks will be c o nfir me d b y t he 
I n v esti gat or.  
A n e xter nal i n de pe n de nt Data M o nit ori n g C o m mittee ( D M C; Secti o n  4. 7 ) will m o nit or safet y 
o ver t he c o urse of t he d o u ble -bli n d treat me nt peri o d a n d u ntil all patie nts ha ve bee n i n t he O L E 
peri o d f or at least [ADDRESS_1025720] u d y disc o nti n uati o n crit eria (see Secti o n  5. 3 ) or u ntil gi v osira n is c o m merciall y a vaila ble i n t he 
patie nt’s territ or y or t h e gi v osira n d e vel o p me nt pr o gra m is disc o nti n ue d ( w hic he ver c o mes first).  
All patie nts are as k e d t o partici pate i n t he S afet y F oll o w -u p visit after t he y ha ve recei ve d t h eir 
last d ose of gi v osira n.  
W here re q uir e d b y l ocal re g ulati o ns, t his trial ma y be re pla ce d wit h a p ost -mar keti n g cli nical trial 
o nce mar k eti n g a ut h orizati o n f or gi v osira n is r ecei ve d.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 4  Fi g ure  2:  St u d y Desi g n   
 
A b bre viati o ns: A M ≤ 2 = ori gi nal pr ot oc ol ( 0 6 Se pt 2 0 1 7), pr ot oc ol a me n d me nt 1 ( 0 4 Ma y 2 0 1 8), a n d pr ot oc ol 
a me n d me nt 2. 0 ( 2 6  J ul y 2 0 1 8); A M 3 = pr ot oc ol a me n d me nt 3 ( 2 1 Se pt 2 0 1 8); A M 5 = pr ot oc ol a me n d me nt 5 
( 1 2  Fe br u ar y 2 0 2 0)  
4. 2.  D ur ati o n of Tre at me nt  
T he esti mate d t otal ti me o n st u d y f or eac h patie nt is a p pr o xi matel y 3 8 m o nt hs, i ncl u di n g u p t o 
2 m o nt hs of scree ni n g, u p t o 3 5 m o nt hs of treat me nt ( d o u ble -bli n d treat me nt peri o d of 6 m o nt hs 
a n d u p t o 2 9 -m o nt h o pe n -la bel e xte nsi o n peri o d), a n d a [ADDRESS_1025721] u d y is a p pr o xi matel y 7 4 A H P patie nts, i ncl u di n g 
a p pr o xi matel y 7 0 AI P patie nts.  
4. 4.  Met h o d of Assi g ni n g P atie nts t o Tre at me nt Gr o u ps  
Patie nts will be ra n d o mize d 1: [ADDRESS_1025722] u d y e ntr y b y A H P t y p e ( AI P [ wit h ge n etic e vi d e nce of m utati o n i n 
t he  H M B S  ge n e] vs H C P, V P, A D P, or a n y A H P wit h o ut i de ntifie d m utati o n i n a p or p h yria -
relate d ge n e ).   
Ra n d o mizat i o n f or AI P p atie nts will be f urt her str atifie d b y eac h patie nt’s use of he mi n 
pr o p h yla xis re gi me n at t he ti me of scree ni n g  a n d b y eac h p atie nt’s  hist orical a n n ualize d attac k 
rate .  Patie nts o n a he mi n pr o p h yla xis re gi me n pri or t o st u d y e ntr y will be strat ifie d b y t heir 
hist orical a n n ualize d attac k rate: < 7 attac ks vs ≥ [ADDRESS_1025723] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 5  a n n ualize d attac k rate: < 1 2 attac ks vs ≥ [ADDRESS_1025724] u d y A L N -A S 1 -N T -0 0 1 
( E X P L O R E, a n o bser vati o nal nat ural hist or y st u d y).  
As ver y fe w n o n -AI P p atie nts are a ntici pat e d t o be e nr olle d i n t he st u d y, n o a d diti o nal 
stratificati o n fact ors will be c o nsi dere d f or t hes e p atie nts.   
Eac h patie nt will be u ni q uel y i de ntifie d i n t he st u d y b y a c o m bi nati o n of t he st u d y ce nter n u m b er 
a n d patie nt i de ntificati o n n u m ber.  U p o n c o m pleti o n of t he i nf or me d c o ns e nt f or m (I C F; a n d 
asse nt, if a p plica ble) b y t he patie nt/ pare nt or g uar dia n , t he patie nt will be assi g ne d a p atie nt 
i de ntificati o n n u m ber b y t he i nteracti ve res p o nse s yste m (I R S).  T h e I n vesti gat or or his/ her 
dele gate will c o ntact t he I R S after c o nfi r mi n g t hat t he patie nt f ulfills all t he i ncl usi o n criteria a n d 
n o ne of t he e x cl usi o n criteria a n d a bli n de d treat m e nt will be assi g n e d.   
4. 5.  Bli n di n g  
I n di vi d ual s u bject treat m e nt assi g n me nts will be mai ntai ne d b y t h e I R S. Me m bers of t he st u d y 
tea m will n ot ha ve access t o u n bli n de d data u ntil t he [ADDRESS_1025725] u g a nti b o d y ( A D A) ma y h a v e tr eat me nt 
assi g n me nt i nf or m ati o n b ut will n ot ha ve access t o s u bject le vel data fr o m t he cli nical trial 
data bases.   
A s u bject’s treat me nt assi g n me nt s h o ul d o nl y b e u n bli n de d w he n k n o wle d ge of t he treat me nt is 
esse ntial f or t he f urt her cli nical ma na ge me n t of t h e patie nt. T he pri n ci pal i n vesti gat or is str o n gl y 
e nc o ura ge d t o c o ntact t he me dical m o nit or bef ore u n bli n di n g a n y patie nt’s treat me nt assi g n me nt 
b ut m ust d o s o wit hi n 1 w or ki n g d a y aft er t he e v e nt.  A rec or d of w he n t h e bli n d was br o ke n, w h o 
br o ke t he bli n d, a n d w h y it was br o ke n, will be mai ntai ne d i n t he trial master file ( T M F).  
Refer t o t he I R S i nstr ucti o ns f or details o n u n bli n di n g.  
La b orat or y res ults of uri nar y A L A, P B G, ( perf or me d at a ce ntral la b orat or y) or A L A S 1 m R N A 
( perf or me d at Al n yla m) wi ll be bli n de d fr o m after t he ti me of t he first d os e u ntil u n bli n di n g of t he 
cli nical data bas e a n d will n ot be re p orte d t o t he i n vesti gat or p ost -s cree ni n g. I n a d diti o n, 
i n vesti gat ors a n d st aff i n v ol ve d wit h t his trial a n d all me dical staff i n v ol ve d i n t he s u bject’s 
me dical care s h o ul d refrai n fr o m o btai ni n g l oc al A L A or P B G meas ure m e nts u ntil at least 
1 2  wee ks after t he M o nt h 6 visit (t o a v oi d p ote ntial u n bli n di n g). If A L A or P B G is meas ure d 
d uri n g t his peri o d, all reas o na ble ste ps m ust be u n derta ke n t o a v oi d i nf or mi n g t he p atie nt a n d 
st u d y pers o n n el of t he res ults.  
A list of all Al n yla m pers o n nel or pers o n n el w or ki n g o n be h alf of Al n yla m w h o are u n bli n de d t o 
st u d y data will be mai ntai ne d i n t he T M F.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 6  4. 6.  P atie nt Electr o nic Di ar y (e Di ar y)  
Patie nts or care gi v ers w ill be pr o vi de d wit h a n ele ctr o nic diar y (e Diar y) at scree ni n g a n d trai ne d 
o n its use.  Dail y e ntri es i nt o t he e Diar y will i ncl u de pai n, na usea, a n d fati g ue se verit y, as well as 
a nal gesic use.  F or f urt her details, see Secti o n  7. 2. [ADDRESS_1025726] u d y:  
1.  A ge ≥ 1 2 years  
2.  D oc u me nte d dia g n osis of AI P, H C P, V P, or A D P base d o n cli nical f eat ur es (e g, ac ut e 
attac ks of a b d o mi nal, b ac k, c hest, e xtre mities, a n d/ or li m b pai n), at least o ne d oc u me nte d 
uri nar y or plas ma P B G or A L A val ue ≥ 4 × u p per li mit of n or mal ( U L N) wit hi n t he past 
year pri or t o or d uri n g Scree ni n g, A N D o ne of t he f oll o wi n g:  
• D oc u me nte d ge n etic e vi d e nce of m utati o n i n a p or p h yria -rel ate d ge n e, defi ne d as 
A N Y  of t he f oll o wi n g:  
− AI P:  m utati o n i n t he h y dr o x y met h yl bila ne s y nt h ase ge ne ( H M B S ; als o    
referre d t o as t he p or p h o bili n o ge n dea mi nase [ P B G D ] ge n e)  
− H C P:  m utati o n i n t he c o pr o p or p h yri n o ge n o xi dase ( C P O X ) ge n e  
− V P:  m utati o n i n t he pr ot o p or p h yri n o ge n o xi dase ( P P O X ) ge n e  
− A D P:  m utati o n i n t he a mi n ole v uli nic aci d de h y dratase ( A L A D)  h o m oz y g o us 
or c o m p o u n d heter oz y g o us ge n es  
• O R  if t he res ults of a pati e nt’s ge netic testi n g d o n ot i de ntif y a m utati o n i n a 
p or p h yri a -relate d ge ne ( < 5 % of cas es), a p atie nt ma y b e eli gi ble f or t h e st u d y if t he y 
ha ve b ot h cli nical f eat ures a n d dia g n ostic bi oc he mical criteria c o nsiste nt wit h A H P 
(Ta ble  1 1 ) 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025727] 2 p or p h yria attac ks re q uiri n g h os pi[INVESTIGATOR_27967] o n, ur ge nt 
healt hcare visit or treat m e nt wit h I V he mi n at h o me wit hi n t he 6 m o nt hs pri or t o 
Scree ni n g  
4.  Willi n g t o disc o nti n ue a n d/ or n ot i nitiate use of pr o p h yla ctic he mi n at t he ti me of 
Scree ni n g a n d f or t he d urati o n of t he st u d y  
5.  Ha ve a d e q uate v e n o us access f or st u d y sa m ple c ollecti o n as j u d ge d b y t he i n vesti gat or  
6.  Be willi n g t o c o m pl y wit h t he c o ntrace pti ve re q uire me nts d uri n g t he st u d y peri o d, as 
descri be d i n  Secti o n  6. [ADDRESS_1025728] u d y r e q uire me nts a n d t o pr o vi de writte n 
i nf or me d c o nse nt per l ocal a n d nati o nal re q uire me nts.  I n t he case of patie nts u n der t he 
a ge of le gal c o nse nt, le gal g uar di a n(s) m ust pr o vi d e writte n i nf or me d c o nse nt a n d t he 
patie nt s h o ul d pr o vi de asse nt per l ocal a n d na ti o nal re q uire me nts a n d i nstit uti o nal 
sta n dar ds.  
5. 2.  E xcl usi o n Criteri a  
Eac h patie nt m ust n ot meet a n y of t he f oll o wi n g e x cl usi o n criteria t o be eli gi ble f or e nr oll me nt i n 
t he st u d y : 
1.  A n y of t he f oll o wi n g la b orat or y para meter assess me nts at Scree ni n g:  
a.  Ala ni ne a mi n otra nsf eras e ( A L T) > 2 × U L N  
b.  T otal bilir u bi n > 1. 5 × U L N. Patie nts wit h ele vate d t otal bilir u bi n t hat is sec o n dar y t o 
d oc u me nte d Gil bert’s s y n dr o me are eli gi ble if t he t otal bilir u bi n is < 2 × U L N  
c.  I nter nati o nal n or malize d rati o (I N R) > 1. 5 ( patie nts o n a n a ntic oa g ula nt [e g, warfari n] 
wit h a n I N R < 3. 5 will be all o we d)  
2.  Esti mate d Gl o mer ular Filtrati o n Rate (e G F R) < 3 0 m L/ mi n/ 1. 7 3 m 2 usi n g t he M o dificati o n 
of Diet i n Re nal Diseas e ( M D R D) f or m ula  
3.  O n a n acti ve li ver tra ns pl a ntati o n waiti n g list, or a ntici pate d t o u n der g o li ver 
tra ns pla ntati o n d uri n g t h e bli n de d st u d y tr eat me nt peri o d  
4.  Hist or y of m ulti ple dr u g aller gies or hist or y of aller gic reacti o n t o a n oli g o n ucle oti de or t o 
N-acet yl galact osa mi ne ( Gal N Ac)  
5.  Hist or y of i nt olera nce t o s u bc uta ne o us i njecti o n(s)  
6.  K n o w n acti ve HI V i nfecti o n; or e vi de nce of c urre nt or c hr o nic he p atitis C vir us ( H C V) or 
he patitis B vir us ( H B V) i nfecti o n  
7.  C urre ntl y e nr olle d i n a n ot her i n vesti gati o nal de vice or dr u g st u d y, or less t h a n 3 0 da ys or 
5 half -li ves ( w hic h e ver is l o n ger) si nce e n di n g a n ot her i n vesti gati o nal de vice or dr u g 
st u d y(s), or recei vi n g ot her i n vesti gati o nal a ge nt(s)  
8.  Fe males w h o are pre g n a nt, breast -fee di n g, or pla n ni n g t o bec o m e pre g n a nt d uri n g t he 
st u d y  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 8  9.  A n y c o n diti o n (e g, me dical c o ncer n or al c o h ol or s u bsta nce a b us e),  w hic h i n t he o pi [INVESTIGATOR_9384] o n 
of t he I n vesti gat or, w o ul d ma ke t he patie nt u ns uita ble f or d osi n g or w hi c h c o ul d i nterfere 
wit h t he st u d y c o m plia nce, t he patie nt’s safet y a n d/ or t he patie nt’s partici pati o n i n t he [ADDRESS_1025729] u d y.  T his i ncl u des  si g nifica nt a cti ve a n d p o orl y 
c o ntr olle d ( u nsta ble) car di o vasc ular, ne ur ol o gi c, gastr oi ntesti nal, e n d o cri n e, re nal or 
ps yc hiatric dis or ders u nrelate d t o p or p h yria i d e ntifie d b y k e y la b orat or y a b n or malities or 
me dical hist or y.  
[ADDRESS_1025730] u g a n d/ or St u d y  
Patie nts or t heir le gal g uar dia ns (i n t he cas e t hat t h e patie nt is a mi n or) are free t o disc o nti n ue 
treat me nt a n d/ or st u d y or wit h dra w t heir c o ns e nt at a n y ti me a n d f or a n y reas o n, wit h o ut pe nalt y 
t o t heir c o nti n ui n g me dical care.  A n y disc o nti n uati o n of treat me nt or of t h e st u d y m ust be f ull y 
d oc u me nte d i n t he ele ctr o nic case re p ort f or m (e C R F) a n d s h o ul d be f oll o w e d u p b y t h e 
I n v esti gat or.  T he I n v esti gat or m a y wit h dra w a patie nt fr o m t he st u d y at a n y ti me if t his is 
c o nsi dere d i n t he p atie nt’s best i nterest.  
Disc o nti n uati o n of st u d y dr u g a n d wit h dra w al fr o m t he st u d y are descri be d i n Secti o n 5. 3. [ADDRESS_1025731] u d y, h e/s he will n ot be a ble t o re -e nr oll i n t he st u d y  
5. 3. 1.  Disc o nti n u ati o n of St u d y Dr u g  
T he I n ves ti gat or or d esi g nee ma y disc o nti n ue d osi n g i n a p atie nt if t he patie nt:  
• Is i n si g nifica nt vi olati o n of t he pr ot oc ol  
• E x perie nces a S A E c o nsi dere d t o be relate d t o t he st u d y dr u g or a n i nt olera ble A E  
• Bec o m es pre g n a nt  
• Is n o n -a d here nt t o t he treat me nt re gi me n  
T he I n vesti gat or will c o nfer wit h t he S p o ns or or me dical m o nit or bef ore disc o nti n ui n g d osi n g i n 
t he patie nt.   
Patie nts w h o are pre g na nt will be disc o nti n ue d fr o m st u d y dr u g d osi n g i m me diatel y (see 
Secti o n  7. 5. 6. 6  f or re p orti n g a n d f oll o w -u p of pre g na n c y).  A p ositi ve uri n e pre g na n c y test s h o ul d 
be c o nfir me d b y a ser u m pre g na nc y t est pri or t o disc o nti n ui n g t he st u d y dr u g.  
If a patie nt disc o nti n ues d o si n g d ue t o a s eri o us a d verse e v e nt ( S A E), t he S A E s h o ul d be f oll o we d 
as descri be d i n Secti o n  7. 5. [ADDRESS_1025732] be rec or de d i n t he electr o nic case re p ort f or m (e C R F).  Patie nts w h o disc o nti n ue st u d y dr u g 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025733] u d y tr eat me nt d uri n g t he 6 -m o nt h treat me nt peri o d ( defi ne d as 
t he ti me t he first d ose of st u d y dr u g is a d mi nistere d o n St u d y Da y 1 t hr o u g h c o m pleti o n of t he 
M o nt h -6 assess me nts) will be e nc o ura ge d t o re m ai n o n t he st u d y a n d c o m plete assess me nts 
t hr o u g h M o nt h 6 a n d c o nti n ue t o re p ort p ote ntial p or p h yri a attac ks as t he y o cc ur; t he y will als o 
be as ke d t o c o m plete a safet y f oll o w -u p 3 m o nt hs ( 8 4 ± 1 4 da ys) after t heir l ast d ose of st u d y dr u g 
(see Ta bl e  3).  
Patie nts w h o disc o nti n ue st u d y treat me nt d uri n g t he O L E peri o d will be as ke d t o ret ur n f or t heir 
ne xt sc he d ule d visit t o c o m plete E O S/ E T assess me nts; t he y will als o be as ke d t o c o m plete a 
safet y f oll o w -u p visit 3 m o nt hs ( 8 4 ± 1 4 da ys) aft er t heir last d ose o f st u d y dr u g (see T a ble  3).  
5. 3. 2.  Disc o nti n u ati o n fr o m t he St u d y  
A patie nt or t heir le gal g uar dia n ma y deci de t o st o p t he patie nt’s partici pati o n i n t he st u d y at a n y 
ti me.  Patie nts c o nsi deri n g st o p pi n g t he st u d y s h o ul d be i nf or me d t hat t he y ca n disc o nti n ue 
treat me nt a n d c o m plet e st u d y assess me nts i ncl u di n g f oll o w -u p, as per t h e S O A, or alter nati vel y 
ma y c o m plete a n y mi ni mal assess me nts f or w hi c h t he patie nt c o nse nts. T he I n v esti gat or ma y 
wit h dra w a patie nt at a n y ti me if t his is c o nsi dere d i n t he patie nt’s best i nterest.  
H o we ver, st u d y i nte grit y a n d i nter pret ati o n are b est mai ntai ne d if all ra n d o mize d patie nts 
c o nti n ue st u d y ass ess me nts a n d f oll o w -u p.  St o p pi n g st u d y partici pati o n c o ul d mea n:  
• If a patie nt st o ps partici p ati o n d uri n g t he [ADDRESS_1025734] u d y 
assess me nts t hr o u g h t h e 6 -m o nt h visit, i ncl u di n g f oll o w -u p.   
• If a patie nt st o ps partici p ati o n d uri n g t he o p e n -la b el e xte nsi o n peri o d, t he y s h o ul d 
be as ke d t o r et ur n f or a n Earl y Ter mi nati o n Visit as well as a Safet y F oll o w -U p 
Visit [ADDRESS_1025735] u g.  
• A patie nt ca n st o p ta ki n g t he st u d y dr u g a n d st o p st u d y -relate d visits, b ut all o w t he 
i n vesti gat or a n d st u d y te a m t o re vie w t he p atie nt’s me dical rec or ds, p u blic rec or ds 
or be c o nta cte d t o recei v e i nf or mati o n a b o ut t he p atie nt’s healt h  
W he n a patie nt st o ps t he st u d y, t he disc o nti n uati o n a n d reas o n f or disc o nti n uati o n m ust be 
rec or de d  i n t he a p pr o priate secti o n of t he el ectr o ni c case re p ort f or m (e C R F) a n d all eff orts will 
be ma de t o c o m plete a n d re p ort t he o bser vati o ns as t h or o u g hl y as p ossi ble.  If a patie nt st o ps t he 
st u d y d ue t o a n a d vers e e ve nt ( A E), i ncl u di n g a n S A E, t he A E s h o ul d be f oll o we d as descri be d i n 
Secti o n  7. 5. [ADDRESS_1025736] u d y, he/s he s h o ul d n otif y t h e st u d y d o ct or i n 
writi n g or i n a n y ot h er f or m t hat ma y b e l ocall y re q uire d. T he pers o nal data alrea d y c ollecte d 
d uri n g t he st u d y, i ncl u di n g patie nt’s bi ol o gic al sa m ples, will still be use d t o get h er wit h t he data 
c ollecte d o n ot her p atie nts i n t he st u d y acc or di n g t o t he i nf or me d c o nse nt a n d a p plica ble la ws.  
I n a d diti o n t o st o p pi n g partici pati o n i n t he st u d y, t he patie nt c o ul d deci de t o wit h dra w his/ her 
c o nse nt as e x plai ne d i n Secti o n  5. 3. [ADDRESS_1025737] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025738] a n d Pr ocess t he P atie nt’s Pers o n al D at a  
T he patie nt ma y deci de t o wit h dra w his/ her c o ns e nt i nf or mi n g t he st u d y d o ct or at a n y ti me i n 
writi n g, or i n a n y ot h er f or m t hat ma y b e l ocall y re q uire d.  T his  mea ns t hat t he patie nt wa nts t o 
st o p partici pati o n i n t he st u d y a n d a n y f urt her c oll ecti o n of his/ her pers o nal data.  
• T he s p o ns or will c o nti n ue t o kee p a n d us e a patie nt's st u d y i nf or mati o n (i n cl u di n g 
a n y d ata res ulti n g fr o m t he a nal ysis of t he patie nt's bi ol o gical sa m ples u ntil ti me of 
wit h dra wal) acc or di n g t o a p plica ble la w.  T his is d o ne t o g u ara nte e t he vali dit y of 
t he st u d y, deter mi ne t he effects of t he st u d y treat me nt, a n d e ns ure c o m plete ness of 
st u d y  d oc u me ntati o n.  
• T he patie nt ca n als o re q u est t hat c ollecte d sa m ples be destr o ye d or ret ur n e d (t o t he 
e xte nt it is per mitte d b y a p plica ble la w) at a n y ti me.  
• Patie nts w h o wit h dra w t heir c o nse nt t o c ollect a n d use pers o nal d ata s h o ul d 
u n dersta n d t hat p u blic r ec or ds ma y be re vie we d t o deter mi ne t he patie nt’s s ur vi val 
stat us as all o we d per l o cal a n d nati o nal re g ulati o ns.    
I n U S a n d J a pa n, ot her wise, sa m ples n ot yet a nal yze d at t he ti me of wit h dra wal ma y still be use d 
f or f urt her testi n g/ a nal ysis i n acc or da nce wit h t he ter ms of t he pr ot oc ol a n d of t he i nf or me d 
c o nse nt f or m.  
I n E U a n d rest of w orl d, i n a n y e ve nt, sa m ples n ot yet a nal yz e d at t he ti me of wit h dra wal will n ot 
be use d a n y l o n ger, u nless per mitte d b y a p plica ble la w. T he y will be st ore d or destr o ye d 
acc or di n g t o a p plic a ble l e gal re q uir e me nts.  
5. 3. 4.  Re pl ace me nt of P atie nts  
Patie nts disc o nti n ui n g fr o m st u d y dr u g or wit h dra wi n g fr o m t he st u d y will n ot be re place d.  
6.  T R E A T M E N T S  
6. 1.  Tre at me nts A d mi nistere d  
St u d y dr u g s u p plie d f or t his st u d y m ust n ot be use d f or a n y p ur p o s e ot her t ha n t he pres e nt st u d y 
a n d m ust n ot be a d mi nistere d t o a n y p ers o n n ot e nr olle d i n t he st u d y.  St u d y dr u g t h at has bee n 
dis pe nse d t o a patie nt a n d ret ur ne d u n us e d m ust n ot be re -dis pe ns e d t o a differe nt patie nt.  
6. 2.  I n vesti g ati o n al St u d y Dr u g  
Detaile d i nf or mati o n des cri bi n g t he pre p arati o n, a d mi nistrati o n, a n d st ora ge of gi v osira n a n d 
place b o is pr o vi de d i n t h e P har mac y M a n ual.  
6. 2. 1.  Descri pti o n  
T he gi v osira n dr u g pr o d u ct ( A L N -A S 1) will be s u p plie d as a sterile s ol uti o n i n water f or S C 
i njecti o n.  See t he P ha r m ac y Ma n ual f or f urt her details of s ol uti o n c o nce ntrati o n a n d fill v ol u me.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025739] u d y will be a pla ce b o (s o di u m c hl ori de 0. 9 % w/ v f or S C 
a d mi nistrati o n).  Place b o will be pr o vi de d b y t h e S p o ns or; it will be pac ka ge d i d e nticall y t o 
gi v osira n a n d a n i de ntic al v ol u me will be a d mi nistere d.  
6. 2. 2.  D ose a n d A d mi nistr ati o n  
T he st u d y dr u g s h o ul d be i njecte d i nt o t he a b d o me n or u p per ar ms or t hi g hs.  Detaile d 
i nstr ucti o ns f or st u d y dr u g a d mi nistrati o n are prese nte d i n t he P har mac y M a n ual. As is c o nsiste nt 
wit h g o o d me dical practi ce f or s u b c uta ne o us dr u g a d mi nistrati o n, patie nt s will be o bser ve d f or a 
mi ni m u m of 2 0 mi n utes after eac h i njecti o n.   Treat me nt f or a n a p h yl actic reacti o ns s h o ul d be 
rea dil y a vaila bl e w here p atie nts are b ei n g d os e d, a n d f oll o w c o u ntr y a n d/ or l ocal h os pi[INVESTIGATOR_750007] g ui deli nes (2 8 ). 
Gi v osira n will be a d mi nistere d b y a q u alifie d a n d a ut h orize d healt h care pr ofessi o nal trai ne d i n 
t he rec o g niti o n a n d ma n a ge m e nt of a na p h yl actic reacti o ns, w he n e ver p ossi ble.  St u d y d r u g 
a d mi nistrati o n ma y be c o n d ucte d at a l ocati o n ot her t ha n t he st u d y ce nter b y a h o m e healt hcare 
pr ofessi o nal, w here a p plica ble c o u ntr y a n d l ocal re g ul ati o ns a n d i nfrastr u ct ure all o w, after 
c o ns ultati o n wit h t he me dical m o nit or, d uri n g p artic ular st u d y v isits, as s p ecifie d i n t he Sc he d ul es 
of Assess me nts ( Ta ble  2 a n d Ta ble  3).  If t he p atie nt is u na ble t o c o me t o t he st u d y site, a n d a 
visit b y a h o me healt hcare pr ofessi o nal is n ot p ossi ble d ue t o circ u msta nces relate d t o t he 
C O VI D -[ADDRESS_1025740] recei ve 
a p pr o priate trai ni n g o n gi v osira n a d mi nistrati o n a n d t he use of e pi [INVESTIGATOR_050] p hri ne (e pi [INVESTIGATOR_5836] n or e q ui val e nt) 
pri or t o d osi n g.  T his meas ure is i nte n de d t o r e mai n i n effect o nl y d uri n g p eri o ds of ti me w he n t he 
C O VI D -[ADDRESS_1025741] u d y site or healt hcare 
pr ofessi o nals  t o g o t o patie nts' h o mes f or d osi n g.  H o we ver, st u d y dr u g a d mi nistrati o n at t he st u d y 
ce nter s h o ul d be c o nsi dere d f or patie nts w h o h a ve o n g oi n g st u d y dr u g -relat e d A Es or k n o w n ris k 
fact ors f or de vel o pi n g a n a p h yl actic reacti o ns, i ncl u di n g b ut n ot li mite d t o:  pri or hist or y of a n 
a na p h ylactic reacti o n t o f o o d, me dicati o ns or d ue t o u n k n o w n eti ol o g y, w orse ni n g i njecti o n site 
reacti o ns wit h re p eat d osi n g, or a n y o ne i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or t hat w o ul d be nefit fr o m 
cli nical o bser vati o n f oll o wi n g d osi n g . 
A L T a n d t otal bilir u bi n ( T B L) res ults c ollecte d wit hi n [ADDRESS_1025742] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025743] u g a d mi nistrati o n are prese nte d i n t he P h ar mac y M a n ual.  I n 
a d diti o n, i nstr ucti o ns a n d pr oce d ures re l ate d t o a d mi nistrati o n of gi v osira n b y a p atie nt or 
care gi v er will be pr o vi de d i n t he Patie nt/ Care gi ver St ora ge a n d A d mi nistrati o n I nstr ucti o ns.  
6. 2. 2. 1.  D uri n g t he 6 -M o nt h Tre at me nt Peri o d ( D a y 1 t o M o nt h 6)   
Patie nts will be a d mi nistere d gi v osira n 2. 5  m g/ k g or place b o as a n S C i njecti o n o nce a m o nt h.  
T o mai ntai n t he bli n d, t he s yri n ges are t o be mas k e d pri or t o st u d y dr u g wit h dra wal fr o m t he 
mas ke d vial.  At t he M o nt h 6 st u d y visit, f oll o wi n g t he c o m pleti o n o f all M o nt h 6 assess me nts, 
i ncl u di n g t he uri ne s a m ple f or A L A a n d P B G l e vels (t o e n d t he d o u ble -bli n d peri o d), patie nts will 
be a d mi nistere d t heir first o pe n -la bel ( u n mas k e d) d ose of gi v osira n t o be gi n t heir partici pati o n i n 
t he o pe n -la bel e xte nsi o n p orti o n of t he st u d y.  
6. 2. 2. 2.  D uri n g t he O pe n -L a bel E xte nsi o n Peri o d ( After M o nt h 6 t hr o u g h E n d of 
Tre at me nt)  
Patie nts w h o cr osse d o ver t o t he O L E peri o d pri or t o i m ple me ntati o n of a me n d me nt 3 (ie, u n der 
a me n d me nt versi o n 1 or 2) a n d are recei vi n g 2. 5  m g/ k g o nce m o nt hl y will re mai n o n t hat d ose.  
U p o n e ntr y t o t he O L E p eri o d u n der a me n d me nt versi o n 3, patie nts will cr oss o ver t o recei ve a 
1. 2 5 m g/ k g o nce m o nt hl y d ose of gi v osira n.  Aft er i m ple me ntati o n of a me n d me nt  3 a n d u ntil 
i m ple me ntati o n of a me n d me nt  5,  a d ose i ncre ase t o 2. 5  m g/ k g o n ce m o nt hl y ma y be p er mitte d 
starti n g at M o nt h 1 3 f or patie nts recei vi n g 1. 2 5  m g/ k g o nce m o nt hl y (s ee S ecti o n  6. 2. 3. 4 ). 
U p o n i m ple m e ntati o n of a me n d me nt  5, all patie nts recei vi n g 1. 2 5  m g/ k g gi v osira n o nce m o nt hl y 
w h o d o n ot ha ve o n g oi n g cli nicall y rele va nt tra nsa mi nase ele vati o ns will ha ve t heir d ose 
i ncreas e d t o 2. 5  m g/ k g gi v osira n o nce m o nt hl y per g ui da n ce i n Secti o n  6. 2. 3. [ADDRESS_1025744] u g d ose m o dificati o ns will be 
all o we d, e x ce pt i n res p o nse t o L F T ele v ati o n s as d escri be d i n Secti o n  6. 2. 3. 1 . 
D uri n g t h e o pe n -la b el e xte nsi o n peri o d, d osi n g m o dificati o ns will be all o we d u n der t he f oll o wi n g 
circ u msta nces:  
• In res p o nse t o L F T ele v ati o ns  as descri be d i n Secti o n 6. 2. 3. 1  
• After i m ple me ntati o n of a me n d me nt  3 a n d u ntil i m ple me ntati o n of a me n d me nt  5, 
patie nts assi g ne d t o t he o nce m o nt hl y 1. 2 5 -m g/ k g treat me nt gr o u p  w h o e x perie nce 
i na de q uate disease c o ntr ol  ma y be all o we d t o ha v e t heir m o nt hl y d ose i n crease d t o 
2. 5  m g/ k g starti n g at M o nt h  1 3 ( w he n 6  m o nt hs of o pe n -la b el gi v osira n d osi n g ha ve 
bee n c o m plete d at 1. 2 5 m g/ k g) bas e d o n disc ussi o n a n d a gree me nt b y t he I n v esti gat or 
a n d me dical m o nit or, de m o nstrati o n of t olera bilit y gi v osira n, a n d f ulfill me nt of A L A 
a n d cli nical acti vit y criteria as descri be d i n Secti o n  6. 2. 3. 4 . 
• U p o n i m ple me ntati o n of a me n d me nt  5, all patie nts recei vi n g 1. 2 5  m g/ k g gi v osira n 
o nce m o nt hl y w h o d o n ot ha ve o n g oi n g cli nicall y rele va nt tra ns a mi nase ele vati o ns 
will ha ve t heir d ose i ncrease d t o 2. 5  m g/ k g gi v osira n o nce m o nt hl y base d o n 
t olera bilit y al o ne, wit h o ut a n y criteria f or A L A re d ucti o n or cli nical acti vit y .  See 
Secti o n  6. 2. 3. [ADDRESS_1025745] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025746] Res ults  
A L T a n d T B L res ults s h o ul d be re vie we d wit hi n 6 wee ks pri or t o d osi n g.  
F or a n y A L T ele v ati o n > 3 ×U L N ( or > 3 ×b aseli ne i n patie nts wit h ele vate d b aseli ne) or > 3 0 0  U/ L 
( w hic he ver is l o wer), res ults s h o ul d be c o nfir me d b y t he ce ntral la b orat or y ( wit hi n 2 t o 3 da ys, 
b ut n o greater t h a n 7 da ys).  If s uc h A L T ele v ati o ns are c o nfir me d, t he a d diti o nal he patic 
assess me nts  s h o w n i n Ta ble  5 s h o ul d be o btai ne d.  
S u bjects wit h a b n or mall y ele vate d h e patic la b orat or y v al ues (e g. A L T, A S T, T B L, or I N R) or 
si g ns/s y m pt o ms of he p a titis ma y meet criteria f or wit h h ol di n g st u d y dr u g.  Criteria f or 
wit h h ol di n g, m o nit ori n g a n d st o p pi n g st u d y dr u g d osi n g are detaile d i n  T a ble  4: 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 4  T a ble  4: M o nit ori n g a n d D osi n g R ules i n P atie nts wit h Al a ni ne Tr a ns a mi n ase ( A L T) 
Ele v ati o ns  
A L T 
Tr a ns a mi n ase 
Le vel  P ati e nts wit h N or m al B aseli ne 
A L T  P ati e nts wit h Ele v ate d B aseli ne 
A L T a 
> 3 × t o 5 × U L N 
or B aseli ne  • Disc o nti n ue d osi n g w h e n A L T 
is > 3 × U L N a n d p atie nt is 
s y m pt o matic b, or has T B L 
≥ 2 × U L N or I N R > 1. 5 (f or 
patie nts n ot o n warfari n), a n d 
t here is n o alter nati ve ca use  
• Ot her wise, d osi n g ma y c o nti n ue 
wit h m o nit ori n g e ver y 2 wee ks 
( ± 7 da ys) c t hat i ncl u des L F Ts 
pe r Ta ble  7 a n d I N R  
• If t he A L T ele vati o n persists f or 
≥ 2  m o nt hs, disc ussi o n wit h t he 
me dical m o nit or is re q uir e d 
bef ore c o nti n ui n g d osi n g.  • Disc o nti n ue d o si n g w h e n A L T 
is > 3 × baseli ne or > 3 0 0 U/ L 
( w hic he ver is l o wer) a n d patie nt 
is s y m pt o matic b, or has T B L 
> 2 × U L N or I N R > 1. 5 (f or 
patie nts n ot o n warfari n), a n d 
t here is n o alter nati ve ca use  
• Ot her wise, d osi n g ma y c o nti n ue 
wit h m o nit ori n g e ver y 2 wee ks 
( ± 7 da ys) d t hat i ncl u des L F Ts per 
Ta ble  7 a n d I N R.  
• If t he A L T ele vati o n persists f or 
≥ 2 m o nt hs, disc ussi o n wit h t he 
me dical m o nit or is re q uir e d 
bef ore c o nt i n ui n g d osi n g.  
> 5 × t o 8 × U L N 
or B aseli ne  • Disc o nti n ue d osi n g w h e n A L T 
> 5 × t o 8 × U L N a n d patie nt is 
s y m pt o matic b, or has T B L 
≥ 2 × U L N or I N R > 1. 5 (f or 
patie nts n ot o n warfari n) a n d 
t here is n o alter nati ve ca use  
• F or patie nts w h o are 
as y m pt o matic a n d d o n ot ha ve 
I N R > 1. 5 or T B L ≥ 2 x U L N:  
− H ol d d osi n g if A L T > 5 × U L N, 
u ntil A L T rec o vers t o 
≤ 2 × U L N  
− D osi n g ca n be res u me d w he n 
A L T rec o v ers t o ≤ 2 x U L N 
acc or di n g t o Secti o n  6. 2. 3. 1. 1 , 
a n d f oll o wi n g disc ussi o n wit h 
t he me dical m o nit or  
• Perf or m wee kl y ( ± 3 da ys) 
m o nit ori n g of L F Ts per  Ta ble  7 
a n d I N R u ntil A L T d ecli nes t o • Disc o nti n ue d osi n g w h e n A L T 
> 5 × t o 8 × bas eli ne or > 3 0 0  U/ L 
( w hic he ver is l o wer) a n d patie nt 
is s y m pt o matic b, or has T B L 
≥ 2 × U L N or I N R > 1. 5 (f or 
patie nts n ot o n warfari n) a n d 
t here is n o alter nati ve ca use  
• F or patie nts w h o are 
as y m pt o matic a n d d o n ot ha ve 
I N R > 1. 5 or  T B L ≥ 2 x U L N:  
− H ol d d osi n g if A L T 
> 5 × bas eli ne or > 3 0 0 U/ L 
( w hic he ver is l o wer), u ntil 
A L T rec o v ers t o ≤ 2 × b aseli ne  
− D osi n g ca n be res u me d w he n 
A L T rec o v ers t o ≤ [ADDRESS_1025747] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 5  A L T 
Tr a ns a mi n ase 
Le vel  P ati e nts wit h N or m al B aseli ne 
A L T  P ati e nts wit h Ele v ate d B aseli ne 
A L T a 
≤ 3 × U L N ; t he n m o nit or e ver y 2 
wee ks ( ± 7 d a ys) u ntil A L T le vel 
reac h es 2 × U L N c  
• If t he A L T ele vati o n persists f or 
≥ 2  m o nt hs, disc ussi o n wit h t he 
me dical m o nit or is re q uir e d 
bef ore c o nti n ui n g d osi n g.  • Perf or m wee kl y ( ± 3 da ys) 
m o nit ori n g of L F Ts per  Ta ble  7 
a n d I N R u ntil A L T d ecli nes t o 
≤ 3 × baseli ne ; t he n m o nit or e ver y 
2 wee ks ( ± 7 d a ys) u ntil A L T 
le vel reac hes 2 × baseli ne d 
• If t he A L T ele vati o n persists f or 
≥ 2  m o nt hs, disc ussi o n wit h t he 
me dical m o nit or is re q uir e d 
bef ore c o nti n ui n g d osi n g.   
> 8 × U L N or 
B aseli ne  Disc o nti n ue d osi n g after 
c o nfir mati o n if A L T > 8 × U L N  Disc o nti n ue d osi n g after 
c o nfir mati o n if A L T > 8 × baseli ne or 
> 5 0 0 U/ L ( w hic h e ver is l o wer)  
A b bre viati o ns:  A L T =ala ni ne a mi n otra nsferase; I N R =i nter nati o nal n or malize d rati o; L F T =li ve r f u ncti o n test(s); 
T B L =t otal bilir u bi n; U/ L = u nits per liter; U L N = u p per li mit of n or mal  
N ote:  I n a d diti o n t o t hese crit eria, ot her assess me nts or e val uati o ns ma y be perf or me d per I n vesti gat or discreti o n, as 
a p pr o priate.  
a If m ulti ple baseli ne A L T me as ure m e nts are a vaila ble, baseli ne A L T will be defi ne d as t he a vera ge of t he [ADDRESS_1025748] d ose a d mi nistere d.  
b S y m pt o ms ma y i ncl u de na us ea, ri g ht u p per q ua dra nt p ai n, j a u n dice, wit h n o k n o w n alter nati ve ca uses i de ntifie d b ut 
p ossi bl y ass ociate d wit h ( b ut n ot li mite d t o) s uc h ca uses as he p at o biliar y tract disease, viral he p atitis, alc o h olic 
he p atitis, or n o n -alc o h olic steat o he p atitis ( N A S H).  A cli nical pi[INVESTIGATOR_648130] c o nsiste nt wit h dr u g -i n d uce d a ut oi m m u ne 
he p atitis, i ncl u di n g b ut n o t li mite d t o t he prese nce of ras h, fe ver, l y m p ha d e n o pat h y a n d e osi n o p hilia i n a d diti o n t o 
ele vate d tra nsa mi nases ma y als o be a ca use f or c o nsi deri n g d osi n g disc o nti n uati o n.  
c T he fre q ue nc y of la b orat or y m o nit ori n g s h o ul d be decrease d fr o m e ver y 2 wee ks ( ± 7  da ys) t o m o nt hl y ( ± [ADDRESS_1025749] u d y visits) o nce A L T has decrease d t o ≤ 2 × U L N.  
d T he fre q ue nc y of la b orat or y m o nit ori n g s h o ul d be decrease d fr o m e ver y 2 wee ks ( ± 7 da ys) t o m o nt hl y ( ± [ADDRESS_1025750] u d y visits) o nce A L T has decrease d t o ≤ 2 × baseli ne.  
 
F or A L T, T B L, a n d I N R testi n g, l ocal la b orat or y res ults ma y be us e d t o i nf or m d osi n g decisi o ns; 
h o we ver, parallel sa m ples s h o ul d be c ollecte d f or a nal ysis at t he ce ntr al la b orat or y.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 6  T a ble  5: He p atic Assess me nts i n P ati e nts W h o E x perie nce Ele v ate d Tr a ns a mi n ases  
He m at ol o g y  
C B C wit h differe ntial   
E xte n de d He p atic P a nel  
Her pes Si m ple x Vir us 1 a n d 2 a nti b o d y I g M, I g G  Her pes Z oster Vir us I g M, I g G  
HI V 1 a n d 2 a H H V -6  
C yt o me gal o vir us a nti b o dies, I g M, I g G  H Bs A g, H Bc a nti b o d y I g M a n d I g G  
A nti -n uclear a nti b o dies  E pstei n -Barr Vir us a nti b o dies, I g M a n d I g G  
A nti -s m o ot h m uscle a nti b o dies  A nti -mit oc h o n drial a nti b o dies  
H C V a nti b o d y  H A V a nti b o d y I g M  
H C V R N A P C R – q ualitati ve a n d q ua ntitati v e H E V a nti b o d y I g M  
C P K   
I m a gi n g  
A b d o mi nal ultras o u n d wit h D o p pler fl o w ( or C T or M RI) i ncl u di n g ri g ht u p per q ua dra nt  
F oc use d Me dic al a n d Tr a vel Hist or y  
Use of a n y p ote ntiall y he pat ot o xic c o nc o mita nt 
me dicati o ns, i ncl u di n g o ver t he c o u nter me dicati o ns 
a n d her bal re me dies  Alc o h ol c o ns u m pti o n  
Ot her p ote ntiall y he pat ot o xic a ge nts i ncl u di n g a n y 
w or k -relate d e x p os ures  Rece nt tra vels t o areas w here he patitis A or E is 
e n de mic  
A b bre viati o ns:  A A T =al p ha -1 a ntitr y psi n; a nti -L K M =a nti -li ver -ki d ne y micr os o mal a nti b o dies; C B C =c o m plete bl o o d 
c o u nt; C P K =creati ne p h os p h o ki nase; C T =c o m p ute d t o m o gr a p h y; H A V = he p atitis A vir us; H B c = he p atitis B c ore; 
H Bs A g = he p atitis B vir us s urface a nti ge n; H C V = he p atitis C vir us; H E V = he p atitis E vir us; H H V -6 = h u ma n 
her pes vir us 6; HI V = h u ma n i m m u n o deficie nc y vir us; I g G =i m m u n o gl o b uli n G a nti b o d y; I g M =i m m u n o gl o b uli n M 
a nti b o d y; M RI = ma g netic res o na nce i ma ger y; P C R = p ol y merase c hai n reacti o n; P T = pr ot hr o m bi n ti me; 
R N A = ri b o n ucleic aci d; S L A =s ol u ble li ver a nti ge n; T S H =t h yr oi d -sti m ulati n g h or m o ne  
N ote:  
• All assess me nts will b e meas ure d i n ce ntral la b orat or y. T he f ull pa nel of assess me nts s h o ul d o nl y be perf or me d 
o nce; i n di vi d ual assess me nts ma y be re p eate d, as nee de d.  
• A d diti o nal sa m ples ma y be c ollecte d f or assess me nt of p ote ntial alter nati ve ca uses of li ver i nj ur y, w hic h ma y 
i ncl u de A A T, cer ul o plas mi n, aceta mi n o p he n/ paraceta m ol le vels, a nti -L K M a nti b o dies, t o xic ol o g y scree n, 
ferriti n, par v o vir us B 1 9, a nti -S L A a nti b o die s, ga m ma -gl o b uli ns (i ncl u di n g I g E a n d I g G l e vels), a n d tra nsferri n 
sat urati o n, as cli nicall y i n dicat e d.  
a  HI V testi n g will n ot b e perf or me d w here pr o hi bite d b y l ocal re g ulati o ns.  
6. 2. 3. 1. 1.  Criteri a f or R ec h alle n ge of Gi v osir a n After Bei n g Wit h hel d f or A L T Ele v ati o n  
F or patie nts i n w h o m gi v osira n d osi n g  is wit h hel d d ue t o ele vate d A L T, res u m pti o n of d osi n g 
ma y b e c o nsi dere d usi n g t he f oll o wi n g g ui deli nes:  
• Patie nts w h o di d n ot meet criteria f or st u d y dr u g disc o nti n uati o n per Ta ble  [ADDRESS_1025751] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 7  res ol uti o n of A L T t o ≤ 2 × U L N or ≤ 2 × baseli ne (f or patie nts w h o ha d ele v ate d 
baseli ne A L T)  
• T he decisi o n t o rec halle n ge t h e patie nt s h o ul d be disc usse d a n d a gree d u p o n b y t he 
patie nt, I n v esti gat or, a n d me dical m o nit or  
• T he d ose re gi me n f or patie nts w h o meet rec halle n ge criteri a, re gar dless of t heir d ose at 
t he ti me of t he A L T ele v ati o n, is a d ose  of eit her 1. 2 5 or 2. 5  m g/ k g m o nt hl y per 
I n v esti gat or j u d ge me nt a n d after disc ussi o n wit h t he me dical m o nit or:  
− L F Ts, I N R a n d T B L will be m o nit ore d e ver y 2 wee ks ( ± 7 da ys) f or t he first 
m o nt h, t he n m o nt hl y ( ± [ADDRESS_1025752] u d y visits) as p er t he 
Sc he d ule of Assess me nts  
− La b orat or y m o nit ori n g a n d d osi n g r ules i n r es p o nse t o L F T ele v ati o n will f oll o w 
Ta ble  4 g ui deli nes  
• If d ose wit h h ol di n g r u les per Ta ble  4 are m et o n r ec halle n ge wit h t he 1. 2 5 -m g/ k g 
d ose, per ma n e ntl y disc o nti n ue d osi n g  
• If a patie nt e x perie nces a sec o n d d ose h ol d d ue t o L F T ele v ati o n w hile o n 2. 5  m g/ k g 
m o nt hl y:  
− F oll o w Ta ble  4 g ui deli nes f or m o nit ori n g a n d e val uati o ns  
− If A L T res ol ves t o ≤ 2 × U L N, re d osi n g wit h 1. 2 5 m g/ k g m o nt hl y ma y b e 
c o nsi dere d after disc ussi o n wit h t he Al n yla m me dical m o nit or.  If d osi n g is 
res u me d, f oll o w t he g ui d a nce a b o ve f or rec halle n ge re gi me n re gar di n g la b orat or y 
m o nit ori n g a n d d osi n g r ules.  N o s u bse q ue nt re -es calati o n t o 2. 5 m g/ k g m o nt hl y 
will b e all o we d.  
6. 2. 3. 2.  M o nit ori n g a n d D osi n g R ules B ase d o n Li p ase a n d A m yl ase Res ults  
Li pas e a n d a m ylas e res ults s h o ul d be re vie we d pri or t o d osi n g.  
T he criteri a f or wit h h ol di n g, m o nit ori n g a n d st o p pi n g st u d y dr u g d osi n g base d o n li pase a n d 
a m ylas e res ults are detai l e d i n Ta ble  6. 
T a ble  6: M o nit ori n g a n d D osi n g R ules i n P atie nts wit h Li p ase or A m yl ase 
Ele v ati o ns  
H ol d F urt her 
D osi n g  • If a li pase or a m ylase ele vati o n > 3 × U L N ( or 3 × b aseli ne i n patie nts wit h 
ele vate d b aseli ne val ue) occ urs, wit h or wit h o ut cli nical s y m pt o ms, u ntil 
c o nfir mati o n fr o m t he ce ntral la b orat or y ( wit hi n 2 t o 3 da ys, b ut n o 
greater t ha n 7 da ys ).  
• If t he ele v ate d li pase/a m yl ase is acc o m p a nie d b y cli nical s y m pt o ms 
c o nsiste nt wit h pa ncreatitis (e g, e pi [CONTACT_6026] p ai n, v o miti n g), d osi n g 
s h o ul d be hel d u ntil a n y a d diti o nal w or k -u p is c o m plete.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 8  T a ble  6: M o nit ori n g a n d D osi n g R ules i n P atie nts wit h Li p ase or A m yl ase 
Ele v ati o ns  
• If t he ele v ati o n of eit her li pase or a m ylase is c o nfir me d, a n i ma gi n g 
e val uati o n s h o ul d be o btai ne d (e g, ri g ht u p p er q ua dra nt ultras o u n d 
a n d/ or ot her testi n g, base d o n I n v esti gat or j u d g m e nt).  
• M o nit or li pase/a m ylas e e ver y 2 wee ks ( ± 7 da ys) u ntil t he ele vate d li pase 
a n d/ or a m yl ase v al ue decli nes t o < 3 × U L N.  
D osi n g M a y 
Res u me  • After c o ns ultati o n wit h t he me dical m o nit or a n d I n vesti gat or if t h e 
patie nt is as y m pt o matic a n d i ma gi n g st u dies d o n ot re veal he p at o biliar y 
or pa ncreatic a b n or malities.  
• If a n alter nate eti ol o g y w as i de ntifie d f or t he ele vati o ns a n d t he 
c o n diti o n has res ol ve d.  
• M o nit or li pase/a m ylas e e ver y 2 wee ks ( ± 7 da ys) u ntil t he val ue decli nes 
t o < 3 ×U L N.  
Per m a ne ntl y 
Disc o nti n ue 
D osi n g  • If t he patie nt is dia g n ose d wit h ac ute pa n creatitis wit h n o k n o w n 
alter nate eti ol o g y (e g, ac ute gallst o nes)  
• If t he patie nt e x perie n ces persiste nt li pase a n d a m yl ase ele vati o ns 
> 3 ×U L N f or > 2 m o nt hs wit h o ut peri o ds of rec o v er y t o < 3 ×U L N  
A b bre viati o ns: U L N = u p per li mit of n or mal  
F or li pase a n d a m ylase testi n g, l ocal la b orat or y res ults ma y be use d t o i nf or m d osi n g decisi o ns; 
h o we ver, parallel sa m ples s h o ul d be c ollecte d f or a nal ysis at t he ce ntr al la b orat or y.  
Li pas e a n d a m ylas e testi n g a n d i ma gi n g e val uati o ns s h o ul d als o be c o nsi d ere d at a n y p oi nt i n t he 
st u d y if a p atie nt e x perie nces u nc haracteristic si g ns a n d s y m pt o ms d uri n g p or p h yri a attac ks a n d 
t here is cli nical s us pi[INVESTIGATOR_37180] o n of pa ncreatitis.  
6. 2. 3. 3.  M o nit ori n g a n d D osi n g R ules i n P atie nts wit h P ote nti al C ases of A n a p h yl actic 
Re acti o n  
A n a na p h yla ctic reacti o n is a se vere, p ote ntiall y fatal, s yste mic aller gic reacti o n wit h ac ute o nset 
( mi n utes t o h o urs).  F or refere nce see Secti o n  1 1. 2  (2 8 ). 
St o p a d mi niste ri n g t he st u d y me dic ati o n i m me di atel y  if a n a na p h yla ctic reacti o n t o t he st u d y 
me dicati o n is s us pecte d.  St u d y m e dicati o n m ust be per ma n e ntl y disc o nti n u e d i n patie nts f or 
w h o m a n a na p h yla ctic reacti o n is assesse d as relat e d t o t he st u d y me dicati o n.  
L a b or at or y testi n g:  O bt ai n bl o o d sa m ple f or tr y ptase, t otal I g E, a n d A D A  a nti dr u g a nti b o dies 
( A D A) i deall y wit hi n 1 5 mi n utes t o 3 h o urs after t he o nset of a s us pe cte d a na p h yl actic reacti o n; 
h o we ver, u p t o 6 h o urs is acce pta ble.  A n a d diti o nal bl o o d sa m ple t o asse ss tr y ptas e, t otal I g E, 
a n d A D A s h o ul d be o btai ne d bet wee n 1 t o 2 wee ks fr o m o nset of e v e nt.  L ocal la b orat or y ma y be 
use d t o a nal yze s a m ples; h o we ver, parallel sa m ples s h o ul d be se nt t o t he ce ntral la b orat or y f or 
a nal ysis.  Sa m ple c ollecti o n a n d s hi p pi n g i nstr ucti o ns are i ncl u de d i n t he La b orat or y Ma n ual.   
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 9  Re p orti n g : T he PI [INVESTIGATOR_1311] g nee m ust n otif y t he s p o ns or or desi g nee wit hi n [ADDRESS_1025753] ( A E CI) a n d S A Es, per A E re p orti n g re q uire me nts  ( Secti o n  7. 5. 6. 1  
t hr o u g h Secti o n  7. 5. 6. 3 ).   
6. 2. 3. 4.  D ose Esc al ati o n G ui d a nce f or Gi v osir a n fr o m 1. 2 5 m g/ k g O nce M o nt hl y t o 
2. 5  m g/ k g O nce M o nt hl y i n t he O pe n -L a bel Peri o d  
After i m ple me ntati o n of a me n d me nt  3 a n d u ntil i m ple me ntati o n of a me n d me nt  5, patie nts 
assi g ne d t o t he o n ce m o nt hl y 1. 2 5 -m g/ k g treat me nt gr o u p ma y b e all o we d t o ha ve t heir m o nt hl y 
d ose i ncrease d t o 2. 5  m g/ k g starti n g at t he M o nt h [ADDRESS_1025754] u d y Visit ( w he n 6 m o nt hs of o pe n -la bel 
gi v osira n d osi n g ha v e b ee n c o m plete d  at 1. 2 5  m g/ k g ), b ase d o n disc ussi o n a n d a gree me nt b y t he 
I n v esti gat or a n d me dical m o nit or.  D ose escalati o n ma y b e c o nsi dere d if t he f oll o wi n g criteria are 
met:  
• T olera bilit y t o gi v osira n at 1. 2 5 m g/ k g o nce m o nt hl y has b ee n de m o nstrat e d base d  o n 
n o d ose i nterr u pti o ns d ue t o L F T ele v ati o ns at t he 1. 2 5  m g/ k g o nce m o nt hl y d ose le vel 
(see Secti o n  6. 2. 3. 1 ) a n d n o si g nifica nt safet y c o n cer ns d ue t o ot her A Es t h at w o ul d 
precl u de a patie nt fr o m recei vi n g a hi g her d ose of gi v osira n as j u d ge d b y t he  
I n v esti gat or a n d S p o ns or.    
• Uri ne A L A le v els ( m m ol/ m ol Cr) are n ot sta bl y m ai ntai ne d ≤ U L N or are i n d uci ble  
• Patie nt has i na de q uate cli nical res p o nse (e g, brea kt hr o u g h attac ks or o n g oi n g c hr o nic 
s y m pt o ms), acc or di n g t o I n v esti gat or j u d ge me nt.  
U p o n i m ple me ntati o n of a me n d me nt  5, all patie nts recei vi n g 1. 2 5  m g/ k g gi v osira n o nce m o nt hl y 
w h o d o n ot ha ve o n g oi n g cli nicall y rele va nt tra nsa mi nase ele vati o ns wi ll ha ve t heir d ose 
i ncreas e d t o 2. 5  m g/ k g gi v osira n o nce m o nt hl y base d o n t olera bilit y al o ne, wit h o ut a n y criteria 
f or A L A re d ucti o n or cli nical acti vit y .  D ose i ncreases s h o ul d ta ke effect as of t he date t hat 
s ufficie nt st u d y dr u g mat erial ca n b e ma de a va ila ble f or t he patie nt.  
6. 2. 4.  Pre p ar ati o n, H a n dli n g, a n d St or a ge  
St u d y dr u g will be st ore d u pri g ht a n d refri gerat e d at a p pr o xi matel y 2 t o 8° C.   
Staff at eac h cli nical st u d y ce nter, or t he h o me healt hcare pr ofessi o nal, will be res p o nsi ble f or 
pre parati o n of gi v o sira n d oses, acc or di n g t o pr oce d ures detaile d i n t he P har mac y Ma n ual.  I n 
cases w h ere gi v osira n is a d mi nistere d at h o me b y a patie nt/care gi ver, d osi n g ma y b e pre p are d a n d 
a d mi nistere d b y t he patie nt/care gi ver acc or di n g t o pr oce d ures detaile d i n t h e Patie nt / Care gi ver 
St ora ge a n d A d mi nistrati o n I nstr u cti o ns.  N o s pecial pr oce d ures f or t he s afe ha n dli n g of st u d y 
dr u g are re q uir e d.  
A S p o ns or re pres e ntati ve or desi g n ee will be p er mitte d, u p o n re q uest, t o a u dit t he s u p plies, 
st ora ge met h o ds, dis pe nsi n g pr oce d ures , a n d rec or ds.  
A d diti o nal st ora ge a n d pre parati o n det ails are pr o vi de d i n t he P har mac y Ma n ual a n d t he 
Patie nt/ Care gi v er St ora ge a n d A d mi nistrati o n I nstr ucti o ns.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025755] u g will be ret ur ne d t o t he S p o ns or ( or desi g nee) or destr o ye d at 
t he cli nical st u d y ce nter acc or di n g t o a p plica bl e re g ulati o ns.   
F urt her i nstr u cti o ns a b o ut dr u g acc o u nta bilit y are detaile d i n t he P har mac y Ma n ual.  
6. 3.  C o nc o mit a nt Me dic ati o ns  
Use of c o n c o mita nt me dicati o ns will be rec or de d o n t he patie nt’s ele ctr o nic case re p ort f or m 
(e C R F) or electr o ni c diar y as i n dicate d i n t he Sc he d ules of Assess me nts ( Ta ble  1, Ta ble  2, a n d  
Ta ble  3).  T his i ncl u des all prescri pti o n me dicati o ns, her bal pre parati o ns, o ver -t he -c o u nter ( O T C) 
me dicati o ns, vita mi ns, a n d mi nerals.  A n y c ha n ges i n me dicati o ns d uri n g t h e st u d y will als o be 
rec or de d o n t he e C R F.  
A n y c o nc o mita nt me dicati o n t hat is re q uire d f or t he patie nt’s welf are ma y be a d mi nistere d b y t he 
I n v esti gat or.  H o w e ver, it is t he res p o nsi bilit y of t he I n vesti gat or t o e ns ur e t hat details re gar di n g 
t he me dicati o n are rec or de d o n t he e C R F.  Patie nts s h o ul d  n ot start ne w me dicati o n re gi me ns 
d uri n g t he st u d y, i ncl u di n g re gi me ns of vita mi ns or her bal me di cati o ns, wit h o ut c o ns ultati o n wit h 
t he I n v esti gat or.  
P or p h yria attac ks ma y b e treate d acc or di n g t o l ocal sta n dar d of care w hic h var y b y re gi o n b ut ca n 
i ncl u de, b ut n ot li mite d t o, car b o h y drate l oa di n g, oral or I V gl u c ose, oral or I V a n al gesics, or al 
ci meti di ne, a n d I V he mi n. Use of t hese m e dicati o ns is per mi tte d at a n y p oi nt i n t he st u d y (e x ce pt 
re g ularl y sc h e d ule d he mi n f or pr o p h yla xis), base d o n cli nical j u d g me nt.  All treat me nts recei ve d 
f or p or p h yria attac ks i ncl u di n g a n y h e mi n use will be ca pt ur e d i n t he c o nc o mita nt me dicati o ns 
e C R F.   
Patie nts wit h p or p h yria c o ul d ha ve altere d he patic he me s y nt h esis, a n d treat me nt wit h gi v osira n 
c o ul d als o m o d ulate t his pat h wa y a n d s ec o n daril y i m pact C Y P e nz y m e acti vit y.  Res ults fr o m a 
D DI st u d y i n AI P p atie nts w h o are C H E are prese nte d i n Secti o n  1. 2. 2. [ADDRESS_1025756] u gs t hat are met a b olize d b y t hes e C Y P e nz y mes.  Base d o n t h e m o derat e decrease i n C Y P 2 D 6 
or C Y P 1 A 2 acti vit y, i n vesti gat ors will re vie w all c o nc o mita nt me dicati o ns t hat are pri maril y 
meta b olize d b y t hese e nz y m es a n d m o nit or t he patie nt's cli nical res p o nse t o t hese me dicati o ns 
d uri n g t he st u d y.  Me dic ati o ns meta b oliz e d pri maril y b y C Y P 2 D 6 a n d C Y P 1 A 2 wit h a narr o w 
t hera pe utic i n de x (ie, t hat re q uire re g ular l a b orat or y m o nit ori n g) ma y nee d t o be m o nit ore d m ore 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025757]’s pres cri pti o n i nf or mati o n t o deter mi ne if t here is a nee d t o m o nit or c o nc o mita nt 
me dicati o ns f or differe n ces i n safet y or effic ac y of t he me dicati o n base d o n re p orte d D DIs wit h 
C Y P 2 D 6 or C Y P 1 A 2.  F or m ore detaile d a n d u p -t o -date i nf or mati o n o n C Y P s u bstrates, see:  
htt ps:// w w w.f da. g o v/ dr u gs/ de vel o p me nt a p pr o val pr ocess/ de vel o p me ntres o urces/ dr u gi nteracti o nsl 
a beli n g/ u c m 0 9 3 6 6 4. ht m.  
Sta n dar d vita mi ns (i ncl u di n g vita mi n B 6 s u p ple m e ntati o n, see Secti o n  6. 3. 4 ) a n d t o pi[INVESTIGATOR_75509] o ns are p er mitte d; h o we ver, t o pi[INVESTIGATOR_32453] m ust n ot be a p plie d a n y w h ere n ear t h e 
i njecti o n site(s) u nless me dicall y i n dicate d.  
6. 3. 1.  He mi n Pr o p h yl a xis  
I n p atie nts w h o were o n re g ul arl y sc he d ul e d he mi n pr o p h yl a xis pri or t o t he st u d y, c ollecti o n of 
uri ne sa m ples f or A L A, P B G, a n d A L A S [ADDRESS_1025758] occ ur 
≥ [ADDRESS_1025759] u d y 
a n d s h o ul d be rec or de d as a c o nc o mita nt me dicati o n i n t he e C R F. If he mi n is use d f or p or p h yria 
attac ks, sc he d ul e d uri ne s a m ples f or A L A, P B G a n d A L A S 1 m R N A assess me nts will be c ollecte d 
4 da ys ( wit h a wi n d o w  of u p t o 8 da ys [ + 4 da ys]) after t he patie nt’s l ast he mi n d ose.   
W here a p plica ble c o u ntr y a n d l o cal re g ul ati o ns a n d i nfrastr uct ur e all o w, Scree ni n g a n d o n -st u d y 
uri ne sa m ples f or A L A, P B G, a n d A L A S [ADDRESS_1025760] u d y ce nter at t he ne xt 
visit.  
6. 3. 2.  G o n a d otr o pi n -Rele asi n g H or m o n e A n al o g ue Tre at me nt  
If, at t he ti me of Scree ni n g, patie nts are recei vi n g treat me nt wit h a g o na d otr o pi n -releasi n g 
h or m o ne ( G n R H) a nal o g ue t o pre ve nt atta c ks, t he y ma y e nr oll i n t he st u d y if t he y me et t he 
i ncl usi o n criteria f or p or p h yria attac ks ( Se cti o n  5. 1 ) a n d a gree t o r e mai n o n G n R H treat me nt 
t hr o u g h o ut t he 6 -m o nt h treat me nt peri o d.  At t he discreti o n of t he i n vesti gat or, G n R H a nal o g u es 
ma y b e disc o nti n ue d aft er patie nts ha ve c o m plete d t he 6 -m o nt h treat me nt peri o d, if cli nicall y 
i n dicate d.  
T he i nitiati o n of treat me nt wit h G n R H a nal o g u es d uri n g t he 6 -m o nt h treat me nt peri o d is 
disc o ura ge d.   
6. 3. 3.  A n al gesic Us a ge  
A nal gesic me dicati o ns, i ncl u di n g o pi [INVESTIGATOR_27968] (s y nt hetic a n d n o n -s y nt hetic s u bsta nces [ narc otics]) or 
n o n -ster oi d a nti -i nfla m m at or y m e dicati o ns  ( N S AI Ds) are per mitte d f or t h e ma na ge me nt of 
p or p h yri a a n d f or p or p h yria attac ks, b ase d o n cli ni cal j u d g m e nt.  All a nal gesia usa ge as ta k e n b y 
t he patie nt at h o me will be ca pt ur e d b y t he patie nt or care gi ver via t h e e Diar y usi n g dail y 
q uesti o ns o n t he t y p e, d ose, a n d fre q ue nc y of a n al gesic us e t hr o u g h M o nt h [ADDRESS_1025761] u d y.  
A d diti o nal me dicati o ns, i ncl u di n g a n al gesics, ta k e n at a healt hcare facilit y (e g, d uri n g a n attac k) 
will be ca pt ure d i n c o n c o mita nt me dicati o ns e C R F.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 2  After M o nt h 1 2, usa ge of a n y a nal gesic m e dicati o ns will be rec or de d i n t he c o nc o mita nt 
me dicati o ns e C R F, al o n g wit h all ot her me dicati o ns use d.  
F or patie nts bei n g tr eate d wit h re g ular o pi [INVESTIGATOR_2495] d a nal gesics b et wee n attac ks, if t he I n v esti gat or ( or a 
treati n g p ai n s peci alist) deter mi nes t hat a  re d ucti o n of t he o pi [INVESTIGATOR_2495] d d ose is cli nicall y i n dicat e d, 
c o u ntr y s p ecific g ui d a nce o n o pi [INVESTIGATOR_2495] d ta peri n g s h o ul d be f oll o we d a n d c o ns ultati o n wit h a pai n 
s pecialist s h o ul d be c o nsi dere d.  A d ecrease of ≤ 1 0 % per wee k is c o nsiste nt wit h c urre nt 
g ui da n ce.  G ui da n ce  o n o pi [INVESTIGATOR_2495] d ta peri n g ma y b e f o u n d at: 
htt ps:// w w w.c dc. g o v/ dr u g o ver d ose/ p df/cli nical _ p oc ket _ g ui de _ta peri n g -a. p df .  
If patie nts use N S AI Ds i nter mitte ntl y or c hr o nicall y, t he y m ust be a ble t o t olerate t he m a n d h a ve 
ha d n o pre vi o us si de effects (e g, gastric dis tr ess or blee di n g).   
6. 3. 4.  Vit a mi n B [ADDRESS_1025762] ei ne le vels ma y s h o w a n i ncreas e c o m pare d t o 
le vels bef ore treat me nt.  Bl o o d h o m oc ystei ne le v els will be assesse d as i n dicate d i n t he Sc he d ul e 
of Assess me nts ( Ta ble  1, Ta ble  2, a n d  T a ble  3) .  It is rec o m me n d e d t hat p atie nts wit h i ncrease d 
bl o o d h o m oc ystei ne le v els recei ve a s u p ple me nt c o ntai ni n g vita mi n B 6 .  All vita mi n s u p ple me nts 
s h o ul d be rec or de d o n t h e c o nc o mita nt me dicati o ns e C R F.  
6. 4.  C o ntr ace pti ve Re q uire me nts  
N o data are a v aila ble o n t he use of gi v osira n i n pr e g n a nc y; h o w e ver, t here is n o s us pi[INVESTIGATOR_37180] o n of 
h u ma n terat o ge nicit y bas e d o n class effects or ge n ot o xic p ote ntial.  Gi v osira n was neit her 
ge n ot o xic n or clast o ge ni c i n i n vitr o a n d i n vi v o st u dies.   
W o me n of c hil d -beari n g p ote ntial m ust be willi n g t o use acce pta ble met h o ds of c o ntrace pti o n 
fr o m [ADDRESS_1025763] u d y pri or t o its c o m pleti o n.   
Birt h c o ntr ol met h o ds w hic h are c o nsi dere d acce pta ble i ncl u de:  
• Place me nt of a n i ntra uteri ne de vice  
• Bilateral t u bal occl usi o n  
• S ur gical steriliz ati o n of male part ner ( wit h t he a p pr o priate p ost -vas ect o m y 
d oc u me ntati o n of t he a bs e nce of s p er m i n t he eja c ulate; f or fe m ale patie nts o n t he 
st u d y, t he vas ect o miz e d male part ner s h o ul d be t he s ole part ner f or t hat p atie nt).  
• Esta blis he d use of oral, i m pla nta ble, i njecta ble, tr a ns der mal h or m o nal, or i ntra uteri ne 
h or m o ne -rel easi n g s yste m as met h o ds of c o ntrace pti o n:  W o me n of c hil d -beari n g 
p ote ntial usi n g h or m o nal met h o ds of c o ntrace pti o n m ust als o use a barrier met h o d 
(c o n d o m or occl usi ve ca p [ dia p hra g m or cer vi cal/ va ult ca p] i n c o nj u ncti o n wit h 
s per mici de [e g, f oa m, gel, fil m, crea m, or s u p p osit or y]).  See Secti o n  6. 3 .  
• If h or m o nal met h o ds of c o ntrace pti o n are me dicall y c o nt rai n dicate d d u e t o u n derl yi n g 
disease, a d o u ble -barrier met h o d (c o m bi nati o n of male c o n d o m wit h ca p, dia p hra g m, 
or s p o n ge, i n c o nj u ncti o n wit h s per mici de) is als o c o nsi dere d a n acce pta ble met h o d of 
c o ntrace pti o n.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 3  • Se x ual a bsti ne nce, w he n t his is i n li ne wit h t he preferre d a n d us ual lifest yle of t he 
patie nt, is c o nsi dere d a n acce pta ble met h o d o nl y if defi ne d as refrai ni n g fr o m 
heter ose x ual i nterc o urs e d uri n g t he e ntire peri o d of ris k ass ociate d wit h t he st u d y dr u g 
( defi ne d a b o ve).  Peri o dic a bsti ne nce (e g,  cale n dar, o v ulati o n, s y m pt ot her mal, p ost -
o v ulati o n met h o ds) a n d wit h dra wal are n ot c o nsi dere d se x ual a bsti ne nce a n d d o n ot 
meet criteria f or a n acce pta ble met h o d of birt h c o ntr ol.  As deter mi ne d b y t he 
i n vesti gat or, t he relia bilit y of s e x ual a bsti ne nce ne e ds t o be e val uat e d i n rel ati o n t o t he 
d urati o n of t he cli nical tri al a n d t he preferre d a n d us ual lifest yle of t he pati e nt.  
A bsti ne nt patie nts m ust a gree t o use [ADDRESS_1025764] u g ( defi ne d a b o ve).  
• W o me n of c hil d -beari n g p ote ntial i ncl u de a n y fe m ale patie nts w h o ha v e e x perie nce d 
me narc h e ( or b e gi n me narc he o ver t he c o urse of t h e st u d y) a n d w h o are n ot 
p ost me n o pa usal or per m a ne ntl y steriliz e d (e g, bilateral t u bal oc cl usi o n, h ysterect o m y, 
or bilateral sal pi n gect o m y).  A p ost me n o pa usal st ate is defi ne d as t he a bse nce of 
me nses f or [ADDRESS_1025765] u d y assess me nts is pr o vi de d i n Ta ble  1 ( Scree ni n g a n d 6 -M o nt h Treat me nt 
Peri o d),  Ta ble  2 ( O pe n -l a bel E xte nsi o n St u d y:  After M o nt h 6 t hr o u g h M o nt h 1 8), a n d  Ta ble  3 
( O pe n -la b el  E xte nsi o n St u d y:  M o nt h 1 9 t hr o u g h E O S).  
W here a p plica ble c o u ntr y a n d l o cal re g ul ati o ns a n d i nfrastr uct ur e all o w f or h o me healt hcare, 
healt hcare ma y ta k e place at a l ocati o n ot her t ha n t he cli nical trial site t o perf or m st u d y 
assess me nts i ncl u di n g tar get e d p h ysical e x a m/ b o d y s yste m assess me nt, assess me nts f or vital 
si g ns, a n d c ollecti o n of bl o o d a n d uri ne sa m ples f or safet y la b orat or y ass ess me nts, a n d P D 
assess me nts, at all ti me p oi nts as s pecifie d i n t he Sc he d ule of Ass ess me nts.  
7. 1.  Scree ni n g Assess me nts  
A n i n f or me d c o ns e nt f or m (I C F), a n d asse nt f or m if a p plica ble, t hat has b ee n a p pr o ve d b y t h e 
a p pr o priate I nstit uti o nal Re vie w B o ar d (I R B)/I n d e pe n de nt Et hics C o m mittee (I E C) m ust be 
si g ne d b y t he p atie nt ( or le gal g u ar dia n) bef ore t h e Scree ni n g pr oce d ures are i n itiate d.  All 
patie nts ( or t heir le gal g u ar dia ns) will be gi ve n a c o p y of t h e si g n e d a n d dat e d I C F a n d/ or asse nt 
f or m.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025766] or y/ disease hist or y will be o btai ne d at Scree ni n g.  Patie nts 
will be scree n e d t o e ns ure t hat t he y mee t all t he i n cl usi o n criteria a n d n o n e of t he e x cl usi o n 
criteria ( Secti o n  5. 1  a n d Secti o n  5. 2 , res pecti vel y) .  If re q uir e d, A L A/ P B G le vels c ollecte d d uri n g 
t he scree ni n g p eri o d f or eli gi bilit y p ur p oses s h o ul d be a nal yz e d l ocall y.  Me dical hist or y c ollecte d 
will i nc or p orate t he p atie nt’s p or p h yri a  hist or y, i ncl u di n g t heir t y pic al attac k c haracteristics, 
tri g gers, a n d treat me nt, as well as ce ntr al ve n o us access hist or y, ir o n o verl oa d hist or y, a n d pri or 
li ver disease hist or y.  
A n y pre vi o us partici pati o n i n a ge ne t hera p y st u d y or ot her p or p h yri a st u d y  s h o ul d be n ote d i n t he 
e C R F.  
I n p atie nts w h o were o n he mi n pr o p h yla xis pri or t o t he st u d y, uri nar y sa m ples f or A L A, P B G, 
a n d A L A S [ADDRESS_1025767] 4 da ys 
after pr o p h yl actic he mi n disc o nti n uati o n a n d after t he patie nt’s last he mi n d ose.  T w o Scree ni n g 
uri ne sa m ples f or A L A a n d P B G s h o ul d be c ollect e d o n a n y 2 differe nt da ys (ca n be c o nsec uti ve 
da ys) d uri n g t he Scree ni n g peri o d; o ne Scree ni n g uri ne sa m ple s h o ul d be c ollecte d f or A L A S [ADDRESS_1025768] ora ge, a n d h a n dli n g.  
7. 1. 1.  Retesti n g  
If, i n t he I n vesti gat or’s j u d g me nt, la b a b n or malities are li kel y t o be tra nsi e nt, la b orat or y tests ca n 
be re peate d.  I N R a n d ot her la b orat or y val ues ca n be reteste d d uri n g Scree ni n g as l o n g as t he 
patie nt ca n be e val uate d f or eli gi bilit y a n d ra n d o miz e d wit hi n t he all o we d Scree ni n g p eri o d.  
7. 1. 2.  Rescree ni n g  
A patie nt w h o d oes n ot meet all st u d y eli gi bilit y criteria d u e t o a tra nsie nt c o n diti o n o bser ve d at 
Scree ni n g (e g, pr o hi bite d me dicati o ns t hat were s u bse q ue ntl y disc o nti n ue d, varia bilit y i n A L T 
meas ure me nts) will be all o we d t o ret ur n f or res cree ni n g.  
A patie nt will be re -c o ns e nte d if res cree ni n g occ urs o utsi de of t he [ADDRESS_1025769] u d y ( Scree ni n g t hr o u g h t he E O S visit).  
If a patie nt e x perie nces a p ote ntial p or p h yri a attac k, t he patie nt or desi g nat e d care gi ver s h o ul d 
n otif y t he st u d y staff vi a t he e Diar y ( Secti o n  4. 6 ).   U n der cir c u msta nces i n w hic h t he e Diar y 
ca n n ot be use d t o rec or d a p ote ntial p or p h yria attac k, patie nts, care gi vers, or treati n g p h ysicia ns 
s h o ul d n otif y t he st u d y ce nter directl y.  I n s o me i nsta nces, t he site ma y be n otifie d of p ote ntial 
p or p h yri a attac ks b y h ealt hcare pr o vi ders n ot parti ci pati n g i n t he st u d y.   T h e st u d y ce nter will 
c o ntact t he patie nt/care gi ver or t he treati n g p h ysicia n t o deter mi ne if a p ote ntial p or p h yri a attac k 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 5  has occ urre d; e v e nts t hat are n ot c o nfir me d as p or p h yria attac ks s h o ul d be re p orte d as A Es or 
S A Es, as defi ne d i n Secti o n  7. 5. [ADDRESS_1025770] 
res ults.  
7. 2. 2.  P ai n a n d P ai n -Rel at e d Assess me nts  
Patie nts or care gi v ers will rec or d a nal gesic us a ge  a n d pai n -relate d ass ess me nts i n t he patie nt’s 
e Diar y dail y fr o m Scree ni n g t hr o u g h M o nt h [ADDRESS_1025771] 6  m o nt hs of t he O L E.  D uri n g t h e scree ni n g peri o d, t here s h o ul d be a mi ni m u m of 4 e ntries 
c o m plete d o n da ys w he n t he patie nt is n ot ha vi n g a n attac k .  
Se verit y of pai n will be ca pt ure d via e Diar y usi n g q uesti o n # 3 (a n N R S) fr o m t he B PI -S F, 
w herei n t he p atie nt is as ke d t o c h o ose t he rati n g t h at descri bes t he w orst le v el of pai n e x perie nce d 
o ver t he past [ADDRESS_1025772] u d y. 
A d diti o nal me dicati o ns, i ncl u di n g a n al gesics, ta k e n at a healt hcare faci lit y (e g, d uri n g a n attac k) 
will be ca pt ure d i n c o n c o mita nt me dicati o ns e C R F.  
After M o nt h 1 2, usa ge of a n y a nal gesic m e dicati o ns will be rec or de d i n t he c o nc o mita nt 
me dicati o ns e C R F, al o n g wit h all ot her me dicati o ns use d.  
7. 2. 3.  Assess me nts of N a use a a n d F ati g u e  
Patie nts or care gi v ers will rec or d t he f oll o wi n g n a usea a n d fati g u e assess m e nts i n t he patie nt’s 
e Diar y dail y fr o m St u d y Da y [ADDRESS_1025773] 2 4 
h o urs.  
Se verit y of fati g ue will b e ca pt ur e d via e Di ar y usi n g q uesti o n # 3 (a n 1 1 -p oi nt N R S) fr o m t he 
Brief Fati g ue I n ve nt or y -S h ort F or m ( B FI -S F), w h erei n t he patie nt is as k e d t o c h o ose t he rati n g 
t hat descri bes t he w orst le vel of fati g u e e x perie nce d o ver t he p ast 2 4 h o urs.  
7. 2. 4.  Q u alit y of Life ( Q O L)  
Q O L q uesti o n naires will be use d t o e val uat e o verall heal t h stat us a n d q ualit y of lif e.  If Q O L 
assess me nts are o bt ai ne d d uri n g a p or p h yria attac k, it s h o ul d be d oc u me nte d i n t he patie nt’s 
e C R F.  
Q O L assess me nts i ncl u d e t he f oll o wi n g:  
• S F -1 2: a [ADDRESS_1025774] 4 wee ks t hat ta k es a p pr o xi matel y 5 mi n utes t o c o m plete. (2 6 ) 
• E Q -5 D -5 L: a 2 -pa ge scal e t hat i ncl u des q uesti o ns t hat ca pt ure h ealt h o n 5 di me nsi o ns 
( m o bilit y, s elf -care, us u al acti vities, pai n/ disc o mf ort, a n d a n xiet y/ de pressi o n) a n d a 
vis ual a nal o g s cale ( V A S) ca pt uri n g t he p atie nt’s self -rat e d healt h (2 7 ).  T h e E Q -[ADDRESS_1025775] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 6  • P GI C: T he Patie nt Gl o bal I m pr essi o n of C ha n ge ( P GI C) is o ne q u esti o n a ns were d 
acc or di n g t o a 7 -p oi nt scale (ra n gi n g fr o m ver y m uc h i m pr o ve d t o ver y m u c h w orse) 
f or t he assess me nt of a p atie nt’s percei ve d o verall healt h stat us c ha n ge si nc e t he 
be gi n ni n g of t he st u d y.  T his q uesti o n naire ta k es a p pr o xi matel y 2 t o 3  mi n utes t o 
c o m plete.  
• P P E Q: T he P or p h yria Patie nt E x perie nce Q uesti o n naire ( P P E Q) is a set of q uesti o ns t o 
assess treat me nt e x perie n ce a n d i m pacts t o t he patie nt's life n ot c ollecte d b y t he ot her 
Q O L assess me nts.  T his q uesti o n naire ta kes a p pr o xi matel y 5  mi n utes t o c o m plete.  
A d diti o nall y, da ys of misse d w or k or sc h o ol d u e t o p or p h yri a s y m pt o ms/attac ks will be assesse d.  
7. 3.  P h ar m ac o d y n a mic Assess me nts  
Uri ne sa m ples will be c ollecte d f or assess me nt of gi v osira n P D para meters pri or t o d osi n g .  T he 
P D effect of gi v osira n will be e val uate d b y s p ot uri ne A L A a n d P B G le vels n or malize d t o s p ot 
uri ne creati ni ne le vels.  Uri ne sa m ples will be c ollecte d f or assess me nt of circ ulati n g A L A S 1 
m R N A le vels.  A nal ysis of uri ne A L A S 1 m R N A l e vels will be perf or me d at Al n yla m; all ot her 
uri ne P D a nal yses will ta ke place at a ce ntral la b orat or y.  Si nce I n v esti gat ors are bli n de d t o 
treat me nt assi g n me nts, t he y will als o be bli n de d t o A L A a n d P B G res ults a nal yze d at t he ce ntr al 
la b orat or y.  I n a d diti o n, i n vesti gat o rs a n d staff i n v ol ve d wit h t his trial a n d all me dical staff 
i n v ol ve d i n t he s u bject’s me dical care s h o ul d refrai n fr o m o btai ni n g l oc al A L A or P B G 
meas ure me nts u ntil at least 1 2 wee ks aft er t he m o nt h 6 visit (t o a v oi d p ote ntial u n bli n di n g).  If 
A L A or P B G i s me as ure d d uri n g t his peri o d, all reas o na ble ste ps m ust be u n derta ke n t o a v oi d 
i nf or mi n g t he s u bject a n d st u d y pers o n n el of t he res ults.    
Uri ne A L A a nal yses ma y be c o n d ucte d at a l ocal l a b orat or y or A L A res ults fr o m pre vi o us visits 
ma y b e e val u ate d i n p atie nts o n t he 1. 2 5  m g/ k g m o nt hl y d ose i n w h o m d ose escalati o n t o 
2. 5  m g/ k g o nce m o nt hl y is bei n g c o nsi dere d d ue t o i na de q uate cli nical res p o nse a n d w h o ha v e 
de m o nstrate d t olera bilit y t o gi v osira n.  D os e escalati o n i n patie nts o n t he 1. 2 5  m g/ k g o nce 
m o nt hl y d os e ca n o cc ur starti n g at M o nt h [ADDRESS_1025776] ora ge a n d a nal ys es will be 
pr o vi de d i n t he La b orat or y M a n ual.  
7. 4.  P h ar m ac o ki netic Asse ss me nts  
Bl o o d a n d uri ne s a m ples will be c ollecte d fr o m all patie nts f or assess me nt of t he P K of gi v osira n 
a n d its maj or meta b olite, 3'( N -1) gi v osira n, at t he ti me p oi nts i n A p pe n di x Secti o n  [ADDRESS_1025777] d ose 
sa m ple ( ± 1 5  mi n utes) will be c ollecte d i n all patie nts; t hese assess me nts will be paire d wit h 
tri plicate E C G meas ur e me nts.   
I n a d diti o n,  2 4 -h o ur ( ± 2 h o urs) p ost d ose P K sa m ples will be c ollecte d i n a s u bset of 
a p pr o xi matel y [ADDRESS_1025778] u d y ce nters (i ncl u di n g all patie nts fr o m East Asia n 
st u d y ce nt ers) ( Ta ble  8 a n d Ta ble  9).  P o p ulati o n P K a nal ysis will be perf or me d o n t he s pars e P K 
sa m ples fr o m all patie nts.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025779] u d y Ce nters  
A f ull 2 4 -h o ur ( ± 2 h o urs) P K e val uati o n will be perf or me d f oll o wi n g t he first d ose ( St u d y Da y 1) 
a n d M o nt h [ADDRESS_1025780] u d y ce nters (J a pa n, Tai wa n, or S o ut h K orea) at 
t he ti me p oi nts s pecifie d i n Ta ble  9 ( A p pe n di x Secti o n  1 1 ).   Plas ma P K para meters s u c h as C ma x , 
tma x , t ½ β , A U C, C L/ F, a n d V/ F will be assesse d f or gi v osira n a n d its maj or meta b olite, 3'( N -1) 
gi v osira n.  
A P K a nal ysis will als o be perf or me d fr o m p o ole d uri ne sa m ples c ollect e d o ver [ADDRESS_1025781] u d y ce nters acc or di n g t o t he sc he d ule pr o v i de d i n Ta ble  1 0  ( A p p e n di x 
Secti o n  1 1 ).   
7. 5.  S afet y Assess me nts  
T he assess me nt of s afet y d uri n g t he st u d y will c o nsist of t he s ur veilla nce a n d rec or di n g of a d verse 
e ve nts ( A Es) i n cl u di n g s eri o us a d vers e e v e nts ( S A Es) ( Secti o n  7. 5. 6 ), rec or di n g of c o nc o mita nt 
me dicati o n a n d meas ure me nts of vital si g ns, wei g ht a n d h ei g ht, p h ysic al e x a mi nati o n, a n d E C G 
fi n di n gs a n d la b orat or y t ests . 
Si nce p or p h yria attac ks ( as defi ne d i n Secti o n  3. 5 ) are rec or de d as a n efficac y assess me nt of 
gi v osira n, t hes e will n ot be treate d as A Es or S A Es.  H o we ver, if a patie nt e x perie nces a n o n -
p or p h yri a A E d uri n g a p or p h yri a attac k, it s h o ul d be re p ort e d.  
Safet y will be m o nit ore d o ver t he c o urse of t he st u d y b y a D M C, as descri be d i n Secti o n 4. 7 . 
7. 5. 1.  Vit al Si g ns  
Vital si g ns will be meas ure d as s pe cifie d i n t he Sc he d ule of Assess me nts ( Ta ble  1, Ta ble  2, a n d  
Ta ble  3) a n d will i ncl u de bl o o d p ress ure, heart rate, b o d y t e m perat ure, a n d res pi[INVESTIGATOR_1305] y rate.  Vital 
si g ns will be meas ur e d i n t he seate d or s u pi [INVESTIGATOR_050] p ositi o n (s h o ul d be c o nsiste nt t hr o u g h o ut t he st u d y 
f or eac h patie nt), after t h e patie nt has reste d c o mf orta bl y f or [ADDRESS_1025782] u d y.  B o d y te m perat ure i n 
de grees Celsi us will be o btai ne d via oral, t y m pa ni c, or a xillar y met h o ds.  H eart rate will be 
c o u nte d f or a f ull mi n ute a n d rec or de d i n be ats per mi n ute, a n d res pi[INVESTIGATOR_1313] o n rate  will be c o u nte d f or 
a f ull mi n ute a n d rec or de d i n breat hs per mi n ute.  
F or t he safet y of t he p atie nt, a d diti o nal vital si g n assess me nts ma y be a d d e d at t he discreti o n of 
t he I n v esti gat or.  
7. 5. 2.  Wei g ht a n d Hei g ht  
Hei g ht, b o d y w ei g ht, a n d B MI me as ure me nts will be c ollecte d as s pecifi e d i n t he Sc he d ule of 
Assess me nts ( Ta ble  1, T a ble  2, a n d  Ta bl e  3).  
Hei g ht will be meas ure d i n ce nti meters a n d b o d y wei g ht will be meas ure d i n kil o gra ms.  B o d y 
mass i n de x will be calc ulate d i n t he data bas e.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025783] u d y ce nter visit or offsite ma y be us e d 
f or d osi n g calc ulati o ns.  
7. 5. 3.  P h ysic al E x a mi n ati o n  
C o m plete a n d tar gete d p h ysical e x a mi nati o ns will be c o n d ucte d as s pecifi e d i n t he Sc he d ule of 
Assess me nts ( Ta ble  1, T a ble  2, a n d  Ta bl e  3); if a p h ysical e x a mi nati o n is sc he d ule d f or a d osi n g 
visit, it s h o ul d be c o n d ucte d pri or t o d osi n g.  
C o m plete p h ysical e x a mi nati o ns will i ncl u de t he e x a mi nati o n of t he f oll o wi n g:  ge n eral 
a p peara nce, hea d, e yes, ears, n ose a n d t hr o at, c hest/res pi[INVESTIGATOR_1305] y, heart/car di o vasc ular, 
gastr oi ntesti nal/li ver, m usc ul os keletal/e xtre mities, der mat ol o gi cal/s ki n, t h yr oi d/ nec k, l y m p h 
n o des, a n d ne ur ol o gic al/ ps yc hiatric.  
Tar gete d p h ysic al e x a mi nati o ns will i ncl u de t he e x a mi nati o n of t he f oll o wi n g:  ge n eral 
a p peara nce, c hest/res pi[INVESTIGATOR_1305] y, heart/car di o vasc ul ar, gastr oi ntesti nal/li ver, a n d 
ne ur ol o gi cal/ ps yc hiatric.  
7. 5. 4.  Electr oc a r di o gr a m  
A si n gle sta n d ar d 1 2 -le a d E C G will be rec or de d at Scree ni n g; all ot her E C Gs will be perf or m e d 
i n tri plicate, usi n g ce ntraliz e d E C G ser vice e q ui p me nt, wit h rea di n gs a p pr o xi matel y [ADDRESS_1025784] u d y 
Da y 1 a n d at t he M o nt h 5, M o nt h 6, a n d M o nt h 1 2 visits ( Ta ble  8 a n d  Ta ble  9); t hese assess me nts 
will be paire d wit h P K meas ure m e nts.   
I n a s u bset of a p pr o xi matel y [ADDRESS_1025785] u d y ce nters (i n cl u di n g all patie nts at 
East Asia n st u d y ce nters), E C Gs at 2 4 -h o urs ( ± 2 h o urs) p ost d ose s h o ul d be perf or me d i n tri plic ate 
(al o n g wit h a 2 4 -h o ur P K assess me nt) o n St u d y D a y 1 a n d a t t he M o nt h 6 Visit ( Ta ble  8 a n d 
Ta ble  9). 
Patie nts s h o ul d be s u pi [INVESTIGATOR_050] f or at least 5 mi n utes bef ore eac h E C G is o btai ne d.  T he 
electr o p h ysi ol o gical para meters assesse d will be r h yt h m, ve ntric ular rat e, R R i nter val, P R 
i nter val, Q R S d urati o n, Q T i nter val, Bazett -c orrecte d Q T i nter val ( Q Tc B), a n d Fri d erici a 
c orrecte d Q T i nter val ( Q Tc F).  
W he n E C G a n d bl o o d sa m ple c ollecti o n (e g, f or P K assess me nt) occ ur at t h e sa me ti me, E C Gs 
s h o ul d be perf or m e d bef ore bl o o d sa m ples are dra w n.  
Si n gle sta n dar d [ADDRESS_1025786] u d y Ma n u al.  
7. 5. 5.  Cli nic al L a b or at or y Assess me nts  
Cli nical la b orat or y assess me nts are  liste d i n Ta ble  7 a n d will be e val uat e d at a ce ntral la b orat or y 
at ti me p oi nts s pecifie d i n t he Sc he d ule of Ass ess me nts ( Ta ble  1, Ta bl e  2, a n d  Ta ble  3).  If a 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025787] u d y Da y 1 a n d at 6 -m o nt h i nter vals, 
t hereafter.  
D-di mer assess me nts will be perf or m e d at t he Scree ni n g, Da y 1, M o nt h 3, M o nt h 6, M o nt h 9, a n d 
M o nt h 1 2 visits o nl y; as a cli nical res earc h para m eter o n l y, d -di mer res ults will n ot be 
c o m m u nicate d t o t he st u d y ce nters.  
S pecific d osi n g a n d m o nit ori n g i nstr ucti o ns are pr o vi de d f or ele v ati o ns i n A L T tr a nsa mi nases 
( Secti o n  6. 2. 3. 1 ) a n d el e vati o ns i n li pase a n d/ or a m ylase ( Secti o n  6. 2. 3. 2 ).  F or a n y ot h er 
u ne x plai ne d cli nicall y rele va nt, a b n or mal la b orat or y test o cc urri n g after st u d y dr u g 
a d mi nistrati o n, t he test s h o ul d be re peate d a n d f oll o we d u p at t he discreti o n of t he I n ves ti gat or 
u ntil it has ret ur ne d t o t he n or mal ra n ge or sta biliz e d, a n d/ or a dia g n osis is ma de t o a de q u atel y 
e x plai n t he a b n or malit y.  
A d diti o nal safet y la b orat or y assess me nts, i ma gi n g, a n d c o ns ultati o n ma y b e perf or me d, as 
i n dicate d b y t he cli nical sit uati o n , f or e val uati o n a n d/ or i n c o ns ultati o n wit h t he me dical m o nit or; 
res ults ma y b e c ollect e d a n d s h o ul d be i ncl u de d i n t he cli nical data bas e.     
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 0  T a ble  7: Cli nic al L a b or at or y Assess me nts  
He m at ol o g y  
C o m plete bl o o d c o u n t wit h differe ntial   
Ser u m C he mistr y  
S o di u m  P otassi u m  
B U N  P h os p hate  
Creati ni ne a n d e G F R  Al b u mi n  
Uric aci d  Calci u m  
T otal pr otei n  Car b o n di o xi de  
Gl uc ose  C hl ori de  
Li pase  
A m ylase  Ferriti n  
Li ver F u ncti o n Tests   
A S T  A L P  
A L T  Bilir u bi n (t otal a n d direct)  
G G T   
Uri n al ysis  
Vis ual i ns pecti o n f or a p peara nce a n d c ol or  Bilir u bi n  
p H ( di pstic k)  Nitrite  
S pecific gra vit y  R B Cs  
Ket o nes  Ur o bili n o ge n  
Al b u mi n  Le u k oc ytes  
Gl uc ose  Micr osc o p y (if cli nicall y i n dicate d)  
Pr otei n   
C o a g ul ati o n   
Pr ot hr o m bi n ti me ( P T)  
Partial T hr o m b o plasti n Ti me ( P T T)  D-di mer a 
I nter nati o nal N or malize d Rati o (I N R)  
P re g n a nc y Testi n g ( F e m ales of c hil d -be ari n g p ote nti al o nl y)  
β-h u ma n c h ori o nic g o na d otr o pi n   
A b bre viati o ns:  A S T =as partate tra nsa mi nase; A L P =al kali ne p h os p hatase; A L T =ala ni ne tra nsa mi nase; 
B U N = bl o o d urea nitr o ge n; e G F R =esti mate d gl o mer ular filtr ati o n rate; G G T = ga m ma -gl uta m yltra nsferase; 
I N R =i nter nati o nal n or malize d rati o; P T = pr ot hr o m bi n ti me; R B C =re d bl o o d cells.  
a   D-di mer assess me nts will be perf or me d at t he Scre e ni n g, Da y 1, M o nt h 3, M o nt h 6, M o nt h 9, a n d M o nt h 1 2 
visits o nl y; as a cli nical resear c h para meter o nl y, d -di mer res ults will n ot b e c o m m u nicate d t o t he st u d y ce nters.  
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025788] u g a nti b o dies ( A D A) 
t o gi v osira n.  Bl o o d sa m ples f or A D A t esti n g m ust be c ollecte d bef ore st u d y dr u g a d mi nistrati o n 
at ti me p oi nts s pecifie d i n t he Sc he d ule of Ass ess me nts ( Ta ble  1, Ta bl e  2, a n d  Ta ble  3); f or 
f urt her det ails, see Ta bl e  [ADDRESS_1025789] will be perf or me d at Scree ni n g a n d ser u m or uri ne pre g na n c y tests will be 
perf or me d t h ereafter per t he Sc he d ule of Ass ess me nts ( Ta ble  1, T a ble  2, a n d  Ta ble  3) a n d a n y 
ti me pre g n a nc y is s us pecte d.  T he res ults of t he pre g n a nc y test m ust be k n o w n bef ore st u d y dr u g 
a d mi nistrati o n.  Patie nts w h o are pre g na nt are n ot eli gi ble f or st u d y p artici p ati o n.   
A n y w o m a n wit h a p ositi ve pre g na n c y test d uri n g t he st u d y will be disc o nti n ue d fr o m st u d y dr u g 
b ut will c o nti n ue t o be f oll o we d f or safet y.  A p ositi ve uri ne pre g n a nc y test s h o ul d be c o nfir me d 
b y a s er u m pre g na nc y test pri or t o disc o nti n ui n g t he st u d y dr u g. Patie nts det er mi ne d t o be 
pre g na nt w hile o n st u d y will be f oll o we d u ntil t he pre g na nc y o ut c o me is k n o w n (see Secti o n 
7. 5. 6. 6  f or f oll o w -u p i nstr ucti o ns).  
7. 5. 6.  A d verse E ve nts  
7. 5. 6. 1.  Defi niti o ns  
A d verse E ve nt  
Acc or di n g t o t he I nt er nati o nal C o nfere nce o n Har m o nizati o n (I C H) E 2 A g ui deli ne Defi niti o ns 
a n d Sta n dar ds f or E x pe dite d Re p orti n g, a n d 2 1 C F R 3 1 2. 3 2, I N D Safet y Re p orti n g, a n a d vers e 
e ve nt ( A E) is a n y u nt o war d me dical oc c urre nce i n a patie nt or cli nical i n vesti gati o nal s u bject 
a d mi nistere d a me dici nal pr o d uct a n d w hic h d o es n ot necessaril y ha v e a ca usal relati o ns hi p wit h 
t his treat me nt.  
Si nce p or p h yria attac ks ( as defi ne d i n Secti o n  3. 5 ) are rec or de d as a n efficac y assess me nt of 
gi v osira n,  t hes e will n ot be treate d as A Es or S A Es. H o we ver, if a patie nt e x perie nces a n o n -
p or p h yri a A E d uri n g a p or p h yri a attac k, it s h o ul d be re p ort e d.  
Seri o us A d verse E ve nt  
A seri o us a d verse e v e nt ( S A E) is a n y u nt o w ar d m e dical oc c urre nce t hat at a n y d os e:  
• Res u lts i n deat h  
• Is life -t hreate ni n g (a n e v e nt w hic h places t he pati e nt at i m me diate ris k of deat h fr o m 
t he e ve nt as it occ urre d.  It d oes n ot i ncl u d e a n e v e nt t hat ha d it occ urre d i n a m ore 
se vere f or m mi g ht h a ve ca use d deat h)  
• Re q uires i n -patie nt h os pi[INVESTIGATOR_27967] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_27967] o n  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 2  • Res ults i n persiste nt or si g nifica nt disa bilit y or i nca pacit y  
• Is a c o n ge nital a n o mal y or birt h defect  
• Is a n i m p orta nt me dical e ve nt t hat ma y n ot b e i m me diatel y life -t hreate ni n g or res ult i n 
deat h or h os pi[INVESTIGATOR_1314] o n b ut ma y je o p ar dize t he patie nt a n d ma y re q uir e i nter ve nti o n t o 
pre ve nt o ne of t he ot her o utc o mes liste d i n t he defi niti o n a b o ve (e g, e v e nts i ncl u de 
aller gic br o n c h os pas m re q uiri n g i nte nsi ve treat me nt i n a n e mer ge n c y r o o m or at h o me, 
bl o o d d yscrasias, c o n v ulsi o ns, or t he de vel o p me nt of dr u g d e pe n d e nc y or a b use).  
P or p h yria attac ks (as defi ne d i n Secti o n  3. 5 ) will be rec or de d f or effic ac y assess me nt of gi v osira n 
a n d will n ot  be treate d as S A Es.  H o we ver, if a patie nt e x perie nces a n o n -p or p h yri a -attac k S A E 
( or S A Es) d uri n g a p or p h yria attac k t hat me ets S A E criteria, t his n o n -p or p h yria -attac k S A E(s) 
s h o ul d be re p orte d.  
A d verse E ve nt Se ve rit y  
A d verse e ve nts are t o be gra de d acc or di n g t o t he cate g ories det aile d bel o w:  
Mil d:  Mil d; as y m pt o matic or mil d s y m pt o ms; cli nical or dia g n ostic o bser vati o ns 
o nl y; i nter ve nti o n n ot i n dicate d  
M o derate:  M o derate; mi ni mal, l ocal or n o ni n vasi ve i nter ve nti o n  i n dicate d; li miti n g a ge 
a p pr o priate i nstr u me ntal acti vities of dail y li vi n g (e g, pre pari n g meals, 
s h o p pi n g f or gr oceries or cl ot hes, usi n g t he tele p h o ne, ma na gi n g m o ne y)  
Se vere:  Se vere or me dicall y si g nifica nt b ut n ot i m me diatel y life -t hreate ni n g; 
h os pit alizati o n or pr ol o n gati o n of h os pi[INVESTIGATOR_1314] o n i n dicate d; disa bli n g; li miti n g 
self -care acti vities of dail y li vi n g (ie, bat hi n g, dressi n g a n d u n dressi n g, fee di n g 
self, usi n g t he t oilet, ta ki n g me dicati o ns, a n d n ot be dri d de n); O R life -
t hreate ni n g c o nse q ue nces ; ur ge nt i nter ve nti o n i n dicate d; O R deat h relate d t o 
a n a d verse e ve nt  
C ha n ges i n s e verit y s h o ul d be d oc u me nte d i n t he me dical rec or d t o all o w assess me nt of t he 
d urati o n of t he e v e nt at eac h le vel of s e verit y.  A d verse e v e nts c haract erize d as i nter mitte nt 
re q uire d o c u me ntati o n of t he start a n d st o p of eac h i nci de nce.  W he n c h a n ges i n t he se verit y of a n 
A E occ ur m ore fre q ue ntl y t ha n o n ce a d a y, t he ma xi m u m se verit y f or t he e x perie nce t hat da y 
s h o ul d be n ote d.  If t he s e verit y cat e g or y c h a n ges o ver a n u m ber o f da ys, t h e n t h ose c ha n ges 
s h o ul d be rec or de d se p aratel y ( wit h disti nct o nset dates).  
A E se verit y a n d s eri o us n ess are assesse d i n de p e n de ntl y.  ‘ Se verit y’ c h aracteriz es t he i nte nsit y of 
a n A E.  ‘ Seri o us’ is a re g ulat or y d efi niti o n a n d ser ves as a g ui de t o t he S p o ns or f or defi ni n g 
re g ulat or y re p orti n g o bli gati o ns (s ee defi niti o n f or S A E).  
Rel ati o ns hi p of t he A d verse E ve nt t o St u d y Tre at me nt  
T he relati o ns hi p of eac h A E t o st u d y treat me nt s h o ul d be e val uate d b y t h e I n v esti gat or usi n g t h e 
f oll o wi n g criteria:  
Defi nitel y relate d:  A cli nical e ve nt, i ncl u di n g la b orat or y test a b n or malit y, occ urri n g i n a pla usi ble 
ti me relati o ns hi p t o t he me dicati o n a d mi nistrati o n, a n d w hic h ca n n ot be 
e x plai ne d b y c o nc urre nt disease or ot her dr u gs or c he micals.  T he res p o nse t o 
wit h dra wal of t he dr u g s h o ul d be cli nicall y pla usi ble.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 3  P ossi bl y relate d:  A cli nical e ve nt, i ncl u di n g la b orat or y test a b n or malit y, wit h a reas o na ble ti me 
se q ue nce t o t he me dicati o n a d mi nistrati o n, b ut w hic h c o ul d als o be e x plai ne d 
b y c o nc urre nt disease or ot her dr u gs or c he micals.  I nf or mati o n o n t he dr u g 
wit h dra wal ma y be lac ki n g or u nclear.  
U nli kel y relate d:  A cli nical e ve nt, i ncl u di n g la b orat or y test a b n or malit y, wit h little or n o 
te m p oral relati o ns hi p t o me dicati o n a d mi nistrati o n, a n d w hic h ot her dr u gs , 
c he micals, or u n derl yi n g disease pr o vi de pla usi ble e x pla nati o ns.  
N ot relate d:  A cli nical e ve nt, i ncl u di n g la b orat or y test a b n or malit y t hat has n o te m p oral 
relati o ns hi p t o t he me dicati o n or has m ore li kel y alter nati ve eti ol o g y.  
A d verse E ve nts of Cli nic a l I nterest  
T he f oll o wi n g e ve nts are c o nsi dere d t o be A Es of cli nical i nterest:  
• A L T ele vati o ns > 3 × U L N ( or > 3 × t h e baseli ne A L T meas ure me nt if b aseli n e is > U L N  
• Li pas e or a m ylas e > 3 ×U L N ( or >3 × t he bas eli ne li pase or a m ylase m eas ur e me nt if 
baseli ne is > U L N)   
• Se vere or s eri o us I S Rs, I S Rs t hat are ass ociate d wit h a recall p he n o m e n o n (reacti o n at 
t he site of a pri or i njecti o n wit h s u bse q ue nt i njecti o ns) or, I S Rs t hat lea d t o te m p orar y 
d ose i nterr u pti o n or per m a ne nt disc o nti n uati o n of st u d y dr u g  
• A na p h yl actic Reac ti o ns. A na p h yl actic reacti o n is a se vere, p ote ntiall y fatal, s yste mic 
aller gic reacti o n wit h ac ute o nset ( mi n utes t o h o urs).  S y m pt o ms of a n a n a p h yla ctic 
reacti o n  ma y i ncl u d e s ki n or m uc osal tiss ue (e. g. ge n eralize d hi ves, pr urit us, 
a n gi o e de ma), res pir at or y c o m pr o mise (e. g. w h eezi n g, br o nc h os pas m, h y p o xia), 
re d uce d bl o o d press ur e or ass ociate d s y m pt o ms (e. g. s y nc o p e, h y p ot o nia).  See 
Secti o n  1 1. 2  f or g ui da nce o n dia g n osi n g a na p h yla ctic reacti o ns (2 8 ).  
7. 5. 6. 2.  Eliciti n g a n d Rec or di n g A d verse E ve nts  
Eliciti n g A d verse E ve nts  
T he patie nt s h o ul d be as k e d a b o ut me dicall y rele v a nt c ha n ges i n his/ her healt h si nce t he last visit.  
T he patie nt s h o ul d als o be as ke d if h e/s he has bee n h os pi[INVESTIGATOR_190153] e d, ha d a n y acci de nts, use d a n y n e w 
me dicati o ns, or c ha n ge d c o nc o mi ta nt me dicati o n r o uti nes ( b ot h prescri pti o n a n d O T C).  I n 
a d diti o n t o patie nt o bser vati o ns, A Es will be d oc u me nte d fr o m a n y cli nicall y rel e va nt la b orat or y 
fi n di n gs, p h ysical e x a mi nati o n fi n di n gs, E C G c h a n ges, or ot her fi n di n gs t h at are rele v a nt t o 
patie nt safet y.  
Rec or di n g A d verse E ve nts  
T he I n vesti gat or is r es p o nsi ble f or rec or di n g n o n -seri o us A Es t hat are o bser ve d or re p orte d b y t he 
patie nt after a d mi nistrati o n of t he first d ose of st u d y dr u g re gar dless of t heir relati o ns hi p t o st u d y 
dr u g t hr o u g h t h e e n d of st u d y.  N o n -s eri o us A Es will be f oll o we d u ntil t he e n d of st u d y.  
T he I n vesti gat or is r es p o nsi ble f or rec or di n g S A Es t hat are o bser ve d or re p orte d b y t h e patie nt 
after t he ti me w h e n t he i nf or me d c o ns e nt is si g ne d re gar dl ess of t heir relati o ns hi p t o st u d y dr u g 
t hr o u g h t he e n d of st u d y.  S A Es will be f oll o we d u ntil satisfact or y res ol uti o n, u ntil baseli ne le vel 
is reac h e d, or u ntil t he S A E is c o nsi dere d b y t he I n vesti gat or t o b e c hr o nic or t he patie nt is sta ble, 
as a p pr o priat e.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025790] be descri be d i n detail:  o nset 
ti me a n d date, descri pti o n of e ve nt, se v erit y, relati o ns hi p t o i n vesti gati o nal dr u g, act i o n ta ke n, a n d 
o utc o me (i ncl u di n g ti me a n d date of res ol uti o n, if a p plica ble).  
F or S A Es, t he e v e nt(s) m ust be rec or de d i n t he e C R F. If t he electr o nic d ata ca pt ure ( E D C) is 
u na vaila ble, a b ac k -u p S A E f or m s h o ul d be c o m plete d.   
F or A Es t hat are c o nsi dere d A Es of cli nical i nterest, t he S p o ns or or its desi g nee s h o ul d be n otifie d 
wit hi n [ADDRESS_1025791] ( A E CI) e C R F.  A d diti o nal cli nical 
a n d la b orat or y i nf or mati o n ma y b e c ollect e d base d u p o n t he se verit y or nat ure of t he e ve nt; see 
Secti o n  6. 2. 3   re gar di n g m o nit ori n g f or li ver or pa ncreas a b n or malities.  
Refer t o C R F c o m pleti o n g ui deli nes f or details o n re p orti n g e ve nts i n t he s u p ple me ntal A E CI 
e C R F.  
Rec or di n g a n I S R  
F or eac h I S R t hat meets A E CI criteria ( Secti o n  7. 5. 6. 1 ), t he I n vesti gat or, or dele gate, s h o ul d 
s u b mit a s u p ple me ntal I S R e C R F, rec or di n g a d diti o nal i nf or mati o n (e g, d es cri pti o ns, o nset a n d 
res ol uti o n date, se verit y, treat me nt gi ve n, a n d e ve nt o utc o me).  A n I S R is defi ne d as a l ocal 
reacti o n at or near t he site of i njecti o n.  “ At or n ear” t he i njecti o n site i ncl u des reacti o ns at t he 
i njecti o n site, a djace nt t o t he i njec ti o n site, or a reacti o n w hic h ma y s hift sli g htl y a wa y fr o m t he 
i njecti o n site d ue t o gra vit y (e g, as ma y occ ur wit h s welli n g or he mat o ma).  A reacti o n wit h o nset 
a n d res ol uti o n wit hi n 4 h o urs of t he i njecti o n (e g, tra nsie nt pai n/ b ur ni n g at i njecti o n site)  d oes n ot 
meet t he st u d y d efi niti o n of a n I S R u nless i m me diate treat me nt is r e q uire d.  A s yste mic reacti o n 
w hic h i ncl u des t he i njecti o n site, e g, ge n eralize d urticaria or ot h er disti nct e ntities or c o n diti o ns 
li ke l y m p ha de n o p at h y t hat ma y b e near t he i njec ti o n site, is n ot c o nsi dere d a n I S R.   
7. 5. 6. 3.  Seri o us A d verse E ve nts Re q uire I m me di ate Re p orti n g t o S p o ns or/ Desi g nee  
A n assess me nt of t he seri o us ness of eac h A E will be ma de b y t he I n v esti gat or.  A n y A E a n d 
la b orat or y a b n or malit y t h at meets t he S A E criteria i n Se cti o n  7. 5. 6. [ADDRESS_1025792] t he f oll o wi n g i nf or mati o n:  
• Patie nt’s st u d y n u m ber  
• Descri pti o n a n d dat e of o nset of t he e ve nt  
• Criteri o n f or seri o us  
• Preli mi nar y assi g n me nt of relati o ns hi p t o st u d y dr u g, a n d  
• I n v esti gat or/st u d y ce nter i nf or mati o n  
T o re p ort t he S A E, c o m plete t he S A E f or m. Wit hi n [ADDRESS_1025793] u d y Ma n ual.  
A p pr o priate re me dial meas ures s h o ul d be ta k e n b y t he I n v esti gat or usi n g his/ her best me dical 
j u d g me nt t o treat t he S A E.  T hese meas ures a n d t he patie nt’s res p o ns e t o t hese meas ur es s h o ul d 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025794] u g A d mi nistrati o n, t he E ur o pea n Me dici nes A ge nc y’s E u dra Vi gila nce ele ctr o nic 
s yste m acc or di n g t o Dir ecti ve 2 0 0 1/ 2 0/ E C, a n d t o all c o u ntr y R e g ulat or y A ut h orities w here t he 
st u d y is bei n g c o n d uct e d, acc or di n g t o l ocal a p plic a ble re g ulati o ns.  
7. 5. 6. 5.  Seri o us A d verse E ve nt N otific ati o n t o t he I nstit uti o n al Re vie w 
B o ar d/I n de pe n de nt Et hics C o m mittee  
S us pecte d u ne x pecte d seri o us a d verse reacti o ns ( S U S A Rs) will be re p orte d t o t he I R B/I E C per 
t heir i nstit uti o nal p olic y b y t he I n vesti gat or or S p o ns or ( or S p o ns or desi g n ee) acc or di n g t o 
c o u ntr y re q uir e me nts.  C o pi[INVESTIGATOR_102182] h re p ort a n d d oc u me ntati o n of I R B/I E C n otificati o n a n d 
ac k n o wle d ge me nt of recei pt will be ke pt i n t he I n vesti gat or’s st u d y file.  
7. 5. 6. 6.  Pre g n a nc y Re p orti n g  
If a fe male patie nt b ec o m es pre g na nt d uri n g t his st u d y t hr o u g h [ADDRESS_1025795] part u m c o m plicati o n, s p o nta ne o us a b orti o n, still birt h, ne o natal deat h, 
or c o n ge nital a n o mal y, t h e n t he I n vesti gat or s h o ul d f oll o w t he pr oce d ures f or re p orti n g a n S A E as 
o utli ne d i n Secti o n  7. 5. 6. 3 .   
7. 5. 6. 7.  O ver d ose Re p orti n g  
A n o ver d ose is defi ne d as a n y d os e a d mi nistere d t o or ta ke n b y a p atie nt (acci de ntall y or 
i nte nti o nall y) t hat e x cee ds t he hi g hest dail y d ose, or is at a hi g h er fre q ue n c y, t ha n i ncl u d e d i n t he 
pr ot oc ol.  It is u p t o t he I n vesti gat or t o d eci de w h et her a d os e is t o be c o nsi dere d a n o v er d ose, i n 
c o ns ultati o n wit h t he S p o ns or.  O ver d ose m ust be rec or de d i n t he e C R F.  
All re p orts of o v er d ose ( wit h or wit h o ut a n A E) m ust be re p orte d wit hi n [ADDRESS_1025796] or at or y Bi o m ar kers  
W here all o we d per l ocal re g ulati o ns a n d I R B/ E C a p pr o val a n d p atie nt c o nse nt (a n d asse nt, w h ere 
a p plica ble), s er u m, plas ma, a n d uri ne sa m ples will be c ollecte d a n d ma y b e arc hi v e d a n d use d f or 
a nal ys es of e x pl orat or y bi o mar kers relate d t o meta b olic pr ofili n g or t he effects of gi v osira n or 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025797] patie nt’s last visit i n t he 
st u d y.  
Details re gar di n g t h e c o ll ecti o n, pr ocessi n g, st ora ge, a n d s hi p pi n g of sa m ples ca n be f o u n d i n t he 
La b orat or y M a n ual.  
7. 6. 2.  D N A S a m ples  
A bl o o d or sali va sa m ple f or D N A will be c ollecte d at Scree ni n g f or ge neti c testi n g of p or p h yria -
relate d ge n es o nl y i n patie nts wit h o ut pri or d oc u me nt e d ge netic testi n g f or p or p h yri a.    
I n a d diti o n, w here l o cal r e g ul ati o ns per mit a n d s u bject t o discreti o nar y a p pr o val fr o m e ac h 
ce nter’s I R B/I E C as well as patie nt c o nse nt ( a n d asse nt, w here a p plica ble), a v ol u ntar y bl o o d 
sa m ple ma y b e c ollecte d as part of  a l ater D N A a n al ysis, w hic h c o ul d i ncl u de a deter mi nati o n of 
t he s pectr u m of p or p h yri a m utati o ns i n patie nts wit h A H Ps a n d t he relati o ns hi p bet wee n 
p or p h yri a m utati o ns a n d t he safet y a n d effi cac y of gi v osira n.   
T he S p o ns or will a nal yze D N A se q ue n ces wit h i n ge n es rel e va nt t o t he m o de of acti o n a n d 
res p o nse t o gi v osira n.  N o a d diti o nal testi n g will be perf or me d o n t he sa m pl es c ollecte d i n t he 
st u d y.  
Details re gar di n g t h e c oll ecti o n, pr ocessi n g, st ora ge, a n d s hi p pi n g of t he sa m ples ca n be f o u n d i n 
t he La b or at or y M a n ual.  T he sa m ple c ollect e d as part of a lat er a n al ysis will be sec urel y st or e d i n 
a ce ntr al bi ore p osit or y f or u p t o [ADDRESS_1025798] u d y (ie, last 
patie nt, last visit), or as l ocal re g ulati o ns all o w.  After 1 5 y ears ha v e ela ps e d, t he sa m ples will be 
destr o ye d.  
7. 7.  C O VI D -1 9 D at a C ollecti o n  
I nf or mati o n o n t he c or o na vir us disease 2 0 1 9 ( C O VI D -1 9) i nfecti o n stat us of t he patie nt, if 
k n o w n, a n d ot her i nf or mati o n o n t he i m pact of t he C O VI D -1 9 p a n de mic o n t he patie nt's 
parti ci pati o n i n t he st u d y will be c ollecte d.  
8.  S T A TI S TI C S  
A detaile d Statistical A nal ysis Pla n ( S A P) will be fi nalize d bef ore a n y i nteri m a nal ysis or 
data base l oc k, w hic he v er occ urs earlier.  T h e pla n will detail t he i m ple me ntati o n of statistical 
a nal ys es i n acc or da n ce wit h t he pri nci pal feat ur es descri be d i n t he pr ot o c ol.  
8. 1.  Deter mi n ati o n of S a m ple Size  
T he pla n ne d t otal e nr oll me nt f or t he st u d y is a p pr o xi matel y [ADDRESS_1025799] 9 0 % p o wer t o dete ct a 4 5 % re d u cti o n i n t he a n n ualize d 
attac k rat e at a 2 -si d e d 5 % si g nifica nce l e vel ass u mi n g a me a n a n n ualize d attac k rat e of 8, a 
sta n dar d de viati o n ( S D) of [ADDRESS_1025800] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025801] 8 0 % p o wer e ve n if t he dr o p o ut rate is as hi g h as 1 5 % u n der t h e sa me ass u m pti o ns.  
8. 2.  St atistic al Met h o d ol o g y  
8. 2. 1.  P o p ul ati o ns t o be A n al yze d  
T he p o p ulati o n a nal ysis sets f or t he 6 -m o nt h treat me nt p hase are defi n e d as f oll o ws:  
• F ull A nal ysis Set ( F A S):  All ra n d o mize d patie nts ( A H P) w h o recei v e d at least o ne 
d ose of st u d y dr u g. Patie nts will be gr o u pe d b y t h eir ra n d o ml y assi g ne d tr eat me nt 
gr o u p (i.e. as r a n d o mize d).  
• F ull A nal ysis Set i n AI P patie nts ( F A S AI P ): All ra n d o mize d AI P patie nts ( wit h 
m utati o n i n t he H M B S  ge ne) w h o recei v e d at least o ne d ose of st u d y dr u g. P atie nts 
will be gr o u pe d b y t heir ra n d o ml y assi g ne d tr eat m e nt gr o u p (i.e. as ra n d o miz e d).  
• Safet y A nal ysis Set:  All patie nts w h o recei ve d at l east o ne d ose of st u d y dr u g, 
gr o u pe d acc or di n g t o t he treat me nt act u all y recei ve d.  Patie nts w h o recei ve d a n y 
a m o u nt of gi v osira n will be i ncl u de d i n t he gi v osira n ar m.   
• P K A nal ysis Set:  All patie nts w h o recei ve d a n y a m o u nt of st u d y dr u g a n d ha ve at 
least o ne p ost d ose bl o o d sa m p le f or P K para meters a n d w h o ha ve e val ua bl e P K data.  
• P D A nal ysis Set:  All patie nts w h o recei ve d a n y a m o u nt of st u d y dr u g a n d w h o ha ve 
at least o ne p ost d ose uri n e sa m ple f or t he d eter mi n ati o n of A L A or P B G will be 
i ncl u de d i n t he P D a nal yses.  
T he pri mar y p o p ulati o n use d t o e val uate effic ac y will be t he F A S AI P  f or t he pri mar y e n d p oi nt a n d 
sec o n dar y e n d p oi nts i n AI P patie nts, a n d F A S f or t he sec o n dar y e n d p oi nt of a n n ualize d attac k 
rate i n A H P patie nts.  Safet y will be a nal yz e d usi n g t he Safet y A nal ysis Set. T he P K a n d P D 
A nal ysis Sets will be use d t o c o n d uct P K a n d P D a nal ys es, res p ecti vel y.  
8. 2. 2.  E x a mi n ati o n of S u b gr o u ps  
S u b gr o u p a n al ys es ma y be c o n d ucte d f or sele cte d e n d p oi nts.  Detaile d met h o d ol o g y will be 
pr o vi de d i n t he S A P.  
8. 2. 3.  H a n dli n g of Missi n g D at a  
Ha n dli n g of  missi n g data will be descri be d i n t he S A P.  
8. 2. 4.  B aseli ne E v al u ati o ns  
De m o gra p hics a n d ot her baseli ne c haracteristics, i ncl u di n g diseas e -s pecific i nf or mati o n, will be 
s u m marize d descri pti vel y b y treat me nt ar m a n d o verall f or t he F A S a n d Safet y A nal ysis Set.   
8. 2. 5.  Effic ac y A n al yses  
T he a nal ysis of t he pri mar y e n d p oi nt a n d t he sec o n dar y e n d p oi nts t hat pert ai n t o t he AI P 
p o p ulati o n will be base d o n t he F A S AI P . T h e a nal ysis of t he sec o n dar y e n d p oi nts t hat pertai n t o 
t he A H P p o p ulati o n will be base d o n t he F A S.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 8  T he o vera ll T y p e I err or rate will be str o n gl y c o ntr olle d at a 2 -si de d 0. 0 5 si g nifica nce l e vel f or t h e 
pri mar y a n d sec o n dar y e n d p oi nts usi n g a n al p ha s pe n di n g f u ncti o n f or t he i nteri m a nal ysis  a n d a 
fi x e d se q ue ntial testi n g pr oce d ure at t he fi n al a nal ysis.  T he pri mar y e n d p oi nt will be c o m pare d 
bet wee n tr eat me nt ar ms at t he fi nal a nal ysis si g nifica nce le vel.  If t he pri m ar y a nal ysis of t he 
pri mar y e n d p oi nt is statisticall y si g nifica nt, t he n t h e sec o n dar y e n d p oi nts will eac h be teste d i n 
t he or der s pecifie d i n t he Se c o n dar y E n d p oi nts secti o n ( Secti o n  3. 2 ).  
If a test of t he pri mar y or a sec o n dar y e n d p oi nt is n ot statisticall y si g nifica nt at t he fi nal a nal ysis 
si g nifica n ce, t he t esti n g of re mai ni n g e n d p oi nts i n t he se q ue nce will st o p.   
8. 2. 5. 1.  Pri m ar y E n d p oi nt  
T he pri mar y e n d p oi nt of t he st u d y is a c o m p osite of t he a n n ualize d rate of p or p h yri a attac ks 
re q uiri n g h os pi[INVESTIGATOR_27967] o n, ur ge nt healt hcare visit, or I V he mi n a d mi ni strati o n at h o me i n patie nts 
wit h AI P o ver t he 6 -m o nt h d o u ble -bli n d treat me nt peri o d ( Secti o n  3. 5 ).  T h e a n n ualize d attac k 
rate ( A A R) will be cal c ulate d as t he t otal n u m ber of p or p h yria attac ks treate d at ur ge nt he alt hcare 
visit or wit h I V he mi n at h o me, di vi de d b y t he t otal n u m ber of da ys i n t he tr eat me nt peri o d, 
m ulti plie d b y t he n u m ber of da ys i n a year,  
t ot al  n u m b er  of  q u alif yi n g  p or p h yri a  att ac ks  
t ot al  n u m b er  of  d a ys  i n  t h e  tr e at m e nt  p eri o d ×[ADDRESS_1025802] ors 
(stat us of he mi n pr o p h yl a xis use pri or t o st u d y e ntr y a n d hist orical attac k rate).  
T he n u m ber of da ys patie nts s pe n d i n t he [ADDRESS_1025803] u d y treat me nt earl y ( bef ore t he e n d of t he 6 -m o nt h treat me nt 
peri o d) will still be f oll o we d f or c ollecti o n of attac k data t hr o u g h t he e n d of t he [ADDRESS_1025804] u d y treat me nt a n d s u bs e q ue ntl y recei ve he mi n pr o p h yla xis, t he pri mar y a nal ysis will i ncl u de 
attac k data c ollecte d u p t o t he start  of he mi n pr o p h yla xis.  
I n a d diti o n t o t he pri mar y a n al ysis p -val ue, a n esti mate d rati o of mea n a n n ualize d attac k rates 
bet wee n tr eat me nt ar ms wit h its c orres p o n di n g 9 5 % c o nfi de n ce i nter val will be esti mate d fr o m 
t he ne gati ve bi n o mial re gressi o n m o del.  Des cri pti ve statistics f or t he me dia n a n d i nter q uartile 
ra n ge of t h e a n n ualize d attac k rate will als o be prese nte d f or eac h tr eat me nt ar m.  
Se nsiti vit y a n al ys es will be detaile d i n t he S A P.  
8. 2. 5. 2.  Sec o n d ar y E n d p oi nts  
Sec o n dar y e n d p oi nts are descri be d i n Secti o n  3. [ADDRESS_1025805] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 9  T he a nal ysis of t he a n n ualize d rate of p or p h yria attac ks  re q uiri n g h os pi[INVESTIGATOR_27967] o n, ur ge nt 
healt hcare visit, or I V he mi n a d mi nistrati o n at h o me i n all A H P patie nts (t he F A S) o v er t he 6 -
m o nt h d o u ble -bli n d peri o d a n d t he a n n ualize d rat e of he mi n d oses will be c o n d ucte d usi n g t he 
sa me a p pr oac h as t he pri mar y a nal ysis.    
F or t he a nal ysis of uri nar y A L A -relate d e n d p oi nts, t he A L A le vels will be c o m par e d b et wee n 
treat me nt ar ms usi n g a mi x e d -effects m o del r e peat e d meas ur es ( M M R M) wit h baseli ne A L A as a 
c o nti n u o us c o variate a n d fi x e d effect ter ms i ncl u di n g treat me nt ar ms, stratificati o n fact ors f or AI P 
patie nts ( pri or he mi n pr o p h yla xis stat us a n d hist oric al attac k rates), visit a n d treat me nt b y visit 
i nteracti o n .  P B G -relat e d e n d p oi nts will als o be a nal yze d usi n g t his met h o d ol o g y.   
Dail y p ai n, na usea, a n d fati g ue s c ores will be a nal yz e d se paratel y usi n g t he area u n d er t he c ur ve 
( A U C) a p pr oac h: t he A U C o ve r [ADDRESS_1025806] orat or y e n d p oi nts ( Secti o n  3. 3 ).  Details will be 
descri be d i n t he S A P.  
8. 2. 6.  P h ar m a c o d y n a mi c A n al ysis  
A nal ys es of A L A a n d P B G are d escri be d i n Secti o n  8. 2. 5. 2 .  I n a d diti o n, A L A a n d P B G le v els 
will be s u m mariz e d descri pti vel y at e ac h s c he d ule d visit.  
8. 2. 7.  P h ar m a c o ki netic A n al ysis  
P o p ulati o n p har mac o ki netic a nal ysis will be perf or me d t o descri be t h e plas ma p har mac o ki n etics 
of gi v osir a n a n d its maj or meta b olite, 3'( N -1) gi v osira n. T he i m pact of rele va nt c o variat es, s uc h 
as, e g, de m o gra p hics, re n al f u ncti o n) o n plas ma P K will be e val uate d.    
I n p atie nts fr o m East Asi a n ce nters wit h 2 4 -h o ur P K c ollecti o n, p har mac o ki netic a nal yses of  
plas ma a n d uri ne will be c o n d ucte d usi n g n o nc o m part me ntal met h o ds. Plas ma p har mac o ki n etic 
para meters i ncl u de b ut will n ot be li mite d t o:  ma xi m u m plas ma c o nce ntrati o n ( C ma x ), ti me t o 
ma xi m u m plas ma c o nce ntrati o n (t ma x ), eli mi nati o n half -life (t ½ β ), area u n der t he c o nce ntr ati o n -
ti me c ur ve ( A U C), a p pare nt cleara nce ( C L/ F), a n d a p pare nt v ol u me of distri b uti o n ( V/ F).  Ot her 
para meters ma y be calc ul ate d, if dee m e d necessar y.  
8. 2. 8.  S afet y A n al yses  
T he pri mar y safet y para meter is t he i nci de nce of a d verse e ve nts ( A Es).   Safet y para meters als o 
i ncl u de vital si g ns, E C Gs, cli nical la b orat or y assess me nts, a n d p h ysic al e x a ms.  T he e xte nt of 
e x p os ure will be s u m mariz e d.  T he pri mar y s u m maries of t he s afet y of gi v osira n vers us place b o 
will be base d o n safet y p ara meters wit hi n t he [ADDRESS_1025807] u g is a d mi nistere d ( St u d y 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  8 0  Da y 1) t hr o u g h t he d urati o n of t he st u d y; S A Es will be c ollecte d starti n g at t he ti me t hat i nf or me d 
c o nse nt is si g ne d a n d t hr o u g h t he d urati o n of t he st u d y.   
T he n u m ber a n d p e rce nta ge of patie nts e x perie nci n g A Es after t h e first d os e of t he st u d y dr u g will 
be s u m mariz e d f or t he f oll o wi n g A E cate g ories; a d diti o nal cate g ories ma y be s pecifie d i n t he 
S A P.  
• A n y A E  
• A n y A E t hat is assesse d as relate d t o st u d y dr u g b y t he I n v esti gat or  
• A n y s eri o us a d verse e v e nt ( S A E)  
• A n y A E lea di n g t o disc o nti n uati o n of st u d y dr u g  
• A n y A E lea di n g t o deat h  
B y -s u bject listi n gs will be pr o vi de d f or deat hs, S A Es, a n d A Es lea di n g t o st u d y disc o nti n uati o n.  
I n ci de nce of a d v erse e ve nts of cli nical i nterest will  als o be s u m marize d b y treat me nt gr o u p, a n d 
b y -s u bject listi n gs will be pr o vi de d.  
Descri pti ve statistics will be pr o vi de d f or cli nical l a b orat or y d ata a n d vital si g ns data, prese nte d as 
b ot h act ual val ues a n d c h a n ges fr o m bas eli ne o ver ti me.   La b orat or y s h ift ta bles fr o m baseli ne t o 
w orst val ues will be pres e nte d.   Baseli ne will be d efi ne d as t he l ast pre d ose o bser vati o n o n or 
bef ore Da y  1.   A b n or mal p h ysical e x a mi nati o n fi n di n gs a n d [ADDRESS_1025808] b o a n d recei ve d gi v osira n at a starti n g d ose 
of 1. 2 5 m g/ k g o nce m o nt hl y d uri n g t he O L E p eri o d ( per a m e n d me nt vers i o n 3) will be assesse d 
t o c haracteriz e t he efficac y a n d safet y f or t he l o w er d ose 1. 2 5 m g/ k g o nce m o nt hl y.    
A nal ys es f or ot her e x pl orat or y e n d p oi nts s uc h as e x pl orat or y bi o mar kers will be detaile d i n t he 
S A P.  
A d diti o nal data s u m maries t o hel p u n dersta n d  a n y i m pact of t he C O VI D -[ADDRESS_1025809] ors f or AI P 
patie nts ( pri or he mi n pr o p h yla xis stat us a n d hist orical attac k rates), a n d  wit h baseli ne A L A as a 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025810] t he si g nifica n ce le vel t o e ns ure t he 
o verall t y p e I err or rate is n ot i nflate d; t he err or s pe n di n g f u ncti o n will be s p ecifie d i n t he 
statistical a nal ysis pla n.   T he si g nifica nce le vel f or t he c o m paris o n at t he i nteri m is 0. 0 0 1 
( 2 -si de d).  T o assess d ura bilit y of t h e st u d y dr u g i n l o weri n g a n d mai ntai ni n g A L A le vel o ver 
ti me, t he o verall treat me nt effect fr o m M o nt h [ADDRESS_1025811] m o del re p eate d meas ure m e nt ( M M R M).  
St o p pi n g f or efficac y or f utilit y is n ot pla n ne d i n t his st u d y.  T o e ns ur e t hat t he st u d y is 
a de q uatel y p o w ere d f or t he pri mar y e n d p oi nt c o m paris o n at t he fi nal a n al ysi s, attac k rates ma y 
als o be e val uat e d i n a bli n de d ma n ner f or sa m ple siz e reassess me nt at t he ti me of t he i nteri m 
a nal ysis.   
T he i nteri m a nal ysis will be descri b e d i n detail i n t he S A P.  
9.  S T U D Y A D MI NI S T R A TI O N  
9. 1.  Et hic al a n d Re g ul at or y C o nsi der ati o ns  
T his st u d y  will be c o n d u cte d i n acc or da n ce wit h t he pr ot oc ol, all a p plica bl e re g ulat or y 
re q uire me nts, a n d t h e g ui deli nes of G o o d Cli nical Practice ( G C P).  C o m plia nce wit h G C P 
pr o vi des p u blic ass ura n ce t hat t he ri g hts, safet y, a n d well -bei n g of st u d y patie nts are pr o te cte d 
c o nsiste nt wit h t he pri nci ples t hat ha ve t heir ori gi n i n t he Declarati o n of Helsi n ki.  
9. 1. 1.  I nf or me d C o nse nt  
T he I n vesti gat or will e ns ure t hat t he patie nt/le gal g uar dia n is gi ve n f ull a n d a de q uate oral a n d 
writte n i nf or mati o n a b o ut t he nat ure, p ur p ose, p o ssi ble ris k a n d be nefit of t he st u d y.  
Patie nts/ Le gal g u ar dia ns m ust als o be n otifie d t hat t he y are free t o disc o nti n ue fr o m t he st u d y at 
a n y ti me.  T h e patie nt/le gal g u ar dia n s h o ul d be gi ve n t he o p p ort u nit y t o as k q uesti o ns a n d 
all o we d ti me t o c o nsi der t h e i nf or mati o n pr o vi de d.  I n t he cas e of patie nts u n der t he a ge of le gal 
c o nse nt, le gal g uar dia n(s) m ust pr o vi de i nf or me d c o nse nt a n d t he patie nt s h o ul d pr o vi de asse nt 
per l ocal r e g ulati o ns a n d i nstit uti o nal sta n dar ds.  
T he patie nt’s/le gal g uar dia n’s si g n e d a n d date d i nf or me d c o nse nt (a n d ass e nt, if a p plica ble) m ust 
be o btai ne d bef ore c o n d u cti n g a n y st u d y pr oce d ures.  
T he I n vesti gat or will i nf or m t he patie nt/le gal g uar dia n if ne w i nf or mati o n bec o mes a v aila ble t hat 
ma y b e rele v a nt t o t he patie nt’s/le gal g u ar dia n’s willi n g ness t o c o nti n ue partici pati o n i n t he st u d y. 
C o m m u nicati o n of t his i nf or mati o n s h o ul d be d oc u me nte d.  
T he I n vesti gat or m ust mai ntai n t he ori gi n al, si g ne d I nf or me d C o nse nt F or m (a n d asse nt, if 
a p plica ble).  A c o p y of t h e si g ne d I nf or m e d C o nse nt F o r m (a n d asse nt, if a p plica ble) m ust be 
gi ve n t o t he p atie nt/le gal g uar dia n.  
9. 1. 2.  Et hic al Re vie w  
T he fi nal st u d y pr ot oc ol, i ncl u di n g t he fi nal v ersi o n of t he I C F, m ust be a p pr o ve d or gi ve n a 
fa v ora bl e o pi [INVESTIGATOR_9384] o n i n writi n g b y a n I R B or I E C, as a p pr o priate.  T h e I n v esti gat or m ust s u b mit 
writte n a p pr o val b ef ore h e or s he ca n e nr oll a n y p atie nt i nt o t he st u d y.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025812] u d y (e x ce pt t h ose t hat s u p p ort t he nee d t o r e m o ve a n a p pare nt i m me diate 
hazar d t o t he patie nt).  T he pr ot oc ol m ust be rea p pr o ve d b y t he I R B or I E C u p o n recei pt of 
a me n d me nts a n d a n n u all y, as l oc al re g ul ati o ns r e q uire.  
I nitial I R B or I E C a p pr o val of t he pr ot oc ol, a n d all materials a p pr o ve d b y t he I R B or I E C f or t his 
st u d y i ncl u di n g t h e patie nt c o nse nt f or m (a n d asse nt f or m, if a p plica ble) a n d recr uit me nt materials 
m ust be mai ntai ne d b y t h e I n vesti gat or a n d m a de a vaila ble f or i ns pecti o n.  
T he I n vesti gat or will s u b mit re p orts of S A Es as o utli ne d i n Secti o n  7. 5. [ADDRESS_1025813] be s u b mitte d i n writi n g t o t he I n vesti gat or’s I R B or I E C 
a n d t he Re g ulat or y A ut h orit y f or a p pr o val bef ore patie nts are e nr olle d u n d er t he a me n d e d 
pr ot oc ol.  
9. 1. 3.  Seri o us Bre ac h of Pr ot oc ol  
I n v esti gat ors m ust n otif y t he me dical m o nit or wit hi n [ADDRESS_1025814] u d y s h o ul d be retai ne d f or t he peri o d re q uire d b y a p plica ble 
l ocal la w.  If it bec o mes necessar y f or t he S p o ns or, t he S p o ns or’s desi g nee, a p plica ble I R B/I E C, 
or a p plica ble re g ulat or y a ut h orities t o re vie w or a u dit a n y d o c u m e ntati o n r elati n g t o t he st u d y, t he 
I n v esti gat or m ust per mit direct access t o all s o urce d oc u me nts/ data.  Rec or ds will n ot be 
destr o ye d wit h o ut i nf or mi n g t he S p o ns or i n writi n g a n d gi vi n g t he S p o ns or t he o p p ort u nit y t o 
st ore t he rec or ds f or a l o n ger per i o d at t he S p o ns or’s e x pe nse.   
T he I n vesti gat or m ust e ns ure t hat t he patie nts’ c o nfi de ntialit y will be mai ntai ne d.  O n t he C R Fs 
or ot her d oc u me nts s u b mitte d t o t he S p o ns or or desi g nees, p atie nts s h o ul d n ot be i de ntifie d b y 
t heir na mes, b ut b y t he assi g ne d  patie nt n u m ber a n d i nitials.  If patie nt na m es are i n cl u de d o n 
c o pi[INVESTIGATOR_1309] d oc u me nts s u b mitte d t o t he S p o ns or or desi g nees, t he na m es (e x ce pt f or i nitials) will be 
o bliterate d a n d t he assi g n e d patie nt n u m ber a d d e d t o t he d oc u me nt.  D oc u m e nts n ot f or 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  8 3  s u b miss i o n t o t he S p o ns or (e g, si g ne d I C Fs) s h o ul d be mai ntai ne d b y t he I n vesti gat or i n strict 
c o nfi de nce.  
T he I n vesti gat or m ust treat all i nf or mati o n relate d t o t he st u d y a n d t he c o m pi[INVESTIGATOR_5829] d data as 
c o nfi de ntial, w h ose use is f or c o n d ucti n g t he st u d y.  T he S p o ns or m ust a p pr o ve a n y tr a nsfer of 
i nf or mati o n n ot directl y i n v ol ve d i n t he st u d y.  
I n c o m plia nce wit h l ocal a n d/ or re gi o nal re g ulati o ns, t his cli nical st u d y m a y be re gistere d, a n d 
st u d y res ults ma y be p ost e d o n p u blic re gistries, s uc h as Cli nical Trials. g o v.  
9. 1. 5.  E n d of St u d y  
T he E n d of St u d y is defi ne d as last patie nt, last visit.  
9. 1. 6.  Disc o nti n u ati o n of t he Cli nic al St u d y  
T he S p o ns or reser ves t he ri g ht t o disc o nti n ue t he st u d y f or cli nical or a d mi nistrati ve reas o ns at 
a n y ti me.  If t he st u d y ce nter d oes n ot recr uit at a reas o na bl e rate, t h e st u d y ma y b e disc o nti n ue d 
at t hat site.  S h o ul d t he st u d y be t er mi nate d, a n d/ or t he st u d y ce nter cl ose d f or w hate v er reas o n, 
all d oc u me ntati o n a n d st u d y dr u g p ertai ni n g t o t he st u d y m ust be ret ur ne d t o t he S p o ns or or its 
re pres e ntati ve , a n d t he I n vesti gat ors, I E C/I R B a n d Re g ulat or y A ut h orities will be pr o m ptl y 
i nf or me d of t he ter mi nati o n a n d t he reas o n f or t he decisi o n.  T he I n vesti gat or s h o ul d pr o m ptl y 
i nf or m t he patie nts a n d ass ure a p pr o priate t hera p y a n d f oll o w -u p.  Patie nts s h o ul d t he n be 
wit h dra w n fr o m t he st u d y.   
9. 2.  D at a Q u alit y C o ntr ol a n d Q u alit y Ass ur a nce  
9. 2. 1.  D at a H a n dli n g  
St u d y d ata m ust be rec or de d o n case re p ort f or ms ( pa per a n d/ or ele ctr o nic) pr o vi de d b y t he 
S p o ns or or desi g n ee o n b e half of t he S p o ns or.  Case re p ort f or ms m ust be c o m plete d o nl y b y 
pers o ns desi g nate d b y t h e I n vesti gat or.  If e C R Fs are use d, st u d y d ata m ust be e ntere d b y trai ne d 
st u d y ce nt er pers o n nel wit h access t o a v ali d a n d sec ure e C R F s yste m.  All data e ntere d i nt o t he 
e C R F m ust als o be a vaila ble i n t he s o urce d o c u me nts.  C orrecti o ns o n pa per C R Fs m ust be ma de 
s o as t o n ot o bliterate t he ori gi nal dat a a n d m ust b e i nitiale d a n d date d b y t he pers o n w h o ma d e 
t he c orrecti o n.  
9. 2. 2.  St u d y M o nit ori n g  
T he cli nical m o nit or, as a re pres e ntati ve of t he S p o ns or, has a n o bli gati o n t o cl osel y f oll o w t he 
st u d y c o n d u ct at t he st u d y ce nter.  T h e m o nit or will visit t he I n v esti gat or a n d cli nical st u d y ce nter 
peri o dicall y a n d will mai ntai n fre q ue nt tele p h o ne a n d writte n c o nta ct.  T he m o nit or will mai ntai n 
c urre nt p ers o nal k n o wle d ge of t he st u d y t hr o u g h o bser vati o n, re vie w of st u d y rec or ds a n d s o urce 
d oc u me ntati o n, a n d disc ussi o n of t he c o n d uct of t he st u d y wit h t he I n v esti gat or a n d staff.  
T he m o nit or will re vie w s o urce d oc u m e nts, s yste ms a n d C R Fs t o e ns ure o verall q ualit y a n d 
c o m plete ness o f t he d ata a n d t o c o nfir m st u d y pr oce d ures are c o m plie d wit h t he re q uire m e nts i n 
t he st u d y pr ot oc ol acc uratel y. T he S p o ns or, or its desi g nee, will be all o we d t o c o n d uct st u d y 
ce nter visits t o t he i n vesti gati o n facilities f or m o nit ori n g a n y as pect of t he st u d y.  T he I n vesti gat or 
a grees t o all o w t he m o nit or t o i ns pect t he dr u g st ora ge area, st u d y dr u g st oc ks, dr u g 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025815] u d y, t he data are t o be s u b mitte d f or p u blicati o n i n a 
scie ntific j o ur nal a n d/ or f or re p orti n g at a s cie ntifi c meeti n g.  A se parate p u blicati o n b y I nstit uti o n 
or I n vesti gat or ca n be s u b mitte d f or p u blicati o n after t his pri mar y ma n uscri pt is p u blis he d or 
f oll o wi n g t he peri o d of [ADDRESS_1025816] u d y ce nter’s 
Cli nical Trial A gree me nt.  
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025817] o ne N R, et al. 
Rec o m me n dati o ns f or t h e dia g n osis a n d treat me nt of t he ac ute p or p h yrias. A n n I nter n Me d. 
2 0 0 5; 1 4 2( 6): 4 3 9 -5 0.  
2.  P u y H, G o u ya L, De y b ac h J C. P or p h yrias. La n cet. 2 0 1 0; 3 7 5( 9 7 1 8): 9 2 4 -3 7.  
3.  B o n k o vs k y H L, Ma d d u k uri V C, Yazici C, A n ders o n K E, Bissell D M, Bl o o mer J R, et al. 
Ac ute p or p h yri as i n t he U S A: feat ures of 1 0 8 s u bjects fr o m p or p h yrias c o ns orti u m. A m J Me d. 
2 0 1 4; 1 2 7( 1 2): [ADDRESS_1025818] h. 2 0 0 0; 8 5( 1): 1 4 3 -5 3.  
5.  Bal wa ni M, D es nic k RJ. T he p or p h yrias: a d v a nces i n dia g n osis a n d treat me nt. Bl o o d. 
2 0 1 2; 1 2 0( 2 3): [ADDRESS_1025819] u g D e vel o p me nt ( P F D D) meeti n g f or t he Ac ute P or p h yrias. 
I n: F o u n dati o n A P,  e dit or. U S A 2 0 1 7. p. 3: 3 3: [ADDRESS_1025820] Cli n Ge net. 2 0 1 5; 8( 8): 2 0 1 -1 4 . 
9.  J ea ns J B, Sa vi k K, Gr oss C R, Wei mer M K, B osse n maier I C, Pi[INVESTIGATOR_750008] h C A, et al. M ortalit y i n 
patie nts wit h ac ute i nter mitte nt p or p h yria re q uiri n g h os pi[INVESTIGATOR_27967] o n: A U nite d States case series. 
A merica n J o ur nal of Me dical Ge netics. 1 9 9 6; 6 5( 4): [ADDRESS_1025821] olz el U, et al., e dit ors. E X P L O R E: 
A Pr os pecti ve, M ulti nati o nal, Nat ural Hist or y St u d y of Patie nts wit h Ac ut e He patic P or p h yrias 
( A H P) wit h Rec urre nt Attac ks. I nter n ati o nal C o n gress o n P or p h yri ns a n d P or p h yri as; 2 0 1 7; 
B or dea u x: I C P P.  
1 1.  A n derss o n C, I n nala E, Bac kstr o m T. Ac ute i nter mitte nt p or p h yria i n w o me n: cli nical 
e x pressi o n, use a n d e x perie nce of e x o ge n o us s e x h or m o nes. A p o p ulati o n -base d st u d y i n n ort her n 
S we de n. J I nter n M e d. 2 0 0 3; 2 5 4( 2): 1 7 6 -8 3.  
1 2 . C he m ma n ur A T, B o n k o vs k y H L. H e patic p or p h yrias: dia g n osis a n d ma n a ge me nt. Cli n Li ver 
Dis. 2 0 0 4; 8( 4): [ADDRESS_1025822] pr actice g ui deli nes o n 
cli nical ma na ge me nt of ac ute attac ks of p or p h yria a n d t heir c o m plicati o ns. A n n Cli n Bi oc he m. 
2 0 1 3; 5 0( Pt 3): 2 1 7 -2 3.  
1 4.  S o o na walla Z F, Or u g T, Ba d mi nt o n M N, El der G H, R h o des J M, Bra m hall S R, et al. Li ver 
tra ns pla ntati o n as a c ure f or ac ut e i nter mitte nt p or p h yria. T he La n cet. 2 0 0 4; 3 6 3( 9 4 1 0): 7 0 5 -6.  
1 5.  A n ders o n K E. A g o n a d otr o pi n releasi n g h or m o n e a nal o g ue pre ve nts c ycli cal attac ks of 
p or p h yri a. Arc h I nter n Me d . 1 9 9 0; 1 5 0 ( 7).  
1 6.  Herric k A L, Mc C oll K E, M o ore M R, C o o k A, G ol d ber g A. C o ntr olle d trial of hae m ar gi nate 
i n ac ute he p atic p or p h yri a. La ncet. 1 9 8 9; 1( 8 6 5 0): [ADDRESS_1025823] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  8 6  1 7.  Hift RJ, Meiss ner P N. A n A nal ysis of 1 1 2 Ac ute P or p h yric Attac ks i n Ca p e T o w n, S o ut h 
Africa. M e dici ne. 2 0 0 5; 8 4( 1): 4 8 -6 0.  
1 8.  D o w ma n J K, G u ns o n B K, Mirza D F, Bra m hall S R, Ba d mi nt o n M N, Ne ws o me P N. Li ver 
tra ns pla ntati o n f or ac ute i nt er mitte nt p or p h yria is c o m plicate d b y a hi g h rate of he patic arter y 
t hr o m b osis. Li ver Tra ns pla ntati o n. 2 0 1 2; 1 8( 2): 1 9 5 -2 0 0.  
1 9.  Yas u da M, Er wi n A L, Li u L U, Bal w a ni M, C he n B, Ka dir v el S, et al. Li v er Tra ns pla ntati o n 
f or Ac ute I nter mitte nt P or p h yri a: Bi oc h e m ical a n d Pat h ol o gic St u dies of t he E x pla nte d Li ver. 
M ol Me d. 2 0 1 5; 2 1: 4 8 7 -9 5.  
2 0.  R y u J Y, S o n g I S, S u n w o o Y E, S h o n J H, Li u K H, C ha IJ, et al. De v el o p me nt of t he "I nj e 
c oc ktail" f or hi g h -t hr o u g h p ut e val uati o n of fi ve h u ma n c yt o c hr o me P 4 5 0 is of or ms i n vi v o. C li n 
P har mac ol T her. 2 0 0 7; 8 2( 5): [ADDRESS_1025824] u g i nteracti o ns wit h c yt oc hr o me P 4 5 0 after a d mi nistrati o n of belatace pt, a 
c osti m ulat or y i m m u n o m o d ulat or . Br J Cli n P har mac ol. 2 0 1 7; 8 3( 2): 3 7 0 -8 0.  
2 2.  Mars de n J T, G u p p y S, Stei n P, C o x T M, Ba d mi nt o n M, Gar di ner T, et al. A u dit of t he Use of 
Re g ular Hae m Ar gi nate I nf usi o ns i n Patie nts wit h Ac ute P or p h yria t o Pre v e nt Rec urre nt 
S y m pt o ms. JI M D Re p. 2 0 1 5; 2 2: 5 7 -6 5.  
2 3.  Ve nt ura P, C orra di ni E, Di Pi[INVESTIGATOR_13011] o E, Marc hi ni S, Marcacci M, C u o g hi C, et al. 
H y p er h o m oc ystei ne mia i n patie nts wit h ac ute p or p h yrias: A p ot e ntiall y d a n ger o us meta b olic 
cr ossr oa d? E ur J I nter n Me d. 2 0 2 0; 7 9: 1 0 1 -7.  
2 4.  T o -Fi g ueras J, L o pez R M, De ul ofe u R , Herrer o C. Preli mi nar y re p ort: h y per h o m oc ystei ne mia 
i n patie nts wit h ac ute i nter mitte nt p or p h yri a. Met a b olis m. 2 0 1 0; 5 9( 1 2): 1 8 0 9 -1 0.  
2 5.  Mar o n B A, L oscalz o J. T he treat me nt of h y p er h o m oc ystei ne mia. A n n u Re v Me d. 2 0 0 9; 6 0: 3 9 -
5 4.  
2 6.  Q ualit y Metri c. User's M a n ual f or t he S F -1 2 v 2 Healt h S ur ve y. T hir d e d. Li n c ol n, RI 2 0 1 2.  
2 7.  Her d ma n M, G u d e x C, Ll o y d A, J a nsse n M, Ki n d P, Par ki n D, et al. De vel o p me nt a n d 
preli mi nar y testi n g of t he ne w fi ve -l e vel versi o n of E Q -5 D ( E Q -5 D -5 L). Q ual Lif e Res. 
2 0 1 1; 2 0( 1 0): 1 7 2 7 -3 6.  
28.  Sa m ps o n H A, M u n oz -F url o n g A, Ca m p b ell R L, A d ki ns o n N F, Jr., B oc k S A, Bra n u m A, et al. 
Sec o n d s y m p osi u m o n t he defi niti o n a n d ma na ge me nt of a na p h yla xis: s u m mar y re p ort -- sec o n d 
Nati o nal I nstit ute of Aller g y a n d I nfecti o us Diseas e/ F o o d Aller g y a n d A na p h yla xis Net w or k 
s y m p osi u m. A n n E mer g Me d. 2 0 0 6; 4 7( 4): [ADDRESS_1025825] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  8 7  1 1.  P H A R M A C O KI N E TI C/ P H A R M A C O D Y N A MI C A S S E S S M E N T TI M E P OI N T S   
Ta ble  8 c o ntai ns a d etaile d sc he d ule f or t he c ollecti o n of E C G a n d bl o o d sa m ples f or P K a n d A D A a nal ysis. Det ails re gar di n g t he 
pr ocessi n g, s hi p pi n g, a n d a nal ysis of t he sa m ples will be pr o vi de d i n t he La b orat or y Ma n ual.  
T a ble  8: P h ar m a c o ki netic, E C G, a n d A D A Ti me P oi nts f or All P atie nts ( E xce pt P ati e nts at E ast Asi a n Sites)  
St u d y P eri o d  St u d y M o nt h/ St u d y 
D a y  P r ot oc ol Ti me  
( h h: m m)  P K  Tri plic ate 
E C G  Si n gle 1 2 -
Le a d E C G 1 A D A  
6-M o nt h Treat me nt 
Peri o d  M o nt h 0  
( Da y  1)  Pre d ose  X X  X 
0 2: 0 0 ( ± 1 5 mi n)  X X   
2 4: 0 0 ( ± 2 h o urs)  X2 X2   
M o nt h 1  
( Da y  2 9 ± 7  da ys)  Pre d ose  X   X 
M o nt h 3  
( Da y  8 5 ± 7  da ys)  Pre d ose  X   X 
M o nt h 5  
( Da y  1 4 1 ± 7  da ys)  Pre d ose  X X   
 0 2: 0 0 ( ± 1 5 mi n)  X X   
M o nt h 6  
( Da y  1 6 9 ± 7  da ys)  Pre d ose  X X  X 
0 2: 0 0 ( ± 1 5 mi n)  X X   
0 4: 0 0 ( ± 1 5 mi n)  3 X    
2 4: 0 0 ( ± 2 h o urs)  X2 X2   
O pe n -La bel 
E xte nsi o n Peri o d  M o nt h 7  
( Da y  1 9 7 ± 7  da ys)  Pre d ose  X   X 
Pre d ose  X X  X 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025826] u d y M o nt h/ St u d y 
D a y  P r ot oc ol Ti me  
( h h: m m)  P K  Tri plic ate 
E C G  Si n gle 1 2 -
Le a d E C G 1 A D A  
M o nt h 1 2  
( Da y  3 3 7 ± 7  da ys)  0 2: 0 0 ( ± 1 5 mi n)  X X   
0 4: 0 0 ( ± 1 5 mi n) 3 X    
M o nt h 1 8  
( Da y  5 0 5 ± 7  da ys)  Pre d ose  X   X 
M o nt h 2 4  
( Da y 6 7 3 ± 1 4 da ys) 4 Pre d ose  X    X 
M o nt h 3 6  
( Da y 1 0 0 9 ± 1 4 
da ys)/ E O S 4 A n y ti me     X 
A b bre viati o ns:  A D A =a nti -dr u g a nti b o dies; E C G =electr ocar di o gra m; E O S =e n d of st u d y; h h = h o urs; m m = mi n utes  
[ADDRESS_1025827] u d y ce nters (i ncl u di n g all p atie nts at East Asia n st u d y ce nters), a n a d diti o nal 2 4 -h o ur ( ± 2 
h o urs) P K a n d tri plicate  E C G sa m ple (see Secti o n  7. 5. 4 ) will b e c ollecte d o n Da y 1 a n d M o nt h 6.  
3 F or patie nts recei vi n g 1. 2 5  m g/ k g gi v osira n m o nt hl y ( patie nts w h o recei ve d t heir first d ose i n t he o pe n -la bel e xte nsi o n peri o d u n der pr ot oc ol a me n d me nt 
versi o n 3), a d diti o nal bl o o d sa m ples f or P K will be c ollecte d [ADDRESS_1025828] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025829] u d y 
ce nters (i n J a pa n, Tai w a n, a n d S o ut h K orea).  Details re gar di n g t he pr o cess i n g, s hi p pi n g, a n d a n al ysis of t he sa m ples will be pr o vi de d 
i n t he La b orat or y M a n ual.  
T a ble  9: P h ar m a c o ki netic, E C G, a n d A nti -Dr u g A nti b o d y Assess me nt Ti me P oi nts f or P atie nts at E ast Asi a n St u d y 
Ce nters ( Bl o o d S a m ples)  
St u d y P eri o d  St u d y M o nt h ( St u d y 
D a y)  S a m pli n g Ti me  
( h h: m m)  P K  Tri plic ate 
E C G  Si n gle 
1 2 -Le a d E C G 1 A D A  
6-M o nt h 
Treat me nt Peri o d  M o nt h 0 ( Da y 1)  Pre d ose  X X  X 
0 0: 1 5 ( ± 5 mi n)  X    
0 0: 3 0 ( ± 5 mi n)  X    
0 1: 0 0 ( ± 1 0 mi n)  X    
0 2: 0 0 ( ± 1 5 mi n)  X X   
0 4: 0 0 ( ± 1 5 mi n)  X    
0 6: 0 0 ( ± 1 5 mi n)  X    
0 8: 0 0 ( ± 1 5 mi n)  X    
2 4: 0 0 ( ± 2 h o urs)  X X   
M o nt h 1 ( Da y  2 9 ± 7  da ys)  Pre d ose  X   X 
M o nt h 3  
( Da y 8 5 ± 7  da ys)  Pre d ose  X   X 
M o nt h 5 
( Da y  1 4 1 ± 7  da ys)  Pre d ose  X X   
0 2: 0 0 ( ± 1 5 mi n)  X X   
M o nt h 6 
( Da y  1 6 9 ± 7  da ys)  Pre d ose  X X  X 
0 0: 1 5 ( ± 5 mi n)  X    
0 0: 3 0 ( ± 5 mi n)  X    
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025830] u d y M o nt h ( St u d y 
D a y)  S a m pli n g Ti me  
( h h: m m)  P K  Tri plic ate 
E C G  Si n gle 
1 2 -Le a d E C G 1 A D A  
0 1: 0 0 ( ± 1 0 mi n)  X    
0 2: 0 0 ( ± 1 5 mi n)  X X   
0 4: 0 0 ( ± 1 5 mi n)  X    
0 6: 0 0 ( ± 1 5 mi n)  X    
0 8: 0 0 ( ± 1 5 mi n)  X    
2 4: 0 0 ( ± 2 h o urs)  X X   
O pe n -La bel 
E xte nsi o n  Peri o d  M o nt h 7  
( Da y  1 9 7 ± 7  da ys)  Pre d ose  X   X 
M o nt h 1 2 
( Da y  3 3 7 ± 7  da ys)  Pre d ose  X X  X 
0 2: 0 0 ( ± 1 5 mi n)  X X   
M o nt h 1 8 
( Da y  5 0 5 ± 7  da ys)  Pre d ose  X   X 
M o nt h 2 4 ( Da y 
6 7 3 ± 1 4  da ys) 2 Pre d ose  X   X 
M o nt h 3 6  
( Da y 1 0 0 9 ± 1 4 da ys)/ 
E O S 2 A n y ti me     X 
A b bre viati o ns: A D A =a nti -dr u g a nti b o dies; E C G =electr ocar di o gra m; E O S =e n d of st u d y; h h = h o urs; m m = mi n utes  
[ADDRESS_1025831] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  9 1  Ta ble  1 0  pr o vi des a s c he d ule f or t he c ollecti o n of s p ot ( pre d ose) a n d p o ole d uri ne sa m ples f or a nal ysis of P K, P D, a n d A D A i n 
patie nts at East Asia n st u d y ce nters. V ol u me m ust be rec or de d.  
T a ble  1 0 : Uri ne P h a r m ac o ki netic/ P h ar m a c o d y n a mic Ti me p oi nts f or P atie nts at E ast Asi a n St u d y Ce nters  
St u d y P eri o d  St u d y M o nt h  
( St u d y D a y)  S a m pli n g Ti me  
( h h: m m)  P K  A L A a n d P B G  
6-M o nt h 
Treat me nt Peri o d  
M o nt h 0  
( Da y 1)  Pre d ose  X Xb 
0-6 h o urs ( ± 3 0 mi n) a X Xb 
6-1 2 h o urs ( ± 3 0 mi n) a X Xb 
1 2 -2 4 h o urs ( ± 2 h o urs) a X  
M o nt h 0  
( Da y 1 5 ± 2  da ys)   A n y ti me   Xc 
M o nt h 1  
( Da y 2 9 ± 7  da ys)  Pre d ose   Xc 
M o nt h 2  
( Da y 5 7 ± 7  da ys)  Pre d ose   Xc 
M o nt h 3  
( Da y 8 5 ± 7  da ys)  Pre d ose   Xc 
M o nt h 4  
( Da y 1 1 3 ± 7  da ys)  Pre d ose   Xc 
M o nt h 5  
( Da y 1 4 1 ± 7  da ys)  Pre d ose   Xc 
M o nt h 6  
( Da y 1 6 9 ± 7  da ys)  Pre d ose  X Xb 
0-6 h o urs ( ± 3 0 mi n) a X Xb 
6-1 2 h o urs ( ± 3 0 mi n) a X Xb 
1 2 -2 4 h o urs ( ± 2 h o urs) a X  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, [ADDRESS_1025832] u d y M o nt h  
( St u d y D a y)  S a m pli n g Ti me  
( h h: m m)  P K  A L A a n d P B G  
A b bre viati o ns: A L A =a mi n ole v uli nic aci d; h h = h o urs; m m = mi n utes; P B G = p or p h o bili n o ge n; P K = p har mac o ki netics  
a O n Da y [ADDRESS_1025833] d ose uri ne sa m ples c ollecte d wit hi n a c ollecti o n i nter val will b e p o ole d  
b At ti me p oi nts w here P K sa m pli n g is perf or me d, uri ne sa m ples f or A L A a n d P B G meas ure me nt will be ali q u ote d fr o m 
i n di vi d ual ti me p oi nt ( n o n -p o ole d) uri ne sa m ples o btai ne d f or P K assess me nts  
c S p ot uri ne sa m ples f or A L A, P B G, a n d A L A S [ADDRESS_1025834] u d y s h o ul d be c ollecte d pre d ose; h o we ver, 
if he mi n is use d f or a n attac k, sc he d ule d uri nar y A L A, P B G a n d A L A S 1 m R N A will b e c ollecte d 4 da ys ( + 4 da ys) after t he 
patie nt’s last he mi n d ose. W here a p plica ble c o u ntr y a n d l ocal re g ulati o ns a n d i nfrastr uct ure all o w, uri ne sa m ples f or A L A, 
P B G, a n d A L A S [ADDRESS_1025835] u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  9 3  1 1. 1.  Bi oc he mic al Di a g n osis of A H P i n t he A bse nce of I de ntifie d M ut ati o n i n a P or p h yri a -rel ate d Ge ne  
T a ble  1 1 : Bi oc he mic al C riteri a i n A d diti o n t o A L A a n d P B G f or Di a g n osis of A H P i n t he A bse nce of a n I de ntifie d 
M ut ati o n i n a P or p h yri a -rel at e d Ge ne  
 AI P wit h o ut i de ntifie d 
ge ne m ut ati o n  H C P wit h o ut i de ntifie d 
ge ne m ut ati o n  V P wit h o ut i de ntifie d 
ge ne m ut ati o n  A D P wit h o ut i de ntifie d 
ge ne m ut ati o n  
Plas ma 
P or p h yri ns  • < 4. 5 μ g/ d L, or < 5 -f ol d 
i ncrease (relati ve t o 
U L N of 0. 9 μ g/ d L)  
• Fl u oresce nce sca n ni n g at 
ne utral p H s h o ws n o 
pea k or a s mall pea k at 
~ 6 2 0 n m.  
N ote : AI P patie nts wit h 
se vere re nal disease are a n 
e xce pti o n a n d ma y ha ve 
s u bsta ntial i ncreases i n 
plas ma p or p h yri ns.  • < 5 μ g/ d L, or < 5 -f ol d 
i ncrease (relati ve t o 
U L N of 0. 9 μ g/ d L)  
• Fl u oresce nce sca n ni n g 
at ne utral p H s h o ws n o 
pea k or a s mall pea k at 
~ 6 2 0 n m.  
Note: t his criteri o n 
a p plies t o H C P patie nts 
wit h o ut s ki n lesi o ns. S ki n 
lesi o ns are rare i n t his 
disease, b ut if prese nt are 
ofte n acc o m pa nie d b y 
s u bsta ntial i ncreases i n 
plas ma p or p h yri ns. A n 
e xce pti o n will be ma de 
f or t his criteri o n i n s uc h 
cases.  • > 2. 7 μ g/ d L, or > 3 -f ol d 
i ncrease (relati ve t o 
U L N of 0. 9 μ g/ d L)  
• Fl u oresce nce sca n ni n g at 
ne utral p H s h o wi n g a 
pea k at ~ 6 2 6 n m.  • Plas ma: sa me as AI P  
• Er yt hr oc ytes: mar ke d 
i ncrease i n zi nc 
pr ot o p or p h yri n I X 
( > 4 0 0  μ g/ d L)  
T otal Fecal 
P or p h yri ns  • W N L ( < 4 0 0 μ g/ g dr y 
wei g ht or < 2 -f ol d 
i ncrease (relati ve t o 
U L N of 2 0 0  μ g/ g dr y 
wei g ht)  • > 4 0 0 μ g/ g dr y wei g ht 
or > 2 -f ol d i ncrease 
(relati ve t o U L N of 
2 0 0  μ g/ g dr y wei g ht)  
• Pre d o mi na nce of 
c o pr o p or p h yri n III a n d 
a c o pr o p or p h yri n III/I 
rati o > 1. 5  • > 4 0 0 μ g/ g dr y wei g ht or 
> 2 -f ol d i ncrease (relati ve 
t o U L N of 2 0 0 μ g/ g dr y 
wei g ht)  
• Pre d o mi na nce of 
c o pr o p or p h yri n III a n d 
pr ot o p or p h yri n I X  • W N L or m o dest i ncrease 
( < 5 0 0  μ g/ g dr y wei g ht or 
< 2. 5 -f ol d i ncrease 
(relati ve t o U L N of 
2 0 0  μ g/ g dr y wei g ht)  
A b bre v iati o ns: A D P = A L A D deficie nt p or p h yria; A H P =ac ute he p atic p or p h yria; AI P =ac ute i nter mitte nt p or p h yria; A L A D = A L A de h y dratase; 
H C P = here ditar y c o pr o p or p h yria; U L N = u p per li mit of n or mal; V P = varie gate p or p h yria; W N L = wit hi n n or mal li mits  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3   gi v osir a n ( A L N -A S 1)  
A me n d me nt 7, 2 9 M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  9 4  1 1. 2.  A n a p h yl actic Re acti o ns  
T a ble  1 2 : S a m ps o n Criteri a f or A n a p h yl actic Re acti o ns  
 
A da pte d fr o m Sa m ps o n et al. 2 0 0 6 (2 8 )   
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 7 S u m m ar y of C h a n ges, 2 9  M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 A L N -A S 1 -0 0 3 P R O T O C O L  A M E N D M E N T 7  
S U M M A R Y O F C H A N G E S D A T E D 2 9  M A R C H 2 0 2 1  
E N VI SI O N: A P h ase [ADDRESS_1025836] u d y 
wit h a n O pe n -l a bel E xte nsi o n  t o E v al u ate t he Effic ac y a n d S afet y of Gi v osir a n i n P atie nts 
wit h Ac ute He p atic P o r p h yri as  
1.  R A TI O N A L E F O R P R O T O C O L A M E N D M E N T  
T he p ur p ose of t his pr ot o c ol a me n d me nt is t o rec o m me n d testi n g of bl o o d h o m oc ystei ne l e vels.  
I n a d diti o n , it is rec o m me n de d t hat patie nts wit h i ncreas e d bl o o d h o m oc ystei ne le vels r ecei ve a 
s u p ple me nt c o ntai ni n g vita mi n B 6.  
 
T hese rec o m me n dati o ns are bei n g ma d e beca use d uri n g gi v osira n  tr eat me nt, i ncreases i n bl o o d 
h o m oc ystei ne l e vels ha v e bee n o bser ve d c o m pare d t o le vels bef ore  gi v os ir a n  treat me nt.  T h us, 
m o nit ori n g f or c h a n ges i n bl o o d h o m oc ystei ne  le vels d uri n g tr eat me nt wit h gi v osira n h as bee n 
i nc or p orate d i nt o t he pr ot oc ol.  Bl o o d h o m oc ystei ne le vels ma y als o be i n crease d i n p atie nts wit h 
ac ute he p atic p or p h yri a ( A H P), vita mi n def icie nci es, or c hr o nic ki d ne y disease.  T h e cli nical 
rele va n ce of t h e ele vati o ns i n bl o o d h o m oc ystei n e d uri n g gi v osira n treat me nt is u n k n o w n.  
Detaile d reas o ns f or eac h c ha n ge are pr o vi de d i n Secti o n  2.  C orrecti o ns t o t y p o gra p hical err ors, 
p u nct uati o n, gra m mar, a b bre viati o ns, a n d f or m atti n g, as w ell as a d mi nistrati ve c ha n ges are n ot 
detaile d.  
 
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 7 S u m m ar y of C h a n ges, 2 9  M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 2.  P R O T O C O L A M E N D M E N T 7  D E T AI L E D S U M M A R Y O F  C H A N G E S  
T he pri mar y secti o n(s) of t he pr ot oc ol affecte d b y t he c ha n ges i n Pr ot oc ol A me n d me nt 7 are  i n dicat e d.  T he c orres p o n di n g te xt has 
bee n re vis e d t hr o u g h o ut t he pr ot oc ol.  Delet e d te xt is i n dicate d b y stri ke o ut  a n d a d de d te xt is i n dicate d b y b ol d  f o nt, rele va nt t o eac h 
p ur p ose descri be d.  
 
P ur p ose:  A d d me as uri n g bl o o d h o m ocystei ne le vels as p art o f t he ex pl or at ory bi o m arker assess me nt.  
T he pri mar y c h a n ge o cc urs i n Secti o n 7. 6. [ADDRESS_1025837] orat or y Bi o mar kers  
Re vise d te xt:  ( o nl y first para gra p h wit h re visi o n is s h o w n)  
W here all o we d per l ocal re g ulati o ns a n d I R B/ E C a p pr o val a n d p atie nt c o nse nt (a n d asse nt, w h ere a p plica ble), ser u m, plas m a, a n d 
uri ne sa m ples will be c ollecte d a n d ma y b e arc hi v e d a n d use d f or a n al ys es of e x pl orat or y bi o mar kers relate d t o meta b olic pr of ili n g or 
t he effects of gi v osira n or ot her pr otei ns r elate d t o A H Ps a n d t heir c o m plic ati o ns.  S a m ples m a y als o be use d f or testi n g 
h o m oc ystei ne le vels.  
Secti o ns als o reflecti n g t his c ha n ge:  
• Ta ble 1, Sc he d ule of Ass ess me nts – Scree ni n g a n d 6 -M o nt h Treat me nt Pe ri o d ( Scree ni n g t hr o u g h M o nt h 6) (f o ot n ote o)  
• Ta ble 2, Sc he d ule of Ass ess me nts – O pe n -La bel E xte nsi o n Peri o d: After M o nt h 6 t hr o u g h M o nt h 1 8 (f o ot n ote l)  
• Ta ble 3, Sc he d ule of Ass ess me nts f or O pe n -La b el E xte nsi o n Peri o d: M o nt h [ADDRESS_1025838] u d y (f o ot n ote j)  
P ur p ose:  T o a d d i ncre as es i n bl o o d h o m ocystei ne levels t o t he be nefit -risk assess me nt, n oti n g t he u nk n o w n cli nic al relev a nce, a n d t o 
i nf or m t he I nvesti g at or a b o ut t he p ossi bility t o s u p ple me nt wit h vit a mi n B 6 s h o ul d i ncre ases i n h o m ocystei ne le vels  occ ur.  
T he pri mar y c h a n ge o cc urs i n Secti o n 1. 5 Be nefit -Ris k Assess me nt  
A d de d te xt:  ( [ADDRESS_1025839] para gra p h)  
Bl o o d h o m oc ystei ne le v els m a y be i ncre ase d i n p atie nts wit h A H P, vit a mi n deficie ncies, or c hr o nic ki d ne y dise ase .( 2 3 -2 5)   
D uri n g tre at me nt wit h gi v osir a n, i ncre ases i n bl o o d h o m oc ystei ne le v els h a ve bee n o bser ve d c o m p are d t o le vels bef ore 
tre at me nt.  T he cli nic al rele v a nce of t he el e v ati o ns i n bl o o d h o m oc ystei ne d uri n g gi v osir a n tre at me nt is u n k n o w n.  T he 
pr ot oc ol i ncl u des m o nit ori n g f or c h a n ges i n bl o o d h o m oc yst ei ne le vels d uri n g tre at me nt wit h gi v osir a n.  It is rec o m me n de d 
t h at p atie nts wit h i ncre ase d bl o o d h o m oc ystei ne le vels recei ve a s u p ple me nt c o nt ai ni n g vit a mi n B 6  (see Secti o n 6. 3. 4).  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 7 S u m m ar y of C h a n ges, 2 9  M arc h 2 0 2 1  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 P ur p ose:  T o a d d t h at vit a mi n B 6 s u p ple me nt ati o n is a n acce pte d p ote nti al c o nc o mit a nt me dic ati o n if i ncre ases i n bl o o d h o m ocystei ne 
levels occ ur.  
T he c ha n ges i ncl u de t he a d diti o n of Secti o n 6. 3. 4 Vita mi n B 6 S u p ple me ntati o n  
A d de d te xt: ( Secti o n 6. 3. 4)  
Secti o n 6. 3. 4 Vit a mi n B 6 S u p ple me nt ati o n  
D uri n g tre at me nt wit h gi v osir a n, bl o o d h o m oc ystei ne le vels m a y s h o w a n i ncre ase c o m p are d t o le vels bef ore tre at me nt.  Bl o o d 
h o m oc ystei ne le vels will be assesse d as i n dic ate d i n t he Sc he d ule of Assess me nts ( T a ble 1, T a ble 2, a n d T a ble 3).  It is 
rec o m me n de d t h at p atie nts wit h i ncre ase d bl o o d h o m oc yst ei ne le vels recei ve a s u p ple me nt c o nt ai ni n g vit a mi n B 6 .  All vit a mi n 
s u p ple me nts s h o ul d be rec o r de d o n t he c o nc o mit a nt me dic ati o ns e C R F.  
Secti o n als o reflecti n g t his c ha n ge:  
• Secti o n 6, C o nc o mita nt Me dicati o ns ( fi nal se nte n ce a d d e d a cr oss -li n k t o t he vita mi n B 6 s u p ple me ntati o n secti o n)  
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 6 S u m m ar y of C h a n ges, 2 3  A pril 2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 A L N -A S 1 -0 0 3 P R O T O C O L  A M E N D M E N T 6  
S U M M A R Y O F C H A N G E S D A T E D 2 3  A P RI L 2 0 2 0  
E N VI SI O N: A P h ase [ADDRESS_1025840] u d y 
wit h a n O pe n -l a bel E xte nsi o n t o E v al u ate t he Effic ac y a n d S afet y of Gi v osir a n i n P atie nts 
wit h Ac ute He p atic P o r p h yri as  
1.  R A TI O N A L E F O R P R O T O C O L A M E N D M E N T  
T he p ur p ose of t his pr ot o c ol a me n d me nt is t o i nc or p orate Ur ge nt Safet y M eas ures ( U S Ms) t hat 
were c o m m u nicate d t o i n vesti gat ors i n a Dear I n v esti gat or Letter t o ass ur e t he safet y of st u d y 
partici pa nts w hile mi ni mizi n g ris ks t o st u d y i nte grit y a mi d t he C O VI D -[ADDRESS_1025841] of cli nical trials d uri n g t he C O VI D -1 9 
pa n de mic .[E M A 2 0 2 0; F D A 2 0 2 0 ] 
T he U S M m o dificati o ns a n d ne w pr o ce d ures are o utli ne d bel o w, a n d a det aile d s u m mar y of t h e 
pr ot oc ol c ha n ges is pr o vi de d i n Secti o n 2. T hese c ha n ges s h o ul d be a d o pte d i m me diatel y per t he 
Dear I n vesti gat or Letter  date d 0 7 A pril 2 0 2 0 . 
• Gi v osir a n D osi n g O utsi de t he St u d y Ce nter b y P a ti e nt or C a re gi ver  
F oll o wi n g a p pr o priat e trai ni n g o n gi v osira n a d mi nistrati o n a n d t he use of e pi [INVESTIGATOR_050] p hri ne 
(e pi [INVESTIGATOR_5836] n or e q ui vale nt), d osi n g will be per mitte d at a l ocati o n ot her t ha n t he st u d y 
ce nter (e g, at h o me) b y t he patie nt or care gi ver at all ti me p oi nt s u n der t he o versi g ht 
of t he  I n vesti gat or  a n d f oll o wi n g c o ns ultati o n wit h t he me dical mo nit or .  T his 
meas ure  is i nte n de d t o r e mai n i n effect o nl y d uri n g peri o ds of ti me w he n t he 
C O VI D -[ADDRESS_1025842] u d y site or 
healt hcare pr ofessi o nals t o g o t o patie nts' h o mes f or d osi n g.  
• St u d y Visit Wi n d o w  
E x ce pt f or assess me nts wit h ot her s pecifie d ti mi n g re q uire me nts ( as n ote d bel o w), 
st u d y assess me nts a n d d osi n g are t o be perf or me d wit hi n a visit wi n d o w of ± 1 4 da ys 
( pre vi o usl y ± 7 da ys). St u d y dr u g d os es m ust be a d mi nistere d at least [ADDRESS_1025843] u d y 
(A L N -A S 1 -0 0 1 ), w hic h e val uate d d osi n g at 5. 0 m g/ k g m o nt hl y (t wic e t h e t hera p e utic 
d ose of 2. 5◦ m g/ k g m o nt hl y).  
• Assess me nts of A d verse E ve nts, C o nc o mit a nt Me dic ati o ns (i ncl u di n g he mi n use), 
H os pit aliz ati o ns/ Pr oce d ures, a n d P or p h yri a Att ac ks  
In sit uati o ns w here a st u d y visit ca n n ot be c o m plete d at t he st u d y ce nter or offsite b y 
a healt hcare pr ofessi o nal v isit, t he st u d y I n v esti gat or ( or dele gate) m a y ver ball y 
c o ntact t he patie nt wit hi n t he st u d y visit wi n d o w t o assess f or a n y a d verse e ve nts, 
c o nc o mita nt me dicati o ns (i ncl u di n g he mi n use), h os pi[INVESTIGATOR_27967] o ns/ pr oce d ures, a n d 
p or p h yri a attac ks.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 6 S u m m ar y of C h a n ges, 2 3  A pril 2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 • Li ver F u ncti o n Te sts  
Ala ni ne a mi n otra nsf eras e ( A L T) a n d t otal bilir u bi n  res ults m ust be o btai ne d fr o m a 
ce ntral or l o cal la b orat or y a n d re vie we d wit hi n 6 wee ks  ( pre vi o usl y 1 4 d a ys) pri or t o 
eac h gi v osira n d os e.  
I n cli nical st u dies t o date, tra nsa mi nase el e vati o ns ha ve pri m aril y occ urre d bet wee n  [ADDRESS_1025844] 6  m o nt hs of treat me nt, a n d as cli nicall y i n dicate d t hereaf ter.  
• Ti me Peri o d t o O bt ai n Wei g ht f or D ose Deter mi n ati o n  
D ose will be base d o n w ei g ht o btai ne d wit hi n 6 m o nt hs  ( pre vi o usl y at t he c urre nt or 
pri or st u d y visit) pri or t o d osi n g.  D osi n g wei g ht ma y b e c ollecte d d uri n g cli nical 
st u d y ce nt er visits or offsite.  
Gi ve n t he e x pa n de d use of offsite a d mi nistrati o n, use of a pri or wei g ht per mits 
acc urate det er mi nati o n of d ose a n d v ol u me wit h o ut ma n ual calc ulati o ns or ver bal 
or ders.   All patie nts are a d ult ; t heref ore, s u bsta ntial  fl uct uati o ns  i n b o d y wei g ht o ver a 
6-m o nt h  peri o d are n ot e x pecte d.   Pri or a nal ys es of t he st u d y d ata ha v e s h o w n mea n 
b o d y w ei g ht t o be sta bl e o ver ti me.  
• Q u alit y of Life ( Q OL) a n d P or p h yri a P atie nt E x perie nce Q uesti o n n aire ( P P E Q) 
Assess me nts  
I n  sit uati o ns w here a pl a n ne d st u d y visit ca n n ot b e c o m plete d at t he st u d y ce nter, t he 
patie nt will c o m plete t he Q O L a n d P P E Q q uesti o n naires at h o me.  
• Assess me nt of E C G  
F urt her assess me nt of E C G is n o l o n ger warra nte d, beca use n o cli nicall y si g nifica nt 
E C G fi n di n gs, i ncl u di n g Q T i nter val pr ol o n gati o n, ha v e bee n o bser ve d f oll o wi n g 
c o m pre he nsi ve a nal yses acr oss t he A L N -A S [ADDRESS_1025845] u d y a n d t he P hase 1/ [ADDRESS_1025846] u d y ( A L N -A S 1 -0 0 2) t o date.  T o mi ni miz e e x p os ure t o C O VI D -[ADDRESS_1025847] u d y .  F or f urt her i nf or mati o n, refer t o t he gi v osira n ( A L N -
A S 1) I n v esti gat or’s Br oc h ure.  
• Assess me nts Re q uire d t o be Perf or me d at St u d y Ce nter Visits  
W here a p plica ble c o u ntr y a n d l o cal re g ul ati o ns a n d i nfrastr uct ur e all o w f or h o me 
healt hcare, healt hcare ma y ta k e place at a l ocati o n ot her t ha n t he cli nical tri al site t o 
perf or m st u d y assess me nts i ncl u di n g tar get e d p h ysical e x a m/ b o d y s yst e m assess m e nt, 
assess me nts f or vital si g ns, a n d c ollecti o n of bl o o d a n d uri ne sa m ples f or safet y 
la b orat or y ass ess me nts, a n d p har mac o d y n a mic ( P D)  assess me nts, at all ti me p oi nts as 
s pecifie d i n t he Sc he d ul e of Assess me nts.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 6 S u m m ar y of C h a n ges, 2 3  A pril 2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 I n t he e ve nt t hat gi v osira n is a d mi nistere d offsite b y t he p atie nt or care gi ver, safet y 
la b orat or y ass ess me nts ( ot her t ha n li ver f u ncti o n tests) m ust be o btai ne d fr o m a 
ce ntral or l o cal la b orat or y wit hi n 3 m o nt hs pri or t o d osi n g ( pre vi o usl y at t he cli nical 
st u d y ce nt er visit).   T his sa me fre q u e nc y for la b orat or y assess me nts was  i m ple me nte d 
i n t he P hase 1/ 2, o pe n -la bel, e xte nsi o n St u d y A L N -A S 1 -0 0 2 aft er 1 8 m o nt hs ( t o date 
all patie nts treate d f or ≥ 3 0 m o nt hs ) a n d t his has bee n acce pta ble f or safet y 
m o nit ori n g.  
• P h ar m a c o ki netic a n d A nti -dr u g A nti b o d y Assess me nts Re q uire d t o be 
Perf or me d at St u d y Ce nter Visits  
Gi ve n  t he e x pa n de d use of offsite d osi n g, p har mac o ki netic ( P K) a n d a nti -dr u g 
a nti b o d y ( A D A) assess me nts ma y b e c o m plete d wit hi n [ADDRESS_1025848] u d y 
ce nter visit  ( pre vi o usl y at t he cli nical st u d y ce nter visit).  
All patie nts ha ve c o m plete d [ADDRESS_1025849] u d y, t here h as bee n o nl y 
1 case of treat me nt -e mer ge nt A D As d ue t o gi v osira n.  T he a nti b o d y titer w as l o w a n d 
tra nsie nt, wit h t he patie nt s u bse q ue ntl y testi n g ne gati ve.  Bas e d o n t he c ollecti ve 
e vi de nce t o d ate, gi v osira n is  c o nsi dere d t o ha ve a ver y l o w ris k of eliciti n g a n 
i m m u ne res p o nse.  
• C ollecti o n of Inf or m ati o n Rel ate d t o C O VI D -[ADDRESS_1025850] of t he C O VI D -1 9 gl o bal 
pa n de mic o n cli ni cal trial data.  
• U p d ates t o St u d y A d mi nistr ati o n  
Te xt was u p date d t o pr o vi de clarificati o n o n I n vesti gat or res p o nsi bilities re gar di n g 
c o m m u nicati o n of ne w st u d y i nf or m ati o n t o patie nts a n d I nstit uti o nal Re vie w B oar ds 
(I R B )/I n d e pe n d e nt Et hics C o m mittees ( I E Cs ). 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 6 S u m m ar y of C h a n ges, 2 3  A pril 2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 Refere n ces:  
F D A G ui da n ce o n C o n d uct of Cli nical Trials of Me dical Pr o d ucts d uri n g C O VI D -1 9 Pa n de mic: 
G ui da nce f or I n d ustr y, I n vesti gat ors, a n d I nstit uti o nal Re vie w B o ar ds. 
htt ps:// w w w.f da. g o v/r e g ulat or y -i nf or mati o n/searc h -f da -g ui da n ce -d oc u me nts/f da -g ui d a nce -
c o n d uct -cli nical -trials -m e dical -pr o d ucts -d uri n g -c o vi d -1 9 -pa n de mic  
G ui da nce o n t he M a na ge me nt of Cli nical Trials d uri n g t he C O VI D -1 9 ( C or o na vir us) Pa n de mic, 
Versi o n 1. 0 ( 2 0/ 0 3/ 2 0 2 0). htt ps:// w w w.e ma.e ur o pa.e u/e n/ ne ws/ g ui da n ce -s p o ns ors -h o w -ma n a ge -
cl i nical -trials -d uri n g -c o vi d -[ADDRESS_1025851] u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 6 S u m m ar y of C h a n ges, 2 3  A pril 2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 2.  P R O T O C O L A M E N D M E N T 6  D E T AI L E D S U M M A R Y O F  C H A N G E S  
T he pri mar y secti o n(s) of t he pr ot oc ol affecte d b y t he c ha n ges i n Pr ot oc ol A me n d me nt 6 are i n dicat e d.  T he c orres p o n di n g te xt  has 
bee n re vis e d t hr o u g h o ut t he pr ot oc ol.  Delet e d te xt is i n dicate d b y stri ke o ut  a n d a d de d te xt is i n dicate d b y b ol d  f o nt , rele va nt t o eac h 
p ur p ose descri be d.  
 
P ur p ose:  T o e x p a n d t he use of offsite a d mi nistr ati o n t o i ncl u de giv osir a n d osi n g by t he p atie nt or c are giver.  
T he pri mar y c h a n ge s o cc ur i n Secti o n 6. 2. 2, D ose a n d A d mi nistrati o n,  
Re vise d te xt:   
1st  para gra p h:  
Gi v osira n will be a d mi nistere d b y a q u alifie d a n d a ut h orize d healt h care pr ofessi o nal trai ne d i n t he rec o g niti o n a n d ma na ge me nt of 
a na p h ylactic reacti o ns.   T he st u d y dr u g s h o ul d be i njecte d i nt o t he a b d o me n or u p per ar ms or t hi g hs.  Detaile d i nstr ucti o ns f or st u d y 
dr u g a d mi nistrati o n are prese nte d i n t he P har m ac y Ma n ual. As is c o nsiste nt wit h g o o d me dical practi ce f or s u b c uta ne o us dr u g 
a d mi nistrati o n, patie nts will be o bser ve d f or a mi ni m u m of 2 0 mi n utes after eac h i njecti o n.   Treat me nt f or a na p h yl actic re acti o ns 
s h o ul d be rea dil y a v aila ble w here p atie nts are bei n g d ose d a n d f oll o w c o u ntr y a n d/ or l ocal h os pi[INVESTIGATOR_550374] g ui deli nes ( 2 5) . 
2n d  para gra p h:   
Gi v osir a n will be a d mi nistere d b y a q u alifie d a n d a ut h orize d he alt h c are pr ofessi o n al tr ai ne d i n t he rec o g niti o n a n d 
m a n a ge me nt of a n a p h yl actic re a cti o ns, w he ne ver p ossi ble.   St u d y dr u g a d mi nistrati o n ma y be c o n d ucte d at a l ocati o n ot her t ha n 
t he st u d y ce nter b y a h o me healt hcare pr ofessi o n al, w here a p plica ble c o u ntr y a n d l o cal r e g ulati o ns a n d i nfrastr u ct ure  all o w, after 
c o ns ultati o n wit h t he me dical m o nit or, d uri n g p artic ular st u d y visits, as s p ecifie d i n t he Sc he d ul es of Assess me nts ( Ta ble 2 a n d 
Ta ble  3).  If t he p atie nt is u n a ble t o c o me t o t he st u d y site, a n d a visit b y a h o me he alt hc a re pr of essi o n al is n ot p ossi ble d ue t o 
circ u mst a nces rel at e d t o t he C O VI D -[ADDRESS_1025852] recei ve a p pr o pri ate tr ai ni n g o n gi v osir a n a d mi nistr ati o n a n d t he u se 
of e pi [INVESTIGATOR_050] p hri ne (e pi [INVESTIGATOR_5836] n or e q ui v ale nt) pri or t o d osi n g.   T his me as ure is i nte n de d t o re m ai n i n effect o nl y d uri n g peri o ds of ti me 
w he n t he C O VI D -[ADDRESS_1025853] u d y site or he alt hc are pr ofessi o n als t o g o t o 
p atie nts' h o mes f or d osi n g.   H o we ver, st u d y dr u g a d mi nistrati o n at t he st u d y ce nter s h o ul d be c o nsi dere d f or patie nts w h o ha ve 
o n g oi n g st u d y dr u g -relat e d A Es or k n o w n ris k fact ors f or de vel o pi n g a n a p h yla ctic reacti o n s, i ncl u di n g b ut n ot li mite d t o: pri or hist or y 
of a n a na p h yl actic reacti o n t o f o o d, me dicati o ns or d ue t o u n k n o w n eti ol o g y, w orse ni n g i njecti o n site reacti o ns w it h re peat d osi n g, or 
a n y o n e i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or t h at w o ul d be nefit fr o m cli nical o bser vati o n f oll o wi n g d osi n g.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt [ADDRESS_1025854] p ara gra p h:  
Detaile d i nstr ucti o ns f or st u d y dr u g a d mi nistrati o n are prese nte d i n t he P h ar mac y M a n ual.  I n a d diti o n, i nstr ucti o ns a n d pr oce d ures 
rel ate d t o a d mi nistr ati o n of gi v osir a n  b y a p atie nt or c are gi ver will be pr o vi de d i n t he P atie nt/ C are gi ve r St or a ge a n d 
A d mi nistr ati o n I nstr ucti o ns.  
Secti o n(s) als o reflecti n g t his c ha n ge:  
• S y n o psis  
• Secti o n 4. 1  
• Secti o n 6. 2. 4  
P ur p ose:  T o e x p a n d t he st u dy visit wi n d o w.  
T he pri mar y c h a n ge o cc urs i n Ta ble 3, Sc he d ule of Assess me nts f or O p e n -La b el E xte nsi o n Peri o d: M o nt h [ADDRESS_1025855] u d y.  
Re vise d te xt:  I n T a ble 3, t he visit wi n d o w was c h a n ge d t o ± 1 4  d a ys  ( pre vi o us l y ± 7 da ys) f or all visits.  
Secti o n(s) als o reflecti n g t his c ha n ge:   
• Secti o n 5. 3. 1  
P ur p ose:  T o a ll o w t he st u dy I nvesti g at or ( or dele g ate) t o ver b ally c o nt a ct t he p atie nt wit hi n t he st u dy visit wi n d o w t o assess f or a ny 
a dverse eve nts, c o n c o mit a nt me dic ati o ns (i n cl u di n g he mi n use), h os pit aliz ati o ns/ pr oce d ures, a n d p or p hyri a att acks.  
T he c ha n ges occ ur i n t he sec o n d b ullet p oi nt f oll o wi n g Ta bl e 3 , Sc he d ule of Assess me nts f or O p e n -La b el E xte nsi o n Peri o d: M o nt h [ADDRESS_1025856] u d y . 
Re vise d te xt:  
• St u d y pr oce d ures, i ncl u di n g gi v osira n a d mi nistrati o n, ma y occ ur at t he p atie nt’s h o me at t he discreti o n of t he I n vesti gat or, 
base d o n safet y a n d t olera bilit y.  I n sit u ati o ns w here a st u d y visit c a n n ot be c o m plete d at t he st u d y ce nter or offsite b y 
a h o me he al t hc a re pr of essi o n al visit, t he st u d y I n vesti g at or ( or del e g ate) m a y ver b all y c o nt act t he p atie nt wit hi n t he 
st u d y visit wi n d o w t o assess f or a n y a d verse e ve nts, c o nc o mit a nt me dic ati o ns (i ncl u di n g he mi n use), 
h os pit aliz ati o ns/ pr oce d ures, a n d p or p h yri a att ac ks.  
P ur p ose:  T o e x p a n d t he wi n d o w f or A L T a n d t ot al bilir u bi n tests f or decisi o ns o n giv osir a n d osi n g.  
T he pri mar y c h a n ge o cc urs i n Secti o n 6. 2. 2., D ose a n d A d mi nistrati o n, [ADDRESS_1025857] u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 6 S u m m ar y of C h a n ges, 2 3  A pril 2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 Re vise d te xt: A L T a n d t otal bilir u bi n ( T B L) res ults c ollecte d wit hi n [ADDRESS_1025858] u g a d mi nistrati o n.  
Secti o n(s) als o reflecti n g t his c ha n ge:   
• Ta ble 3, f o ot n ote f  
• Secti o n 6. 2. 3. 1  
• Secti o n 7. 5. 5  
P ur p ose: T o i ncre ase t he wi n d o w f or o bt ai ni n g b o dy wei g ht f or d ose deter mi n ati o n.  
T he pri mar y c h a n ge o cc urs i n Secti o n 7. 5. 2, Wei g ht a n d Hei g ht , 3 r d  para gra p h  
Re vise d te xt:  B o d y wei g ht o bt ai ne d wit hi n [ADDRESS_1025859] u d y ce nter visit  ma y be us e d f or d osi n g calc ulati o ns.  
Secti o n(s) als o reflecti n g t his c ha n ge:  
• Ta ble 3, f o ot n ote c  
P ur p ose: T o a ll o w f or re m ote c o nt act a n d c o m pl eti o n of Q OL a n d P P E Q q uesti o n n aires.  
T he c ha n ges occ ur i n Ta ble 3, Sc he d ule of Ass ess me nts f or O pe n -La bel E xte nsi o n Peri o d: M o nt h [ADDRESS_1025860] u d y  
Re vise d te x t:  
F o ot n ote m  
m Q O L q u esti o n naires t o be c o m plete d i ncl u de S F -1 2, E Q -5 D -5 L, a n d misse d da ys of w or k/sc h o ol.  I n sit u ati o ns w here a pl a n ne d 
st u d y visit c a n n ot be c o m plete d at t he st u d y ce nter, t he p atie nt will c o m plete t he Q o L q uesti o n n aires at h o me . 
F o ot n o te n  
n T he P P E Q is a set of q uesti o ns t o assess treat me nt e x perie nce a n d i m pacts t o t he patie nt's life n ot c ollecte d b y t he ot her Q O L 
assess me nts.  I n sit u ati o ns w here a pl a n ne d st u d y visit c a n n ot be c o m plete d at t he st u d y ce nter, t he p atie nt will c o m plete  t he 
P P E Q q uesti o n n aire at h o me.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 6 S u m m ar y of C h a n ges, 2 3  A pril 2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  8 P ur p ose: T o re m ove re q uire me nts f or E C Gs.  
T he pri mar y c h a n ge o cc urs i n Secti o n 7. 5. 4, Electr ocar di o gra m, 1 st  para gra p h  
Re vise d te xt: A si n gle sta n dar d 1 2 -le a d E C G will be rec or de d at Scree ni n g , M o nt h 2 4, a n d at t he E n d of Treat me nt ( E O S) Visit ; all 
ot her E C Gs will be perf or me d i n tri plicate, usi n g ce ntralize d E C G ser vice e q ui p me nt, wit h rea di n gs a p pr o xi matel y [ADDRESS_1025861] u d y Da y 1 a n d  at t he M o nt h 5, M o nt h 6, a n d 
M o nt h 1 2 visits ( Ta ble 8 a n d Ta ble 9); t hes e assess me nts will be paire d wit h P K meas ure me nts.  
Secti o n(s) als o reflecti n g t his c ha n ge:  
• Ta ble 3, 7 t h  r o w a n d f o ot n ote e  
• Ta ble 8  
• Ta ble 9  
P ur p ose: T o a ll o w cert ai n st u dy visit assess me nts t o be perf or me d offsite a n d pr ovi de a wi n d o w f or s afety l a b or at ory res ults pri or t o 
d osi n g by t he p atie nt or c are give r. 
T he c ha n ge occ ur s i n Secti o n [ADDRESS_1025862] u d y Assess me nts . 
Re vise d te xt:   T he sc he d ule of st u d y assess me nts is p r o vi de d i n Ta ble 1 ( S cree ni n g a n d 6 -M o nt h Treat me nt Peri o d), Ta bl e 2 ( O pe n -
la bel E xte nsi o n St u d y:  After M o nt h 6 t hr o u g h M o nt h 1 8), a n d Ta ble 3 ( O pe n -la bel E xte nsi o n St u d y:  M o nt h 1 9 t hr o u g h E O S).  
W here a p plic a ble c o u ntr y a n d l oc al re g ul ati o ns a n d i nfr astr uct ure all o w f or h o me he alt hc are, he alt hc are m a y t a ke pl ace at a 
l oc ati o n ot her t h a n t he cli nic al tri al site t o perf or m st u d y assess me nts i ncl u di n g t ar gete d p h ysic al e x a m/ b o d y s yste m 
assess me nt, assess me nts f or vit al si g ns, a n d c ollecti o n of bl o o d a n d uri n e s a m ples f or s af et y l a b or at or y assess me nts, a n d P D 
assess me nts, at all ti me p oi nts as s pecifie d i n t he Sc he d ule of Assess me nts . 
A d diti o nall y, Secti o n 6. 2. 2 , D ose a n d A d mi nistrati o n, 3 r d  para gra p h, is affecte d b y t hese  c h a n ge s. 
Re vise d te xt:   
A L T a n d t otal  bilir u bi n ( T B L) res ults c ollecte d wit hi n [ADDRESS_1025863] rati o n.  
Ot her s ecti o n(s) als o reflecti n g t h ese  c h a n ge s: 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 6 S u m m ar y of C h a n ges, 2 3  A pril 2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  9 • Ta ble 3,  f o ot n otes b, c, d, a n d f  
• Secti o n 7. 5. 2  
• Secti o n 7. 5. 5  
P ur p ose: T o b r o a de n t he wi n d o w f or P K a n d A D A assess me nts re q uire d t o be perf or me d at st u dy ce nter visits.  
T he pri mar y c h a n ges o cc ur i n Ta ble 3 , Sc he d ule of Assess me nts f or O p e n -La b el E xte nsi o n Peri o d: M o nt h [ADDRESS_1025864] u d y . 
Re vise d te xt:  
F o ot n ote  k 
k Bl o o d sa m ples f or P K a nal ysis will be c ollecte d pri or t o d osi n g at t he ti m e p oi nts liste d i n Ta ble [ADDRESS_1025865] u d y ce nter visit . 
Secti o n(s) als o reflecti n g t hese c ha n ges:  
• Ta ble 8  
• Ta ble 9  
P ur p ose: C ollect i nf or m ati o n rel ate d t o t he i m p act of t he C O VI D -[ADDRESS_1025866] of t he C O VI D -1 9 gl o b al p a n de mic o n cli nic al tri al d at a.  
T he pri mar y c h a n ge o cc urs i n a ne wl y a d d e d Secti o n 7 . 7, C O VI D -1 9 D ata C ollecti o n.  
A d de d te xt:  
Secti o n 7. 7  C O VI D -1 9 D at a C olle cti o n  
I nf or m ati o n will be c ollecte d o n t he c o r o n a vir us dise ase 2 0 1 9 ( C O VI D -1 9) i nfecti o n st at us of t he p atie nt, if k n o w n, a n d ot her 
i nf or m ati o n o n t he i m p act of t he C O VI D -1 9 p a n de mic o n t he p atie nt's p artici p ati o n i n t he st u d y.  
Secti o n(s) als o reflecti n g t his c ha n ge:  
• Secti o n 8. 2. [ADDRESS_1025867] u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1)  
A me n d me nt 6 S u m m ar y of C h a n ges, 2 3  A pril 2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 0  P ur p ose: T o pr ovi de cl arific ati o n o n I nvesti g at or res p o nsi bilities re g ar di n g c o m m u nic ati o n of ne w st u dy i nf or m ati o n t o p atie nts a n d 
I R B/I E Cs . 
T he se c h a n ge s occ ur i n Secti o n 9. 1. 1, I nf or me d C o nse nt , a n d Secti o n 9. 1. 2, Et hical Re vie w . 
A d de d te xt:  
Secti o n 9. 1. 1 , 3 r d  para gra p h  
T he I n vesti g at or will i nf or m t he p atie nt/le g al g u ar di a n if ne w i nf or m ati o n bec o mes a v ail a ble t h at m a y be rele v a nt t o t he 
p atie nt’s/le g al g u ar di a n’s willi n g ness t o c o nti n ue p artici p ati o n i n t he st u d y.  C o m m u nic ati o n of t his i nf or m ati o n s h o ul d be 
d oc u me nte d.  
Secti o n 9. 1. 2, [ADDRESS_1025868] u d y (e xce pt t h ose t h at s u p p ort t he nee d t o re m o ve a n 
a p p are nt i m me di ate h az ar d t o t he p atie nt) .  T h e pr ot oc ol m ust be rea p pr o ve d b y t h e I R B or I E C u p o n recei pt of a me n d me nts a n d 
a n n uall y, as l ocal r e g ulati o ns re q uire.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1 ) 
A me n d me nt 5 S u m m ar y of C h a n ges , 1 2  Fe br u ar y 2 0 2 0  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 A L N -A S 1 -0 0 3  P R O T O C O L A M E N D M E N T 5 
S U M M A R Y O F C H A N G E S D A T E D  1 2  F E B R U A R Y 2 0 2 0  
E N VI SI O N: A P h ase [ADDRESS_1025869] u d y 
wit h a n O pe n -l a bel E xte nsi o n t o E v al u ate t he Effic ac y a n d S afet y of Gi v osir a n i n P atie nts 
wit h Ac ute He p atic P o r p h yri as  
 
R ati o n ale f or Pr ot oc ol A me n d me nt  
T he pri mar y p ur p os e f or t his pr ot oc ol a me n d me nt is t o i ncrease t he d os e of gi v osira n f or patie nts 
recei vi n g 1. 2 5  m g/ k g gi v osira n s u bc uta ne o usl y ( S C) o nce m o nt hl y t o t he rec o m me n de d  d ose of 
2. 5  m g/ k g gi v osira n S C o nce m o nt hl y , w hi c h was a p pr o ve d b y t he U nite d States F o o d a n d Dr u g 
A d mi nistrati o n ( F D A)  i n N o ve m ber 2 0 1 9  a n d recei ve d a C o m mittee f or M e dici nal Pr o d ucts f or 
H u ma n Use ( C H M P) p ositi ve o pi [INVESTIGATOR_9384] o n i n J a n uar y  [ADDRESS_1025870] b o -c o ntr olle d, d o u ble -bli n d ( D B ) peri o d a n d o pe n -la bel e xte nsi o n ( O L E ) peri o d t hr o u g h t he 
M o nt h  1 2 data -c ut ha v e de m o nstrate d t hat treat me nt at 2. 5  m g/ k g gi v osira n S C o nce  m o nt hl y 
res ult e d  i n s ustai ne d l o w eri n g of t he diseas e ca usal fact ors a mi n ole v uli nic aci d ( A L A ) a n d 
p or p h o bili n o ge n ( P B G ) a n d is  ass ociate d wit h s u bsta ntial be nefits i ncl u di n g re d uci n g de bilitati n g 
ne ur o visceral attac ks a n d i m pr o vi n g c hr o ni c disease as pect s s uc h as he mi n use, dail y p ai n, 
a nal gesic use, p h ysic al f u ncti o ni n g, a n d q u alit y of life.  T hese be n eficial effects were 
acc o m pa ni e d b y a n acce pta ble a n d ma na gea ble s afet y pr ofile t hr o u g h t he M o nt h  1 2 data -c ut, 
w hic h s u p p orts a fa v ora ble be nefit -ris k pr of ile f or gi v osira n at t he 2. 5 -m g/ k g S C o nce m o nt hl y 
d ose .  A tre n d t o war d i ncrease d b e nefit as i n dicate d b y greater re d u cti o n i n c o m p osite attac ks, 
he mi n use, a n d A L A a n d P B G le vels was o bs er ve d d uri n g t he first 6  m o nt hs of treat me nt i n  t he 
O L E wit h t he 2. 5 -m g/ k g S C o nce m o nt hl y  d os e c o m pare d t o t he 1. 2 5 -m g/ k g S C o nce m o nt hl y  
d ose i n patie nts w h o recei ve d place b o d uri n g t he D B peri o d.  F urt h er m ore, I n v esti gat ors 
re q ueste d t o i ncreas e t he d ose  t o 2. 5  m g/ k g  gi v osira n S C o nce m o nt hl y f or  14 of t he 3 7  patie nts 
(38%) recei vi n g 1. 2 5  m g/ k g gi v osira n S C o nce m o nt hl y  i n t he O L E beca us e of i na de q u ate 
cli nical res p o nse  as per mitte d i n Secti o n  6. 2. 3. 4 of t he pr ot oc ol.  Gi ve n t he tre n d t o war d 
i ncreas e d be nefit wit h t he 2. 5 -m g/ k g S C o nce m o nt hl y  d ose of gi v osira n c o m pare d t o t he 
1. 2 5 -m g/ k g S C o nce m o nt hl y  d ose a n d c o nsi deri n g t hat ac ute he p atic  p or p h yria ( A H P ) is a 
disease i n w hic h  eac h attac k is seri o us, hi g hl y m or bi d, a n d carries p ote ntial f or irre v ersi ble 
ne ur ol o gi c da ma ge, all p atie nt s, i n t he a bse nce of  o n g oi n g  cli nicall y rele va nt tra nsa mi nase 
ele vati o ns , will be  treate d wit h t he rec o m me n de d  d ose of 2. 5  m g/ k g gi v osira n S C o nce m o nt hl y.  
T he f oll o wi n g  a d diti o nal c ha n ges are als o bei n g i m ple me nte d : 
• All o w p atie nts w h o de vel o p a tra nsa mi nase ele vati o n t hat meet s a pr o t oc ol -defi ne d 
d ose h ol di n g r ule w hile recei vi n g 2. 5  m g/ k g gi v osira n S C o nce m o nt hl y t o res u me 
d osi n g at eit her t he 1. 2 5 - or 2. 5 -m g/ k g gi v osira n S C o nce m o nt hl y d ose after 
res ol uti o n of ala ni ne a mi n otra nsferase ( A L T ) t o ≤ 2 × u p per li mit of n or mal ( U L N ; or 
≤ 2 × baseli ne f or patie nts w h o ha d ele v ate d baseli n e A L T) per t he I n v esti gat or’s 
j u d ge me nt a n d after disc ussi o n wit h t he me dical m o nit or .  T his c ha n ge will e na ble t he 
c ollecti o n of r o b ust safet y dat a at t he c o m merical  d ose after a d ose i nterr u pti o n f or 
A L T ele vati o n i n a cli nical trial setti n g.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1 ) 
A me n d me nt 5 S u m m ar y of C h a n ges , 1 2  Fe br u ar y 2 0 2 0  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 • Disc o nti n uati o n of m o nit ori n g b y t he Data Mo nit ori n g Co m mittee ( D M C):  I n 
Oct o ber  [ADDRESS_1025871] u d y  ( 6  m o nt hs 
d uri n g t he D B p eri o d a n d 6  m o nt hs d uri n g t he O L E  peri o d) .  T he D M C deter mi ne d 
t hat t he safet y pr ofile f or gi v osira n c o nti n ue d t o be acce pta ble a n d a gree d wit h t he 
S p o ns or’ s rec o m me n d ati o n t o ter mi nate t he D M C f or t he re m ai n der of t h e O L E 
peri o d  of t he st u d y .  Base d o n t he fa v ora ble safet y pr ofile f or gi v osira n , a p pr o val of 
gi v osira n b y t he F D A i n N o v e m ber  2 0 1 9 , a n d C H M P p ositi ve o pi [INVESTIGATOR_9384] o n i n 
J a n uar y  2 0 2 0 , t he D M C c harter is bei n g a me n de d i n parallel wit h t his a me n d me nt t o 
per mit disc o nti n uati o n of t he D M C .  Patie nt safet y will c o nti n ue t o be m o nit ore d o n a 
re g ular b asis  b y t he S p o ns or acc or di n g t o sta n d ar d o perati n g pr oce d ures . 
• Re m o v al  of t he re q uir e m e nt t o test a n d re vie w t h e res ults f or i nter nati o nal n or malize d 
rati o (I N R) wit hi n 1 4  da ys pri or t o d osi n g :  Base d o n data fr o m t he gi v osira n 
de vel o p me nt pr o gra m, testi n g of I N R pri or t o d osi n g has n ot e n ha nce d t he detecti o n 
of ac ute h e patic i nj ur y be y o n d t he pre d ose assess me nt of A L T a n d t otal bilir u bi n 
( T B L) .  A d diti o nall y, n o cli nicall y si g nifica nt c ha n ges i n c oa g ulati o n para meters ha ve 
bee n see n i n p atie nts wit h A L T ele vati o ns > 3 × U L N.  M ore o ver, testi n g of I N R o n 
eac h p atie nt  pri or t o d osi n g re q uires c ollecti o n of a d diti o nal a n d u n necess ar y bl o o d 
sa m ples .  I n all patie nts wit h A L T ele vati o n > 3 × U L N, I N R testi n g will still be  
re q uire d t o pr o vi de f urt h er i nf or mati o n o n t he se v erit y of he patic i nj ur y (see 
Secti o n  6. 2. 3. 1).  E val uati o n of A L T a n d T B L wit hi n 1 4  da ys pri or t o d osi n g  a n d 
testi n g of I N R wit h r e g ular cli nical la b orat ories as s pecifie d i n t he Sc he d ul e of 
Assess me nts  will c o nti n ue . 
• U p date p ote ntial safet y c o ncer ns t o be c o nsiste nt wit h e mer gi n g d ata a n d t o ali g n 
wit h t he I n v esti gat ors Br oc h ure.  
A detaile d s u m mar y of c ha n g es is pr o vi de d i n  Ta ble  1.  C orrecti o ns t o t y p o gra p hical err ors, 
p u nct uati o n, gra m mar, a b bre viati o ns, a n d f or m atti n g  (i ncl u di n g a d mi nistrati ve c ha n ges bet w ee n 
pr ot oc ol a me n d me nt s 4 a n d  5) are n ot d etaile d.  
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1 ) 
A me n d me nt 5 S u m m ar y of C h a n ges , 1 2  Fe br u ar y 2 0 2 0  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 T a ble  1: Pr ot oc ol A me n d me nt 5 Det aile d S u m m a r y of C h a n ges  
T he pri mar y secti o n(s) of t he pr ot oc ol affecte d b y t he c ha n ges i n Pr ot oc ol A me n d me nt 5 are i n dicat e d.  T he c orres p o n di n g te xt has 
bee n re vis e d t hr o u g h o ut t he pr ot oc ol.   Delet e d te xt is i n dicate d b y stri ke o ut ; a d de d te xt is i n dicate d b y b ol d  f o nt.  
P ur p ose:  To i ncre ase t he d ose of giv osir a n f or p atie nts receivi n g 1. 2 5  m g/k g giv osir a n S C o nce m o nt hly t o t he rec o m me n de d  d ose of 2. 5  m g/k g 
giv osir a n S C o nce m o nt hly.  
T he pri mar y c ha n ge occ urs i n Secti o n 6. 2. 3. 4,  D ose Escalati o n G ui da nce f or Gi v osira n fr o m 1. 2 5  m g/ k g O nc e M o nt hl y t o 2. 5  m g/ k g O n ce 
M o nt hl y i n t he O pe n -La bel Peri o d  
N o w rea ds:  
6. 2. 3. 4  D ose Esc al ati o n G ui d a nce f or Gi v osir a n fr o m 1. 2 5 m g/ k g O nce M o nt hl y t o  2. 5  m g/ k g O nce 
M o nt hl y i n t he O pe n -L a bel Peri o d  
After i m ple me nt ati o n of a me n d me nt  3 a n d u ntil i m ple me nt ati o n of a me n d me nt  5, p atie nts assi g ne d t o 
t he o nce m o nt hl y 1. 2 5 -m g/ k g tre at me nt gr o u p m a y be  all o w e d t o h a ve t heir m o nt hl y d ose i ncre ase d t o 
2. 5  m g/ k g Sstarti n g at t he M o nt h  [ADDRESS_1025872] u d y Visit ( w he n 6  m o nt hs of o pe n -l a bel gi v osira n d osi n g h a ve  bee n 
c o m plete d  at 1. 2 5  m g/ k g ), b ase d o n disc ussi o n a n d a gree me nt b y t he I n vesti g at or a n d me dic al m o nit or.  
D ose esc al ati o n m a y be  c o nsi dere d patie nts recei vi n g o pe n la b el gi v osira n at S C d oses of 1. 2 5  m g/ k g m o nt hl y 
ma y b e per mitte d t o i ncrease t heir m o nt hl y d ose t o 2. 5 m g/ k g base d o n I n v esti gat or j u d ge me nt.  I n v esti gat ors 
ma y c o nsi der d ose escal ati o n  if t he f oll o wi n g criteria are met:  
• T olera bilit y t o gi v osira n at 1. 2 5 m g/ k g o nce m o nt hl y has b ee n de m o nstrat e d base d o n n o d ose 
i nterr u pti o ns d ue t o L F T ele vati o ns at t he 1. 2 5  m g/ k g o nce m o nt hl y d ose le vel (see Secti o n  6. 2. 3. 1) 
a n d n o si g nifica nt safet y c o ncer ns d u e t o ot her A Es t hat w o ul d precl u de a p atie nt fr o m recei vi n g a  
hi g her d os e of gi v osira n as j u d ge d b y t he  I n vesti gat or a n d S p o ns or.    
• Uri ne A L A le v els ( m m ol/ m ol Cr) are n ot sta bl y m ai ntai ne d ≤ U L N or are i n d uci ble  
• Patie nt has i na de q uate cli nical res p o nse (e g, brea kt hr o u g h attac ks or o n g oi n g c hr o nic s y m pt o ms), 
acc or di n g t o I n v esti gat or j u d ge me nt.  
U p o n i m ple me nt ati o n of a me n d me nt  5, all p atie nts recei vi n g 1. 2 5  m g/ k g gi v osir a n o nce m o nt hl y w h o d o 
n ot h a ve o n g oi n g cli nic all y rele v a nt tr a ns a mi n ase ele v ati o ns will h a ve t heir d ose i ncre ase d t o 2. 5  m g/ k g 
gi v osir a n o nce m o nt hl y  b ase d o n t oler a bilit y al o ne, wit h o ut a n y criteri a f or A L A re d ucti o n or cli nic al 
acti vit y .  D ose i ncre ases s h o ul d t a ke effect as of t he d ate t h at s ufficie nt st u d y dr u g m ateri al c a n be m a de 
a v ail a ble f or t he p atie nt.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1 ) 
A me n d me nt 5 S u m m ar y of C h a n ges , 1 2  Fe br u ar y 2 0 2 0  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 Uri ne A L A a nal yses ma y be c o n d ucte d at a  l ocal l a b orat or y or A L A res ults fr o m pre vi o us visits ma y be 
e val uate d i n patie nts o n t he 1. 2 5 m g/ k g m o nt hl y d ose i n w h o m d ose escalati o n t o 2. 5  m g/ k g o n ce m o nt hl y is 
bei n g c o nsi dere d  
T he decisi o n t o i ncrease t he gi v osira n d ose fr o m 1. 2 5 m g/ k g m o nt hl y t o 2. 5  m g/ k g m o nt hl y will be disc usse d 
a n d a gree d u p o n b y t he I n vesti gat or a n d me dical m o nit or pri or t o i nitiati o n of t he ne xt d ose.  
U p o n i ncreas e of t he gi v osira n d ose t o 2. 5 m g/ k g m o nt hl y:  
• L F Ts, I N R, a n d T B L will be m o nit ore d e ver y 2 w ee ks ( ± 7 da ys) f or t he  first m o nt h f oll o wi n g t he 
d ose i ncrease t o 2. 5 m g/ k g, t he n m o nt hl y ( ± [ADDRESS_1025873] u d y visits) as per t he 
Sc he d ule of Assess me nts  
• La b orat or y m o nit ori n g a n d d osi n g r ules i n r es p o nse t o L F T ele v ati o n will f oll o w Ta ble  4 g ui d eli nes  
• F or pat ie nts i n w h o m gi v osira n d osi n g is wit h hel d d ue t o ele vate d A L T, res u m pti o n of d osi n g ma y 
be c o nsi dere d base d o n t he g ui d a nce i n Secti o n  6. 2. 3. 1. 1 . 
 
Secti o n(s) als o c o ntai ni n g t his c ha n ge:  
• S y n o psis , St u d y Desi g n  
• T a ble 3, f o ot n otes h a n d j  
• Secti o n 1. 3, St u d y Desi g n Rati o nale  
• Secti o n 1. 4, D ose Rati o nale  
• Secti o n 4. 1, S u m mar y of St u d y Desi g n  
• Fi g ure 2, St u d y Desi g n  
• Secti o n 6. 2. 2. 2, D uri n g t he O pe n -La bel E xte nsi o n Peri o d ( After M o nt h 6 t hr o u g h E n d of Treat me nt)  
• Secti o n 6. 2. 3, D ose M o dificati o ns  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1 ) 
A me n d me nt 5 S u m m ar y of C h a n ges , 1 2  Fe br u ar y 2 0 2 0  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 P ur p ose:  All o w p atie nts w h o devel o p a tr a ns a mi n ase elev ati o n t h at meets a pr ot oc ol defi ne d d ose h ol di n g r ule w hile receivi n g 2. 5  m g/k g 
giv osir a n S C o nce m o nt hly t o res u me d osi n g at eit her t he 1. 2 5 - or 2. 5 -m g/k g giv osir a n S C o nce m o nt hly d ose after res ol uti o n of A L T  t o ≤ 2 × U L N 
( or ≤ 2 × b aseli ne f or p atie nts w h o h a d elev ate d b aseli ne A L T) per t he I nvesti g at or’s j u d ge me nt a n d after disc ussi o n wit h t he me dic al m o nit o r. 
T he pri mar y c ha n ge occ urs i n Secti o n 6. 2. 3. 1. 1 , Criteria f or Rec halle n ge of Gi v osira n After Bei n g Wit h he l d f or A L T Ele vati o n  
N o w rea ds:  
6. 2. 3. 1. 1  Criteri a f or R ec h alle n ge of Gi v osir a n After Bei n g Wit h hel d f or A L T Ele v ati o n  
F or patie nts i n w h o m gi v osira n d osi n g  is wit h hel d d ue t o ele vate d A L T, res u m pti o n of d osi n g ma y b e 
c o nsi dere d usi n g t he f oll o wi n g g ui deli nes:  
• Patie nts w h o di d n ot meet criteria f or st u d y dr u g disc o nti n uati o n per Ta ble 4  ma y b e c o nsi dere d f or 
rec halle n ge f oll o wi n g c o ns ultati o n wit h t he me dical m o nit or a n d res ol uti o n of A L T t o ≤ 2 × U L N or 
≤ 2 × baseli ne (f or patie nts w h o ha d ele v ate d ba seli ne A L T)  
• T he decisi o n t o rec halle n ge t h e patie nt s h o ul d be disc usse d a n d a gree d u p o n b y t he p atie nt, 
I n v esti gat or, a n d me dical m o nit or  
• T he d ose re gi me n f or patie nts w h o meet rec halle n ge criteri a, re gar dless of t heir d ose at t he ti me of 
t he A L T ele v ati o n , is a d ose of eit her 1. 2 5 or 2. 5  m g/ k g m o nt hl y  per I n vesti gt or j u d ge me nt  a n d 
after disc ussi o n wit h t he me dic al m o nit or : 
− L F Ts, I N R a n d T B L will be m o nit ore d e ver y 2 wee ks ( ± 7 da ys) f or t he first m o nt h, t he n 
m o nt hl y ( ± [ADDRESS_1025874] u d y vi sits) as per t he Sc he d ule of Assess me nts  
− La b orat or y m o nit ori n g a n d d osi n g r ules i n r es p o nse t o L F T ele v ati o n will f oll o w Ta ble 4  
g ui deli nes  
• If d ose wit h h ol di n g r ules per Ta ble 4  are m et o n t his rec h alle n ge wit h  t he 1. 2 5 -m g/ k g  d ose, 
per ma ne ntl y disc o nti n ue d osi n g  
• F or patie nts treate d wit h 2. 5 m g/ k g m o nt hl y gi v osira n at t he ti me of t he A L T ele vati o n, d ose re 
escalati o n t o 2. 5 m g/ k g m o nt hl y m a y be c o nsi dere d if t he f oll o wi n g criteria are m et:  
 A p pr o val b y t he me dic al m o nit or afte r at least 3 d oses of 1. 2 5 m g/ k g m o nt hl y f or p atie nts w h o 
meet b ot h criteria b el o w:  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1 ) 
A me n d me nt 5 S u m m ar y of C h a n ges , 1 2  Fe br u ar y 2 0 2 0  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 o Patie nt has n ot met d ose wit h h ol di n g or disc o nti n uati o n r ules per T a ble 4  d uri n g tr eat me nt 
wit h 1. 2 5 m g/ k g m o nt hl y  
o Patie nt has i na de q uate c o ntr ol of p or p h yria s y m pt o ms o n t he 1. 2 5 m g/ k g m o nt hl y re gi me n, 
per i n vesti gat or’s ass ess me nt  
 L F Ts, I N R, a n d T B L will be m o nit ore d e ver y 2 w ee ks ( ± 7 da ys) f or t he first m o nt h after d ose 
re es calati o n, a n d t he n m o nt hl y as per t he Sc he d ul e of Assess me nts  
• If a patie nt e x perie nces a sec o n d d ose h ol d d ue t o L F T ele v ati o n w hile o n 2. 5  m g/ k g m o nt hl y:  
− F oll o w Ta ble 4  g ui deli nes f or m o nit ori n g a n d e val uati o ns  
− If A L T res ol ves t o ≤ 2 × U L N, re d osi n g wit h 1. 2 5 m g/ k g m o nt hl y ma y b e c o nsi dere d if t hi s d ose 
was pre vi o usl y t olerat e d a n d t here is a p pr o val b y after disc ussi o n wit h  t he Al n yla m me dical 
m o nit or.  If d osi n g is res u me d, f oll o w t he g ui d a nce a b o ve f or rec halle n ge re gi me n re gar di n g 
la b orat or y m o nit ori n g a n d d osi n g r ules.  N o s u bs e q ue nt re -escal ati o n t o 2. 5 m g/ k g m o nt hl y will 
be all o we d  
o L F Ts, I N R, a n d T B L will be m o nit ore d e ver y 2 w ee ks ( ± 7 da ys) f or t he first m o nt h after 
d ose res u mi n g 1. 2 5 m g/ k g, a n d t h e n m o nt hl y as p er t he Sc he d ule of Assess me nts  
 
P ur p ose:  Disc o nti n u ati o n of m o nit ori n g by t he D at a M o nit ori n g C o m mittee ( D M C)  
T he pri mar y c ha n ge occ urs i n Secti o n 4. 7, I n de pe n de nt Data M o nit ori n g C o m mittee  
N o w rea ds:  4. [ADDRESS_1025875] u d y . A n al ys es f or t he D M C are 
pr o vi de d b y a n i n de pe n d e nt bi ostatistics gr o u p. D etails are pr o vi d e d i n t he D M C C harter . 
Secti o n(s) als o c o ntai ni n g t his c ha n ge:  
• S y n o psis , St u d y Desi g n  
• Secti o n 1. 5, Be nefit -Ris k Assess me nt  
• Secti o n 4. 1, S u m mar y of St u d y Desi g n  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n ( A L N -A S 1 ) 
A me n d me nt 5 S u m m ar y of C h a n ges , 1 2  Fe br u ar y 2 0 2 0  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 • Fi g ure 2, St u d y Desi g n  
• Secti o n 6. 2. 2. 2, D uri n g t he O pe n -La bel E xte nsi o n Peri o d ( After M o nt h 6 t hr o u g h E n d of Treat me nt)  
• Secti o n 6. 2. 3, D ose M o dificati o ns  
P ur p ose:  Re m ov al of t he re q uire me nt t o test a n d revie w t he res ults f or i nter n ati o n al n or m alize d r ati o (I N R) wit hi n 1 4  d ays pri or t o d osi n g  
T he pri mar y c ha n ge occ urs i n Secti o n 6. 2. 2, D ose a n d A d mi nistrati o n  
N o w rea ds:  A L T  a n d , t otal bilir u bi n ( T B L)  a n d I N R  res ults c ollecte d wit hi n [ADDRESS_1025876] be re vie we d 
pri or t o d osi n g.   
Secti o n(s) als o c o ntai ni n g t his c ha n ge:  
• T a ble 3, f o ot n ote f  
• Secti o n 6. 2. 3. 1, M o nit ori n g a n d D osi n g R ules Base d o n Li ver F u ncti o n T est Res ults  
• Secti o n 7. 5. 5,  Cli nical La b orat or y Assess me nts  
P ur p ose:  U p d ate p ote nti al s afety c o ncer ns t o be c o nsiste nt wit h e mer gi n g d at a a n d t o ali g n wit h t he I nvesti g at ors Br oc h ure . 
T he pri mar y c ha n ge occ urs i n Secti o n 1. 5, Be nefit -Ris k Assess me nt  
N o w rea ds:  Gi ve n t he bi ol o gical tar get of gi v osira n, t he a vaila ble n o ncli nical a n d cli nical data, a n d t he m o de of a d mi nistrati o n, ot her 
i m p orta nt p ote ntial ris ks s afet y c o ncer ns  i ncl u de i njecti o n site reacti o ns (I S Rs),  ele v ati o n of  li ver tra nsa mi nase s 
a b n or malities , incre ase d ser u m cre ati ni ne / decre ase d e sti m ate d gl o mer ul ar filtr ati o n r ate  (e G F R ),  pa ncreatitis , a n d 
a na p h ylactic reacti o n s. 
P ur p ose:  C orrect ty p o gr a p hic al err ors, p u nct u ati o n, gr a m m ar, a b brevi ati o ns, a n d f or m atti n g [, i ncl u di n g a d mi nistr ative c h a n ges , if a p pr o pri ate]  
T hese c ha n ges are n ot liste d i n di vi d uall y.  
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n  (A L N -A S 1 ) 
A me n d me nt 4 S u m m ar y of C h a n ges , 2 8 M a y  2 0 1 9  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 A L N -A S 1 -0 0 3 P R O T O C O L  A M E N D M E N T 4  
S U M M A R Y O F C H A N G E S D A T E D 2 8 M A Y  2 0 1 9  
E N VI SI O N: A P h ase [ADDRESS_1025877] u d y  ( A L N -A S 1 -0 0 4) perf or m e d i n AI P patie nts w h o 
are as y m pt o matic hi g h e x creters (als o r eferre d t o as c hr o nic hi g h e x cret ers [ C H E]) i n t he 
c o nc o mita nt me dicati o ns secti o n ( Secti o n  6. 3).  T he res ults of t he st u d y i n dicate d t hat gi v osira n 
treat me nt res ulte d i n m o derate re d ucti o n i n C Y P 1 A 2 a n d C Y P 2 D 6 acti vit y, wea k re d ucti o n i n 
C Y P 3 A 4 a n d C Y P 2 C 1 9 acti vit y, a n d n o c ha n ge i n t he acti vit y of C Y P 2 C 9.  
A d diti o nal u p dates are b ei n g i m ple me nte d as n ote d bel o w:   clarificati o n t hat patie nts ma y 
c o nti n ue t o recei ve gi v osira n  u ntil it is c o m merciall y a vaila ble i n t he p atie nt’s territ or y, u p date t o 
clarif y t hat staff d o n ot nee d t o wait u ntil t he e n d of t he st u d y b ef ore o btai ni n g l ocal A L A or 
P B G meas ur e me nt s, u p d ates t o be c o nsiste nt wit h c ha n ges ma d e i n a me n d me nt 3, a d diti o n of 
g ui da n ce f or seri o us breac hes of pr ot oc ol, u p date d P K, E C G a n d A D A ti me p oi nts, a n d deleti o n 
of Secti o n  [ADDRESS_1025878] uati o n, gra m mar, a b bre viati o ns, a n d f or m atti n g (i ncl u di n g a d mi nistrati ve c ha n ges bet w ee n 
pr ot oc ol a me n d me nts  3 a n d  4) a re n ot d etaile d.  
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n  (A L N -A S 1 ) 
A me n d me nt 4 S u m m ar y of C h a n ges , 2 8 M a y  2 0 1 9  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 T a ble  1: Pr ot oc ol A me n d me nt  4 Det aile d S u m m a r y of C h a n ges  
T he pri mar y secti o n(s) of t he pr ot oc ol affecte d b y t he c ha n ges i n Pr ot oc ol A me n d me nt  4 are i n dicat e d.  T he c orres p o n di n g te xt has 
bee n re vis e d t hr o u g h o ut t he pr ot oc ol.  Delet e d te xt is i n dicate d b y stri ke o ut ; a d de d te xt is i n dicate d b y b ol d  f o nt.  
P ur p ose:  U p d ate d Secti o n 1. 2. 2, S u m m ary of Cli nic al D at a wit h Giv osir a n, wit h res ults of t he o pe n -l a bel dr u g -dr u g i nter acti o n st u dy ( A L N -A S 1 -
0 0 4) t o s u p p ort c h a n ges i n Secti o n 6. 3, C o nc o mit a nt Me dic ati o ns.  
T he pri mar y c ha n ge is t he a d diti o n of Secti o n  1. 2. 2. 3, Dr u g -dr u g I nteracti o n St u d y A L N -A S 1 -0 0 4  
A d de d te xt : 
1. 2. 2. [ADDRESS_1025879] u g i nter acti o n ( D DI) st u d y ( A L N- A S 1- 0 0 4) w as c o n d ucte d i n AI P patie nts w h o are 
C H E t o e v al u ate t he effect of a si n gle d ose of 2. 5 m g/ k g gi v osir a n a d mi nistere d SC o n t he ph ar m a c o ki netics 
of pr o be s u bstr ates f or 5 m aj or c yt oc hr o me P 4 5 0 ( C Y P) e nz y mes t h at acc o u nt f or t he met a b olis m of 
a p pr o xi m atel y 8 0 % of prescri be d dr u gs ( 2 4, 2 5).  Res ults fr o m t his st u d y de m o nstr ate d t h at gi v osir a n 
tre at me nt res ulte d i n we a k t o m o der ate re d ucti o n i n t he met a b olic acti vit y of s o m e of t he [ADDRESS_1025880] u die d, t here b y le a di n g t o hi g her co nce ntr ati o ns of s o m e s u bstr ates a n d t heir met a b olites.  Tre at me nt wit h 
gi v osir a n res ulte d i n a n a p pr o xi m atel y 3-f ol d incre ase i n ex p os ure ( as me as ure d by A U C) t o c affei ne ( a 
se nsiti ve s u bstr ate for C Y P 1 A 2) a n d a n a p pr o xi m atel y 2-f ol d i n cre ase i n ex p os ure t o de xtr o met h or p h a n ( a 
se nsiti ve s u bstr ate for C Y P 2 D 6).  E x p os ure of mi d az ol a m ( a se nsit i ve s u bstr ate for C Y P 3 A 4) a n d 
o me pr az ole ( a se n siti ve s u bstr ate for C Y P 2 C 1 9) i ncre ase d less t h a n 2-f ol d af ter tr e at me nt wit h gi v os ir a n.  
T here was n o effect of gi v os ir a n tre at me nt o n l os art a n ( a se nsiti ve s u bstr ate for C Y P 2 C 9). 
P ur p ose:   Cl arify t h at s u bjects m ay c o nti n ue u ntil giv osir a n is c o m merci ally av ail a ble or t he giv osir a n devel o p me nt pr o gr a m is disc o nti n ue d.  
T he pri mar y c ha n ge is t he a d diti o n of [ADDRESS_1025881] u d y Desi g n.  
A d de d te xt : D uri n g t he O L E Peri o d, p atie nts m a y recei ve gi v osir a n as l o n g as t he y d o n ot f ulfill a n y of t he st u d y disc o nti n u ati o n 
criteri a (see Secti o n  5. 3 ) or u ntil gi v osir a n is c o m merci all y a v ail a ble i n t he p atie nt’s territ or y or t he gi v osir a n 
de vel o p me nt pr o gr a m is disc o nti n ue d ( w hic he ver c o mes first).  
All p atie nts are as ke d t o p artici p ate i n t he S afet y F oll o w -u p visit after t he y h a ve recei ve d t heir l ast d ose of gi v osir a n.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n  (A L N -A S 1 ) 
A me n d me nt 4 S u m m ar y of C h a n ges , 2 8 M a y  2 0 1 9  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 Secti o n(s) als o c o ntai ni n g t his c ha n ge:  
Sy n o psis, St u dy Desi g n 
P ur p ose:  U p d ate d c o nc o mit a nt me dic ati o ns t o i n dic ate t h at giv osir a n tre at me nt c o ul d affect dr u gs t h at are met a b olize d pri m arily by C Y P 2 D 6 
a n d C Y P 1 A 2.  
T he pri mar y c ha n ge occ urs i n Secti o n  6. 3, C o nc o mita nt Me dicati o ns  
F or merl y rea d:  Patie nts wit h p or p h yria c o ul d ha ve altere d he me s y nt hesis a n d tr eat me nt wit h gi v osira n c o ul d als o m o d ulate t his 
pat h wa y an d ca n sec o n daril y i m pact c yt o c hr o me p4 5 0 ( C Y P) e nz y me ac ti vit y. St u dies i n m o n ke y s c o ul d n ot 
e x cl u de t he p ote ntial f or gi v osira n t o alter t he cle ara nce of dr u gs meta b olize d b y t h e CY P [ADDRESS_1025882] of c o m m o n me dicati o ns t hat are se nsiti ve C Y P 3 A s u bstrates or C Y P 3 A s u bstrates 
wit h a narr o w t hera pe utic ra n ge ca n be f o u n d i n Secti o n 1 1. 2. F or m ore detaile d a n d u p-t o- date i nf or mati o n o n 
C Y P 3 A s u bstrates, see: 
htt ps:// w w w.f da. g o v/ dr u gs/ de vel o p me nta p pr o val pr ocess/ de vel o p me ntres o urces/ dr u gi nteracti o nsla beli n g/ uc m 0 9 3 6 
6 4 .ht m. 
N o w rea ds:  Patie nts wit h p or p h yria c o ul d ha ve altere d he p atic  he me s y nt hesis , a n d tr eat me nt wit h gi v osira n c o ul d als o 
m o d ulate t his pa t h wa y a n d ca n sec o n d aril y i m pa ct c yt oc hr o me p 4 5 0 ( C Y P) e nz y me acti vit y .  St u dies Res u lts fr o m 
a D DI st u d y  i n  m o n ke ys c o ul d n ot e xcl u de t he p ote ntial f or AI P p atie nts w h o are C H E are prese nte d i n Secti o n 
1. 2. 2. 3.  T he D DI st u d y de m o nstr ate d t h at gi v osira n t o altert he cleara nce tre at me nt res ulte d i n we a k t o 
m o der ate re d ucti o n i n ac ti vit y of s o me of t he C Y P enz y mes res ulti n g i n corres p o n di n g l o w t o mo der ate 
i ncre ase i n t he pl as m a l e ve ls of dr u g s t h at a re meta b olize d b y t hese C Y P e nz y mes.  B ase d o n t he m o de r ate 
decre ase i n b y the CY P [ADDRESS_1025883] u d y star t a n d m o ni t or t he p atie nt’ s cli nical  
res p o nse t o t hese me di cati o ns d uri n g t he st u d y.  Me dicati o ns met a b olize d pri m aril y b y C Y P 2 D 6 a n d C Y P 1 A 2  
wit h a narr o w t h era p e utic i n de x (ie, t hat re q uire re g ul a r l a b or at or y m o nit ori n g ) m a y ne e d t o b e m o nit ore d m ore 
fre q ue ntl y i n t he i ni tial sta ges of t he st u d y t o deter mi ne w het her if a d ose adj ust me nt of t he c o nc o mita nt me dicati o n 
is re q uire d.  A list of c o m m o n me dicati o ns t hat are se nsiti ve C Y P [ADDRESS_1025884] u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n  (A L N -A S 1 ) 
A me n d me nt [ADDRESS_1025885]’s prescri pti o n i nf or m ati o n t o 
deter mi ne if t here is a n ee d t o m o nit or c o nc o mit a nt me dic ati o ns f or differe nces i n s af et y or effic ac y of t he 
me dic ati o n b ase d o n re p orte d D DIs  wit h a narr o w t hera pe utic ra n ge ca n be f o u n d i n Secti o n  1 1. 2 .C Y P 2 D 6 or 
C Y P 1 A 2.  F or m ore detaile d a n d u p-t o- date i nf or mati o n o n C Y P 3 A s u bstrates, see: 
htt ps:// w w w.f da. g o v/ dr u gs/ de vel o p me nta p pr o val pr ocess/ de vel o p me ntres o urces/ dr u gi nteracti o nsla beli n g/ uc m 0 9 3 6 
6 4. ht m. 
P ur p ose:  C orrect a n err or i n Secti o n  7. [ADDRESS_1025886] u dy bef ore o bt ai ni n g a l oc al A L A or P B G 
me as ure me nt.  
T he pri mar y c ha n ge occ urs i n Secti o n  7. 3, P har mac o d y na mic Assess me nts  
F or merl y  rea d:  Uri ne sa m ples wi ll be c ollecte d f or assess me nt of gi v osira n P D para meters pri or t o d osi n g.  T he P D effect of 
gi v osira n will be e val uat e d b y s p ot uri n e A L A a n d P B G le vels n or maliz e d t o s p ot uri ne creati ni ne l e vels.  Uri ne 
sa m ples will be c ollecte d f or assess me nt of circ ula ti n g A L A S 1 m R N A le vels.  A nal ysis of uri n e A L A S 1 m R N A 
le vels will be perf or me d at Al n yla m; all ot her uri ne P D a nal yses will ta ke place at a ce ntr al la b orat or y.  Si nce 
I n v esti gat ors are bli n de d t o treat me nt assi g n m e nts, t he y will als o be bli n de d t o A L A a n d P B G res ults a nal yze d at 
t he ce ntral la b orat or y.  I n a d diti o n, i n vesti gat ors a n d staff i n v ol ve d wit h t his trial a n d all me dical staff i n v ol ve d i n 
t he s u bject’s me dical care s h o ul d refrai n fr o m o bt ai ni n g l oc al A L A or P B G meas ure m e nts u ntil at least [ADDRESS_1025887] u d y, w hic h e ver is later (t o a v oi d p ote ntial u n bli n di n g).  If A L A 
or P B G is meas ur e d d uri n g t his peri o d, all reas o n a ble ste ps m ust be u n dert a ke n t o a v oi d i nf or mi n g t he s u bject a n d 
st u d y pers o n n el of t h e res ults.  
N o w rea ds:  Uri ne sa m ples will be c ollecte d f or assess me nt of gi v osira n P D para meters pri or t o d osi n g.  T he P D effect of 
gi v osira n will be e val uat e d b y s p ot uri n e A L A a n d P B G le vels n or maliz e d t o s p ot uri ne creati ni ne l e vels.  Uri ne 
sa m ples will be c ollecte d f or asses s me nt of circ ulati n g A L A S 1 m R N A le vels.  A nal ysis of uri n e A L A S 1 m R N A 
le vels will be perf or me d at Al n yla m; all ot her uri ne P D a nal yses will ta ke place at a ce ntr al la b orat or y.  Si nce 
I n v esti gat ors are bli n de d t o treat me nt assi g n m e nts, t he y will als o be bli n de d t o A L A a n d P B G res ults a nal yze d at 
t he ce ntral la b orat or y.  I n a d diti o n, i n vesti gat ors a n d staff i n v ol ve d wit h t his trial a n d all me dical staff i n v ol ve d i n 
t he s u bject’s me dical care s h o ul d refrai n fr o m o bt ai ni n g l oc al A L A or P B G meas ure m e nts u ntil at  least [ADDRESS_1025888] u d y, w hic h e ver is later (t o a v oi d p ote ntial u n bli n di n g).  If A L A 
or P B G is meas ur e d d uri n g t his peri o d, all reas o n a ble ste ps m ust be u n dert a ke n t o a v oi d i nf or mi n g t he s u bject a n d 
st u d y  pers o n n el of t he res ults.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n  (A L N -A S 1 ) 
A me n d me nt 4 S u m m ar y of C h a n ges , 2 8 M a y  2 0 1 9  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 P ur p ose:  Up d ate d wi n d o w f or vit al si g ns, tri plic ate 1 2 -le a d E C Gs, a n d P K s a m ples at t he 2  h o ur ti me p oi nts  at t he D ay  1 a n d M o nt h  5, 6, a n d 
1 2  visits fr o m 1 0  t o 1 5   mi n utes t o be c o nsiste nt wit h c h a n ges i m ple me nte d i n A me n d me nt  3.  
T he pri mar y c ha n ge occ urs i n S y n o psis, T a ble  1, F o ot n otes h a n d j  
F or merl y  rea d:  h Vital si g ns i ncl u de bl o o d press ure, heart rate, b o d y te m perat ure, a n d res pi[INVESTIGATOR_1305] y rate a n d will b e meas ure d w he n patie nts are  i n a seate d 
or s u pi [INVESTIGATOR_050] p ositi o n (s h o ul d be  c o nsiste nt acr oss st u d y visits wit h eac h patie nt) after t he patie nt has reste d f or [ADDRESS_1025889] d ose ( + 1 0 mi n utes).  O n all ot her d osi n g da ys, vital si g ns will be 
c ollecte d pre d ose. 
i Si n gle 1 2 -lea d E C G will be perf or me d i n t he s u pi [INVESTIGATOR_050] p ositi o n after t he patie nt has reste d c o mf orta bl y f or 5 mi n utes. E C Gs will be 
c ollecte d pri or t o a n y bl o o d dra ws.  
j Tri plicate 1 2 -lea d E C Gs will be perf or me d at pre d ose a n d 2 -h o urs ( + 1 0 mi n utes ) p ost -d ose o n t he Da y  1, M o nt h 5, a n d M o nt h 6 visits, 
usi n g vali date d E C G ser vices e q ui p me nt fr o m a ce ntral facilit y; tri plicate meas ure me nts s h o ul d be se p arate d b y a p pr o xi matel y [ADDRESS_1025890] e c ollecti o n (e g, 
f or P K assess me nt) occ ur at t he sa me ti me,  E C G assess me nts s h o ul d be perf or me d bef ore bl o o d sa m ples are dra w n .  I n a pres pecifie d 
s u bset of a p pr o xi matel y [ADDRESS_1025891] u d y ce nters (i ncl u di n g all p atie nts at East Asia n st u d y ce nters [i n J a pa n, S o ut h 
K orea, a n d T ai wa n]), a n a d diti o nal E C G ( wit h paire d P K assess me nt) at 2 4 h o urs ( ± 2 h o urs) p ost -d ose will be c ollecte d at Da y 1 a n d 
M o nt h 6.  
N o w rea ds:  h Vital si g ns i ncl u de bl o o d press ure, heart rate, b o d y te m perat ure, a n d res pi[INVESTIGATOR_1305] y rate a n d will b e meas ure d w he n patie nts are i n a seate d 
or s u pi [INVESTIGATOR_050] p ositi o n (s h o ul d be c o nsiste nt acr oss st u d y visits wit h eac h patie nt) after t he patie nt has reste d f or [ADDRESS_1025892] d ose ( + 1 0 1 5  mi n utes).  O n all ot her d osi n g da ys, vital si g ns will be 
c ollecte d pre d ose. 
i Si n gle 1 2 -lea d E C G will be perf or me d i n t he s u pi [INVESTIGATOR_050] p ositi o n after t he patie nt has reste d c o mf or ta bl y f or 5 mi n utes. E C Gs will be 
c ollecte d pri or t o a n y bl o o d dra ws.  
j Tri plicate 1 2 -lea d E C Gs will be perf or me d at pre d ose a n d 2 -h o urs ( + 1 0 1 5  mi n utes) p ost -d ose o n t he Da y  1, M o nt h 5, a n d M o nt h 6 
visits, usi n g vali date d E C G ser vices e q ui p me nt fr o m a ce ntr al facilit y; tri plicate meas ure me nts s h o ul d be se p arate d b y a p pr o xi matel y 1 
mi n ute wit h t he patie nt i n t he s u pi [INVESTIGATOR_050] p ositi o n after he or s he has reste d c o mf orta bl y f or 5 mi n utes.  W he n E C G a n d bl o o d sa m ple 
c ollecti o n (e g, f or P K assess me nt) occ ur at t he s a me ti me,  E C G assess me nts s h o ul d be perf or me d bef ore bl o o d sa m ples are dra w n .  I n a 
pres pecifie d s u bset of a p pr o xi matel y [ADDRESS_1025893] u d y ce nters (i ncl u di n g all p atie nts at East Asia n st u d y c e nters [i n J a p a n, 
S o ut h K orea, a n d T ai wa n]), a n a d diti o nal E C G ( wit h paire d P K assess me nt) at 2 4 h o urs ( ± 2 h o urs) p ost -d ose will be c ollecte d at Da y [ADDRESS_1025894] u d y Pr ot oc ol A L N -A S 1 -0 0 3  gi v osir a n  (A L N -A S 1 ) 
A me n d me nt 4 S u m m ar y of C h a n ges , 2 8 M a y  2 0 1 9  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 Secti o n(s) als o c o ntai ni n g t his c ha n ge:  
Sy n o psis, T a ble 2, F o ot n ote f 
Secti o n 7. 4, P h ar m ac oki netic Assess me nts 
P ur p ose:  Secti o n 9. 1. 3, Seri o us Bre ac h of Pr ot oc ol , w as a d de d t o ali g n wit h t he pr ocess f or t he re p orti n g pote nti al seri o us bre ac hes of pr ot oc ol . 
T he pri mar y c ha n ge is t he a d diti o n of Secti o n  9. 1. 3 , Seri o us Bre ac h of Pr ot oc ol  
A d de d te xt : 9. 1. 3.  Seri o us Bre ac h of P r ot oc ol  
I n vesti g at ors m ust n otif y t he Me dic al M o nit or wit hi n [ADDRESS_1025895] ness of t he d at a ge ner ate d i n t he cli nic al tri al.  
P ur p ose:  U p d ate d T a ble 8, P h ar m ac oki netic, E C G, a n d A D A Ti me P oi nts f or All P atie nts ( Exce pt P atie nts at E ast Asi a n Sites), t o i n dic ate t h at 
E C G assess me nt as are n ot re q uire d at [ADDRESS_1025896] d ose at t he M o nt h 6 or M o nt h 1 2 visits . 
T he pri mar y c ha n ge occ urs i n Secti o n  1 1, P h ar m ac oki netic/ P h ar m ac o dy n a mic Assess me nt Ti me P oi nts  
Re vise d te xt:  Re m o ve d Xs i n Tri plicate E C G c ol u m n at t he [ADDRESS_1025897] d ose ti me p oi nts at t he M o nt h  6 a n d M o nt h  1 2 visits.  
P ur p ose:  Bec a use d at a fr o m t he h u m a n dr u g -dr u g i nter acti o n st u dy s h o we d t h at giv osir a n tre at me nt res ulte d i n a m o der ate ( > 2 -f ol d) re d ucti o n 
of C Y P [ADDRESS_1025898] u dy, giv osir a n tre at me nt res ults i n o nly a we ak ( < 2 -f ol d) re d ucti o n of C Y P [ADDRESS_1025899] of Se nsiti ve C Y P 3 A S u bstrates a n d T h ose wit h a Narr o w T hera pe utic Ra n ge . 
Secti o n 1 1. 2  was delete d.  
P ur p ose:  C orrect ty p o gr a p hic al err ors, p u nct u ati o n, gr a m m ar, a b brevi ati o ns, a n d f or m atti n g  
T hese c ha n ges are n ot liste d i n di vi d uall y.  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  A L N -A S 1  (gi v osir a n ) 
A me n d me nt 3 S u m m ar y of C h a n ges , 2 1 Se pte m ber 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 A L N -A S 1 -0 0 3  P R O T O C O L A M E N D M E N T 3  
S U M M A R Y O F C H A N G E S D A T E D  2 1 Se pte m ber 2 0 1 8  
E N VI SI O N: A P h ase [ADDRESS_1025900] u d y, a  l o wer gi v osira n d ose  of 
1. 2 5  m g/ k g o nce m o nt hl y w as  i nt r o d uce d i n A me n d me nt 2  as a rec halle n ge  d ose f or p atie nts 
w h o res u me d osi n g aft er res ol uti o n of li ver tra nsa mi n ase ele vati o ns.  I n or der t o ge nerate 
a d diti o nal data at t his d ose le vel, e v al uati o n of t he 1. 2 5  m g/ k g o nce m o nt hl y d ose is pr o p os e d f or  
patie nts cr ossi n g o v er t o t he o pe n -la bel e xte nsi o n [ O L E ] peri o d u n der t his a me n d me nt , after  t heir  
c o m pleti o n of t he [ADDRESS_1025901] b o -c o ntr olle d peri o d . W hile t he 2. 5 m g/ k g o nce 
m o nt hl y d os e has bee n d e m o nstrate d t o pr o vi de n ear -n or malizati o n of  A L A le vels i n t he 
maj orit y of AI P p atie nts wit h rec urre nt attac ks i n t he c o m plete d P hase [ADDRESS_1025902] u d y 
( Part C) a n d t he o n g oi n g P hase 1/ [ADDRESS_1025903]  t hat a gi v osira n d ose of  1. 2 5 m g/ k g o n ce m o nt hl y w o ul d 
re d uce  A L A le v els i n  a s u bsta ntial n u m ber  of pati e nts .  T h is st u d y desi g n will e na ble t he 
e val uati o n of t he P D, effi cac y, a n d safet y of t he 1. 2 5  m g/ k g o nce m o nt hl y d ose of gi v osira n  i n 
t he O L E peri o d , w hile c o nti n ui n g  t o pr o vi de data o n t he 2. 5  m g/ k g o nce m o nt hl y d ose.     
The pri mar y p ur p os e f or t his pr ot oc ol a me n d me nt is t o:  
 I m ple me nt  t he i n cl usi o n of a n a d diti o nal, l o wer d ose of gi v osira n ( 1. 2 5 m g/ k g o nce 
m o nt hl y) d uri n g t he o pe n -la bel e xte nsi o n peri o d  
 Pr o vi de s pecif ic g ui da n ce f or i ncreasi n g d ose fr o m 1. 2 5  m g/ k g o n ce m o nt hl y t o 
2. 5  m g/ k g o nce m o nt hl y i n patie nts w h o t olerate  1. 2 5  m g/ k g o nce m o nt hl y d ose b ut 
w h o are e x perie nc i n g  i na de q uate diseas e c o ntr ol . 
 A d d s tatistical a nal ys es t o e val uate t he d ura bilit y of t he tre at me nt effect.  
A detaile d s u m mar y of c ha n ges is pr o vi de d i n  Ta ble  1.  C orrecti o ns t o t y p o gra p hical err ors, 
p u nct uati o n, gra m mar, a b bre viati o ns, a n d f or m atti n g  (i ncl u di n g a d mi nistrati ve c ha n ges bet w ee n 
pr ot oc ol a me n d me nt s 2 a n d 3) are n ot d etaile d.  
 
 
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  A L N -A S 1  (gi v osir a n ) 
A me n d me nt 3 S u m m ar y of C h a n ges , 2 1 Se pte m ber 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 T a ble  1: Pr ot oc ol A me n d me nt 3 Det aile d S u m m a r y of C h a n ges   
T he pri mar y secti o n(s) of t he pr ot oc ol affecte d b y t he c ha n ges i n Pr ot oc ol A me n d me nt 3 are i n dicat e d.  T he c orres p o n di n g te xt has 
bee n re vis e d t hr o u g h o ut t he pr ot oc ol.  Delet e d te xt is i n dicate d b y stri ke o ut ; a d de d te xt is i n dicate d b y b ol d  f o nt.  
P ur p ose:  U p d ate  t he d ose r ati o n ale t o i ncl u de t he  a d diti o n of t he  1. 2 5 m g/k g o nce m o nt hly d os e 
T he pri mar y c ha n ge occ urs i n Secti o n 1. 4 D ose Rati o nale . 
A d de d te xt : I n li g ht of L F T ele v ati o ns o bser ve d i n t he st u d y, a l o wer gi v osir a n d ose of 1. 2 5 m g/ k g o nce m o nt hl y h as bee n 
i ntr o d uce d as a d o w n -titr ati o n d ose, as det aile d i n Secti o n 6. 2. 3. 1.  I n o r der t o ge ner ate a d diti o n al d at a at t his d ose 
le vel, e v al u ati o n of t he 1. 2 5 m g/ k g o nce m o nt hl y d ose is pr o p ose d f or p atie nts cr ossi n g o ver t o t he O L E peri o d 
u n der a me n d me nt 3. W hile t he 2. 5 m g/ k g o nce m o nt hl y d ose h as bee n de m o nstr ate d t o pr o vi de ne ar -
n or m aliz ati o n of A L A le vels i n t he m aj orit y of AI P p atie nts wit h rec urre nt att ac ks i n t he c o m plete d P h ase [ADDRESS_1025904] u d y ( P art C) a n d t he o n g oi n g P h ase 1/ [ADDRESS_1025905] t h at a gi v os ir a n d ose of 1. 2 5 m g/ k g o nce m o nt hl y w o ul d re d uce A L A le vels i n a 
s u bst a nti al n u m ber of p atie nts. T he pr o p ose d st u d y desi g n will e n a ble t he e v al u ati o n of t he P D, effic ac y, a n d s afet y 
of t he 1. 2 5 m g/ k g m o nt hl y d ose of gi v osir a n, w hile c o nti n ui n g t o pr o vi de d at a o n t he 2. 5 m g/ k g m o nt hl y d ose.  
T he c o nce ntrati o n of gi v osira n i n t he li ver is t he pri mar y dri ver f or its p har mac o d y na mic effects, w hic h is pri maril y 
affecte d b y b o d y wei g ht. P o p ulati o n p har mac o ki netic -p har mac o d y na mic m o deli n g a n d si m ulati o n acr oss differe nt b o d y 
wei g hts s h o w si milar li v er e x p os ures of gi v osira n i n a d olesce nts a n d a d ults  f oll o wi n g 2. 5 m g/ k g  m o nt hl y d osi n g a n d 
c o nse q ue ntl y si milar e xte nt a n d d urati o n of uri nar y A L A s u p pressi o n i n a d olesce nts a n d a d ults.  As a res ult, t he 2. 5 
m g/ k g m o nt hl y d ose re gi me n was selecte d f or t he pr o p ose d P hase [ADDRESS_1025906] u d y . 
Secti o ns c o ntai ni n g relate d c ha n ges :   
 Secti o n 1. 3 St u d y Desi g n Rati o nale  
 Secti o n 8. 2. [ADDRESS_1025907] u d y Pr ot oc ol A L N -A S 1 -0 0 3  A L N -A S 1  (gi v osir a n ) 
A me n d me nt 3 S u m m ar y of C h a n ges , 2 1 Se pte m ber 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 P ur p ose:  Revise t he ex pl or at ory o bjective a n d e n d p oi nt t o i n dic ate t h at m ulti ple d oses will be assesse d d uri n g t he O L E peri o d  
T he pri mar y c ha n ge occ urs i n Secti o n 2. [ADDRESS_1025908] orat or y O bjecti ves  
Re vise d te xt :  Assess t he wit hi n patie nt treat me nt effect of gi v osira n at e v al u ate d d oses  o ver t he O L E p eri o d i n  p atie nts 
wit h AI P a n d i n p atie nts wit h a n y A H P w h o ha d pre vi o usl y b ee n ra n d o mize d t o place b o tr eat me nt  
Secti o ns als o c o ntai ni n g t his c ha n ge:  
 S y n o psis  
 Secti o n 3. [ADDRESS_1025909] orat or y E n d p oi nts  
P ur p os e:  U p d ate  st u dy desi g n text  a n d ass oci ate d st u dy desi g n fi g ure  t o i ncl u de t he  cr oss over str ate gy f or  ev al u ati o n of a sec o n d  d ose 
( 1. 2 5  m g/k g o nce m o nt hly) d uri n g t he O L E peri o d . 
T he pri mar y c ha n ge occ urs i n Secti o n 4. [ADDRESS_1025910] u d y Desi g n  
A d de d te xt:  P ati e nts  e nteri n g t he O L E peri o d w h o cr osse d o ver t o t he O L E peri o d pri or t o i m ple me nt ati o n of a me n d me nt 3 
(ie, u n der a me n d me nt versi o n 1 or 2) a n d are recei vi n g a 2. 5  m g/ k g o nce m o nt hl y  gi v osir a n d ose  will re m ai n o n 
t h at d ose. U p o n e ntr y t o t he O L E peri o d u n der a me n d me nt versi o n 3, p atie nts will cr oss o ver t o recei ve a 1. 2 5 
m g/ k g o nce m o nt hl y d ose of gi v osir a n. St arti n g at t he M o nt h 1 3 Visit ( w he n [ADDRESS_1025911] ete d) , p atie nts i n t he 1. 2 5  m g/ k g m o nt hl y tre at me nt gr o u p w h o e x perie nce i n a de q u ate 
dise ase c o ntr ol m a y  h a ve t heir m o nt hl y d ose i ncre ase d t o 2. 5  m g/ k g gi v osir a n u p o n disc ussi o n a n d a gree me nt b y 
t he I n vesti g at or a n d me dic al mo nit or  a n d de m o nstr ati o n of t ole r a bilit y t o gi v osir a n a n d if A L A criteri a are met .  
F or f urt her det ails, see Secti o n 6. 2. 3. [ADDRESS_1025912] m o nt h of t he O L E peri o d a n d 
t he n m o nt hl y t hr o u g h M o nt h 1 8, a n d e ver y 3 m o nt hs t h ereafter.  
Secti o ns c o ntai ni n g relate d c ha n ges : 
 S y n o psis  
 T a ble 1: Sc he d ule of Assess me nts  – Scree ni n g a n d 6 -M o nt h Treat me nt Peri o d ( Scree ni n g t hr o u g h M o nt h 6) ; ne w f o ot n ote a d de d  
 T a ble 2: Sc he d ule of Assess me nts – O pe n -La bel E xte nsi o n Peri o d: After M o nt h 6  t hr o u g h M o nt h 1 8;  ne w f o ot n ote a d de d  
 T a ble 3: Sc he d ule of Assess me nts f or O pe n -La bel E xte nsi o n Peri o d: M o nt h [ADDRESS_1025913] u d y; ne w f o ot n ote a d de d  
 Fi g ure 2: St u d y Desi g n ; revise d fi g ure  t o s h o w 1. 2 5 m g/k g d ose  
 Secti o n 1. [ADDRESS_1025914] u d y Pr ot oc ol A L N -A S 1 -0 0 3  A L N -A S 1  (gi v osir a n ) 
A me n d me nt 3 S u m m ar y of C h a n ges , 2 1 Se pte m ber 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4  Secti o n 1. 4 D ose Rati o nale  
 Secti o n 6. 2. 2. 2  D uri n g t he O pe n -La bel E xte nsi o n Peri o d ( After M o nt h 6 t hr o u g h E n d of Treat me nt)  
 Secti o n 6. 2. 3  D ose M o dificati o ns  
 Sec tio n 6. 2. 3. 4 D ose Escalati o n G ui da nce f or Gi v osira n fr o m 1. 2 5 m g/ k g O nce M o nt hl y t o 2. 5 m g/ k g O nc e M o nt hl y i n t he O pe n -La bel 
Peri o d  
 Secti o n 8. 2. 9 Ot her A nal yses  
  
P ur p ose:   A d d  ne w secti o n o n d ose esc al ati o n g ui d a nce f or p atie nts receivi n g t he 1. 2 5 m g/k g o nce m o nt hly d ose . 
T he pri mar y c ha n ge occ urs i n Secti o n 6. 2. 3. 4 D ose Escalati o n G ui da nce f or Gi v osira n fr o m 1. 2 5 m g/ k g O nce M o nt hl y t o 2. 5 m g/ k g O nce 
M o nt hl y i n t he O pe n -La bel Peri o d  
A d de d te xt:  St arti n g at t he M o nt h [ADDRESS_1025915] u d y Visit ( w he n 6 m o nt hs of o pe n -l a bel gi v osir a n d osi n g h a ve bee n 
c o m plete d) , p atie nts recei vi n g o pe n -l a bel gi v osir a n at S C d oses of 1. 2 5  m g/ k g m o nt hl y m a y be per mitte d 
t o i ncre ase t h eir m o nt hl y d ose t o 2. 5 m g/ k g b ase d o n I n vesti g at or j u d ge me nt.  I n vesti g at o rs m a y c o nsi der 
d ose esc al ati o n if t he f oll o wi n g criteri a ar e met:  
 T oler a bilit y t o gi v osir a n at 1. 2 5 m g/ k g o nce m o nt hl y h as bee n de m o nstr ate d b ase d o n n o d ose 
i nterr u pti o ns d ue t o L F T ele v ati o ns at t he 1. 2 5  m g/ k g o nce m o nt hl y d ose le vel (see Secti o n 
6. 2. 3. 1 ) a n d n o si g nific a nt s afet y c o ncer ns d ue t o ot her A Es t h at w o ul d precl u d e a p atie nt fr o m 
recei vi n g a hi g her d ose of gi v osir a n as j u d ge d b y t he  I n vesti g at or a n d S p o ns or.    
 Uri ne A L A le vels ( m m ol/ m ol Cr) are n ot st a bl y m ai nt ai ne d ≤ U L N or a re i n d uci ble .  
 P ati e nt h as i n a de q u ate cli nic al res p o nse (e g, bre a kt hr o u g h att ac ks or o n g oi n g c hr o nic 
s y m pt o ms), acc o r di n g t o I n vesti g at or j u d ge me nt.  
Uri ne A L A a n al yses m a y be c o n d ucte d at a l oc al l a b or at or y or A L A res ults fr o m pre vi o us visits m a y be 
e v al u ate d i n p atie nts o n t he 1. 2 5 m g/ k g m o nt hl y d ose i n w h o m d ose es c al ati o n t o 2. 5  m g/ k g o nce m o nt hl y 
is bei n g c o nsi dere d .  
T he decisi o n t o i ncre ase t he gi v osir a n d ose fr o m 1. 2 5 m g/ k g m o nt hl y t o 2. 5  m g/ k g m o nt hl y will be 
disc usse d a n d a gree d u p o n b y t he I n vesti g at or a n d me dic al m o nit or pri or t o i niti ati o n of t he ne xt d ose.  
U p o n i ncre ase of t he gi v o sir a n d ose t o 2. 5 m g/ k g m o nt hl y:  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  A L N -A S 1  (gi v osir a n ) 
A me n d me nt 3 S u m m ar y of C h a n ges , 2 1 Se pte m ber 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5  L F Ts, I N R, a n d T B L will be m o nit ore d e v er y 2 w ee ks ( ± 7 d a ys) f or t he first m o nt h f oll o wi n g 
t he d ose i ncre ase t o 2. 5 m g/ k g, t he n m o nt hl y ( ± [ADDRESS_1025916] u d y visits) as 
per t he Sc he d ule of Assess me nts . 
 L a b o r at or y m o nit ori n g a n d d osi n g r ules i n res p o nse t o L F T ele v ati o n will f oll o w T a ble 4 
g ui deli nes . 
 F or p ati e nts i n w h o m gi v osir a n d osi n g is wit h hel d d ue t o ele v ate d A L T, res u m pti o n of d osi n g 
m a y be c o nsi dere d b ase d o n t he g ui d a nce i n Secti o n 6. 2. 3. 1. 1.  
Secti o ns  c o ntai ni n g relate d c ha n ges : 
 S y n o psis  
 T a ble 2: Sc he d ule of Assess me nts – O pe n -La bel E xte nsi o n Peri o d: After M o nt h 6 t hr o u g h M o nt h 1 8;  ne w f o ot n ote a d de d  
 T a ble 3: Sc he d ule of Assess me nts f or O pe n -La bel E xte nsi o n Peri o d: M o nt h [ADDRESS_1025917] u d y; ne w  f o ot n ote a d de d  
 Secti o n 4. [ADDRESS_1025918] u d y Desi g n  
 Secti o n 6. 2. 2. 2  D uri n g t he O pe n -La bel E xte nsi o n Peri o d ( After M o nt h 6 t hr o u g h E n d of Treat me nt)  
 Secti o n 6. 2. 3  D ose M o dificati o ns  
  
P ur p ose:   A d d  g ui d a nce o n ev al u ati o n of  uri ne A L A i n t he c o ntext of d ose esc al ati o n fr o m t he 1. 2 5 m g/k g o nce m o nt hly d ose t o t he 2. 5 m g/k g o nce 
m o nt hly d ose . 
T he pri mar y c ha n ge occ urs i n Secti o n 7. 3 P har mac o d y na mic Assess me nts  
A d de d te xt:  Uri ne A L A a n al yses m a y be c o n d ucte d at a l oc al l a b or at or y or A L A res ults fr o m pre vi o us v isits m a y be 
e v al u ate d i n p atie nts o n t he 1. 2 5 m g/ k g m o nt hl y d ose i n w h o m d ose es c al ati o n t o 2. 5 m g/ k g o nce m o nt hl y 
is bei n g c o nsi dere d d ue t o i n a de q u ate cli nic al res p o nse a n d w h o h a ve de m o nstr ate d t oler a bilit y t o 
gi v osir a n.  D ose esc al ati o n i n p atie nts o n  t he 1. 2 5 m g/ k g o nce m o nt hl y d ose c a n occ ur st a rti n g a t M o nt h 
1 3.  See Secti o n 6. 2. 3. 4  f or f urt her i nf or m ati o n o n d ose esc al ati o n.  
Secti o ns  c o ntai ni n g relate d c ha n ges : 
 Secti o n 6. 2. 3. 4 D ose Escalati o n G ui da nce f or Gi v osira n fr o m 1. 2 5 m g/ k g O nce M o nt hl y t o 2. 5 m g/ k g O nce M o nt hl y i n t he O pe n -La bel 
Peri o d  
 T a ble 8: P har mac o ki netic, E C G, a n d A D A Ti me P oi nts f or All Patie nts ( E xce pt Patie nts at East Asia n Sites)  
Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  A L N -A S 1  (gi v osir a n ) 
A me n d me nt 3 S u m m ar y of C h a n ges , 2 1 Se pte m ber 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 P ur p ose:   Re m ove se nsit ivity a n alysis det ails  a n d e m p h asize  t he st atistic al a n alysis pl a n f or t hese det ails . 
T he pri mar y c ha n ge occ urs i n Secti o n 8. 2. 5. 1  Pri mar y E n d p oi nt  
Delete d  te xt:  A se nsiti vit y a nal ysis of t he a n n ualize d e ve nt r ates, wit h o ut a dj ust me nt f or t he le n gt h of ti me i n t he treat me nt 
peri o d, will als o be c o n d ucte d. A d diti o nal se nsiti vit y S e nsiti vit y a nal yses will be detaile d i n t he S A P . 
Secti o n als o c o ntai ni n g t his c ha n ge:  
 S y n o psis  
P ur p ose:   U p d ate  a n alysis  met h o d fr o m a n alysis of c ov ari a nce ( A N C O V A ) t o mixe d effect m o del re pe ate d me as ure me nt ( M M R M ) f or f ull d o u ble -
bli n d a n alysis of A L A a n d c h a n ge fr o m b aseli ne i n p hysic al c o m p o ne nt s u m m ary ( P C S ) of S F -1 2  
T he pri mar y c ha n ge occ urs i n Secti o n 8. 2. 5. 2  Sec o n dar y E n d p oi nts  
Re vise d  te xt:  F or t he a nal ysis of uri nar y A L A -relate d e n d p oi nts, t he A L A le vels will be c o m pare d b et wee n treat me nt ar ms  
usi n g a n a nal ysis of c o varia nce ( A N C O V A) m o del wit h a mi xe d -effects m o del re pe ate d me as ures ( M M R M) 
wit h b aseli ne A L A as a c o nti n u o us c o v ari ate a n d fi x e d effect of ter ms i n cl u di n g  treat me nt ar ms, 
stratificati o n fact ors f or AI P p atie nts ( pri or he mi n pr o p h yl a x is stat us a n d hist orical attac k rates), a n d wit h t he 
baseli ne A L A as a c o v ari ate visit a n d tre at me nt b y visit i nter acti o n .  P B G -relate d e n d p oi nts will als o be 
a nal yze d usi n g t his met h o d ol o g y.   
Dail y p ai n, na usea, a n d fati g ue s c ores will be a nal yz e d se parat el y usi n g t he area u n d er t he c ur ve ( A U C) 
a p pr oac h: t he A U C o ver 6 m o nt hs i n t he res pecti ve sc ore will be calc ulat e d f or eac h patie nt, a n d t h e mea n A U C 
will be c o m pare d b et wee n treat me nt ar ms i n a n A N C O V A m o del.  T he c h a n ge fr o m b aseli ne i n P C S of S F -1 2 
at 6 m o nt hs will  als o  be a nal yze d use a n  A N C O V A M M R M  m o del.   Details o n t he A N C O V A m o d el f or eac h 
c o nti n u o us sec o n dar y e n d p oi nt a n d t he c o variat es t o be i ncl u de d  will be descri be d  i n t he S A P . 
Secti o ns  c o ntai ni n g relate d c ha n ges : 
 S y n o psis  
 Secti o n 8. 2. [ADDRESS_1025919] u d y Pr ot oc ol A L N -A S 1 -0 0 3  A L N -A S 1  (gi v osir a n ) 
A me n d me nt 3 S u m m ar y of C h a n ges , 2 1 Se pte m ber 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 P ur p ose:   C h a n ge a n alysis met h o d o n  d ur a bility of effect  f or i nteri m a n alysis  fr o m A N C O V A t o M M R M . 
T he pri mar y c ha n ge occ urs i n Secti o n 8. 2. 1 0 I nteri m A nal ysis  
Re vise d te xt:  T o assess d ura bilit y of t he st u d y dr u g i n l o w eri n g a n d mai ntai ni n g A L A le vel o ver ti me, t he A L A l e vels at [ADDRESS_1025920] m o del re pe ate d me as ure me nt ( M M R M) . 
Secti o ns als o c o ntai ni n g relate d c ha n ges : 
 S y n o psis  
 Secti o n 8. 2. 5. 2 Sec o n dar y E n d p oi nts  
P ur p ose:   I n T a ble 8, i ncre ase  t he s a m ple c ollecti o n ti me wi n d o ws , a n d f or t he ne w 1. 2 5 m g/k g o nce m o nt hly d ose, a d d [ADDRESS_1025921] d ose 
assess me nts of P K a n d Tri plic ate E C G f or M o nt h s 6 a n d 1 2.  
T he pri mar y c ha n ge occ urs i n T a ble 8: P har mac o ki netic, E C G, a n d A D A Ti me P oi nts f or All Patie nts ( E xce pt Patie nts at East Asia n Sites)  
Re vise d  : I n ta bl e, f or m o nt hs 0, 5, 6, a n d 1 2, c orrecte d t h e ti me p oi nt 0 2: 0 0 ( ± 1 0  mi n)  t o bec o me: 0 2: 0 0 ( ± 1 5 mi n)  
     0 2: 0 0 ( ± 1 0 1 5  mi n)  
F or m o nt hs 6 a n d 1 2, als o a d de d t he ti me p oi nt 0 4: 0 0 ( ± 1 5 mi n)  i n P K a n d Tri plicate E C G c ol u m n cells  a n d 
ne w f o ot n ote s pecific t o t his ti me p oi nt.  
     0 4: 0 0 ( ± 1 5 mi n) 3 
F o ot n ote:  
     3F or  p atie nts recei vi n g 1. 2 5 m g/ k g gi v osir a n m o nt hl y ( p atie nts w h o recei ve d t heir first d ose i n t he 
o pe n -l a bel e xte nsi o n peri o d u n der pr ot oc ol a me n d me nt versi o n 3), a d diti o n al bl o o d s a m ples f or P K 
will be c ollecte d [ADDRESS_1025922] -d ose at t he M o nt h 6 a n d M o nt h 1 2 visits.  
Secti o ns c o ntai ni n g relate d c ha n ges:   
 T a ble 9: P har mac o ki netic, E C G, a n d A nti -Dr u g A nti b o d y Assess me nt Ti me P oi nts f or Patie nts at East Asia n St u d y Ce nters ( Bl o o d 
Sa m ples)  
P ur p ose:  C orrect ty p o gr a p hic al err ors, p u nct u ati o n, gr a m m ar, a b brevi ati o ns, a n d f or m atti n g, a n d a p ply a d mi nistr ative c h a n ges .   
T hese c ha n ges are n ot liste d i n di vi d uall y.  
 
A L N -A S 1 ( gi v osir a n)   Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  
  A me n d me nt 2 S u m m ar y of C h a n ges , _ 2 6 J ul y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 A L N -A S 1 -0 0 3 P R O T O C O L A M E N D M E N T 2  
S U M M A R Y O F C H A N G E S D A T E D 2 6 JU L Y 2 0 1 8  
 
E N VI SI O N: A P h ase [ADDRESS_1025923] u d y 
wit h a n O pe n -l a bel E xte nsi o n t o E v al u ate t he Effic ac y a n d S afet y of Gi v osir a n i n P atie nt s 
wit h Ac ute He p atic P o r p h yri as  
 
R ati o n ale f or Pr ot oc ol A me n d me nt  
D ue t o rece nt cas e re p orts of a n i ncrease i n li ver tr a nsa mi nases, t he pri mar y p ur p ose f or t his 
pr ot oc ol a me n d me nt is t o : 
• Re q uire i n vesti gat or s t o r e vie w pre d os e li ver f u n cti o n tests  pri or t o st u d y dr u g 
a d mi nistrati o n  
• I m ple me nt a sta n dar d he patic assess me nt pa n el if patie nts de vel o p si g nifi ca nt A L T 
ele vati o n  
• Pr o vi de s pecific g ui da n ce f or rec halle n ge usi n g a l o wer d ose i n patie nts w h ose  A L T 
res ol ves aft er st u d y dr u g d osi n g has bee n wit h hel d d ue t o A L T ele v ati o n  
• E x pa n d t he me dical h ist or y c ollecti o n t o i ncl u de a s pecific i n q uir y i nt o ir o n o verl oa d a n d 
ot her li ver diseas e  
A detaile d s u m mar y of c ha n ges is pr o vi de d i n  Ta ble  1.  C orrecti o ns t o t y p o gra p hical err ors, 
p u nct uati o n, gra m mar, a b bre viati o ns, a n d f or m atti n g ( i ncl u di n g a d mi nistrati ve c ha n ges bet w ee n 
t he a me n d m e nt 1 a n d a me n d me nt 2 ) are n ot detail e d.  
 
A L N -A S 1 ( gi v osir a n)   Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  
  A me n d me nt 2 S u m m ar y of C h a n ges, _ 2 6 J ul y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 T a ble  1: Pr ot oc ol A me n d me nt 2 Det aile d S u m m a r y of C h a n ges  
T he pri mar y secti o n(s) of t he pr ot oc ol affecte d b y t he c ha n ges i n Pr ot oc ol A me n d me nt 2 are i n dicat e d.  T he c orres p o n di n g te xt has 
bee n re vis e d t hr o u g h o ut t he pr ot oc o l.  Delet e d te xt is i n dicate d b y stri ke o ut ; a d de d te xt is i n dicate d b y b ol d  f o nt.  
 
P ur p ose:  A d d cli nic al l a b or at ory assess me nts s o t h at assess me nts occ us at e ac h st u dy  visit i n t he o pe n -l a bel exte nsi o n peri o d  
T he pri mar y c ha n ge occ urs i n T a ble 3, Sc he d u le of Assess me nts f or O pe n -La bel E xte nsi o n Peri o d: M o nt h [ADDRESS_1025924] u d y  
Re vise d te xt:  A d de d “ Xs” i n r o w “ Cli nical La b orat or y Assess me nts” at M o nt h 1 9/ 2 0, M o nt h 2 2/ 2 3, M o nt h 2 5/ 2 6, M o nt h 2 8/ 2 9, 
M o nt h 3 1/ 3 2, a n d M o nt h 3 4/ 3 5.  
P ur p ose: A d d t h at d ose  m o dific ati o n  is all o we d i n res p o nse  t o elev ate d  LF Ts . 
T he pri mar y c ha n ge occ urs i n Secti o n 6. 2. 3, D ose M o dificati o ns  
A d de d te xt:  N o st u d y dr u g d ose m o dificati o ns will be all o we d , e xce pt i n res p o nse t o L F T ele v ati o ns as descri be d i n Secti o n  
6. 2. 3. 1.  
P ur p ose: S pecify  a d diti o n al he p atic assess me nts f or p atie nts w h o devel o p si g nific a nt A L T elev ati o n ; si m plify text  (first se nte nce) . 
T he pri mar y c ha n ge occ urs i n Secti o n 6. 2. 3. [ADDRESS_1025925] Res ults  
Re vise d te xt : L F T  A L T, T B L, a n d I N R  res ults fr o m t he pre vi o us visit  s h o ul d be re vie we d wit hi n 1 4 d a ys  pri or t o d osi n g.  
F or a n y A L T ele vati o n > 3 × U L N ( or > 3 × baseli ne i n patie nts wit h ele vate d baseli ne) or > 3 0 0  U/ L ( w hic he ver is l o wer), 
res ults s h o ul d be c o nfir me d  b y t he ce ntral la b orat or y ( wit hi n 2 t o 3 da ys, b ut n o greater t ha n 7 da ys).   If s uc h A L T 
ele v ati o ns are c o nfir me d, t he a d diti o n al he p atic assess me nts s h o w n i n T a ble  s h o ul d be o bt ai ne d.  
S u bj ects wit h a b n or mall y ele vate d he patic la b orat or y val ues (e g. A L T, A S T, t otal bilir u bi n [ T B L ],  or i n ter nati o nal 
n or malize d rati o I N R) or si g ns/s y m pt o ms of he patitis ma y meet criteria f or wit h h ol di n g st u d y dr u g. Criteria f or 
wit h h ol di n g, m o nit ori n g a n d st o p pi n g st u d y dr u g d osi n g are detaile d i n  T a ble 4.  
Secti o n(s) als o c o ntai ni n g t his c ha n ge:  
 Secti o n 1. 5, Be nefit -Ris k Assess me nt  
  
A L N -A S 1 ( gi v osir a n)   Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  
  A me n d me nt 2 S u m m ar y of C h a n ges, _ 2 6 J ul y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 P ur p ose:  U p d ate m o nit ori n g a n d d osi n g  r ules f or  p atie nts w h o devel o p si g nific a nt A L T elev ati o n; re m ove re d u n d a ncy (f o ot n ot e e)  
T he pri mar y c ha n ge occ urs i n  T a ble 4 : M o nit ori n g a n d D osi n g R ules i n Patie nts wit h Ala ni ne Tra nsa mi nase ( A L T) Ele vati o ns  
Re vise d te xt:   
A L T Tr a ns a mi n ase 
Le vel  P atie nts wit h N or m al B aseli ne A L T  P atie nts wit h Ele v ate d B aseli ne A L T a 
> 3 × t o 5 × U L N or 
B aseli ne   Disc o nti n ue d osi n g w he n A L T is > 3 × U L N a n d 
patie nt is s y m pt o matic b wit h  or h as  T B L ≥ 2 × U L N 
or I N R > 1. 5 (f or patie nts n ot o n warfari n) , a n d 
t here is n o alter n ati ve c a use  
 Ot her wise, d osi n g ma y c o nti n ue wit h m o nit ori n g 
e ver y 2 wee ks ( ± 7 da ys) c t hat i ncl u des he mat ol o g y, 
bi oc he mistr y, L F T, a n d c oa g ulati o n 
assess me nts L F Ts  per T a ble 6 7 an d I N R  
 If t he A L T ele vati o n persists f or ≥ 2  m o nt hs, 
disc ussi o n wit h t he me dical m o nit or is re q uire d 
bef ore c o nti n ui n g d osi n g.   Disc o nti n ue d osi n g w he n A L T is > 3 × ba seli ne or 
> 3 0 0 U/ L ( w hic he ver is l o wer) a n d patie nt is 
s y m pt o matic b, wit h  or h as  T B L > 2 × U L N or I N R 
> 1. 5 (f or patie nts n ot o n warfari n) , a n d t here is n o 
alter n ati ve c a use  
 Ot her wise, d osi n g ma y c o nti n ue wit h m o nit ori n g 
e ver y 2 wee ks ( ± 7 da ys) d t hat i ncl u des  he mat ol o g y, 
bi oc he mistr y, L F T, a n d c oa g ulati o n assess me nts L F Ts  
per T a ble 6 7 a n d I N R  
 If t he A L T ele vati o n persists f or ≥ 2 m o nt hs, 
disc ussi o n wit h t he me dical m o nit or is re q uire d bef ore 
c o nti n ui n g d osi n g  
> 5 × t o 8 × U L N or 
B aseli ne   Disc o nti n ue d osi n g w he n A L T > 5 × t o 8 × U L N a n d 
patie nt is s y m pt o matic b wit h  or h as  T B L ≥ 2 × U L N 
or I N R > 1. 5 (f or p atie nts n ot o n w arf ari n) a n d 
t here is n o alter n ati ve c a use   
 F or  patie nts n ot o n warfari n) w h o are as y m pt o m atic 
a n d d o n ot h a ve I N R > 1. 5 or T B L ≥ 2 x  U L N:  
 H ol de H ol d  d osi n g if A L T > 5 × U L N , u ntil A L T 
rec o vers t o ≤ 2 × U L N   Disc o nti n ue d osi n g w he n A L T > 5 × t o 8 × baseli ne or 
> 3 0 0  U/ L ( w hic he ver is l o wer) a n d patie nt is 
s y m pt o matic b wit h  or h as  T B L ≥ 2 × U L N or I N R 
> 1. 5 (f or patie nts n ot o n warfari n) a n d t here is n o 
alter n ati ve c a use  
 F or p atie nts w h o are as y m pt o m atic a n d d o n ot 
h a ve I N R > 1. 5 or T B L ≥ 2 x U L N:  
 H ol de H ol d  d osi n g if A L T > 5 × baseli ne or > 3 0 0 U/ L 
( w hic he ver is l o wer), u ntil A L T rec o vers t o 
≤ 2 × baseli ne  
A L N -A S 1 ( gi v osir a n)   Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  
  A me n d me nt 2 S u m m ar y of C h a n ges, _ 2 6 J ul y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4  D osi n g c a n be res u me d w he n A L T rec o vers t o 
≤ 2 x U L N acc or di n g t o Secti o n  6. 2. 3. 1. 1 , a n d 
f oll o wi n g disc ussi o n wit h t he me dic al m o nit or  
 Perf or m wee kl y ( ± 3 da ys) m o nit ori n g , i ncl u di n g 
he mat ol o g y, bi oc he mistr y, a n d c oa g ulati o n  of L F Ts  
per T a ble 6 7 a n d I N R  u ntil A L T decli nes t o 
≤ 3 × U L N ; t he n m o nit or e ver y 2 wee ks ( ± 7 da ys) 
u ntil A L T le vel reac hes 2 × U L N c  
  If t he A L T ele vati o n persists f or ≥ 2  m o nt hs, 
disc ussi o n wit h t he me dical m o nit or is re q uire d  
bef ore c o nti n ui n g d osi n g.   D osi n g c a n be res u me d w he n A L T rec o vers t o 
≤ 2 x b aseli ne acc or di n g t o Secti o n  6. 2. 3. 1. 1 , a n d 
f oll o wi n g disc ussi o n wit h t he me dic al m o nit or  
 Perf or m wee kl y ( ± 3 da ys) m o nit ori n g , i ncl u di n g 
he mat ol o g y, bi oc he mistr y, a n d c oa g ulati o n  of L F Ts  
per T a ble 6 7 a n d I N R  u ntil A L T decli nes t o 
≤ 3 × baseli ne ; t he n m o nit or e ver y 2 wee ks ( ± 7 da ys) 
u ntil A L T le vel rea c hes 2 × baseli ne d 
 If t he A L T ele vati o n persists f or ≥ 2  m o nt hs, 
disc ussi o n wit h t he me dical m o nit or is re q uire d 
bef ore c o nti n ui n g d osi n g.   
 e After d osi n g is hel d, o nce A L T has decrease d t o ≤ 2 × U L N or ≤ 2 × baseli ne ( w hic he ver is hi g her), re d osi n g ma y be c o nsi dere d. I n 
patie nts wit h n or mal baseli ne A L T, per ma ne ntl y disc o nti n ue d osi n g if A L T i ncreases t o > 5 × U L N f oll o wi n g re peat d osi n g.  I n pat ie nts 
wit h ele vate d baseli ne A L T, per ma ne ntl y disc o nti n ue d osi n g if A L T i ncreases t o > 5 × baseli ne or > 3 0 0 U/ L ( w hic he ver c o mes first) 
f oll o wi n g re peat d osi n g.  
 
P ur p ose: Cl arify t h at s a m ples are c ollecte d f or a n alyses at t he ce ntr al l a b or at ory.  
T he pri mar y c ha n ge occ urs i n Secti o n 6. 2. 3. 1, M o nit ori n g a n d D osi n g R ules Base d o n Li ver F u ncti o n T est Res ults  
Re vise d te xt:  F or A L T, A S T, P T/I N R T B L , a n d T B L I N R  testi n g, l ocal la b orat or y res ults ma y be use d t o i nf or m d osi n g decisi o ns; 
h o we ver, parallel sa m ples s h o ul d be c o nfir me d c ollecte d f or a n al ysis at t he ce ntral la b orat or y.  
. 
A L N -A S 1 ( gi v osir a n)   Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  
  A me n d me nt 2 S u m m ar y of C h a n ges, _ 2 6 J ul y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 P ur p ose:  A d d a st a n d ar d he p atic assess me nt p a n el f or p atie nts w h o devel o p si g nific a nt A L T elev ati o n  
T he pri mar y c ha n ge occ urs i n ( ne w) T a ble 5: He patic Assess me nts i n Patie nts W h o E x perie nce Ele vate d Tra nsa mi nases  
A d de d te xt:  T a ble 5: He p atic Assess me nts i n P atie nts W h o E x perie nce Ele v ate d Tr a ns a mi n ases  
He m at ol o g y  
C B C wit h differe nti al   
E xte n de d He p atic P a nel  
Her pes Si m ple x Vir us 1 a n d 2 a nti b o d y I g M, I g G  Her pes Z oster Vir us I g M, I g G  
HI V 1 a n d 2 a H H V -6  
C yt o me g al o vir us a nti b o dies, I g M, I g G  H Bs A g, H Bc a nti b o d y I g M a n d I g G  
A nti -n ucle ar a nti b o dies  E pstei n -B arr Vir us a nti b o dies, I g M a n d I g G  
A nti -s m o ot h m uscle a nti b o dies  A nti -mit oc h o n dri al a nti b o dies  
H C V a nti b o d y  H A V a nti b o d y I g M  
H C V R N A P C R – q u alit ati ve a n d q u a ntit ati ve  H E V a nti b o d y I g M  
C P K   
 
 I m a gi n g  
A b d o mi n al ultr as o u n d wit h D o p pler fl o w ( or C T or M RI) i ncl u di n g ri g ht u p per q u a dr a nt  
F oc use d Me dic al a n d Tr a vel Hist or y  
Use of a n y p ote nti all y he p at ot o xic c o nc o mit a nt 
me dic ati o ns, i ncl u di n g o ver t he c o u nter me dic ati o ns a n d 
her b al re me dies  Alc o h ol c o ns u m pti o n  
Ot her p ote nti all y he p at ot o xic a ge nts i ncl u di n g a n y w or k -
rel ate d e x p os ures  Rece nt tr a vels t o are as w here he p atitis A or E is 
e n de mic  
 
 A b bre vi ati o ns:  A A T = al p h a -1 a ntitr y psi n; a nti -L K M = a nti -li ver -ki d ne y micr os o m al a nti b o dies; C B C =c o m plete bl o o d c o u nt; 
C P K =cre ati ne p h os p h o ki n as e; C T =c o m p ute d t o m o gr a p h y; H A V = he p atitis A vir us; H B c = he p atitis B c o re; H Bs A g = he p atitis B 
vir us s urf ace a nti g e n; H C V = he p atitis C vir us; H E V = he p atitis E vir us; H H V -6 = h u m a n her pes vir us 6; HI V = h u m a n 
i m m u n o deficie nc y vir us; I g G =i m m u n o gl o b uli n G a nt i b o d y; I g M =i m m u n o gl o b uli n M a nti b o d y; M RI = m a g netic res o n a nce 
i m a ger y; P C R = p ol y mer ase c h ai n re acti o n; P T = pr ot hr o m bi n ti me; R N A =ri b o n uclei c aci d; S L A =s ol u ble li ver a nti ge n; 
T S H =t h yr oi d -sti m ul ati n g h o r m o ne  
N ote:  
 All assess me nts will be me as ure d i n ce ntr al l a b or at or y. T he f ull p a nel of assess me nts s h o ul d o nl y be perf or me d o nce; 
i n di vi d u al assess me nts m a y be re pe ate d, as nee de d.  
 A d diti o n al s a m ples m a y be c ollecte d f or assess me nt of p ote nti al alter n ati ve c a uses of li ver i nj ur y, w hic h m a y i ncl u de 
A A T, cer ul o pl as mi n, acet a mi n o p he n/ p ar a cet a m ol le vels, a nti -L K M a nti b o dies, t o xic ol o g y scree n, ferriti n, p ar v o vir us 
B 1 9, a nti -S L A a nti b o dies, g a m m a -gl o b uli ns (i ncl u di n g I g E a n d I g G le vels), a n d tr a nsferri n s at ur ati o n, as cli nic all y 
i n dic ate d.  
a  HI V testi n g will n ot be per f or me d w here pr o hi bite d b y l oc al re g ul ati o ns.  
A L N -A S 1 ( gi v osir a n)   Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  
  A me n d me nt 2 S u m m ar y of C h a n ges, _ 2 6 J ul y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 P ur p ose:  A d d  s pecific g ui d a nce f or rec h alle n ge i n p atie nts w h o meet criteri a after d ose i nterr u pti o n  
T he pri mar y c ha n ge occ urs i n Secti o n 6. 2. 3. 1. 1 , Criteria f or Rec halle n ge of Gi v osira n After Bei n g Wit h hel d  f or A L T Ele vati o n  
A d de d te xt:  F or p atie nts i n w h o m gi v osir a n d osi n g is wit h hel d d ue t o ele v ate d A L T, res u m pti o n of d osi n g m a y be c o nsi dere d 
usi n g t he f oll o wi n g g ui deli nes:  
 P atie nts w h o di d n ot meet criteri a f or st u d y dr u g disc o nti n u ati o n per  T a ble 4  m a y be c o nsi dere d f or 
rec h alle n ge f oll o wi n g c o ns ult ati o n wit h t he me dic al m o nit or a n d res ol uti o n of A L T t o ≤ 2 x U L N or ≤ 2 x 
b aseli ne (f or p atie nts w h o h a d ele v ate d b aseli ne A L T)  
 T he decisi o n t o rec h alle n ge t he p atie nt s h o ul d be disc usse d a n d a gree d u p o n b y t he p atie nt, 
I n vesti g at or, a n d me dic al m o nit or  
 T he rec h alle n ge re gi me n is a re d uce d d ose of 1. 2 5 m g/ k g m o nt hl y:  
 L F Ts a n d I N R will be m o nit ore d e ver y 2 wee ks ( ± 7 d a ys) f or t he first m o nt h, t he n m o nt hl y ( ± [ADDRESS_1025926] u d y visits) as per  t he Sc he d ule of Assess me nts  
 L a b or at or y m o nit ori n g a n d d osi n g r ules i n res p o nse t o L F T ele v ati o n will f oll o w  T a ble 4  g ui deli nes  
 If d ose wit h h ol di n g r ules per T a ble 4 are met o n t his d ose, per m a ne ntl y disc o nti n ue d osi n g  
 D ose re -esc al ati o n t o 2. 5 m g/ k g m o nt h l y m a y be c o nsi dere d if t he f oll o wi n g criteri a are met:  
 A p pr o v al b y t he me dic al m o nit or after at le ast 3 d oses of 1. 2 5 m g/ k g m o nt hl y f or p atie nts w h o meet 
b ot h criteri a bel o w:  
o P atie nt h as n ot met d ose wit h h ol di n g or disc o nti n u ati o n r ules per T a ble 4 d uri n g tre at me nt 
wit h 1. 2 5 m g/ k g m o nt hl y  
o P atie nt h as i n a de q u ate c o ntr ol of p or p h yri a s y m pt o ms o n t he 1. 2 5 m g/ k g m o nt hl y re gi me n, per 
i n vesti g at or’s assess me nt   
A L N -A S 1 ( gi v osir a n)   Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  
  A me n d me nt 2 S u m m ar y of C h a n ges, _ 2 6 J ul y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 A d de d te xt  
(c o nti n ue d) :  L F Ts a n d I N R will be m o nit ore d e ver y 2 wee ks ( ± 7 d a ys) f or t he first m o nt h after d ose re -
esc al ati o n, a n d t he n m o nt hl y as per t he Sc he d ule of Assess me nts  
 If a p atie nt e x perie nces a sec o n d d ose h ol d d ue t o L F T ele v ati o n w hile o n 2. 5  m g/ k g m o nt hl y:  
o F oll o w T a ble 4 g ui deli nes f or m o nit ori n g a n d e v al u ati o ns  
o If A L T res ol ves t o ≤ 2 x U L N, re d osi n g wit h 1. 2 5 m g/ k g m o nt hl y m a y be c o nsi dere d if t his d ose 
w as pre vi o usl y t oler ate d a n d t here is a p pr o v al b y t he Al n yl a m me dic al m o nit or.  If d osi n g is 
res u me d, f oll o w t he g ui d a nce a b o ve f or rec h alle n ge re gi me n re g ar di n g l a b or at or y m o n it ori n g 
a n d d osi n g r ules.  N o s u bse q ue nt esc al ati o n t o 2. 5 m g/ k g m o nt hl y will be all o we d  
o L F Ts a n d I N R will be m o nit ore d e ver y 2 wee ks ( ± 7 d a ys) f or t he first m o nt h after d ose 
res u mi n g 1. 2 5 m g/ k g, a n d t he n m o nt hl y as per t he Sc he d ule of Assess me nt  
P ur p ose:   A d d t h at l oc al l a b or at ory res ults m ay be use d t o i nf or m d osi n g decisi o ns a n d cl arify t h at s a m ples are als o t o be c ollecte d f o r a n alyses 
at t he ce ntr al l a b or at ory.  
T he pri mar y c ha n ge occ urs i n Secti o n 6. 2. 3. 2, M o nit ori n g a n d D osi n g R ules Base d o n Li pase a n d A m ylase Res ults  
Re vise d te xt  Li pase a n d a m ylase res ults fr o m t he pre vi o us visit  s h o ul d be re vie we d pri or t o d osi n g.  
... F or li pase a n d a m ylase testi n g, l ocal la b orat or y res ults ma y be use d t o i nf or m d osi n g decisi o ns; h o we ver, parallel 
sa m ples s h o ul d be c o nfi me d  c ollecte d f or a n al ysis  at t he ce ntral la b orat or y.  
Secti o n(s) als o c o ntai ni n g t his c ha n ge:  
 Secti o n 1. 5, Be nefit -Ri s k Assess me nt  
P ur p ose:  Pr ovi de det ails t h at i nf or m ati o n o n ir o n overl o a d a n d ot her liver dise ases are i ncl u de d i n t he c ollecti o n of me dic al hist ory.  
T he pri mar y c ha n ge occ urs i n Secti o n 7. 1, Scree ni n g Assess me nts  
A d de d te xt:  Me dical hist or y c ollecte d will i nc or p orate t he patie nt’s p or p h yria hist or y, i ncl u di n g t heir t y pi[INVESTIGATOR_750006] k c haracteristics, 
tri g gers, a n d treat me nt, as well as ce ntral ve n o us access hist or y , ir o n o verl o a d hist or y, a n d pri or li ver dise ase hist or y.  
Secti o n(s) als o c o ntai ni n g t his c h a n ge:  
 T a ble 1, Sc he d ule of Assess me nts – Scree ni n g a n d 6 -M o nt h Treat me nt Peri o d ( Scree ni n g t hr o u g h M o nt h 6); f o ot n ote c  
A L N -A S 1 ( gi v osir a n)   Cli nic al St u d y Pr ot oc ol A L N -A S 1 -0 0 3  
  A me n d me nt 2 S u m m ar y of C h a n ges, _ 2 6 J ul y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  8 P ur p ose:  A d d t h at i nvesti g at ors m ust revie w pre d ose liver f u ncti o n tests wit hi n [ADDRESS_1025927] u g a d mi nistr ati o n, w hic h c a n be fr o m a 
l oc al l a b or at ory.  Cl arify t h at a d diti o n al s a m ples are als o c ollecte d f or ce ntr al l a b or at ory a n alysis  
T he pri mar y c ha n ge occ urs i n Secti o n 7. 5. 5, Cli nical La b orat or y Assess me nts  
A d de d te xt:  A L T, T B L, a n d I N R c ollecte d wit hi n [ADDRESS_1025928] als o be c ollecte d o n t he d a y of d osi n g pri or t o t he d ose a d mi nistr ati o n . 
Secti o n(s) als o c o ntai ni n g t his c ha n ge:  
 T a ble 1, Sc he d ule of Assess me nts – Scree ni n g a n d 6 -M o nt h Treat me nt Peri o d ( Scree ni n g t hr o u g h M o nt h 6); f o ot n ote j  
 T a ble 2, Sc he d ule of Assess me nts – O pe n -La bel E xte nsi o n Peri o d: After M o nt h 6 t hr o u g h M o nt h 1 8; f o ot n ote f  
 T a ble 3, Sc he d ule of Assess me nts f or O pe n -La bel E xte nsi o n Peri o d: M o nt h [ADDRESS_1025929] u d y ( E O S), f o ot n ote f  
 Secti o n 6. 2. 2, D ose a n d A d mi nistrati o n  
P ur p ose:  C orrecte d p u nct u ati o n, gr a m m ar, a n d f or m atti n g.  
T hese c ha n ges are n ot liste d i n di vi d uall y.  
 
A L N -A S [ADDRESS_1025930] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of C h a n ges _04 M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 A L N -A S 1 -0 0 3 Pr ot oc ol A me n d me nt 1  
S u m m ar y of C h a n ges ( d ate d 04 M a y  2 0 1 8 )  
c o m p are d t o Ori gi n al Pr ot oc ol  ( 0 6 Se pte m ber 2 0 1 7 ) 
E N VI SI O N: A P h ase [ADDRESS_1025931] u d y 
wit h a n O pe n -l a bel E xte nsi o n t o E v al u ate t he Effic ac y a n d S afet y of Gi v osir a n i n P atie nts 
wit h Ac ute He p atic P o r p h yri as  
R ati o n ale f or Pr ot oc ol A me n d me nt  
T he p ur p ose of t h e a me n d me nt is t o:  
 I n cl u de cli nical d ata o n a si n gle case of a na p h yla ctic reacti o n, i nf or m ati o n re gar di n g t he 
p ote ntial ris k f or a na p h yl actic reacti o n s, a n d pr o vi de u p date d g ui da n ce  f or d osi n g a n d 
m o nit ori n g  f or a n a p h ylactic reacti o ns .  T he e ve nt of a na p h yla ctic reacti o n was pre vi o usl y 
re p orte d t o a p plic a ble re g ulat or y a ut h orities a n d I nstit uti o nal Re vie w B oar ds/ Et hics 
C o m mittees.  
 A d d t w o q ualit y of lif e meas ures:  
o Patie nt Gl o bal I m pr essi o n  of C ha n ge ( P GI C) at M o nt hs 6 a n d 1 2  
o P or p h yria Patie nt E x peri e nce Q u esti o n naire ( P P E Q)  at M o nt hs 6, 1 2, 1 8, a n d 2 4 .   
 U p date g ui da nce a n d pr o ce d ures  o n p atie nt wit h dra wal fr o m st u d y.  
 Clarif y t hat A L A/ P B G le vels meas ure d d ur i n g s cree ni n g are acce pta bl e f or use as  e ntr y 
criteria  
 pr o vi de t he f oll o wi n g a d d iti o nal clarificati o ns :  
o pre d ose sa m ples  ( n ot restricte d t o 6 0 mi n utes bef ore d osi n g) , 
o i nteri m a nal ysis f or sa m ple si ze reassess me nt  is bli n de d  
o defi niti o n of se x ual a bsti ne nce  
o co ntrace pti o n wit h a n i ntra uteri ne h or m o ne -releasi n g s yste m als o re q uir es use of a 
barrier m et h o d    
A detaile d s u m mar y of t h e c ha n ges is pr o vi de d i n  Ta ble  1.  C orrecti o ns t o t y p o gra p hical err ors 
f or matti n g, a n d ali g ni n g t e xt bet wee n secti o ns , a n d ot her mi n or u p dates  are n ot o utli ne d i n t he 
ta ble . 
 
A L N -A S [ADDRESS_1025932] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  2 T a ble  1: Pr ot oc ol A me n d me nt  1 Det aile d S u m m a r y of C h a n ges  
T he pri mar y secti o n(s) of t he pr ot oc ol affecte d b y t he c ha n ges i n t he pr ot oc ol a me n d me nt are i n d ic at e d.  T he c orres p o n di n g te xt has 
bee n re vis e d t hr o u g h o ut t he pr ot oc ol.  Delet e d te xt is i n dicate d b y stri ke o ut ; a d de d te xt is i n dicate d b y b ol d  f o nt.  
 
P ur p ose: Pr ovi de det ails of  a n a n a p hyl actic re acti o n re p orte d i n St u dy A L N -A S 1 -0 0 2  
T he pri mar y c h a n ge o cc urs i n Secti o n 1. 2. 2. 2 - P hase 1/ [ADDRESS_1025933] u d y A L N -A S 1 -0 0 2  
A d de d te xt:  I n a d diti o n, o ne patie nt i n t he 2. 5 m g/ k g m o nt hl y d ose gr o u p wit h a hist or y of ast h ma a n d m ulti ple aller gies 
e x perie nce d a n S A E of  a na p h yl a ctic reacti o n  t hat was deter mi ne d b y t h e I n vesti gat or t o b e defi nitel y relate d t o 
st u d y dr u g gi ve n t he t e m p oral relati o ns hi p of gi v osira n treat me nt t o t he o ns et of t he reacti o n ( wit hi n mi n utes).  
T he patie nt was tr eate d a n d rec o vere d a n d was dis c o nti n ue d fr o m t he st u d y.  
Secti o n(s) als o c o ntai ni n g t his c ha n ge  
 Secti o n 1. 5  Be nefit -Ris k Assess me nt  
 
P ur p ose: C orrect t h at p atie nts will receive o pe n -l a bel giv osir a n f or u p t o [ADDRESS_1025934] u d y Desi g n Rati o nal e  
N o w rea ds:  T he e n d p oi nts will be e v al uate d a gai nst a place b o c o m para t or f or t he first [ADDRESS_1025935] u d y (t h e d o u ble -
bli n d treat me nt peri o d); after t his, all patie nts will recei v e o pe n -l a bel gi v osira n f or u p t o a n a d diti o nal [ADDRESS_1025936] u d y.  
Secti o n(s) als o c o ntai ni n g t his c ha n ge  
 S y n o psis:  St u d y Desi g n  
 Secti o n 4. 1:  S u m mar y of St u d y Desi g n   
 
A L N -A S [ADDRESS_1025937] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  3 P ur p ose:  A d d a n a p hyl actic re acti o n t o giv osir a n p ote nti al risks  
T he pri mar y c h a n ge o cc urs i n Secti o n 1. 5 -  Be n efit -Ris k Assess me nt  
N o w rea ds:  F urt her details o n t he n o ncli nical res ults  a n d safet y res ults f or St u d y A L N -A S 1 -0 0 1 ca n be f o u n d i n t he 
gi v osira n I B. Gi v e n t he bi ol o gical tar get of gi v osira n, t he a vaila ble n o ncli nical a n d cli nical d ata, a n d t he m o de 
of a d mi nistrati o n, ot her p ote ntial  i m p ort a nt  t he oretical  ris ks i ncl u de t he ris k of se vere or seri o us  i njecti o n site 
reacti o ns (I S Rs), li ver tr a nsa mi nase a b n or malities, pa ncreatitis , a n d a n a p h yl actic re a cti o n .  A s u m mar y of 
preli mi nar y cli nical data fr o m o n g oi n g P has e 1 a n d P hase 1/ 2 st u dies of gi v osira n ca n b e f o u n d i n Secti o n  1. 2. 2  
a n d i n t he gi v osira n I B.   
T his cli nical pr ot oc ol i ncl u des e x cl usi o n criteria i nte n de d t o mi ni mize t he ris k of tra nsa mi nitis, I S R a n d 
pa ncreatitis, a n d als o i nc or p orates o n g oi n g m o nit ori n g f or ele v ate d tra ns a mi nases, ser u m li pase, a n d  
a n a p h yl actic re acti o n  ( Secti o n  6. 2. 3 ). 
 
P ur p ose: Cl arify t h at ot her me dic ati o ns m ay b e c o nsi dere d i n t he defi niti o n of  p or p hyri a att ack  
T he pri mar y c h a n ge o cc urs i n Secti o n 3. 5 Defi niti o n of P or p h yri a Attac ks  
A d de d te xt:  re q uires tr eat me nt wit h I V de xtr ose or he mi n, car b o h y drates, or a nal gesics ( o pi [INVESTIGATOR_2495] d [s y nt hetic a n d n o n -s y nt hetic 
s u bsta nces] or n o n -o pi [INVESTIGATOR_2495] d ), or ot her me dic ati o ns s uc h as a ntie metics, at d ose or fre q ue nc y b e y o n d t he 
patie nt’s us ual dail y p or p h yria m a na ge m e nt  
  
 
P ur p ose: Cl arify t h at t his st u dy m ay be  re pl a ce d wit h a p ost -m arketi n g st u dy i n re gi o ns t h at receive m arketi n g a ut h oriz ati o n f or 
giv osir a n  
T he pri mar y c h a n ge o cc urs i n Secti o n 4. [ADDRESS_1025938] u d y Desi g n  
A d de d te xt:  W here re q uire d b y l oc al re g ul ati o ns, t his tri al m a y be re pl ace d wit h a p ost -m a r keti n g cli nic al tri al o nce 
m a r keti n g a ut h oriz ati o n f or gi v osir a n is recei ve d.  
 
A L N -A S [ADDRESS_1025939] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  4 P ur p ose: Cl arify t h at  d oc u me nte d P B G or A L A elev ati o ns  me as ure d d uri n g scree ni n g are a cce pt a ble f or use as e ntry criteri a   
T he pri mar y c h a n ge o cc urs i n Secti o n 5. 1  I n cl usi o n Criteria # [ADDRESS_1025940] o ne d oc u me nt e d uri nar y or plas ma P B G or A L A val ue ≥ 4 × u p per li mit of n or mal ( U L N) wit hi n t he past 
year pri or t o or d uri n g Scree ni n g . 
 
P ur p ose: U p d ate i ncl usi o n re g ar di n g i nf or me d c o nse nt t o cl arify h a n dli n g of c o nse nt f or p atie nts u n der le g al a ge t o c o nse nt   
T he pri mar y c h a n ge o cc urs i n Se cti o n 5. 1  I n cl usi o n Criteria # 7  
N o w rea ds:  Be willi n g a n d a ble t o c o m pl y wit h t he st u d y re q uire me nts a n d t o pr o vi de writte n i nf or me d c o ns e nt per l ocal 
a n d  asse nt  n ati o n al re q uire me nts .  I n t h e cas e of patie nts u n der t he a ge of le gal c o nse nt, per l ocal a n d nati o nal 
re q uire me nts  le g al g u ar di a n(s) m ust pr o vi de w ritte n i nf or me d c o nse nt a n d t he p atie nt s h o ul d pr o vi de 
asse nt per l oc al re g ul ati o ns a n d i nstit uti o n al st a n d ar ds.  
 
 
P ur p ose:  C h a n ge d ti mi n g f or pl a n ne d s ur gery excl usi o n s o it w as n ot t o o restrictive f or t he t ar get p atie nt p o p ul ati o n  
T he pri mar y c h a n ge o cc urs i n Secti o n 5. 2  E x cl usi o n Criteria # 1 1  
N o w rea ds:  Has pla n ne d el ecti ve  a  maj or s ur ger y s c he d ule d t o occ ur  pl a n ne d  d uri n g t he st u d y  first [ADDRESS_1025941] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 P ur p ose:  U p d ate d  secti o n title a n d w or di n g t o reflect c urre nt C o m p a ny l a n g u a ge  
T he pri mar y c h a n ge o cc urs i n Secti o n  5. [ADDRESS_1025942] u g a n d/ or St u d y  ( ne w title)  
N o w rea ds:  Patie nts or t heir le gal g uar dia ns (i n t he cas e t hat t h e patie nt is a mi n or) are free t o disc o nti n ue st u d y dr u g  
treat me nt a n d/ or st u d y  or wit h dra w fr o m t he st u d y   t heir c o nse nt  at a n y ti me a n d f or a n y reas o n, wit h o ut 
pe nalt y t o t heir c o nti n ui n g me dical care.  A n y disc o nti n uati o n of treat me nt or wit h dra wal fr o m  of  t he st u d y 
m ust be f ull y d oc u me nt e d i n t he electr o nic case re p ort f or m (e C R F), a n d s h o ul d be f oll o we d u p b y t he 
I n v est i gat or.  T he I n v esti gat or m a y wit h dra w a patie nt fr o m t he st u d y at a n y ti me if t his is c o nsi dere d t o be i n 
t he patie nt’s best i nterest.  
Pr oce d ures f or t he disc o nti n uati o n Disc o nti n u ati o n  of st u d y dr u g a n d wit h dra wal fr o m t he st u d y are descri b e d 
i n Secti o n 5. 3. [ADDRESS_1025943] u d y, he/s he will n ot be a ble t o re -e nr oll i n t he st u d y  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A L N -A S [ADDRESS_1025944] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  6 P ur p ose:  U p d ate d t o cl arify o pti o ns f or p atie nts w h o pre m at urely disc o nti n ue st u dy dr u g a n d t o ali g n pr ot oc ol text wit h s a m ple 
I nf or me d C o nse nt F or m.    
T he pri mar y c h a n ge o cc urs i n Secti o n 5. 3. [ADDRESS_1025945] u d y  
N o w rea ds:  A patie nt ma y wit h dra w fr o m t he st u d y at a n y ti me.   A p atie nt or t hei r le g al g u ar di a n m a y deci de t o st o p t he 
p atie nt’s p artici p ati o n i n t he st u d y at a n y ti me.  P ati e nts c o nsi deri n g t o st o p t he st u d y s h o ul d be 
i nf or me d t h at t he y c a n disc o nti n ue tre at me nt a n d c o m plete st u d y assess me nts i nc l u di n g f oll o w -u p, as per 
t he S O A, or alter n ati vel y m a y c o m plete a n y mi ni m al assess me nts f or w hic h t he p atie nt c o nse nts. T he 
I n vesti g at or m a y wit h dr a w a p atie nt at a n y ti me if t his is c o nsi dere d t o be i n t he p atie nt’s best i nterest.  
H o we ver, st u d y i nte grit y  a n d i nter pret ati o n is best mai ntai ne d if all ra n d o mi ze d patie nts c o nti n ue st u d y 
assess me nts a n d f oll o w -u p.   Patie nts c o nsi deri n g wit h dra wi n g fr o m t he st u d y s h o ul d be i nf or me d t hat t he y ca n 
disc o nti n ue treat me nt a n d c o m plete t heir st u d y assess me nts t hr o u g h t he [ADDRESS_1025946] earl y t h e assess me nts sc he d ule d t o be perf or me d at t he 6 m o nt h visit (see ).  
St o p pi n g st u d y p artici p ati o n c o ul d me a n:  
 If a p atie nt st o ps p artici p ati o n d uri n g t he [ADDRESS_1025947] u d y 
assess me nts t hr o u g h t he 6 -m o nt h visit, i ncl u di n g f oll o w -u p.   
 If a p atie nt st o ps p artici p ati o n d uri n g t he o pe n -l a bel e xte nsi o n peri o d, t he y s h o ul d be 
as ke d t o ret ur n f or a n E arl y Ter mi n ati o n Visit as well as a S afet y F oll o w -U p Visit [ADDRESS_1025948] u g.  
 A p atie nt  c a n st o p t a ki n g t he st u d y dr u g a n d st o p st u d y -rel ate d visits, b ut all o w t he 
i n vesti g at or a n d st u d y te a m t o re vie w t he p atie nt’s me dic al rec or ds, p u blic rec or ds or be 
c o nt acte d i n or der t o recei ve i nf or m ati o n a b o ut t he p atie nt’s he alt h  
W he n a patie nt wit h d ra ws fr o m st o ps  t he st u d y, t h e pri mar y disc o nti n u ati o n a n d  reas o n f or disc o nti n uati o n 
m ust be rec or de d  i n t he a p pr o priate secti o n of t he electr o nic case re p ort f or m (e C R F) a n d all eff orts will be 
ma de t o c o m plete a n d re p ort t he o bser vati o ns as t h or o u g hl y as p ossi ble.  If a patie nt wit h dra ws st o ps t he st u d y  
d ue t o a n a d verse e v e nt ( A E), i ncl u di n g a n S A E, t he A E s h o ul d be f oll o we d as descri be d i n Secti o n  7. 5. 6.  
If t he p atie nt w a nts t o st o p p artici p ati o n i n t he st u d y, he/s he s h o ul d n otif y t he st u d y d oct or i n w riti n g or 
i n a n y ot her f or m t h at m a y be l o c all y re q uire d. T he pers o n al d at a alre a d y c ollecte d d uri n g t he st u d y, 
A L N -A S [ADDRESS_1025949] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  7 i ncl u di n g p atie nt’s bi ol o gic al s a m ples, will still be use d t o get her wit h t he d at a c ollecte d o n ot h er p atie nts 
i n t he st u d y acc or di n g t o t he i nf or me d c o nse nt a n d a p plic a ble l a ws.  
I n a d diti o n t o st o p pi n g p artici p ati o n i n t he st u d y, t he p atie nt c o ul d deci de t o wit h dr a w his/ her c o nse nt as 
e x pl ai ne d i n Se cti o n 5. 3. 3.  
 
P ur p ose: Ne w secti o n a d de d t o disc uss wit h dr a w al of c o nse nt     
T he pri mar y c h a n ge o cc urs i n Secti o n 5. 3. 3 ( ne w s ecti o n)  Wit h dra wal  of C o nse nt t o C ollect a n d Pr ocess t he Patie nt’s Pers o nal Data  
Ne w te xt:  T he patie nt ma y deci de t o wit h dra w his/ her c o ns e nt i nf or mi n g t he st u d y d o ct or at a n y ti me i n writi n g, or i n a n y 
ot her f or m t hat ma y be l o call y re q uir e d.  T his  mea ns t hat t he patie nt wa nts t o st o p partici pati o n i n t he st u d y a n d 
a n y f urt her c ollecti o n of his / her pers o nal dat a.  
 T he s p o ns or will c o nti n ue t o kee p a n d us e a patie nt's st u d y i nf or mati o n (i n cl u di n g a n y d ata 
res ulti n g fr o m t he a nal ysis of t he patie nt's bi ol o gi cal sa m ples u ntil ti me of wit h dra wal) acc or di n g 
t o a p plica ble la w.  T his is d o ne t o g u ara nt ee t he v ali dit y of t he st u d y, deter mi ne t he effects of t he 
st u d y treat me nt, a n d e ns ure c o m plete n ess of st u d y d oc u me ntati o n.  
 T he patie nt ca n als o re q u est t hat c ollecte d sa m ples be destr o ye d or ret ur n e d (t o t he e xte nt it is 
per mitte d b y a p plica ble l a w) at a n y ti me.  
 Patie nts w h o wit h dra w t heir c o nse nt t o c ollect a n d use pers o nal data s h o ul d u n dersta n d t hat 
p u blic rec or ds ma y b e re vie we d t o deter mi ne t h e patie nt’s s ur vi val stat us as all o we d per l ocal 
a n d nati o nal re g ulati o ns.    
I n U S a n d J a pa n, ot her wise, sa m ples n ot yet a nal yze d at t he ti me of wit h dra wal ma y still be use d f or f urt her 
testi n g/a nal ysis i n acc or da nce wit h t he ter ms of t he pr ot oc ol a n d of t h e i nf or me d c o nse nt f or m.  
I n E U a n d rest of w orl d, i n a n y e ve nt, sa m ples n ot yet a nal yz e d at t he ti me of wit h dra wal will n ot be use d a n y 
l o n ger, u nless per mitte d b y a p plica ble la w. T he y will be st ore d or destr o ye d acc or di n g t o a p plic a ble le gal 
re q uire me nts.  
 
 
A L N -A S [ADDRESS_1025950] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  8 P ur p ose: Pr ovi de g ui d a n ce o n m o nit ori n g a n d m a n a ge me nt of p ote nti al a n a p hyl actic re acti o n s d ue t o st u dy dr u g  
( N ote: n o c h a n ges t o t he sc he d ule of assess me nts re g ar di n g visits c o n d ucte d at t he st u dy ce nter vs. ot her l oc ati o ns were m a de  i n t he 
a me n d me nt)  
T he pri mar y c h a n ge o cc urs i n Secti o n 6. 2. 2  D ose a n d A d mi nistrati o n  
Re vise d  te xt:  Gi v osira n will be a d mi nistere d b y a q u alifie d a n d a ut h orize d staff at t he st u d y ce nter.  I n t he e v e nt t hat a patie nt 
is u na ble t o c o me t o t he st u d y ce nter f or a sc h e d ul e d cli nical st u d y visit , he alt h c are pr ofessi o n al tr ai ne d i n 
t he rec o g niti o n a n d m a n a ge me nt of a n a p h yl actic re acti o ns.  T he st u d y dr u g s h o ul d be i njecte d i nt o t he 
a b d o me n or u p per ar ms or t hi g hs.  Det aile d i nstr ucti o ns f or st u d y dr u g a d mi nistr ati o n are prese nte d i n 
t he P h ar m ac y M a n u al. As is c o nsiste nt wit h g o o d me dic al pr actice f or s u bc ut a ne o us dr u g  
a d mi nistr ati o n, p atie nts will be o bser ve d f or a mi ni m u m of 2 0 mi n utes after e ac h i njecti o n.  Tre at me nt 
f or  a n a p h yl actic re acti o n s s h o ul d be re a dil y a v ail a ble w here p atie nts are bei n g d ose d , a n d f oll o w  c o u ntr y 
a n d/ or  l oc al h os pit al tre at me nt g ui deli nes. [2 5 ] 
St u d y dr u g a d mi nistrati o n ma y b e c o n d uct e d at a l ocati o n ot her t ha n t he st u d y ce nter b y a h o me healt hcare 
pr ofessi o nal, w here a p plica ble c o u ntr y a n d l ocal re g ul ati o ns a n d i nfrastr u ct ure all o w, after c o ns ultati o n wit h t he 
me dical m o nit or .  F or , d uri n g par tic ular st u d y visits, as s pecifie d i n t he Sc he d ules of Ass ess me nts ( Ta ble 2  a n d 
), d osi n g ma y als o be perf or me d Ta ble 3 ).  H o w e ver, s t u d y dr u g a d mi nistr ati o n  at a l ocati o n ot her t ha n t he 
st u d y ce nt er  s h o ul d be  b y a q ualifie d h o me healt hcare pr ofessi o nal w h ere a p plica ble  c o u ntr y a n d l o cal 
re g ulati o ns a n d i nfrastr uct ure all o w . T he st u d y dr u g  s h o ul d be i nject e d i nt o c o nsi dere d f or p atie nts w h o h a ve 
o n g oi n g st u d y dr u g -rel ate d A Es or k n o w n ris k f act ors f or de vel o pi n g a n a p h yl actic re acti o n s, i ncl u di n g 
b ut n ot li mite d t o: a pri or hist or y of a n a n a p h yl actic re a cti o n t o f o o d, me dic ati o ns or u n k n o w n eti ol o g y, 
w orse ni n g i njecti o n site re acti o ns wit h re pe at d osi n g, or a n y o ne i n t he a b d o me n or u p per ar ms or t hi g hs.  
Patie nts m ust de m o nstrate t hat t he y ca n t olerate d ose opi [INVESTIGATOR_9384] o n of t he i n vesti g at or t h at w o ul d be nefit fr o m 
cli nic al o bser v ati o n f oll o wi n g  d osi n g. at a l ocati o n ot her t ha n t he st u d y ce nter is per mitte d . 
Secti o n(s) als o c o ntai ni n g si milar or relate d c ha n ges  
 Secti o n 6. 2. 3 . 3 ( ne w secti o n)   M o nit ori n g a n d D osi n g R ules i n Patie nts wit h P ote ntial A na p h ylacti c Reacti o n s 
 
P ur p ose:  cl arify t h at M o nt h 6 A L A a n d P B G assess me nts ( at t he e n d of t he d o u ble -bli n d peri o d) m ust be c o m plete d pri or t o 
a d mi nistr ati o n of t he first o pe n -l a bel d ose of giv osir a n  
T he pri mar y c h a n ge  o cc urs i n Secti o n 6. 2. 2. 1   D uri n g t he 6 -M o nt h Treat m e nt Peri o d ( Da y 1 t o M o nt h 6)  
A L N -A S [ADDRESS_1025951] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  9 A d de d te xt:  At t he M o nt h 6 st u d y visit, f oll o wi n g t he c o m pleti o n of all M o nt h 6 assess me nts , i ncl u di n g t he uri ne s a m ple 
f or A L A a n d P B G le vels  (t o e n d t he d o u ble -bli n d peri o d), patie nts will be a d mi nistere d t heir first o pe n -la bel 
( u n mas ke d) d ose of gi v osira n t o be gi n t heir partici pati o n i n t he o pe n -la bel e xte nsi o n p orti o n of t he st u d y.  
 
P ur p ose:  A d d g ui d a nce a n d pr oce d ures f or m a n a ge me nt of p ote nti al c ases of a n a p hyl actic re acti o n  
A d de d te xt:  A n a na p h yla ctic reacti o n is a se vere, p ote ntiall y fatal, s yste mic aller gic reacti o n wit h ac ute o nset ( mi n utes t o 
h o urs).  F or refere nce s ee Secti o n [ADDRESS_1025952] u d y me dicati o n.  
 
L a b or at or y testi n g:  O bt ai n bl o o d sa m pl e f or tr y ptase , t otal I g E, a n d A D A  a nti dr u g a nti b o dies ( A D A), i deall y 
wit hi n 1 5 mi n utes t o 3 h o urs after t h e o nset of a s us pecte d a n a p h yl actic reacti o n; h o we ver, u p t o 6 h o urs is 
acce pta ble.  A n a d diti o nal bl o o d sa m ple t o assess tr y ptas e, t otal I g E, a n d A D A s h o ul d be o btai ne d b et wee n 1 t o 
2 wee ks  fr o m o nset of e v e nt.  L o cal la b orat or y ma y be us e d t o a nal yz e sa m ples; h o we ver, parallel sa m ples 
s h o ul d be se nt t o t he ce ntral la b orat or y f or a n al ysis.  Sa m ple c ollecti o n a n d s hi p pi n g i nstr ucti o ns are i ncl u de d 
i n t he La b orat or y M a n ual.  
  
Re p orti n g : T he PI [INVESTIGATOR_1311] g nee m ust n otif y t he s p o ns or or desi g nee wit hi n [ADDRESS_1025953] 
( A E CI) a n d S A Es, p er A E re p orti n g re q uir e me nts  ( Secti o ns  7. 5. 6. 1  t hr o u g h Secti o n 7. 5. 6. 3 ).  
Secti o n(s) als o c o ntai ni n g si milar or relate d c ha n ges  
 Secti o n  7. 5. 5. 1  I m m u n o ge ni cit y  
 Secti o n 7. 5. 6. [ADDRESS_1025954]  
 Secti o n [ADDRESS_1025955] of Re fere nces  
 Secti o n [ADDRESS_1025956] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 0  P ur p ose:  Revis e d defi niti o n of sex u al a bsti ne nce t o ali g n wit h c urre nt st a n d ar ds  a n d cl arifie d t h at i ntr a uteri ne h or m o ne rele asi n g 
syste m is a met h o d re q uiri n g a b arrier met h o d  
T he pri mar y c h a n ge o cc urs i n Secti o n 6. [ADDRESS_1025957] u g ( defi ne d a b o ve).   Peri o dic a bsti ne n ce (e g, cal e n dar, o v ul ati o n, 
s y m pt ot her mal, p ost -o v ulati o n met h o ds) a n d wit h dra wal are n ot acce pta ble met h o ds of c o ntrace pti o n.  
c o nsi dere d se x u al a bsti ne nce a n d d o n ot meet criteri a f or a n acce pt a ble met h o d of birt h c o ntr ol.  As 
deter mi ne d b y t he i n vesti g at or, t he reli a bilit y of se x u al a bsti ne nce nee ds t o be e v al u ate d i n rel ati o n t o t he 
d ur ati o n of t he cli nic al tri al a n d t he preferre d a n d us u al lifest yle of t he p atie nt .  A bsti ne nt patie nts m ust 
a gree t o us e [ADDRESS_1025958] u g ( defi ne d a b o ve).  
N o w rea ds  Esta blis he d use of oral, i m pla nta ble, i njecta ble, or  tra ns der mal h or m o n al , or i ntr a uteri ne h or m o ne -rele asi n g 
s yste m as  met h o ds of c o ntrace pti o n:  W o me n of c hil d -beari n g p ote ntial usi n g h or m o n al met h o ds of 
c o ntrace pti o n m ust als o use a barrier met h o d ( c o n d o m or occl usi ve ca p [ dia p hra g m or cer vical/ va ult ca p] i n 
c o nj u ncti o n wit h s per mici de [e g, f oa m, gel, fil m, crea m, or s u p p osit or y]).  See Secti o n  6. 3 a n d Secti o n 1 1. 2 . 
 
P ur p ose: Cl arify re q uire me nts P B G or A L A elev ati o ns d uri n g Scree ni n g  
T he pri m ary c h a n ge occ urs i n Secti o n 7. 1 Scree ni n g Assess me nts  
A d de d te xt:  If re q uir e d, A L A/ P B G le vels c ollecte d d uri n g t he scree ni n g p eri o d f or eli gi bilit y p ur p os es s h o ul d be a nal yze d 
l ocall y.   
 
P ur p ose: Cl arify e Di ary c o m pleti o n re q uire me nts d uri n g Scree ni n g  
T he pri m ary c h a n ge occ urs i n Secti o n 7. 2. 2 P ai n a n d P ai n -Rel ate d Assess me nts  
A d de d te xt:  D uri n g t h e scree ni n g peri o d, t here s h o ul d be a mi ni m u m of [ADDRESS_1025959] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 1  P ur p ose: I ncl u d e d a n a d diti o n al Q u ality of Life assess me nt s 
T he pri mar y c h a n ge o cc urs i n Secti o n 7. 2. 4  Q ualit y of Life ( Q O L)  
A d de d te xt:   P GI C: T he Patie nt Gl o bal I m pr essi o n of C ha n ge ( P GI C) is o ne q u esti o n a ns were d acc or di n g t o a 7 -p oi nt 
scale (ra n gi n g fr o m ver y m uc h i m pr o ve d t o ver y m uc h w orse) f or t he assess me nt of a patie nt’s percei ve d 
o verall healt h stat us c h a n ge si nc e t he be gi n ni n g of t he st u d y.  T his q uesti o n naire ta kes a p pr o xi matel y 2 t o 
3 mi n utes t o c o m plete.  
 P P E Q: T he P or p h yria Patie nt E x perie nce Q uesti o n naire ( P P E Q)  is a set of q uesti o ns t o assess treat me nt 
e x perie nce a n d i m pacts t o t he patie nt's life n ot c ollec te d b y t he ot her Q O L  assess me nts.  
Secti o n(s) als o c o ntai ni n g si milar or relate d c ha n ges  
 Ta ble 1 a n d F o ot n ote s t o Ta ble 1: Sc he d ule of Assess me nts  
 Ta ble 2 a n d F o ot n ote s t o Ta ble 2: Sc he d ule of Assess me nts  
 Ta ble 3 a n d F o ot n otes t o Ta ble 3: Sc he d ule of Assess me nts  
 Secti o n 2. 3:  E x pl orat or y O bjecti ves  
 Secti o n 3. 3:  E x pl orat or y E n d p oi nts  
 
P ur p ose: t o u p d ate t he g ui d a nce o n wei g ht c ollecti o n f or d osi n g c alc ul ati o ns  
T he pri mar y c h a n ge o cc urs i n Secti o n 7. 5. 2 - Wei g ht a n d Hei g ht  
A d de d te xt:  B o d y wei g ht eit her  at t h e pre vi o us st u d y ce nter visit w here wei g ht is c ollecte d will  or c urre nt st u d y ce nter 
visit m a y  b e use d f or d osi n g calc ulati o ns.  
Secti o n(s) als o c o ntai ni n g si milar or relate d c ha n ges  
 F o ot n otes t o Ta ble 1: Sc he d ule of Assess me nts  
 F o ot n otes t o Ta ble 2:  Sc he d ule of Assess me nts  
 F o ot n otes t o Ta ble 3: Sc he d ule of Assess me nts  
 
A L N -A S [ADDRESS_1025960] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 2  P ur p ose: A d de d a n a p h yl actic re acti o ns t o list of A dverse Eve nts of Cli nic al I nterest  
T he pri mar y c h a n ge o cc urs i n Secti o n 7. 5. 6. 1  Defi niti o ns 
A d de d te xt:  A na p h yl actic Reacti o ns. An a na p h yla ctic reacti o n is a se vere, p ote ntiall y fatal, s yste mic aller gic reacti o n wit h 
ac ute o nset ( mi n utes t o h o urs).  S y m pt o ms of a n a na p h yl actic reacti o n  ma y i ncl u de s ki n or m uc osal tiss ue (e. g. 
ge n eralize d hi ves, pr urit us, a n gi oe de ma), res pi[INVESTIGATOR_1305] y c o m pr o mise (e. g. w heezi n g, br o nc h os p as m, h y p o xia), 
re d uce d bl o o d press ur e or ass ociate d s y m pt o ms (e. g. s y nc o p e, h y p ot o nia) . See Secti o n 1 1. 3 f or g ui d a nce o n 
dia g n osi n g a n a p h yl actic reacti o ns.  [2 6 ]   
P ur p ose: U p d ate d det ails of st atistic al a n alyses f or bi o m arkers   
T he pri mar y c h a n ge o cc urs i n Secti o n 8. 2. 5. 2  Sec o n dar y E n d p oi nt 
N o w rea ds: F or t he a nal ysis of uri nar y A L A -relate d e n d p oi nts, t he A L A le vels will be c o m pare d b et wee n treat me nt ar ms 
usi n g a n a nal ysis of c o varia nce ( A N C O V A) m o del wit h  fi xe d effect of tre at me nt ar ms, str atific ati o n f act ors 
f or AI P p atie nts ( pri or he mi n pr o p h yl a xis s t at us a n d hist oric al att ac k r ates), a n d wit h t he baseli ne A L A as 
a c o vari ate.  P B G -rel ate d e n d p oi nts will als o be a nal yze d usi n g t his met h o d ol o g y.   
Secti o n(s) als o c o ntai ni n g si milar or relate d c ha n ges  
Secti o n 8. 2. 1 0: I nteri m A nal ysis 
A L N -A S [ADDRESS_1025961] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 3  P ur p ose: re m o ve d t he pr es pecifie d wi n d o w f or pre d ose s a m pli n g ti me f or all uri ne P K, P D a n d A D A assess me nts  
T he pri mar y c h a n ge o cc urs i n Secti o n 1 1 P har mac o ki netic/ P har mac o d y na mic Assess me nt Ti me P oi nts  Ta ble 7 ( P har mac o ki netic, 
E C G, a n d A D A Ti me P oi nts f or All Patie nts [ E x ce pt Patie nts at East Asia n Sites]) ,  
N o w rea ds:  Pre d ose ( wit hi n 6 0 mi n utes bef ore d osi n g)  
Secti o n(s) als o c o ntai ni n g si milar or relate d c ha n ges  
 Ta ble 8 ( P har mac o ki neti c, E C G, a n d A nti -Dr u g A nti b o d y ( A D A) Ass ess me nt Ti me P oi nts f or Patie nts at East Asia n St u d y 
Ce nters [ Bl o o d Sa m ples])  
 Ta ble 9 ( Uri n e P har mac o ki netic/ P har mac o d y na mi c Ti me p oi nts f or Patie nts at East Asia n St u d y Ce nters)  
 
A L N -A S [ADDRESS_1025962] u d y Pr ot oc ol A L N -A S 1 -0 0 3  
 A me n d me nt 1 S u m m ar y of  C h a n ges _ 04M a y 2 0 1 8  
 
Al n yl a m P h ar m ace utic als  C o nfi de nti al  1 4  P ur p ose: A d d  g ui d a nce f or di a g n osi n g a n a p hyl actic re acti o ns  
T he pri mar y c h a n ge o cc urs  i n Secti o n 1 1. 3 ( ne w s ecti o n)  A na p h yla ctic R eacti o n s 
A d de d te xt:  T a ble  2 S a m ps o n  Criteri a  f or A n a p h yl actic Re acti o ns  
 
A da pte d fr o m Sa m ps o n et al. 2 0 0 6 [ 2 6 ] 
 
 